association_info.ancestry association_info.doi association_info.gwas_catalog_id association_info.neg_log_pval association_info.otg_id association_info.pubmed_id association_info.url gold_standard_info.evidence.class gold_standard_info.evidence.confidence gold_standard_info.evidence.curated_by gold_standard_info.evidence.description gold_standard_info.evidence.pubmed_id gold_standard_info.evidence.source gold_standard_info.gene_id gold_standard_info.highest_confidence metadata.comments metadata.date_added metadata.reviewed_by metadata.set_label metadata.submitted_by metadata.tags sentinel_variant.alleles.alternative sentinel_variant.alleles.reference sentinel_variant.locus_GRCh37.chromosome sentinel_variant.locus_GRCh37.position sentinel_variant.locus_GRCh38.chromosome sentinel_variant.locus_GRCh38.position sentinel_variant.rsid trait_info.ontology trait_info.reported_trait_name trait_info.standard_trait_name EUR GCST000324 23.699 GCST000324_3 19185284 expert curated High Eric Fauman BCO1 (previously referred to as BCMO1) encodes beta-carotene oxygenase 1 which uses a molecule of oxygen to produce two molecules of retinol from beta-carotene. Enzyme deficiency results in accumulation of beta-carotene. 11401432 ENSG00000135697 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G T 16 81264597 16 81230992 rs6564851 HMDB0000561 Carotenoid and tocopherol levels (beta-carotene) B-Carotene unknown GCST000386 323.301 GCST000386 19414484 expert curated High Eric Fauman UGT1A1 encodes an enzyme with bilirubin glucuronidating activity. Bilirubin is derived from biliverdin. 01898728 ENSG00000242366 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T G 2 234672639 2 233763993 rs6742078 HMDB0000054 Bilirubin levels Bilirubin ASW|EUR GCST000388 8.046 GCST000388 19419973 expert curated High Eric Fauman G6PD encodes the glucose-6-phosphate dehydrogenase, an enzyme critical to red blood cell metabolism. G6PD deficiency results in accumulation of bilirubin, a breakdown product of heme. 11445808 ENSG00000160211 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G C X 153554404 X 154326058 rs766420 HMDB0000054 Bilirubin levels Bilirubin EUR GCST000493 65.046 GCST000493_3 19798445 expert curated High Eric Fauman SGPP1 encodes a sphingosine-1-phosphate phosphatase which dephosphorylates sphingosine-1-phosphate to sphingosine which can then be incorporated into sphingomyelin. 10859351 ENSG00000126821 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T G 14 64235556 14 63768838 rs7157785 HMDB0012097 Sphingolipid levels (SM 14:0Mol%) sphingomyelin 14∶0 molar percentage EUR GCST000568 217.046 GCST000568 20081858 expert curated High Eric Fauman G6PC2 encodes a pancreas-specific glucose-6-phosphatase. This enzyme influences the fasting glucose set point for basal insulin secretion. 23274894 ENSG00000152254 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 2 169763148 2 168906638 rs560887 HMDB0000122 Fasting glucose-related traits (FPG) D-Glucose EUR GCST000697 108.699 GCST000697 20541252 expert curated High Eric Fauman GC encodes the vitamin D binding protein which transports multiple forms of vitamin D 00049052 ENSG00000145321 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G T 4 72608383 4 71742666 rs2282679 HMDB0001438 Vitamin D insufficiency 25-Hydroxyvitamin D2 EUR GCST000697 19.523 GCST000697 20541252 expert curated High Eric Fauman CYP2R1 encodes the vitamin D 25-hydroxylase which produces the detected metabolite. 12867411 ENSG00000186104 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 11 14914878 11 14893332 rs10741657 HMDB0001438 Vitamin D insufficiency 25-Hydroxyvitamin D2 EUR GCST000697 26.699 GCST000697 20541252 expert curated High Eric Fauman DHCR7 encodes 7-dehydrocholesterol reductase, which acts on 7-dehydrocholesterol, a precursor of vitamin D. 10807690 ENSG00000172893 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T G 11 71167449 11 71456403 rs12785878 HMDB0001438 Vitamin D insufficiency 25-Hydroxyvitamin D2 EUR GCST000703 27.0 GCST000703 20558539 expert curated High Eric Fauman ALPL encodes the liver alkaline phosphatase. Loss of function of alkaline phosphatase causes hypophosphatasia. 03174660 ENSG00000162551 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 1 21823292 1 21496799 rs1697421 HMDB0001315 Phosphorus levels Phosphorus EUR GCST000703 8.398 GCST000703 20558539 expert curated High Eric Fauman FGF23 encodes a fibroblast growth factor which regulates phosphate levels through multiple mechanisms, including regulation of levels of kidney phosphate transporters 15863037 ENSG00000118972 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A T 12 4606168 12 4497002 rs2970818 HMDB0001315 Phosphorus levels Phosphorus EUR GCST000756 35.699 GCST000756 20700443 expert curated High Eric Fauman MUC1 encodes a mucin protein which forms a mucosal layer in intestines and kidney and may regulate absorption of magnesium 01983814 ENSG00000185499 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 1 155162067 1 155192276 rs4072037 HMDB0000547 Magnesium levels Magneseium EUR GCST000756 14.097 GCST000756 20700443 expert curated High Eric Fauman TRPM6 encodes a cation transporter with demonstrated activity toward magnesium. 14576148 ENSG00000119121 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 9 77499796 9 74884880 rs11144134 HMDB0000547 Magnesium levels Magnesium EUR GCST000925 17.523 GCST000925_3 21203500 expert curated High Eric Fauman FUT8 encodes a fucosyltransferase that catalyzes the transfer of fucose to complex glycopeptides. 00985526 ENSG00000033170 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 14 65758642 14 65291924 rs7159888 EFO_0004999 N-glycan levels (DG1) N-glycan measurement EUR GCST001049 51.222 GCST001049 21502573 expert curated High Eric Fauman F3 encodes coagulation factor 3, also known as tissue factor, which is involved in the initiation of the clotting cascade, which eventually results in the production of fibrin. The D-dimer metabolite is a degredation product of fibrin clots. 12223078 ENSG00000117525 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G T 1 95053353 1 94587797 rs12029080 EFO_0004507 D-dimer levels D dimer measurement EUR GCST001049 13.699 GCST001049 21502573 expert curated High Eric Fauman F5 encodes coagulation factor 5, an essential element of the clotting cascade, which eventually results in the production of fibrin. The D-dimer metabolite is a degredation product of fibrin clots. 25231258 ENSG00000198734 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C A 1 169477574 1 169508336 rs6687813 EFO_0004507 D-dimer levels D dimer measurement EUR GCST001142 10.0 GCST001142 21729881 expert curated High Eric Fauman CYP4F2 encodes a cytochrome P450 with a special role in the production of Vitamin E 11997390 ENSG00000186115 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 19 15990431 19 15879621 rs2108622 HMDB0001893 Vitamin E levels Alpha-Tocopherol EUR GCST001179 43.0 GCST001179 21829377 expert curated High Eric Fauman ELOVL2 encodes a long chain fatty acid elongase. The coenzyme A derivative of DPA (22:5n3) is both a product and a substrate for the enzyme. 12371743 ENSG00000197977 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 6 10982973 6 10982740 rs3734398 HMDB0006528 Phospholipid levels (plasma) (DPA) Docosapentaenoic acid EUR GCST001216 14.155 GCST001216 21878437 expert curated High Eric Fauman RBP4 encodes a retinol-binding protein that transports retinol in the blood. 02444024 ENSG00000138207 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 10 95348182 10 93588425 rs10882272 HMDB0000305 Retinol levels Vitamin A EUR GCST001216 13.222 GCST001216 21878437 expert curated High Eric Fauman TTR encodes a thyroid hormone-binding protein which transports thryroxine and retinol. 04607556 ENSG00000118271 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C A 18 29187279 18 31607316 rs1667255 HMDB0000305 Retinol levels Vitamin A EUR GCST001217 14.301 GCST001217_23 21886157 expert curated|expert curated High|High Eric Fauman|Eric Fauman AHR encodes the aromatic hydrocarbon receptor, a transcription factor which activates CYP1A1 and CYP1A2. These enzymes metabolize caffeine.|AHR encodes the aromatic hydrocarbon receptor, a transcription factor which activates CYP1A1 and CYP1A2. These enzymes metabolize caffeine. 10605936|08095225 ENSG00000106546 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 7 17309279 7 17269655 rs12670403 HMDB0001847|HMDB0003072 Metabolic traits (caffeine/quinate + 3 other traits) Caffeine / Quinic acid EUR GCST001217 12.155 GCST001217_30 21886157 expert curated High Eric Fauman NT5E encodes the ecto-5'-nucleotidase which can generate inosine 06271180 ENSG00000135318 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 6 86117129 6 85407411 rs494562 HMDB0000195 Metabolic traits (inosine + 1 other trait) Inosine EUR GCST001264 41.0 GCST001264_2 21998597 expert curated High Eric Fauman SHBG encodes the sex-hormone binding globulin which binds which binds to and transports testosterone. 07626508 ENSG00000129214 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T G 17 7521915 17 7618597 rs12150660 HMDB0000234 Testosterone levels (Testosterone) Testosterone EUR GCST001391 21.523 GCST001391_3 22286219 expert curated High Eric Fauman SLC1A4 encodes a neutral amino acid transporter with demonstrated activity for alanine, serine, cysteine and threonine. 2-aminobutyrate is structurally similar to these amino acids. 07896285 ENSG00000115902 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 2 65220910 2 64993776 rs2160387 HMDB0000161|HMDB0000883 Metabolite levels (Ala, Val) L-Alanine / L-Valine EUR GCST001391 16.699 GCST001391_10 22286219 expert curated High Eric Fauman TAT encodes tyrosine aminotransferase which converts tyrosine to 4-hydroxyphenylpyruvate. Enzyme deficiency in this enzyme causes tyrosine build up. 01973834 ENSG00000198650 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T A 16 71634811 16 71600908 rs4788815 HMDB0000159|HMDB0000158 Metabolite levels (Phe, Tyr) L-Phenylalanine / L-Tyrosine EUR GCST001392 11.097 GCST001392_5 22286219 expert curated High Eric Fauman CPT1A encodes a carnitine O-palmitoyltransferase which acts the CoA version of the free fatty acid metabolite detected here 01865762 ENSG00000110090 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 11 68562328 11 68794860 rs2229738 HMDB0000673 Lipid metabolism phenotypes (LA/PUFA) Linoleic acid EUR GCST001414 9.097 GCST001414_2 22359512 expert curated High Eric Fauman AGPAT1 encodes 1-acyl-sn-glycerol-3-phosphate acyltransferase alpha, an enzyme which produces phosphatidic acid. 17707131 ENSG00000204310 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G T 6 32136547 6 32168770 rs1061808 HMDB0008031|HMDB0008003 Phospholipid levels (plasma) (proportions (PC 32∶0/PC 34∶1)) similar to Phosphatidylcholine(18:0/14:0)|Phosphatidylcholine(16:1/18:0) EUR GCST001413 18.699 GCST001413 22359512 expert curated High Eric Fauman ATP10D encodes a phospholipid flippase. Closely related gene family members have demonstrated activity versus phosphatidylcholine. 25947375 ENSG00000145246 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G T 4 47551863 4 47549846 rs13106975 EFO_0004622 Sphingolipid levels (levels) sphingolipid measurement SAS GCST001421 8.523 GCST001421 22383894 expert curated High Eric Fauman AS3MT encodes arsenite methyltransferase which acts on methylarsonite to produce dimethylarsinate (also known as cacodylate) 20621156 ENSG00000214435 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 10 104623578 10 102863821 rs9527 HMDB0011625 Arsenic metabolism (DMA%) Dimethylarsinate EAS GCST001608 62.523 GCST001608 22797727 expert curated|expert curated High|High Eric Fauman|Eric Fauman SLC22A12 encodes the URAT1 transporter, a kidney urate reuptake transporter. The nearby gene SLC22A11 encodes the hOAT4 transporter which primarily transports steroid molecules and has only very weak affinity for urea.|SLC22A12 encodes the URAT1 transporter, a kidney urate reuptake transporter. The nearby gene SLC22A11 encodes the hOAT4 transporter which primarily transports steroid molecules and has only very weak affinity for urea. 12024214|27105641 ENSG00000197891 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A T 11 64464085 11 64696613 rs504915 HMDB0000294 Renal function-related traits (urea) Urea EAS GCST001608 17.155 GCST001608 22797727 expert curated High Eric Fauman SLC14A2 encodes a urea transporter expressed in kidney. 11502588 ENSG00000132874 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 18 43187130 18 45607165 rs7227483 HMDB0000294 Renal function-related traits (BUN) Urea EUR 17.068 22885924 expert curated High Eric Fauman SLC2A2 encodes a glucose transporter (GLUT2) 02479026 ENSG00000163581 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 3 170713290 3 170995501 rs1280 HMDB0000122 MAGIC Fasting Glucose GWAS/Metabochip 2012 D-Glucose EUR 7.757 22885924 expert curated High Eric Fauman IGF2BP2 encodes a protein which binds insulin-like growth factor 2 mRNA. 09891060 ENSG00000073792 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 3 185513392 3 185795604 rs7651090 HMDB0000122 MAGIC Fasting Glucose GWAS/Metabochip 2012 D-Glucose EUR 14.991 22885924 expert curated High Eric Fauman PCSK1 encodes a protease which is involved in maturation of insulin 01843283 ENSG00000175426 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 5 95539448 5 96203744 rs4869272 HMDB0000122 MAGIC Fasting Glucose GWAS/Metabochip 2012 D-Glucose EUR 98.541 22885924 expert curated High Eric Fauman GCK encodes glucokinase which directly phosphorylates glucose and thus contributes to glucose homeostasis 01871135 ENSG00000106633 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 7 44231886 7 44192287 rs6975024 HMDB0000122 MAGIC Fasting Glucose GWAS/Metabochip 2012 D-Glucose EUR 214.971 22885924 expert curated High Eric Fauman MTNR1B encodes a melatonin receptor. Melatonin stimulates glucose uptake. 16842543 ENSG00000134640 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G C 11 92708710 11 92975544 rs10830963 HMDB0000122 MAGIC Fasting Glucose GWAS/Metabochip 2012 D-Glucose EUR 14.876 22885924 expert curated|expert curated High|High Eric Fauman|Eric Fauman PDX1 encodes a pancreas-specific transcription factor which induces expression of insulin and SLC2A2 (GLUT2) which each influence glucose levels|PDX1 encodes a pancreas-specific transcription factor which induces expression of insulin and SLC2A2 (GLUT2) which each influence glucose levels 07901001|08923459 ENSG00000139515 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 13 28487599 13 27913462 rs11619319 HMDB0000122 MAGIC Fasting Glucose GWAS/Metabochip 2012 D-Glucose EUR GCST001791 29.0 GCST001791 23263486 expert curated High Eric Fauman PDZK1 encodes a protein that binds to and regulates the activity of URAT1 (encoded by SLC22A12), which is a urate transporter. 15304510 ENSG00000174827 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C A 1 145723739 1 145711327 rs1471633 HMDB0000289 Urate levels Uric acid EUR GCST001791 700.0 GCST001791 23263486 expert curated High Eric Fauman SLC2A9 encodes a urate transporter. 18327257 ENSG00000109667 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 4 9944052 4 9942428 rs12498742 HMDB0000289 Urate levels Uric acid EUR GCST001791 134.0 GCST001791 23263486 expert curated High Eric Fauman ABCG2 encodes a urate transporter. 19506252 ENSG00000118777 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T G 4 89052323 4 88131171 rs2231142 HMDB0000289 Urate levels Uric acid EUR GCST001840 8.523 GCST001840 23362303 expert curated High Eric Fauman LPGAT1 encodes a lysophosphatidylglycerol acyltransferase which transfers long-chain acyl-CoAs to lysophosphatidylglycerol with a demonstrated preference for stearoyl-CoA. 15485873 ENSG00000123684 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A T 1 211918244 1 211744902 rs11119805 HMDB0000827 Stearic acid (18:0) plasma levels Stearic acid EUR GCST001856 31.097 GCST001856_4 23408906 expert curated High Eric Fauman DIO1 encodes an iodothyronine deiodinase which deiodinates of thyroxine (T4) to produce the biologically active hormone T3 01400883 ENSG00000211452 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 1 54375570 1 53909897 rs2235544 HMDB0000248 Thyroid hormone levels (FT4: free thyroxine) Thyroxine EUR GCST001856 10.699 GCST001856_4 23408906 expert curated High Eric Fauman FOXE1 encodes a transcription factor expressed specifically in thyroid gland, the source of the thyroxine (FT4 thyroid hormone) 09214635 ENSG00000178919 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 9 100591463 9 97829181 rs7045138 HMDB0000248 Thyroid hormone levels (FT4: free thyroxine) Thyroxine EUR GCST001856 13.699 GCST001856_4 23408906 expert curated High Eric Fauman LHX3 encodes pituitary-specific transcription factor which is critical for pituitary gland development. The pituitary gland produces thyroid stimulating hormone which directs the thyroid gland to produce thyroxine (T4). 08638120 ENSG00000107187 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 9 139089679 9 136197833 rs7860634 HMDB0000248 Thyroid hormone levels (FT4: free thyroxine) Thyroxine AFR|EAS|EUR|ZZ1 GCST001914 7.523 GCST001914 23518928 expert curated High Eric Fauman TSPYL5 induces CYP19A1 expression, which in turn encodes a key enzyme involved in the biosynthesis of estradiol. 23518928 ENSG00000180543 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 8 98282189 8 97269961 rs1864729 HMDB0000151 Estradiol plasma levels (breast cancer) Estradiol EUR GCST002041 19.523 GCST002041 23720494 expert curated High Eric Fauman SELENBP1 encodes a selenium-binding protein. The Arabidopsis ortholog (61% identity) has been shown to bind copper. 25274629 ENSG00000143416 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G T 1 151344741 1 151372265 rs2769264 HMDB0000657 Blood trace element (Cu levels) Copper ASW GCST002043 9.222 GCST002043 23726366 expert curated High Eric Fauman CD36 encodes a platelet glycoprotein which binds HDL 09867808 ENSG00000135218 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 7 80340622 7 80711306 rs2366858 EFO_0004612 HDL cholesterol (AA) high density lipoprotein cholesterol measurement EUR 32.18 23823483 expert curated High Eric Fauman DMGDH encodes dimethylglycine dehydrogenase which takes dimethlyglycine as a substrate. Enzyme deficiency results in excess dimethlyglycine. 10102904 ENSG00000132837 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 5 78330227 5 79034404 rs248386 HMDB0000092 Dimethlyglycine Dimethlyglycine EUR 9.854 23823483 expert curated High Eric Fauman AGA encodes the enzyme aspartylglucosaminidase which generates asparagine from N-acetylglucosamines. Deficiency results in an accumulation of asparagine-linked glycopeptides. 01281977 ENSG00000038002 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 4 178361051 4 177439897 rs4690522 HMDB0000168 Asparagine L-Asparagine EUR 9.119 23823483 expert curated High Eric Fauman UMPS encodes uridine monophosphate synthetase, the enzyme which converts orotic acid to uridine. Enzyme deficiency results in accumulation of orotic acid. 06893554 ENSG00000114491 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 3 124451064 3 124732217 rs9844948 HMDB0000226 Orotic acid Orotic acid EUR 19.886 23823483 expert curated High Eric Fauman SERPINA7 encodes the thyroxine-binding globulin protein. 03094014 ENSG00000123561 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A X 105276609 X 106032618 rs7883218 HMDB0000248 Thyroxine Thyroxine EUR GCST002087 103.398 GCST002087 23824729 expert curated High Eric Fauman MTHFR encodes methylenetetrahydrolate reductase, an enzyme that catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is the methyl donor in the conversion of homocysteine to methionine. Defects in MTHFR lead to homocysteinuria. 05057914 ENSG00000177000 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 1 11856378 1 11796321 rs1801133 HMDB0000742 Homocysteine levels Homocysteine EUR GCST002087 8.699 GCST002087 23824729 expert curated High Eric Fauman MMACHC encodes a cobalamin-binding protein. Defects in MMACHC are a known cause of homocystinuria. 16311595 ENSG00000132763 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 1 45978675 1 45513003 rs4660306 HMDB0000742 Homocysteine levels Homocysteine EUR GCST002087 9.699 GCST002087 23824729 expert curated High Eric Fauman MTR encodes 5-methyltetrahydrofolate-homocysteine methyltransferase. The enzyme acts on homocysteine to produce methionine 02407589 ENSG00000116984 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T G 1 237048676 1 236885376 rs2275565 HMDB0000742 Homocysteine levels Homocysteine EUR GCST002087 9.699 GCST002087 23824729 expert curated High Eric Fauman MUT is a cobalamin-dependent enzyme. Cobalamin is also needed in a reaction taking the homocysteine as a substrate 07901104 ENSG00000146085 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 6 49382193 6 49414480 rs9369898 HMDB0000742 Homocysteine levels Homocysteine EUR GCST002087 19.699 GCST002087 23824729 expert curated High Eric Fauman FOLH1B encodes a liver-enriched polyglutamylfolate hydrolase which will influence folate availability for the conversion of homocysteine to methionine 09816319 ENSG00000134612 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 11 89148372 11 89415204 rs7130284 HMDB0000742 Homocysteine levels Homocysteine EUR GCST002087 42.699 GCST002087 23824729 expert curated High Eric Fauman DPEP1 encodes a dipeptidase that acts on glutathione, which is a downstream product of homocysteine metabolism. Glutathione and homocysteine levels have been shown to be negatively correlated. 06122685 ENSG00000015413 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 16 89708096 16 89641688 rs154657 HMDB0000742 Homocysteine levels Homocysteine EUR GCST002196 45.0 GCST002196 24047826 expert curated High Eric Fauman GATM encodes glycine amidinotransferase. This enzyme produces the Homoarginine when using lysine as a substrate. 23010440 ENSG00000171766 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 15 45652703 15 45360505 rs1153858 HMDB0000670 Homoarginine levels Homo-L-arginine EAS GCST002195 30.155 GCST002195_2 24049095 expert curated High Eric Fauman CYP19A1 encodes aromatase which produces estradiol (the measured analyte) from testosterone. 04153532 ENSG00000137869 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 15 51524292 15 51232095 rs2414095 HMDB0000151 Hormone measurements (Oestradiol) Estradiol EUR GCST002201 10.097 GCST002201 24068962 expert curated High Eric Fauman TRPM8 encodes a calcium-permeable channel activated by menthol and cold. 11882888 ENSG00000144481 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G C 2 234264848 2 233356202 rs1550532 HMDB0000464 Calcium levels Calcium EUR GCST002201 85.046 GCST002201 24068962 expert curated High Eric Fauman CASR encodes the calcium sensing receptor, a GPCR which binds calcium and regulates parathyroid hormone secretion which in turn regulates circulating levels of calcium. 11013439 ENSG00000036828 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T G 3 122003757 3 122284910 rs1801725 HMDB0000464 Calcium levels Calcium EUR GCST002201 8.097 GCST002201 24068962 expert curated High Eric Fauman GUSB encodes a glucuronidase which induces the opening of the calcium-specific kidney-specific channel, TRPV5. 18495742 ENSG00000169919 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 7 65271197 7 65806210 rs17711722 HMDB0000464 Calcium levels Calcium EUR GCST002201 11.046 GCST002201 24068962 expert curated High Eric Fauman CYP24A1 encodes the 1,25-dihydroxyvitamin D(3) 24-hydroxylase which produces the biologically active form of vitamin D, which regulates calcium levels. 09333115 ENSG00000019186 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 20 52774427 20 54157888 rs1570669 HMDB0000464 Calcium levels Calcium AFR|EAS|EUR|SAS GCST002221 27.153 GCST002221 24097068 expert curated High Eric Fauman IRF2BP2 encodes a protein which binds to the interferon regulatory factor 2 transcription factor. This transcription factor is essential for the activation of the ABCA1 cholesterol transporter. 26195219 ENSG00000168264 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 1 234853406 1 234717659 rs558971 HMDB0000067 Total Cholesterol Cholesterol EUR GCST002221 11.398 GCST002221 24097068 expert curated High Eric Fauman ABCB11 encodes a transporter for taurocholate, a bile acid derived from cholesterol 01862084 ENSG00000073734 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 2 169830155 2 168973645 rs2287623 HMDB0000067 Cholesterol, total Cholesterol AFR|EAS|EUR|SAS GCST002221 16.075 GCST002221 24097068 expert curated High Eric Fauman PPARG encodes a transcription factor that upreguates ABCA1 among other proteins involved in lipid metabolism. 11135616 ENSG00000132170 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 3 12267648 3 12226148 rs7616006 HMDB0000067 Total Cholesterol Cholesterol AFR|EAS|EUR|SAS GCST002221 16.141 GCST002221 24097068 expert curated High Eric Fauman LPA encodes the lipoprotein(a) protein, a constituent of the lipoprotein(a) particle, a carrier of cholesterol. 24977982 ENSG00000198670 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 6 161010118 6 160589086 rs10455872 HMDB0000067 Total Cholesterol Cholesterol AFR|EAS|EUR|SAS GCST002221 22.952 GCST002221 24097068 expert curated|expert curated High|High Eric Fauman|Eric Fauman CYP7A1 encodes a cytochrome P450 which is the rate limiting step in the conversion of cholesterol to bile acids. CYP7A1 deficiency results in excess cholesterol.|CYP7A1 encodes a cytochrome P450 which is the rate limiting step in the conversion of cholesterol to bile acids. CYP7A1 deficiency results in excess cholesterol. 02993784|12093894 ENSG00000167910 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 8 59393273 8 58480714 rs4738684 HMDB0000067 Total Cholesterol Cholesterol AFR|EAS|EUR|SAS GCST002221 9.176 GCST002221 24097068 expert curated High Eric Fauman VLDLR encodes the very low density lipoprotein receptor 08294473 ENSG00000147852 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 9 2640759 9 2640759 rs3780181 HMDB0000067 Total Cholesterol Cholesterol AFR|EAS|EUR|SAS GCST002221 8.006 GCST002221 24097068 expert curated High Eric Fauman PPARA encodes a transcription factor which regulates expression of HDL apolipoproteins 09808609 ENSG00000186951 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 22 46627603 22 46231706 rs4253772 HMDB0000067 Total Cholesterol Cholesterol AFR|EAS|EUR|SAS GCST002223 7.744 GCST002223 24097068 expert curated High Eric Fauman NAXE (formerly APOA1BP) encodes an APOA1 binding protein which promotes cholesterol efflux into high density lipoprotein (HDL) particles. 23719382 ENSG00000163382 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G T 1 156700651 1 156730859 rs12145743 EFO_0004612 HDL Cholesterol high density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002223 40.454 GCST002223 24097068 expert curated High Eric Fauman GALNT2 encodes an acetylgalactosaminyltransferase which glycosylates the APOC3 protein, which in turn inhibits the lipoprotein lipase (LPL) enzyme which hydrolyzes triglycerides from triglyceride-containing lipoproteins, leading to the generation of HDL 22152306 ENSG00000143641 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 1 230295691 1 230159944 rs4846914 EFO_0004612 HDL Cholesterol high density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002223 8.663 GCST002223 24097068 expert curated High Eric Fauman GPIHBP1 encodes the glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1, a receptor for the HDL. 12496272 ENSG00000182851 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 8 144303418 8 143221248 rs10087900 EFO_0004612 HDL Cholesterol high density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002223 64.825 GCST002223 24097068 expert curated High Eric Fauman ABCA1 encodes a cholesterol transporter. Deficiency results in reduced HDL. 10431237 ENSG00000165029 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 9 107664301 9 104902020 rs1883025 EFO_0004612 HDL Cholesterol high density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002223 37.481 GCST002223 24097068 expert curated High Eric Fauman NR1H3 encodes the LXR-alpha nuclear hormone receptor. This transcription factor upreguates ABCA1, a cholesterol transporter with a direct impact on HDL levels. 11090131 ENSG00000025434 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 11 47333685 11 47312134 rs3847502 EFO_0004612 HDL Cholesterol high density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002223 7.951 GCST002223 24097068 expert curated High Eric Fauman DGAT2 encodes a diacylglycerol O-acyltransferase which produces triglycerides from diaglycerides. 11481335 ENSG00000062282 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 11 75455021 11 75743976 rs499974 EFO_0004612 HDL Cholesterol high density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002223 19.604 GCST002223 24097068 expert curated High Eric Fauman MVK encodes mevalonate kinase which synthesizes a precursor to cholesterol. 02153681 ENSG00000110921 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 12 109950144 12 109512339 rs2241210 EFO_0004612 HDL Cholesterol high density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002223 32.135 GCST002223 24097068 expert curated High Eric Fauman SCARB1 encodes a scavanger receptor which can act as an HDL receptor. 08560269 ENSG00000073060 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 12 125259888 12 124775342 rs838876 EFO_0004612 HDL Cholesterol high density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002223 8.019 GCST002223 24097068 expert curated High Eric Fauman AKT1 encodes a protein kinase which activates SREBP which induces transcription of enzymes involved in cholesterol biosynthesis. 16007182 ENSG00000142208 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 14 105277209 14 104810872 rs4983559 EFO_0004612 HDL Cholesterol high density lipoprotein cholesterol measurement EUR GCST002223 188.0 GCST002223 24097068 expert curated High Eric Fauman LIPC encodes hepatic triglyceride lipase which hydrolyses triglycerides. The enzyme plays a key role in regulating levels of HDL. 07417375 ENSG00000166035 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 15 58683366 15 58391167 rs1532085 EFO_0004612 HDL cholesterol high density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002223 801.939 GCST002223 24097068 expert curated High Eric Fauman CETP encodes the cholesterol ester transfer protein which acts on high density lipoprotein (HDL). Deficiency of this enzyme results in increased HDL. 02586614 ENSG00000087237 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 16 56989590 16 56955678 rs247616 EFO_0004612 HDL Cholesterol high density lipoprotein cholesterol measurement EUR GCST002223 53.097 GCST002223 24097068 expert curated High Eric Fauman LCAT encodes lecithin-cholesterol acyltransferase which travels with HDL, esterifying cholesterol to cholesterol ester for incorporation into the HDL particles for transport back to the liver. 04868699 ENSG00000213398 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 16 67928042 16 67894139 rs16942887 EFO_0004612 HDL cholesterol high density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002223 19.264 GCST002223 24097068 expert curated High Eric Fauman STARD3 encodes the StAR-related lipid transfer protein 3 which promotes export of cholesterol to HDL 25014273 ENSG00000131748 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL GT G 17 37821435 17 39665182 rs113612868 EFO_0004612 HDL Cholesterol high density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002223 65.746 GCST002223 24097068 expert curated High Eric Fauman LIPG encodes endothelial lipase which acts on HDL. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo 12569161 ENSG00000101670 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 18 47167214 18 49640844 rs4939883 EFO_0004612 HDL Cholesterol high density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002223 33.785 GCST002223 24097068 expert curated High Eric Fauman HNF4A drives expression of many cholesterol related genes including HMGCR 21071704 ENSG00000101076 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 20 43042364 20 44413724 rs1800961 EFO_0004612 HDL Cholesterol high density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002222 16.519 GCST002222 24097068 expert curated High Eric Fauman LDLRAP1 encodes an adapter protein which binds to the LDL receptor. Mutations in this gene cause a form of familial hypercholesterolemia. 15166224 ENSG00000157978 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 1 25768937 1 25442446 rs10903129 EFO_0004611 LDL Cholesterol low density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002222 142.067 GCST002222 24097068 expert curated High Eric Fauman PCSK9 encodes a protein that binds to the LDLR receptor, promoting its degradation and thus influencing circulating LDL cholesterol levels. Rare gain of function mutations result in greatly elevated LDL cholesterol levels. 12730697 ENSG00000169174 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T G 1 55505647 1 55039974 rs11591147 EFO_0004611 LDL Cholesterol low density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002222 271.788 GCST002222 24097068 expert curated High Eric Fauman SORT1 encodes sortilin, a receptor with a role in VLDL secretion from the liver 20686566 ENSG00000134243 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 1 109818530 1 109275908 rs646776 EFO_0004611 LDL Cholesterol low density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002222 182.023 GCST002222 24097068 expert curated High Eric Fauman APOB encodes apolipoprotein B, a major component of LDL particles. Defects in APOB can lead to familial hypercholesterolemia. 00052771 ENSG00000084674 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 2 21263900 2 21041028 rs1367117 EFO_0004611 LDL Cholesterol low density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002222 11.77 GCST002222 24097068 expert curated High Eric Fauman INSIG2 encodes a protein that plays a key role in regulating the SREBP cleavage-activating protein (SCAP), thus providing a means for feedback regulation of cholesterol synthesis over a wide range of sterol concentrations. 12242332 ENSG00000125629 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 2 118835841 2 118078265 rs10490626 EFO_0004611 LDL Cholesterol low density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002222 77.108 GCST002222 24097068 expert curated High Eric Fauman HMGCR encodes HMG-CoA reductase, the rate-limiting enzyme for cholesterol biosynthesis 01967820 ENSG00000113161 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 5 74656539 5 75360714 rs12916 EFO_0004611 LDL Cholesterol low density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002222 16.68 GCST002222 24097068 expert curated High Eric Fauman MYLIP encodes an E3 ubiquitin ligase which ubiquitinates the low density lipoprotein receptor (LDLR), which promotes the degradation of LDLR, influencing the circulating levels of LDL-cholesterol. 19520913 ENSG00000007944 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 6 16127407 6 16127176 rs3757354 EFO_0004611 LDL Cholesterol low density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002222 20.716 GCST002222 24097068 expert curated High Eric Fauman NPC1L1 encodes a transporter for cholesterol in the intestine. 14976318 ENSG00000015520 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 7 44582331 7 44542732 rs2073547 EFO_0004611 LDL Cholesterol low density lipoprotein cholesterol measurement EUR GCST002222 40.398 GCST002222 24097068 expert curated High Eric Fauman HP encodes haptoglobin which binds to ApoA-I, the primary protein component of HDL. 23420675 ENSG00000257017 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 16 72108093 16 72074194 rs2000999 EFO_0004611 LDL cholesterol low density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002222 11.008 GCST002222 24097068 expert curated High Eric Fauman ApoH increases the enzymic activity of lipoprotein lipase (LPL) in the presence of apoC-II by 45.7 percent [ 7417307]. a small molecule inhibitor of PKC alpha, HBDDE, show minimal inhibition of cholesterol accumulation while a small molecule inhibitor of PKC beta, LY333513, could completely account for the inhibition of cholesterol accumulation by the classical group PKC isoenzyme [16930534] 07417307 ENSG00000091583 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C A 17 64210580 17 66214462 rs1801689 EFO_0004611 LDL Cholesterol low density lipoprotein cholesterol measurement AFR|EAS|EUR|SAS GCST002222 261.415 GCST002222 24097068 expert curated High Eric Fauman LDLR encodes the LDL receptor. 00226968 ENSG00000130164 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T G 19 11202306 19 11091630 rs6511720 EFO_0004611 LDL Cholesterol low density lipoprotein cholesterol measurement Caucasian GCST002219 81.456 GCST002219 24097068 expert curated High Eric Fauman ANGPTL3 encodes a protein that regulates triglyceride clearance by reducing the activity of lipoprotein lipase (LPL). 22063269 ENSG00000132855 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 1 63133930 1 62668259 rs4587594 EFO_0004530 Triglycerides triglyceride measurement Caucasian GCST002219 11.795 GCST002219 24097068 expert curated High Eric Fauman LRPAP1 encodes a protein which binds the LDL-receptor-related protein and the VLDL receptor affecting distribution of lipoprotein particles. 07538675 ENSG00000163956 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 4 3473139 4 3471412 rs6831256 EFO_0004530 Triglycerides triglyceride measurement Caucasian GCST002219 7.676 GCST002219 24097068 expert curated High Eric Fauman CAV1 encodes caveolin-1, a scaffolding protein. Very rare CAV1 frameshift mutations appear to be associated with atypical lipodystrophy and hypertriglyceridemia. 18237401 ENSG00000105974 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 7 116358044 7 116717990 rs38855 EFO_0004530 Triglycerides triglyceride measurement Caucasian GCST002219 198.74 GCST002219 24097068 expert curated High Eric Fauman LPL encodes the lipoprotein lipase which hydrolyzes triglycerides. LPL deficiency results in accumulation of triglycerides. 13712364 ENSG00000175445 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 8 19844222 8 19986711 rs12678919 EFO_0004530 Triglycerides triglyceride measurement Caucasian GCST002219 112.652 GCST002219 24097068 expert curated High Eric Fauman TRIB1 regulates hepatic lipogenesis. 26517927 ENSG00000173334 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 8 126482621 8 125470379 rs2954022 EFO_0004530 Triglycerides triglyceride measurement EUR GCST002242 40.0 GCST002242 24159190 expert curated High Eric Fauman DDAH1 encodes dimethylarginine dimethylaminohydrolase which acts directly on dimethylarginine. 07608105 ENSG00000153904 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 1 85797110 1 85331427 rs28489187 HMDB0001539 Serum dimethylarginine levels (asymmetric) Asymmetric dimethylarginine EUR 36.538 24507774 expert curated High Eric Fauman ANGPTL4 regulates TG clearance by reducing the activity of LPL 16081640 ENSG00000167772 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 19 8429323 19 8364439 rs116843064 EFO_0004530 Triglycerides triglyceride measurement EUR GCST002549 15.699 GCST002549_7 24528284 expert curated High Eric Fauman CYP2C19 encodes a cytochrome P450 which acts on xenobiotics including the selective serotonin reuptake inhibitor citalopram. 08451774 ENSG00000165841 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 10 96681846 10 94922089 rs1074145 HMDB0060576|HMDB0005038 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) (S-DCT/S-CT ratio) Desmethylcitalopram / Citalopram EUR GCST002549 15.699 GCST002549_8 24528284 expert curated High Eric Fauman CYP2D6 encodes a cytochrome P450 which acts on many xenobiotics including the conversion of desmethylcitalopram to didesmethylcitalopram (DDCT) 08451774 ENSG00000100197 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 22 42526694 22 42130692 rs1065852 HMDB0060472 Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels) (S-DDCT concentration) Didemethylcitalopram AMR|EUR GCST002364 35.523 GCST002364_35 24586186 expert curated High Eric Fauman FUT2 encodes a galactoside 2-alpha-L-fucosyltransferase, which adds fucose moeities to various proteins. 07876235 ENSG00000176920 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 19 49228272 19 48725015 rs2287921 HMDB0000174 Urinary metabolites (H-NMR features) (5.2125, Fucose) L-Fucose AMR|EUR GCST002364 33.0 GCST002364_9 24586186 expert curated High Eric Fauman SLC7A9 encodes an amino acid transporter which can transport a range of amino acids including lysine 24107421 ENSG00000021488 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 19 33364628 19 32873722 rs8101881 HMDB0000182 Urinary metabolites (H-NMR features) (1.7325, Lysine) L-Lysine ASW GCST002388 15.046 GCST002388_14 24625756 expert curated High Eric Fauman ACY3 encodes an aminoacylase which preferentially deacetylates N-acetylaromatic amino acids including N-acetyl-L-phenylalanine. 14656720 ENSG00000132744 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 11 67421341 11 67653870 rs12288023 HMDB0000512 Serum metabolite levels (N-acetylphenylalanine) N-Acetyl-L-phenylalanine ASW GCST002388 29.523 GCST002388_18 24625756 expert curated High Eric Fauman TREH encodes trehalase which hydrolyses the disaccharide trehalose. 09427547 ENSG00000118094 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 11 118549582 11 118678873 rs507080 HMDB0000975 Serum metabolite levels (Trehalose) Trehalose AFR|EUR GCST002391 12.155 GCST002391 24651765 expert curated High Eric Fauman ALDH1L1 encodes a multifunctional enzyme which includes 10-formyltetrahydrofolate dehydrogenase activity. The gene thus plays a key role in one carbon metabolism. 07702556 ENSG00000144908 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 3 125906179 3 126187336 rs10934753 HMDB0000742 Plasma homocysteine levels (post-methionine load test) Homocysteine AFR|EUR GCST002391 62.699 GCST002391 24651765 expert curated High Eric Fauman GNMT encodes an enzyme which produces S-adenosylhomocysteine. S-adenosylhomocysteine can be converted to homocysteine by the enzyme S-adenosylhomocysteine hydrolase 10843803 ENSG00000124713 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 6 42925803 6 42958065 rs9296404 HMDB0000742 Plasma homocysteine levels (post-methionine load test) Homocysteine AFR|EUR GCST002391 25.523 GCST002391 24651765 expert curated High Eric Fauman CBS encodes the cystathionine beta-synthase which acts on homocysteine to produce cystathionine 16545978 ENSG00000160200 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 21 44488033 21 43067923 rs234714 HMDB0000742 Plasma homocysteine levels (post-methionine load test) Homocysteine EUR GCST002443 11.0 GCST002443_34 24816252 expert curated High Eric Fauman ADHFE1 encodes the hydroxyacid-oxoacid transhydrogenase which catalyzes the oxidation of 4-hydroxybutanoic acid to 4-oxobutanoic acid, while reducing 2-oxoglutarate to 2-hydroxyglutarate. 16616524 ENSG00000147576 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 8 67360725 8 66448490 rs1030420 HMDB0000337 Blood metabolite levels (X-04499--3,4-dihydroxybutyrate) (S)-3,4-Dihydroxybutyric acid EUR GCST002443 25.222 GCST002442_19 24816252 expert curated High Eric Fauman F12 encodes coagulation factor XII, a protease which activates kallikrein which releases bradykinin from kininogen. 03521732 ENSG00000131187 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 5 176842474 5 177415473 rs2731672 HMDB0004246 Blood metabolite ratios (X-12038/bradykinin, des-arg(9)) / Bradykinin EUR GCST002443 60.0 GCST002443_9 24816252 expert curated High Eric Fauman NAT2 encodes an N-acetyltransferase which can produce methylxanthine as a downstream metabolite of caffeine. 10744128 ENSG00000156006 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 8 18272438 8 18414928 rs4921914 HMDB0010738 Blood metabolite levels (1-methylxanthine) 1-methylxanthine EUR GCST002443 22.699 GCST002443_71 24816252 expert curated|expert curated High|High Eric Fauman|Eric Fauman ALOX12 encodes arachidonate 12-lipoxygenase, which catalyzes the regio-selective addition of oxygen into arachidonic acid, generating 12R-hydroperoxyeicosatetraenoic acid (12R-HPETE). 12R-HPETE is rapidly reduced to the corresponding 12S-hydroxy compound, 12-HETE.|ALOX12 encodes arachidonate 12-lipoxygenase, which catalyzes the regio-selective addition of oxygen into arachidonic acid, generating 12R-hydroperoxyeicosatetraenoic acid (12R-HPETE). 12R-HPETE is rapidly reduced to the corresponding 12S-hydroxy compound, 12-HETE. 04215079|02377602 ENSG00000108839 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G C 17 6915401 17 7012082 rs2271316 HMDB0006111 Blood metabolite levels (X-12441--12-hydroxyeicosatetraenoate (12-HETE)) 12-HETE EUR GCST002443 7.77 GCST002443_2 24816252 expert curated High Eric Fauman PEMT encodes the phosphatidylethanolamine N-methyltransferase which converts phosphatidylethanolamine to phosphatidylcholine. 09370326 ENSG00000133027 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G T 17 17422768 17 17519454 rs748196 HMDB0061699 1-arachidonoylglycerophosphocholine - M33228 2-Arachidonoylglycerophosphocholine EUR GCST002443 11.751 GCST002443_99 24816252 expert curated High Eric Fauman HAO2 encodes a 2-hydroxyacid oxidase which catalyzes the oxidation of L-alpha-hydroxy acids; alpha-hydroxyisovalerate or a related metabolite may be a potential substrate 10777549 ENSG00000116882 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 1 119952776 1 119410153 rs12141041 HMDB0000407 alpha-hydroxyisovalerate - M33937 2-Hydroxy-3-methylbutyric acid EUR GCST002443 30.0 GCST002443_99 24816252 expert curated High Eric Fauman LDHA encodes lactate dehydrogenase. In addition to producing pyruvate from lactate, this enzyme can produce the observed metabolite from the keto acid 3-methyl-2-oxobutanoate 26014429 ENSG00000134333 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 11 18325146 11 18303599 rs2403254 HMDB0000407 Blood metabolite levels (alpha-hydroxyisovalerate) 2-Hydroxy-3-methylbutyric acid EUR GCST002443 10.155 GCST002443_69 24816252 expert curated High Eric Fauman IDO1 and IDO2 encode the two indoleamine 2,3-dioxygenase isozymes. Both enzymes take tryptophan and tryptophan-related metabolites as substrates, but IDO1 is more active [18282734]. IDO1 has known activity against 5-hydroxy-tryptophan [10833386]. Common polymorphisms in IDO2 ablate activity but have no effect on this endpoint [17671174] 10833386 ENSG00000131203 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T A 8 39823145 8 39965626 rs2160860 HMDB0000472 Blood metabolite levels (X-12100--hydroxytryptophan) 5-Hydroxy-L-tryptophan EUR GCST002443 10.699 GCST002443_49 24816252 expert curated High Eric Fauman UGT3A1 encodes a UDP glycosyltransferase. This enzyme has demonstrated activity against the bile acid ursodeoxycholic acid. The metabolite detected here is structurally related to the bile acids. 18981171 ENSG00000145626 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 5 35968000 5 35967898 rs10491431 HMDB0094650 Blood metabolite levels (X-11445--5-alpha-pregnan-3beta,20alpha-disulfate) 5alpha-pregnan-3beta,20alpha-diol disulfate EUR GCST002443 37.398 GCST002443_83 24816252 expert curated High Eric Fauman ECI2 encodes the enoyl-CoA delta isomerase 2, which is known to act on octenoyl-CoA and could possibly act on decenoyl-CoA as well. 10419495 ENSG00000198721 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 6 4146198 6 4145964 rs9392556 HMDB0013205 Blood metabolite levels (X-13435, a 10:1 acylcarnitine) 9-Decenoylcarnitine EUR GCST002443 20.097 GCST002443_70 24816252 expert curated High Eric Fauman GADL1 encodes the glutamate decarboxylase-like protein 1 which produces beta-alanine, a component of the dipeptide carnosine 23038267 ENSG00000144644 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 3 30753573 3 30712081 rs6804368 HMDB0012881 Blood metabolite levels (X-12244--N-acetylcarnosine) Acetylcarnosine EUR GCST002443 37.523 GCST002443_100 24816252 expert curated High Eric Fauman AKR1C4 encodes a 3 alpha-hydroxysteroid dehydrogenase (HSD) isoform, which is expressed in the liver and acts on androsterone. The nearby paralogous gene AKR1C3 is expressed in prostate and mammary gland and the encoded enzyme does not act on androsterone. 15026176 ENSG00000198610 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 10 5256272 10 5214309 rs17134585 HMDB0002759|HMDB0062657 Blood metabolite ratios (androsterone sulfate/epiandrosterone sulfate) Androsterone sulfate / Epiandrosterone Sulfate EUR GCST002443 360.699 GCST002442_26 24816252 expert curated High Eric Fauman FADS1 encodes a delta-5 desaturase, which converts dihomo-linolenate (20:3n6) to arachidonate (20:4n6). 10601301 ENSG00000149485 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G C 11 61571348 11 61803876 rs174548 HMDB0060102|HMDB0002925 Blood metabolite ratios (arachidonate (20:4n6)/dihomo-linolenate (20:3n3 or n6)) Arachidonate / 8,11,14-Eicosatrienoic acid EUR GCST002443 28.699 GCST002442_26 24816252 expert curated High Eric Fauman MBOAT7 encodes a lysophosphatidylinositol acyltransferase that has specificity for arachidonoyl-CoA as an acyl donor. Arachidonate is readily converted to arachidonoyl-CoA. Thus the associated ratio is closely linked to the substrate/product pair for this enzyme. The associated ratio is closely linked to the substrate/product pair for this enzyme. 18094042 ENSG00000125505 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 19 54676433 19 54172738 rs2576452 HMDB0060102|HMDB0061690 Blood metabolite ratios (arachidonate (20:4n6)/1-arachidonoylglycerophosphoinositol) Arachidonate|1-Arachidonoylglycerophosphoinositol EUR GCST002443 37.0 GCST002442_28 24816252 expert curated High Eric Fauman ACE encodes an angiotensin-converting enzyme. This carboxypeptidase can generate aspartylphenylalanine from cholecystokinin-8. 02554881 ENSG00000159640 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 17 61566031 17 63488670 rs4343 HMDB0000706 Blood metabolite ratios (aspartylphenylalanine/X-14450--phenylalanylleucine) Aspartylphenylalanine / EUR GCST002443 19.0 GCST002443_104 24816252 expert curated|expert curated High|High Eric Fauman|Eric Fauman BHMT encodes a betaine-homocysteine methyltransferase which converts betaine to dimethylglycine. Conversely, the homologous enzyme encoded by the nearby BHMT2 gene cannot use betaine.|BHMT encodes a betaine-homocysteine methyltransferase which converts betaine to dimethylglycine. Conversely, the homologous enzyme encoded by the nearby BHMT2 gene cannot use betaine. 06746658|18230605 ENSG00000145692 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 5 78346769 5 79050946 rs16876394 HMDB0000043 Blood metabolite levels (betaine) Betaine EUR GCST002443 12.097 GCST002443_104 24816252 expert curated High Eric Fauman SLC6A12 encodes a sodium- and chloride-dependent betaine transporter. 08198549 ENSG00000111181 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A T 12 320920 12 211754 rs499368 HMDB0000043 Blood metabolite levels (betaine) Betaine EUR GCST002443 12.222 GCST002443_109 24816252 expert curated High Eric Fauman KNG1 includes the coding sequence for the bradykinin peptide. 02989293 ENSG00000113889 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C A 3 186454180 3 186736391 rs5030062 HMDB0004246 Blood metabolite levels (bradykinin, des-arg(9)) Bradykinin EUR GCST002443 47.398 GCST002443_109 24816252 expert curated High Eric Fauman KLKB1 encodes kallikrein, a serine protease which releases bradykinin from kininogen. 08662673 ENSG00000164344 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 4 187174683 4 186253529 rs4253311 HMDB0004246 Blood metabolite levels (bradykinin, des-arg(9)) Bradykinin EUR GCST002443 629.523 GCST002443_110 24816252 expert curated High Eric Fauman ACADS encodes the short chain acyl-CoA dehydrogenase which takes butyrl-CoA as a substrate. Butyryl-CoA and butyrylcarnitine readily interconvert. 03597357 ENSG00000122971 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 12 121160615 12 120722812 rs2066938 HMDB0002013 Blood metabolite levels (butyrylcarnitine) Butyrylcarnitine EUR GCST002443 7.657 GCST002443_25 24816252 expert curated High Eric Fauman CFH encodes complement factor H which binds complement factor 3. The detected analyte is a peptide fragment of complement factor 3. 06219696 ENSG00000000971 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 1 196682346 1 196713216 rs7535263 EFO_0004983 HWESASXX - M32836 C3f, complement C3 derived peptide EUR GCST002443 11.752 GCST002443_25 24816252 expert curated|expert curated High|High Eric Fauman|Eric Fauman ANPEP encodes Aminopeptidase N, which is a broad specificity aminopeptidase. HWESASXX, a peptide derived from C3 complement is a possible substrate.|ANPEP encodes Aminopeptidase N, which is a broad specificity aminopeptidase. HWESASXX, a peptide derived from C3 complement is a possible substrate. 07957888|09647737 ENSG00000166825 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 15 90345335 15 89802104 rs2007084 EFO_0004983 HWESASXX - M32836 C3f, complement C3 derived peptide EUR GCST002443 10.097 GCST002443_115 24816252 expert curated High Eric Fauman ALDH18A1 encodes delta-1-pyrroline-5-carboxylate synthetase which catalyzes a step in the de novo production of ornithine which is subsequently converted to citrulline. Mutations in ALDH18A1 cause hypocitrullinemia. 11092761 ENSG00000059573 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 10 97395962 10 95636205 rs56322409 HMDB0000904 Blood metabolite levels (citrulline) Citrulline EUR GCST002443 44.0 GCST002442_17 24816252 expert curated High Eric Fauman SRD5A2 encodes the type II steroid 5 alpha-reductase enzyme best known for converting testosterone to dihydrotestosterone. The metabolites represented by the ratio detected here are also steroid molecules differing in reduction at carbon 5. The enzyme has known activity against corticosterone. 07734398 ENSG00000049319 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A T 2 31810974 2 31585905 rs559555 HMDB0010320 Blood metabolite ratios (X-11444/X-12844) (X-11444 is tentatively identified by Metabolon as urocortisol glucuronide or cortolone glucuronide and X-12844 is tentatively identified as tetrahydrocortisone glucuronide) cortolone glucuronide EUR GCST002443 12.699 GCST002443_117 24816252 expert curated High Eric Fauman GGT1 encodes gamma-glutamyltransferase 1 which catalyzes the transfer of the glutamyl moiety of glutathione to a number of different amino acids and can take the analyte reported here (the cysteine-glutathione mixed disulfide) as a substrate. 06130452 ENSG00000100031 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 22 25002081 22 24606114 rs2330809 HMDB0000656 Blood metabolite levels (cysteine-glutathione disulfide) Cysteineglutathione disulfide EUR GCST002443 37.061 GCST002443_118 24816252 expert curated High Eric Fauman ETFDH encodes a mitochondrial electron transfer flavoprotein dehydrogenase which is essential for electron transfer from the short-, medium- and long-chain acyl-CoA dehydrogenases. Mutations in ETFDH lead to multiple acyl-CoA dehydrogenase deficiency, which is characterized by elevated short-, medium- and long-chain acyl carnitines. 17412732 ENSG00000171503 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 4 159630817 4 158709665 rs8396 HMDB0000651 decanoylcarnitine - M33941 Decanoylcarnitine EUR GCST002443 11.699 GCST002443_124 24816252 expert curated High Eric Fauman AKR1A1 encodes an aldehyde reductase which can catalyze the production of erythritol 04402936 ENSG00000117448 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 1 46990681 1 46525009 rs7542172 HMDB0002994 Blood metabolite levels (erythritol) erythritol EUR GCST002443 13.398 GCST002442 24816252 expert curated High Eric Fauman SLC27A2 encodes a very-long-chain acyl-CoA synthetase which activates fatty acids by forming their coenzyme A derivatives. 10198260 ENSG00000140284 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 15 50477138 15 50184941 rs1365505 HMDB0034286 Blood metabolite ratios (10-undecenoate (11:1n1)/X-11438) Ethyl 10-undecenoate / EUR GCST002443 36.046 GCST002442_4 24816252 expert curated High Eric Fauman ABO encodes a glycosyltransferase that determines the blood group. ABO blood group contributes to von Willebrand Factor levels perhaps by protecting it from susceptibility to ADAMTS13-mediated proteolysis. As part of the coagulation cascade, von Willebrand Factor effects rates of fibrinogen cleavage. 17894864 ENSG00000175164 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 9 136154304 9 133278860 rs649129 EFO_0004623 Blood metabolite ratios (ADSGEGDFXAEGGGVR/ADpSGEGDFXAEGGGVR) Fibrinopeptide A EUR GCST002443 27.553 GCST002443_128 24816252 expert curated High Eric Fauman CPT2 encodes carnitine palmitoyltransferase II, which catalyzes the transfer of palmitate and related metabolites from carnitine to coenzyme A in the mitochondrial inner membrane. 09654057 ENSG00000157184 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 1 53695882 1 53230210 rs13375749 HMDB13130 Blood metabolite levels (glutaroyl carnitine) Glutarylcarnitine EUR GCST002443 44.222 GCST002443_128 24816252 expert curated High Eric Fauman GCDH encodes a glutaryl-CoA dehydrogenase which catalyzes the oxidative decarboxylation of glutaryl-CoA to crotonyl-CoA. 03081514 ENSG00000105607 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 19 13010520 19 12899706 rs8012 HMDB13130 Blood metabolite levels (glutaroyl carnitine) Glutarylcarnitine EUR GCST002443 16.0 GCST002443_135 24816252 expert curated High Eric Fauman MCCC1 encodes methylcrotonoyl-CoA carboxylase 1 which catalyzes the conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA in the breakdown of leucine. An alternate fate of 3-methylcrotonyl-CoA is 3-hydroxyisovaleryl-CoA. 3-Methylcrotonyl-CoA carboxylase deficiency has been associated with elevated urinary 3-hydroxyisovalerylcarnitine levels. 19339287 ENSG00000078070 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G T 3 182755209 3 183037421 rs2270968 HMDB0062555 Blood metabolite levels (hydroxyisovaleroyl carnitine) hydroxyisovaleroyl carnitine EUR GCST002443 15.699 GCST002443_136 24816252 expert curated High Eric Fauman GMPR encodes guanosine monophosphate reducatase which converts guanosine monophosphate to inosine monophosphate which can subsequently be converted to hypoxanthine by the enzyme purine-nucleoside phosphorylase. 00218932 ENSG00000137198 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 6 16288192 6 16287961 rs6459467 HMDB0000157 Blood metabolite levels (hypoxanthine) Hypoxanthine EUR GCST002443 9.795 GCST002443_137 24816252 expert curated High Eric Fauman DDC encodes dopa decarboxylase which converts tryptophan to tryptamine, which can be further metabolized to indoleacetic acid. 13610897 ENSG00000132437 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T A 7 50610379 7 50542681 rs7809234 HMDB0000197 indoleacetate - M27513 Indoleacetic acid EUR GCST002443 12.0 GCST002443_137 24816252 expert curated High Eric Fauman CCBL1 encodes a kyneurenine aminotransferase, also known as hKAT-1, which can convert tryptophan to indolepyruvate. Indolepyruvate is then converted to indolelactate. 15606768 ENSG00000171097 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 9 131572027 9 128809748 rs15676 HMDB0000671 Blood metabolite levels (indolelactate) Indolelactic acid EUR GCST002443 48.303 GCST002443_140 24816252 expert curated High Eric Fauman SLC22A1 encodes OCT1, an organic cation transporter with activity towards acylcarnitine. 28942964 ENSG00000175003 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G C 6 160564476 6 160143444 rs662138 HMDB0062556 isobutyrylcarnitine - M33441 isobutyrylcarnitine EUR GCST002443 12.449 GCST002443_140 24816252 expert curated High Eric Fauman ETFA encodes a mitochondrial-specific electron transfer flavoprotein. Enzyme deficiency results in urinary excretion of isobutyric acid and isobutyrylglycine; the urinary levels of these metabolites should reflect plasma levels of the analyte reported here, isobutyrylcarnitine. 07360517 ENSG00000140374 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 15 77030792 15 76738451 rs2404602 HMDB0062556 isobutyrylcarnitine - M33441 isobutyrylcarnitine EUR GCST002443 7.343 GCST002443_17 24816252 expert curated High Eric Fauman SUCLA2 encodes a subunit of succinyl-CoA synthetase a key enzyme in the Krebs cycle. SUCLA2 deficiency results in elevated urinary excretion of leucine degradation products downstream of the analyte detected here (specifically 3-hydroxyisovaleric acid and 3-methylglutaconic acid). 19666145 ENSG00000136143 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 13 48459901 13 47885766 rs4941615 HMDB0000695 4-methyl-2-oxopentanoate - M22116 Ketoleucine EUR GCST002443 171.699 GCST002442_23 24816252 expert curated High Eric Fauman ACADM encodes an acyl-CoA dehydrogenase with a preference for medium chain length acyl-CoAs. Acyl-CoAs are converted to acyl-carnitines for circulation which are then detected in the plasma. 03597357 ENSG00000117054 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 1 76161889 1 75696204 rs4949874 HMDB0000201|HMDB0000705 Blood metabolite ratios (acetylcarnitine/hexanoylcarnitine) L-Acetylcarnitine|Hexanoylcarnitine EUR GCST002443 8.831 GCST002443_102 24816252 expert curated High Eric Fauman ASRGL1 encodes an asparaginase which hydrolyzes asparagine to produce aspartate. 24768817 ENSG00000162174 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 11 62176943 11 62409471 rs3017098 HMDB0000168 asparagine - M34283 L-Asparagine EUR GCST002443 40.806 GCST002443_102 24816252 expert curated High Eric Fauman ASPG encodes an asparaginase homolog which which can hydrolyse asparagine to form aspartic acid 09575212 ENSG00000166183 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 14 104608068 14 104141731 rs2011069 HMDB0000168 asparagine - M34283 L-Asparagine EUR GCST002443 25.046 GCST002443_142 24816252 expert curated High Eric Fauman SLC7A5 encodes LAT1 which mediates tryptophan/kynurenine exchange. 17896864 ENSG00000103257 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 16 87878822 16 87845216 rs8051149 HMDB0000684 Blood metabolite levels (kynurenine) L-Kynurenine EUR GCST002443 26.155 GCST002443_161 24816252 expert curated High Eric Fauman PHGDH encodes a phosphoglycerate dehydrogenase which catalyses the first and rate-limiting step in serine biosynthesis. 16589713 ENSG00000092621 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 1 120209755 1 119667132 rs1163251 HMDB0000187 Blood metabolite levels (serine) L-Serine EUR GCST002443 11.046 GCST002443_167 24816252 expert curated High Eric Fauman TDO2 encodes tryptophan 2,3-dioxygenase which acts on tryptophan. 08666386 ENSG00000151790 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 4 156808288 4 155887136 rs13122250 HMDB0000929 Blood metabolite levels (tryptophan) L-Tryptophan EUR GCST002443 50.523 GCST002442_46 24816252 expert curated High Eric Fauman SLC22A5 encodes the OCTN2 protein, which is the primary transporter reponsible for carnitine homeostasis. 20648231 ENSG00000197375 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 5 131665378 5 132329685 rs272889 HMDB0000883|HMDB0000688 Blood metabolite ratios (valine/isovalerylcarnitine) L-Valine / Isovalerylcarnitine EUR GCST002443 37.398 GCST002442_37 24816252 expert curated High Eric Fauman THEM4 is a broad range acyl-CoA thioesterase with a preference for medium and long chain acyl-CoAs. [19453107]. X-12442 has been identified as 5,8-tetradecadienoate. 19453107 ENSG00000159445 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 1 151930645 1 151958169 rs6693388 HMDB0000673|HMDB0000560 Blood metabolite ratios (linoleate (18:2n6)/X-12442--5,8-tetradecadienoate) Linoleic acid / 5,8-Tetradecadienoic acid EUR GCST002443 13.097 GCST002443_59 24816252 expert curated High Eric Fauman FMO3 encodes a flavin containing monooxygenase which can act on S-allyl-cysteine and methionine. Methylcysteine is a plausible substrate. This isozyme prefers smaller substrates and shows highest expression in liver. 18775983 ENSG00000007933 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C G 1 171080615 1 171111474 rs7061710 HMDB0002108 Blood metabolite levels (X-11786--methylcysteine) Methylcysteine EUR GCST002443 13.301 GCST002443_148 24816252 expert curated High Eric Fauman ISYNA1 encodes an inositol-3-phosphate synthase, which converts d-glucose 6-phosphate to 1-d-myo-inositol 3-phosphate. 15024000 ENSG00000105655 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 19 18618867 19 18508057 rs4808136 HMDB0000211 Blood metabolite levels (myo-inositol) myo-Inositol EUR GCST002443 115.0 GCST002442_40 24816252 expert curated High Eric Fauman SCD encodes a stearyl-CoA desaturase which acts on medium chain-length acyl-CoAs to bring about the delta 9 desaturation of various fatty acids, such as the conversion of myristate (14:0) to myristoleate (14:1n5). 00008453 ENSG00000099194 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 10 102075479 10 100315722 rs603424 HMDB0000806|HMDB0002000 Blood metabolite ratios (myristate (14:0)/myristoleate (14:1n5)) Myristic acid / Myristoleic acid EUR GCST002443 13.523 GCST002443_31 24816252 expert curated High Eric Fauman AOC1 encodes an amine oxidase which deaminates N1-acetylspermidine to produce N-[3-(2-oxopyrrolidin-1-yl)propyl]acetamide (also known as acisoga). 12072962 ENSG00000002726 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G T 7 150543721 7 150846633 rs1005390 HMDB0061384 Blood metabolite levels (X-03056--N-[3-(2-Oxopyrrolidin-1-yl)propyl]acetamide) N-(3-acetamidopropyl)pyrrolidin-2-one EUR GCST002443 12.523 GCST002443_32 24816252 expert curated|expert curated High|High Eric Fauman|Eric Fauman PAOX encodes an N1-acetylspermidine oxidase. The detected analyte is a downstream metabolite of N1-acetylspermidine. |PAOX encodes an N1-acetylspermidine oxidase. The detected analyte is a downstream metabolite of N1-acetylspermidine. 12660232|03558558 ENSG00000148832 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T A 10 135197336 10 133383832 rs11101730 HMDB0061384 Blood metabolite levels (X-03056--N-[3-(2-Oxopyrrolidin-1-yl)propyl]acetamide) N-(3-acetamidopropyl)pyrrolidin-2-one EUR GCST002443 497.301 GCST002442_10 24816252 expert curated High Eric Fauman NAT8 shows sequence similarity to N-acetyltransferases. N-acetylornithine may be a product or related to a product. Ornithine itself is part of the urea cycle and myoinositol levels are altered in patients with urea cycle disorders. 18662894 ENSG00000144035 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 2 73868328 2 73641201 rs13538 HMDB0003357|HMDB0000211 Blood metabolite ratios (N-acetylornithine/myo-inositol) N-Acetylornithine / myo-Inositol EUR GCST002443 11.222 GCST002443_68 24816252 expert curated|expert curated High|High Eric Fauman|Eric Fauman ACMSD encodes alpha-Amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, the key enzyme regulating de novo synthesis of nicitinamide adenine dinucleotide (NAD) from tryptophan. The metabolite in question, N1-methyl-3-pyridone-4-carboxamide, is an endproduct of NAD degradation.|ACMSD encodes alpha-Amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, the key enzyme regulating de novo synthesis of nicitinamide adenine dinucleotide (NAD) from tryptophan. The metabolite in question, N1-methyl-3-pyridone-4-carboxamide, is an endproduct of NAD degradation. 16807375|12694300 ENSG00000153086 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 2 135631400 2 134873830 rs6430553 HMDB0004194 Blood metabolite levels (X-12095--N1-methyl-3-pyridone-4-carboxamide) N1-Methyl-4-pyridone-3-carboxamide EUR GCST002443 134.0 GCST002443_82 24816252 expert curated High Eric Fauman ACADL encodes Long-chain acyl-CoA dehydrogenase which has activity against a variety of medium and long chain acyl-CoAs . Intracellular acyl-CoAs are converted to acyl-carnitines for circulation. 10832093 ENSG00000115361 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 2 210874246 2 210009522 rs3738934 HMDB0013288 Blood metabolite levels (X-13431--nonanoylcarnitine) Nonanoylcarnitine EUR GCST002443 177.301 GCST002443_58 24816252 expert curated High Eric Fauman COMT encodes the catechol-O-methyltransferase which can methylate ascorbate to produce O-methylascorbate. 07129800 ENSG00000093010 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 22 19951271 22 19963748 rs4680 HMDB0000044 Blood metabolite levels (X-11593--O-methylascorbate) O-methylascorbate EUR GCST002443 17.155 GCST002443_44 24816252 expert curated High Eric Fauman ARSA encodes the arylsulfatase A, which can act on L-tyrosine O-sulfate. 00033715 ENSG00000100299 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 22 51063477 22 50625049 rs6151429 HMDB0000158 Blood metabolite levels (X-11423--O-sulfo-L-tyrosine) O-Sulfotyrosine EUR GCST002443 10.097 GCST002443_154 24816252 expert curated High Eric Fauman SLC5A6 encodes a solute transporter with demonstrated activity for pantothenate 09516450 ENSG00000138074 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 2 27424636 2 27201768 rs1395 HMDB0000210 Blood metabolite levels (pantothenate) Pantothenic acid EUR GCST002443 23.523 GCST002442_42 24816252 expert curated High Eric Fauman GOT2 encodes the enzyme aspartate aminotransferase which can take each of the aromatic amino acids as substrates. In particular, GOT2 catalyzes the conversion of phenylalanine to phenylpyruvate which is then converted to phenyllactate. 04623131 ENSG00000125166 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 16 58829790 16 58795886 rs12709013 HMDB0000779|HMDB0000159 Blood metabolite ratios (phenyllactate (PLA)/phenylalanine) Phenyllactic acid / L-Phenylalanine EUR GCST002443 22.046 GCST002442_43 24816252 expert curated High Eric Fauman TKT encodes transkelolase, an enzyme with a prefererence for D-erythrose 4-phosphate as a substrate. 09924800 ENSG00000163931 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 3 53282188 3 53248172 rs4687717 HMDB0001429|HMDB0000613 Blood metabolite ratios (phosphate/erythronate) Phosphate / Erythronic acid EUR GCST002443 42.046 GCST002442_44 24816252 expert curated High Eric Fauman IVD encodes isovaleryl-CoA dehydrogenase which acts on isovaleryl-CoA in the third step of leucine catabolism. Isovaleryl-CoA is converted to isovalerylcarnitine for circulation. 03597357 ENSG00000128928 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 15 40703211 15 40411012 rs9635324 HMDB0000824|HMDB0000688 Blood metabolite ratios (propionylcarnitine/isovalerylcarnitine) Propionylcarnitine / Isovalerylcarnitine EUR GCST002443 109.222 GCST002443_22 24816252 expert curated High Eric Fauman OPLAH encodes 5-oxoprolinase which catalyzes the ATP-dependent hydrolysis of 5-oxoproline to glutamic acid 09233839 ENSG00000178814 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 8 145155408 8 144100505 rs12550729 HMDB0000267 Blood metabolite levels (5-oxoproline) Pyroglutamic acid EUR GCST002443 190.523 GCST002442_15 24816252 expert curated High Eric Fauman SULT2A1 encodes a bile salt sulfotransferase which can catalyze the sulfation of steroids and bile acids. 08575776 ENSG00000105398 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 19 48385057 19 47881800 rs2547231 HMDB03818 Blood metabolite ratios (X-11440/4-androsten-3beta,17beta-diol disulfate 2) similar to 5-Androstenediol EUR GCST002443 10.155 GCST002443_164 24816252 expert curated High Eric Fauman SUCLG2 encodes the beta subunit of succinate-CoA ligase which acts on succinate-CoA. Acyl-CoAs and acyl-carnitines are readily interconverted. 18392745 ENSG00000172340 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 3 67416322 3 67365898 rs17806888 HMDB0061717 Blood metabolite levels (succinylcarnitine) Succinylcarnitine EUR GCST002443 85.097 GCST002442 24816252 expert curated High Eric Fauman CYP4A11 encodes a fatty acid omega-hydroxylase. X-11438 may be a hydroxylated tridecenoic acid (C13:1(OH)) so may represent a product. 10860550 ENSG00000187048 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 1 47331966 1 46866294 rs6678639 HMDB33724|HMDB0035881 Blood metabolite ratios (10-undecenoate (11:1n1)/X-11438) Undecylenic acid / 11-Hydroxy-9-tridecenoic acid EUR GCST002443 7.467 GCST002443_170 24816252 expert curated High Eric Fauman CDA encodes cytidine deaminase which deaminates cytidine, producing uridine. 08422236 ENSG00000158825 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 1 20915172 1 20588679 rs532545 HMDB0000296 uridine - M00606 Uridine EUR GCST002443 7.724 GCST002443_170 24816252 expert curated High Eric Fauman UPP1 encodes uridine phosphorylase which catalyzes the interconversion of uridine and uracil. 07488099 ENSG00000183696 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 7 48102911 7 48063314 rs2686796 HMDB0000296 uridine - M00606 Uridine EUR GCST002443 15.398 GCST002443_170 24816252 expert curated High Eric Fauman TYMP encodes thymidine phosphorylase, which catalyzes the phosphorolysis of thymidine and deoxyuridine. These pyrimidines are metabolically linked to uridine. 07284378 ENSG00000025708 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C A 22 50971752 22 50533323 rs131794 HMDB0000296 Blood metabolite levels (uridine) Uridine AFR|EUR GCST002559 12.699 GCST002559_2 25147783 expert curated High Eric Fauman CUBN encodes cubilin, a protein involved in the uptake of vitamin B12 (cobalamin). CUBN deficiency results in reduced levels of cobalamin. 09478979 ENSG00000107611 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 10 17156151 10 17114152 rs1801222 HMDB0002174 Vitamin B levels in ischemic stroke (Vitamin B12) Cobalamin EAS GCST002586 11.719 GCST002586 25187374 expert curated High Eric Fauman FOXA2 encodes a transcription factor that impacts the expression of many genes (i.e., GCK, SLC2A2) previously related to the glucose levels. 11875061 ENSG00000125798 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 20 22581268 20 22600630 rs6048216 HMDB0000122 Fasting plasma glucose (East Asian) D-Glucose EUR GCST002623 18.398 GCST002623 25245031 expert curated High Eric Fauman ARG1 encodes an arginase which hydrolyzes arginine. Enzyme deficiency causes argininemia. 03540966 ENSG00000118520 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 6 131924689 6 131603549 rs2248551 HMDB0000517 L-arginine levels L-Arginine AMR|ASW|EUR|JPT|ZZ2 GCST002652 154.699 GCST002652 25293881 expert curated High Eric Fauman UGT2B10 encodes a UDP glucuronosyltransferase which glucuronidates cotinine to produce cotinine glucuronide 17576790 ENSG00000109181 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 4 69673553 4 68807835 rs34100980 HMDB0001013 Cotinine glucuronidation Cotinine glucuronide EUR GCST002679 19.177 GCST002679 25352340 expert curated High Eric Fauman TF encodes transferrin, a key transporter for iron. 01809186 ENSG00000091513 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G T 3 133477701 3 133758857 rs8177240 HMDB0015531 Iron|serum Iron EUR GCST002679 96.565 GCST002679 25352340 expert curated High Eric Fauman HFE encodes the hereditary hemochromatosis protein which binds transferrin receptor which binds transferrin which binds iron 09465039 ENSG00000010704 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 6 26093141 6 26092913 rs1800562 HMDB0015531 Iron|serum Iron EUR GCST002679 18.0 GCST002679 25352340 expert curated High Eric Fauman TFR2 encodes a receptor for transferrin which binds iron 10409623 ENSG00000106327 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 7 100235970 7 100638347 rs7385804 HMDB0015531 Iron status biomarkers (iron levels) Iron EUR GCST002679 139.0 GCST002679 25352340 expert curated High Eric Fauman TMPRSS6 encodes a protease which regulates levels of hepcidin which regulates iron levels 25588876 ENSG00000187045 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 22 37462936 22 37066896 rs855791 HMDB0015531 Iron status biomarkers (iron levels) Iron EUR GCST002690 39.577 GCST002690 25378659 expert curated High Eric Fauman CERS4 encodes a ceramide synthase which produces ceramides from sphingosine and a long chain acyl CoA, derived from long chain free fatty acids. 12912983 ENSG00000090661 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 19 8281635 19 8216751 rs2100944 HMDB0002212 FA 20:0|plasma Arachidic acid unknown GCST002712 48.523 GCST002712_9 25500335 expert curated High Eric Fauman LPCAT3 encodes a lysophosphatidylcholine acyltransferase which takes the CoA version of oleic acid to convert lysophosphatidylcholine to phosphatidylcholine. 18781350 ENSG00000111684 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 12 7075882 12 6966719 rs2110073 HMDB0000207 Red blood cell fatty acid levels (OA) Oleic Acid unknown GCST002831 13.398 GCST002831 25820613 expert curated High Eric Fauman ALAD encodes aminolevulinate dehydratase, an enzyme which binds to lead. 01713045 ENSG00000148218 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 9 116151191 9 113388911 rs1805313 HMDB0004628 Lead levels in blood Lead unknown GCST002932 13.658 GCST002932 26025379 expert curated High Eric Fauman SLC30A10 encodes a transporter with specificity for manganese. 25319704 ENSG00000196660 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 1 220080028 1 219906686 rs1776029 HMDB0001333 Manganese|plasma Manganese EUR GCST002964 31.699 GCST002964_2 26068415 expert curated High Eric Fauman SPTLC3 encodes a subunit of serine palmitoyltransferase, which catalyzes the first step in de novo sphingolipid biosynthesis. 17023427 ENSG00000172296 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 20 12959398 20 12978750 rs4814176 HMDB0013469 Sphingolipid levels (Hydroxysphingomyeline C24:1) Hydroxysphingomyeline C24:1 EUR GCST002961 80.82 GCST002961_2 26068415 expert curated High Eric Fauman SLC16A9 encodes a carnitine efflux transporter. 21886157 ENSG00000165449 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 10 61469538 10 59709780 rs1171614 HMDB0000062 C0 L-Carnitine EUR GCST002966 58.523 GCST002966_4 26068415 expert curated High Eric Fauman PRODH encodes proline dehydrogenase which catalyzes the first step in proline degradation 16874462 ENSG00000100033 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 22 18959684 22 18972171 rs2540641 HMDB0000162 Blood metabolite levels (proline) L-Proline EUR GCST002966 17.353 GCST002966_5 26068415 expert curated High Eric Fauman PSPH encodes phosphoserine phosphatase which produces serine 16589713 ENSG00000146733 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 7 56079094 7 56011401 rs4947534 HMDB0000187 Ser L-Serine EUR GCST002966 12.552 GCST002965_33 26068415 expert curated High Eric Fauman MFSD2A encodes a lysophosphotidylcholine transporter. 24828044 ENSG00000168389 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T G 1 40403370 1 39937698 rs7529794 HMDB0010382 lysoPC a C16:0 LysoPC(16:0) EUR GCST002966 9.39 GCST002965_13 26068415 expert curated High Eric Fauman AGPS encodes the alkylglycerone phosphate synthase which generates ether phospholipids such as the metabolite detected here. 10215861 ENSG00000018510 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 2 178370631 2 177505903 rs7582179 HMDB0013456 PC ae C44:5 PC(o-22:2(13Z,16Z)/22:3(10Z,13Z,16Z)) EUR GCST002966 10.475 GCST002965_13 26068415 expert curated High Eric Fauman ACSL1 encodes a long-chain fatty-acid-coenzyme A ligase which produces acyl-CoAs. These in turn can be used in the synthesis of plasmalogens, e.g., via LPCAT4 08584017 ENSG00000151726 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 4 185773811 4 184852657 rs7700133 HMDB0013456 PC ae C44:5 PC(o-22:2(13Z,16Z)/22:3(10Z,13Z,16Z)) EUR GCST002966 10.419 GCST002965_2 26068415 expert curated High Eric Fauman ABHD3 encodes a phospholipase with demonstrated activity against PC(32:2), specifically the PC(14:0/18:2) stereoisomer. 21926997 ENSG00000158201 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G T 18 19263128 18 21683167 rs7343008 HMDB0007874 PC aa C32:2 Phosphatidyl choline PC(14:0/18:2(9Z,12Z)) is a specific example EUR GCST003119 251.625 GCST003119_11 26352407 expert curated|expert curated High|High Eric Fauman|Eric Fauman AGXT2 encodes an alanine-glyoxylate aminotransferase, an enzyme which can take 3-aminoisobutyrate as a substrate.|AGXT2 encodes an alanine-glyoxylate aminotransferase, an enzyme which can take 3-aminoisobutyrate as a substrate. 08427875|05773299 ENSG00000113492 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 5 35037115 5 35037010 rs37369 HMDB0003911 3-aminoisobutyrate|urine 3-Aminoisobutanoic acid EUR GCST003119 17.159 26352407 expert curated High Eric Fauman AGXT encodes alanine-glyoxylate aminotransferase. When acting on valine, rather than alanine, as a substrate, the enzyme will produce alpha-ketoisovaleric acid as a product (see EC code EC 2.6.1.66). The mouse and rat orthologs have demonstrated activity on valine. 00629740 ENSG00000172482 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 2 241837452 2 240898035 rs6748734 HMDB0000019 alpha-ketoisovalerate|urine alpha-Ketoisovaleric acid EUR GCST003119 59.074 GCST003119_14 26352407 expert curated High Eric Fauman SLC6A20 encodes a transporter for N-methylglycine, proline and other specific amino acids. 15632147 ENSG00000163817 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A G 3 45814094 3 45772602 rs17279437 HMDB0000092|HMDB0000161 N,N-dimethylglycine/alanine|urine Dimethylglycine / L-Alanine EUR GCST003119 27.146 26352407 expert curated High Eric Fauman ETNPPL encodes the ethanolamine-phosphate phospho-lyase which acts on the phosphorylated form of ethanolamine. AGXT2L1 is a common synonym for this gene. 22241472 ENSG00000164089 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 4 109705967 4 108784811 rs56043887 HMDB0000149 ethanolamine|urine Ethanolamine EUR GCST003119 14.68 GCST003119_16 26352407 expert curated High Eric Fauman SLC36A2 encodes the a proton-coupled amino acid transporter, which is specific for glycine and proline. 19033659 ENSG00000186335 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 5 150698806 5 151319245 rs3846710 HMDB0000123|HMDB0000094 glycine/citrate|urine Glycine / Citric acid EUR GCST003119 13.53 GCST003119_17 26352407 expert curated High Eric Fauman XYLB encodes a xylulokinase homolog which phosphorylates D-xylulose, a precursor of glycolate 09783918 ENSG00000093217 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 3 38395562 3 38354071 rs3132440 HMDB0000115 glycolate|urine Glycolic acid EUR GCST003119 261.126 GCST002443_168 26352407 expert curated|expert curated High|High Eric Fauman|Eric Fauman SLC6A19 encodes a neutral amino acid transporter which can act on tyrosine. The nearby paralog, SLC6A18, is specific for glycine.|SLC6A19 encodes a neutral amino acid transporter which can act on tyrosine. The nearby paralog, SLC6A18, is specific for glycine. 15044460|15804236 ENSG00000174358 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 5 1183560 5 1183445 rs11750211 HMDB0000158 tyrosine|urine L-Tyrosine EUR GCST003119 65.034 GCST002443_148 26352407 expert curated High Eric Fauman SLC5A11 encodes a sodium/myo-inositol transporter (SMIT2) which can also transport scyllo-inostiol. 21887366 ENSG00000158865 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 16 25002600 16 24991279 rs17702912 HMDB0000211 myo-inositol|urine myo-Inositol EUR GCST003119 15.845 GCST003666_3 26352407 expert curated High Eric Fauman SLC13A3 encodes a high affinity succinate transporter enriched in kidney tissue. 10794676 ENSG00000158296 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C A 20 45261041 20 46632402 rs941206 HMDB0000254|HMDB0000094 sucinate/citrate|urine Succinic acid / Citric acid EUR GCST006879 36.131 GCST006879_4 26401656 expert curated High Eric Fauman SLC22A16 encodes transporter specific for carnitine 12089149 ENSG00000004809 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 6 110760008 6 110438805 rs12210538 EFO_0005059 total acylcarnitine acylcarnitine measurement EUR GCST006879 11.622 GCST006879_5 26401656 expert curated High Eric Fauman GPT encodes alanine aminotransferase which takes alanine as a substrate and produces glutamate which is one step removed from aspartate. 09119391 ENSG00000167701 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C A 8 145701453 8 144476070 rs750472 HMDB0000161|HMDB0000168 metabolite ratio (Ala/Asp) L-Alanine / L-Asparagine EUR GCST006879 82.375 GCST006879_17 26401656 expert curated High Eric Fauman CRAT encodes carnitine O-acetyltransferase, which catalyzes the interconversion of short chain acylcarnitines and acyl-coenzyme A derivatives. 02351134 ENSG00000095321 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 9 131865027 9 129102748 rs746872 HMDB0013133 Methylmalonylcarnitine Methylmalonylcarnitine EUR GCST006879 7.269 GCST006879_2 26401656 expert curated High Eric Fauman HLCS encodes a biotin apo-protein ligase which attaches biotin to four biotin-dependent enymes, including enzymes involved in branched chain amino acid catabolism. Holocarboxylase synthetase deficiency results in increased levels of 3-Hydroxyisovalerylcarnitine. 19201116 ENSG00000159267 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 21 38336834 21 36964534 rs1571700 HMDB0061189 2-Hydroxyisovalerylcarnitine Similar to 3-Hydroxyisovalerylcarnitine FIN 85.239 26407342 expert curated High Eric Fauman CYP2A6 encodes a cytochrome P450 which is the primary enzyme responsible for the conversion of nicotine to cotinine. 08937855 ENSG00000255974 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 19 41353107 19 40847202 rs56113850 HMDB0001390|HMDB0001046 Nicotine Metabolite Ratio ratio of Hydroxycotinine to Cotinine EUR GCST003666 17.319 GCST003666_3 27005778 expert curated High Eric Fauman SLC13A5 encodes NaCT, a sodium-coupled citrate transporter. 16973915 ENSG00000141485 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C A 17 6595398 17 6692079 rs172642 HMDB0000094 Citrate Citric acid EUR GCST003666 21.886 GCST003666_3 27005778 expert curated High Eric Fauman SLC25A1 encodes the mitochondrial-localized tricarboxylate transporter of citrate. 02804096 ENSG00000100075 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 22 19161935 22 19174422 rs2040771 HMDB0000094 Citrate Citric acid EUR GCST003666 300.0 GCST003666_7 27005778 expert curated High Eric Fauman CPS1 encodes a mitochondrial carbamoyl phosphate synthetase which takes ammonia as a substrate. Glycine and ammonia are interconverted via the glycine cleavage complex. 18941301 ENSG00000021826 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 2 211540507 2 210675783 rs1047891 HMDB0000123 Glycine Glycine EUR GCST003666 39.432 GCST003666_7 27005778 expert curated High Eric Fauman GLDC encodes glycine dehydrogenase which takes glycine as a substrate. GLDC deficiency causes excess of glycine. 04585091 ENSG00000178445 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL TA T 9 5877295 9 5877295 rs140348140 HMDB0000123 Glycine Glycine EUR GCST003666 12.523 GCST003666_7 27005778 expert curated High Eric Fauman GCSH encodes the glycine cleavage system H protein which is involved in the degradation of glycine. GCSH deficiency leads to excess plasma glycine. 18941301 ENSG00000140905 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 16 81065282 16 81031677 rs10083777 HMDB0000123 Glycine Glycine EUR GCST003665 10.495 GCST003665_10 27005778 expert curated High Eric Fauman APOA2 encodes apolipoprotein A-II, a major component of HDL particles 24089247 ENSG00000158874 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 1 161190250 1 161220460 rs4503368 EFO_0004612 XL.HDL.PL high density lipoprotein cholesterol measurement EUR GCST003665 54.585 GCST003665 27005778 expert curated High Eric Fauman PLTP encodes phospholipid transfer protein which acts directly on HDL particles. 08664337 ENSG00000100979 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C T 20 44551855 20 45923216 rs6073958 EFO_0004612 S.HDL.P high density lipoprotein cholesterol measurement EUR GCST003666 12.215 GCST003666 27005778 expert curated|expert curated High|High Eric Fauman|Eric Fauman SLC38A4 encodes a liver-enriched amino acid transporter (ATA3) with affinity for most cationic and neutral amino acids including alanine.|SLC38A4 encodes a liver-enriched amino acid transporter (ATA3) with affinity for most cationic and neutral amino acids including alanine. 11342143|11118514 ENSG00000139209 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 12 47201814 12 46808031 rs4554975 HMDB0000161 Alanine L-Alanine EUR GCST003666 69.481 GCST003666_6 27005778 expert curated High Eric Fauman GLS2 encodes the mitochondrial phosphate-activated glutaminase which catalyzes the hydrolysis of glutamine to glutamate and ammonia. 10620514 ENSG00000135423 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 12 56865338 12 56471554 rs2657879 HMDB0000641 Glutamine L-Glutamine EUR GCST003666 14.137 GCST003666_10 27005778 expert curated High Eric Fauman HAL encodes histidine ammonia-lyase which catalyzes the first step in the degradation of histidine to glutamate. 13018112 ENSG00000084110 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 12 96314795 12 95921017 rs7954638 HMDB0000177 Metabolite levels (small molecules and protein measures) (Histidine) L-Histidine EUR GCST003666 14.602 GCST003666_11 27005778 expert curated High Eric Fauman PAH encodes the enzyme phenylalanine hydroxylase which is the rate-limiting step in phenylalanine catabolism. 04150152 ENSG00000171759 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G A 12 103242396 12 102848618 rs1718309 HMDB0000159 Phenylalanine L-Phenylalanine EUR GCST003666 23.854 GCST003666_13 27005778 expert curated High Eric Fauman SLC16A10 encodes the T?type amino acid transporter?1 (TAT1); this transporter transports tryptophan, tyrosine and phenylalanine 11827462 ENSG00000112394 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL A C 6 111543944 6 111222741 rs14399 HMDB0000158 Tyrosine L-Tyrosine EUR GCST003666 34.77 GCST003666_15 27005778 expert curated High Eric Fauman PPM1K encodes a phosphatase called PP2Cm for the branched-chain keto acid dehydrogenase (BCKD) complex. BCKD catalyzes an essential step in the catabolism of valine and the other branched chain amino acids. 19411760 ENSG00000163644 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL C A 4 89206230 4 88285078 rs9637599 HMDB0000883 Valine L-Valine EUR GCST003666 10.678 GCST003666_12 27005778 expert curated High Eric Fauman PDPR encodes a component of the pyruvate dehydrogenase complex (PDC) which converts pyruvate into acetyl-CoA. 09395502 ENSG00000090857 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL T C 16 69979271 16 69945368 rs74249229 HMDB0000243 Pyruvate Pyruvic acid EUR GCST003665 99.866 GCST003217 28334899 expert curated High Eric Fauman MLXIPL encodes the carbohydrate-responsive element-binding protein, a transcription factor for multiple lipogenic enzymes. 16890538 ENSG00000009950 High 2019-05-17 Ed Mountjoy ProGeM Eric Fauman metabolite|mQTL G T 7 72863249 7 73448919 rs17145738 EFO_0004530 Triglycerides triglyceride measurement European=341215 GCST007798 10.221848749616356 GCST007798 30929738 drug Low Ed Mountjoy PI3-kinase p110-delta subunit inhibitor drug DUVELISIB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000171608 at this locus (355116bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171608 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 1 9356676 1 9296617 EFO_0000270 Asthma asthma European, Other=1157 GCST001476 7.301029995663981 GCST001476_7 22491018 drug Low Ed Mountjoy PI3-kinase p110-delta subunit inhibitor drug DUVELISIB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000171608 at this locus (302833bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171608 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 1 9408959 1 9348900 EFO_0000685 Response to tocilizumab in rheumatoid arthritis [CSJC , EA, RF-] rheumatoid arthritis European=488|African American or Afro-Caribbean=111|Hispanic or Latin American=60|Other=56 GCST004250 8.0 GCST004250_2 28090653 drug Low Ed Mountjoy CAMPATH-1 antigen inhibitor drug ALEMTUZUMAB is Phase II for the indiciation EFO_0000220 and targets the gene ENSG00000169442 at this locus (491379bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169442 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 1 27138393 1 26811902 EFO_0000220 Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL) [AA] acute lymphoblastic leukemia Other=1097|NR=150064 GCST003048 8.522878745280337 GCST003048 26198764 drug Low Ed Mountjoy Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (419487bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196517 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 1 44037685 1 43572014 EFO_0000692 Schizophrenia schizophrenia East Asian=26026|European=82315 GCST004946 12.0 GCST004946 28991256 drug Low Ed Mountjoy Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196517 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 1 44097530 1 43631859 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 8.397940008672037 GCST007201_2 30285260 drug Low Ed Mountjoy Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196517 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 1 44097530 1 43631859 EFO_0000692 Schizophrenia [EA] schizophrenia European=105318 GCST006803 11.0 GCST006803 29483656 drug Low Ed Mountjoy Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196517 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 1 44097530 1 43631859 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 10.0 GCST007201 30285260 drug Low Ed Mountjoy Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (359642bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196517 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 1 44097530 1 43631859 EFO_0000692 Schizophrenia schizophrenia European=82315|East Asian=5219 GCST002539 9.522878745280337 GCST002539 25056061 drug Low Ed Mountjoy Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (357087bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196517 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 1 44100084 1 43634413 EFO_0000692 Schizophrenia schizophrenia European=13574|NR=2380 GCST004521 9.397940008672037 GCST004521 28540026 drug Low Ed Mountjoy Glycine transporter 1 inhibitor drug BITOPERTIN is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000196517 at this locus (357087bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196517 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 1 44100084 1 43634413 EFO_0000692 Autism spectrum disorder or schizophrenia schizophrenia European=139274 GCST004988 7.530472520812986 GCST004988 29059683 drug Low Ed Mountjoy Anandamide amidohydrolase inhibitor drug ACETAMINOPHEN is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000117480 at this locus (259073bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000117480 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 1 46600917 1 46135245 EFO_0000305 Breast cancer breast carcinoma European=361141 28.214189147749966 NEALE2_20002_1473 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (17875bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 1 55487346 1 55021673 HP_0003124 High cholesterol | non-cancer illness code, self-reported Hypercholesterolemia European=361141 28.214189147749966 NEALE2_20002_1473 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (17875bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 1 55487346 1 55021673 HP_0003124 High cholesterol | non-cancer illness code, self-reported Hypercholesterolemia European=361141 28.214189147749966 NEALE2_20002_1473 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (17875bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 1 55487346 1 55021673 HP_0003124 High cholesterol | non-cancer illness code, self-reported Hypercholesterolemia European=406276 10.1038/s41588-018-0184-y 11.88941028970075 SAIGE_272_11 drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (15680bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 1 55489542 1 55023869 HP_0003124 Hypercholesterolemia Hypercholesterolemia European=408961 10.1038/s41588-018-0184-y 12.71669877129645 SAIGE_272 drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (15680bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 1 55489542 1 55023869 Orphanet_309005 Disorders of lipoid metabolism Disorder of lipid metabolism European=406276 10.1038/s41588-018-0184-y 11.88941028970075 SAIGE_272_11 drug Low Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (15680bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 1 55489542 1 55023869 HP_0003124 Hypercholesterolemia Hypercholesterolemia European=408961 10.1038/s41588-018-0184-y 12.71669877129645 SAIGE_272 drug Medium Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (15680bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 1 55489542 1 55023869 Orphanet_309005 Disorders of lipoid metabolism Disorder of lipid metabolism European=408878 10.1038/s41588-018-0184-y 12.79860287567955 SAIGE_272_1 drug Medium Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation EFO_0003774 and targets the gene ENSG00000169174 at this locus (15680bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 1 55489542 1 55023869 EFO_0003774 Hyperlipidemia hyperlipidemia European=406276 10.1038/s41588-018-0184-y 11.88941028970075 SAIGE_272_11 drug Medium Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (15680bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 1 55489542 1 55023869 HP_0003124 Hypercholesterolemia Hypercholesterolemia European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323 GCST003116 7.698970004336019 GCST003116 26343387 drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (9183bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 1 55496039 1 55030366 EFO_0000378 Coronary artery disease coronary artery disease European=408878 10.1038/s41588-018-0184-y 23.57186520597121 SAIGE_272_1 drug Medium Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase III for the indiciation EFO_0003774 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 1 55505647 1 55039974 EFO_0003774 Hyperlipidemia hyperlipidemia European=406276 10.1038/s41588-018-0184-y 20.25103713874384 SAIGE_272_11 drug Medium Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 1 55505647 1 55039974 HP_0003124 Hypercholesterolemia Hypercholesterolemia NR=250736 GCST005196 24.69897000433602 GCST005196 29212778 drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 1 55505647 1 55039974 EFO_0000378 Coronary artery disease coronary artery disease European=408458 10.1038/s41588-018-0184-y 11.844663962534938 SAIGE_411 drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 1 55505647 1 55039974 EFO_0000378 Ischemic heart disease coronary artery disease European=406276 10.1038/s41588-018-0184-y 20.25103713874384 SAIGE_272_11 drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 1 55505647 1 55039974 HP_0003124 Hypercholesterolemia Hypercholesterolemia European=406276 10.1038/s41588-018-0184-y 20.25103713874384 SAIGE_272_11 drug Low Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 1 55505647 1 55039974 HP_0003124 Hypercholesterolemia Hypercholesterolemia European=459000 GCST007072 11.0 GCST007072 30595370 drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 1 55505647 1 55039974 EFO_0000319 Cardiovascular disease cardiovascular system disease European=361141 64.89219328560758 NEALE2_20002_1473 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 1 55505647 1 55039974 HP_0003124 High cholesterol | non-cancer illness code, self-reported Hypercholesterolemia European, NR=63731 GCST004787 9.522878745280337 GCST004787 28714975 drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 1 55505647 1 55039974 EFO_0000378 Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) coronary artery disease European=361141 64.89219328560758 NEALE2_20002_1473 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 1 55505647 1 55039974 HP_0003124 High cholesterol | non-cancer illness code, self-reported Hypercholesterolemia NR=296525 GCST005194 21.731656086048936 GCST005194 29212778 drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 1 55505647 1 55039974 EFO_0000378 Coronary artery disease coronary artery disease NR=547261 GCST005195 17.82390874094432 GCST005195 29212778 drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 1 55505647 1 55039974 EFO_0000378 Coronary artery disease coronary artery disease European=408961 10.1038/s41588-018-0184-y 23.614393726401687 SAIGE_272 drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 1 55505647 1 55039974 Orphanet_309005 Disorders of lipoid metabolism Disorder of lipid metabolism European=408961 10.1038/s41588-018-0184-y 23.614393726401687 SAIGE_272 drug Medium Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation Orphanet_309005 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 1 55505647 1 55039974 Orphanet_309005 Disorders of lipoid metabolism Disorder of lipid metabolism European=361141 64.89219328560758 NEALE2_20002_1473 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 1 55505647 1 55039974 HP_0003124 High cholesterol | non-cancer illness code, self-reported Hypercholesterolemia European=459000 GCST007072 11.0 GCST007072 30595370 drug Medium Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 1 55505647 1 55039974 EFO_0000319 Cardiovascular disease cardiovascular system disease European=361141 14.0 NEALE2_20002_1473 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug ALIROCUMAB is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 1 55521313 1 55055640 HP_0003124 High cholesterol | non-cancer illness code, self-reported Hypercholesterolemia European=361141 14.0 NEALE2_20002_1473 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug BOCOCIZUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 1 55521313 1 55055640 HP_0003124 High cholesterol | non-cancer illness code, self-reported Hypercholesterolemia European=361141 14.0 NEALE2_20002_1473 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Subtilisin/kexin type 9 inhibitor drug EVOLOCUMAB is Phase III for the indiciation HP_0003124 and targets the gene ENSG00000169174 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169174 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 1 55521313 1 55055640 HP_0003124 High cholesterol | non-cancer illness code, self-reported Hypercholesterolemia European=406276 10.1038/s41588-018-0184-y 7.812479279163537 SAIGE_272_11 drug Low Ed Mountjoy Angiopoietin-related protein 3 inhibitor drug EVINACUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000132855 at this locus (14882bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132855 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 1 63048277 1 62582606 HP_0003124 Hypercholesterolemia Hypercholesterolemia European=361141 24.119709018294724 NEALE2_20002_1473 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Angiopoietin-related protein 3 inhibitor drug EVINACUMAB is Phase II for the indiciation HP_0003124 and targets the gene ENSG00000132855 at this locus (49271bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132855 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II TC T 1 63121101 1 62655430 HP_0003124 High cholesterol | non-cancer illness code, self-reported Hypercholesterolemia European=6889 GCST001957 8.698970004336019 GCST001957 23563609 drug Medium Ed Mountjoy Leptin receptor agonist drug METRELEPTIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000116678 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000116678 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 1 65979280 1 65513597 EFO_0001073 Obesity (early onset extreme) obesity European=26621 GCST001198 9.426548177964515 GCST001198 21833088 drug Low Ed Mountjoy Sphingosine 1-phosphate receptor Edg-1 agonist drug SIPONIMOD is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000170989 at this locus (294903bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000170989 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 1 101407519 1 100941963 EFO_0003885 Multiple sclerosis multiple sclerosis European=26621 GCST001198 9.426548177964515 GCST001198 21833088 drug Low Ed Mountjoy Sphingosine 1-phosphate receptor Edg-1 agonist drug PONESIMOD is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000170989 at this locus (294903bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000170989 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 1 101407519 1 100941963 EFO_0003885 Multiple sclerosis multiple sclerosis European=33394 GCST005527 14.221848749616356 GCST005527 23143594 drug Low Ed Mountjoy T-cell surface antigen CD2 inhibitor drug SIPLIZUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000116824 at this locus (9698bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000116824 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 1 117287354 1 116744732 EFO_0000676 Psoriasis psoriasis European=33394 GCST005527 14.221848749616356 GCST005527 23143594 drug High Ed Mountjoy T-cell surface antigen CD2 inhibitor drug ALEFACEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000116824 at this locus (9698bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000116824 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 1 117287354 1 116744732 EFO_0000676 Psoriasis psoriasis Other=1097|NR=150064 GCST003048 9.397940008672037 GCST003048 26198764 drug Medium Ed Mountjoy Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (141651bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C HG1287_PATCH 150745909 1 150059494 EFO_0000692 Schizophrenia schizophrenia European=105318 GCST006803 9.154901959985743 GCST006803 29483656 drug Medium Ed Mountjoy Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (141651bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C HG1287_PATCH 150745909 1 150059494 EFO_0000692 Schizophrenia schizophrenia European=82315|East Asian=5219 GCST002539 9.397940008672037 GCST002539 25056061 drug Medium Ed Mountjoy Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (141651bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C HG1287_PATCH 150745909 1 150059494 EFO_0000692 Schizophrenia schizophrenia NR=150064|European=70017 GCST007257 10.301029995663981 GCST007257 30626913 drug Medium Ed Mountjoy Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000159164 at this locus (225954bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 1 150115974 1 150143798 EFO_0000692 Broad depression or schizophrenia schizophrenia NR=150064|European=70017 GCST007257 10.301029995663981 GCST007257 30626913 drug Medium Ed Mountjoy Synaptic vesicle glycoprotein 2A modulator drug LEVETIRACETAM is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000159164 at this locus (225954bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 1 150115974 1 150143798 EFO_0003761 Broad depression or schizophrenia unipolar depression European=140254 GCST006085 11.0 GCST006085 29892016 drug Medium Ed Mountjoy Cathepsin K inhibitor drug ODANACATIB is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000143387 at this locus (110398bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000143387 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 1 150658287 1 150685811 EFO_0001663 Prostate cancer prostate carcinoma European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080 GCST002606 10.221848749616356 GCST002606_3 25217961 drug Medium Ed Mountjoy Cathepsin K inhibitor drug ODANACATIB is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000143387 at this locus (110398bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000143387 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 1 150658287 1 150685811 EFO_0001663 Prostate cancer [EA] prostate carcinoma European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080 GCST002606 8.522878745280337 GCST002606 25217961 drug Medium Ed Mountjoy Cathepsin K inhibitor drug ODANACATIB is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000143387 at this locus (110398bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000143387 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 1 150658287 1 150685811 EFO_0001663 Prostate cancer prostate carcinoma European=459000 GCST007072 9.096910013008056 GCST007072 30595370 drug High Ed Mountjoy Atrial natriuretic peptide receptor A agonist drug NESIRITIDE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000169418 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169418 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 1 153662423 1 153689947 EFO_0000319 Cardiovascular disease cardiovascular system disease European=361141 10.209025579976215 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Atrial natriuretic peptide receptor A agonist drug NESIRITIDE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000169418 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169418 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 1 153662423 1 153689947 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=22647|East Asian=3117 GCST005529 14.698970004336019 GCST005529_3 23749187 drug Medium Ed Mountjoy Interleukin-6 receptor alpha subunit inhibitor drug TOCILIZUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160712 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 1 154426264 1 154453788 EFO_0003898 Ankylosing spondylitis [EA] ankylosing spondylitis European=86475 GCST005537 17.045757490560675 GCST005537 26974007 drug Medium Ed Mountjoy Interleukin-6 receptor alpha subunit inhibitor drug TOCILIZUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160712 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 1 154426264 1 154453788 EFO_0003898 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ankylosing spondylitis European=22647|East Asian=3117 GCST005529 12.522878745280337 GCST005529 23749187 drug Low Ed Mountjoy Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160712 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 1 154426264 1 154453788 EFO_0003898 Ankylosing spondylitis ankylosing spondylitis European=22647|East Asian=3117 GCST005529 14.698970004336019 GCST005529_3 23749187 drug Low Ed Mountjoy Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160712 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 1 154426264 1 154453788 EFO_0003898 Ankylosing spondylitis [EA] ankylosing spondylitis European=86475 GCST005537 17.045757490560675 GCST005537 26974007 drug Low Ed Mountjoy Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160712 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 1 154426264 1 154453788 EFO_0003898 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ankylosing spondylitis European=22647|East Asian=3117 GCST005529 12.522878745280337 GCST005529 23749187 drug Medium Ed Mountjoy Interleukin-6 receptor alpha subunit inhibitor drug TOCILIZUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000160712 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160712 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 1 154426264 1 154453788 EFO_0003898 Ankylosing spondylitis ankylosing spondylitis European=58284|East Asian=22515 GCST002318 8.397940008672037 GCST002318 24390342 drug High Ed Mountjoy Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000160712 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160712 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 1 154426970 1 154454494 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis European=47580 GCST005569 7.8807441107220635 GCST005569 23143596 drug High Ed Mountjoy Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000160712 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160712 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 1 154426970 1 154454494 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis African American or Afro-Caribbean=2308 GCST006959 8.522878745280337 GCST006959 30423114 drug High Ed Mountjoy Interleukin-6 receptor alpha subunit antagonist drug SARILUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000160712 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160712 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 1 154426970 1 154454494 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis European=140254 GCST006085 8.0 GCST006085 29892016 drug Low Ed Mountjoy Farnesyl diphosphate synthase inhibitor drug ZOLEDRONIC ACID is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000160752 at this locus (447041bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160752 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 1 154834183 1 154861707 EFO_0001663 Prostate cancer prostate carcinoma European=22548 GCST001942 7.698970004336019 GCST001942 23535732 drug Low Ed Mountjoy Farnesyl diphosphate synthase inhibitor drug ZOLEDRONIC ACID is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000160752 at this locus (447041bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160752 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 1 154834183 1 154861707 EFO_0001663 Prostate cancer prostate carcinoma European=86475 GCST005537 9.522878745280337 GCST005537 26974007 drug Medium Ed Mountjoy Farnesyl diphosphate synthase inhibitor drug PAMIDRONIC ACID is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000160752 at this locus (150834bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160752 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 1 155130391 1 155157915 EFO_0003898 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ankylosing spondylitis European=139274 GCST004988 10.316502682320188 GCST004988 29059683 drug Medium Ed Mountjoy Farnesyl diphosphate synthase inhibitor drug ZOLEDRONIC ACID is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000160752 at this locus (132444bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160752 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 1 155148781 1 155176305 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 10.316502682320188 GCST004988 29059683 drug Medium Ed Mountjoy Farnesyl diphosphate synthase inhibitor drug ALENDRONIC ACID is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000160752 at this locus (132444bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160752 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 1 155148781 1 155176305 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 10.316502682320188 GCST004988 29059683 drug Low Ed Mountjoy Mucin-1 other drug HUHMFG1 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000185499 at this locus (9520bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000185499 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 1 155148781 1 155176305 EFO_0000305 Breast cancer breast carcinoma European=360527 33.801755413771765 NEALE2_6152_7 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Coagulation factor V inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000198734 at this locus (15751bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198734 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 1 169467654 1 169498416 EFO_0003827 Blood clot in the lung | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor pulmonary embolism European=361141 34.79160702064111 NEALE2_20002_1093 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Coagulation factor V inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000198734 at this locus (15751bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198734 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 1 169467654 1 169498416 EFO_0003827 Pulmonary embolism +/- dvt | non-cancer illness code, self-reported pulmonary embolism European=258962 GCST003390 136.39794000867204 GCST003390 26908601 drug Low Ed Mountjoy Coagulation factor V inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000198734 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198734 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 1 169519049 1 169549811 EFO_0003827 Thrombosis pulmonary embolism European=361141 7.340779989063745 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (452003bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000117586 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 1 172700868 1 172731728 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=341215 GCST007798 11.154901959985743 GCST007798 30929738 drug Low Ed Mountjoy Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (21377bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000117586 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 1 173131493 1 173162354 EFO_0000270 Asthma asthma European=157242 GCST003987 7.522878745280337 GCST003987 27182965 drug Low Ed Mountjoy Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (834bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000117586 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 1 173152036 1 173182897 EFO_0000270 Asthma asthma European=361141 8.202546175019036 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000117586 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 1 173170618 1 173201479 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=360527 8.11264155329629 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Tumor necrosis factor ligand superfamily member 4 inhibitor drug OXELUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000117586 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000117586 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 1 173170618 1 173201479 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=455221 GCST007093 8.0 GCST007093 30664745 drug Low Ed Mountjoy Antithrombin-III activator drug HEPARIN SODIUM is Phase IV for the indiciation EFO_0002506 and targets the gene ENSG00000117601 at this locus (305887bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000117601 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T TAAAAAAAAAAAAAAAAA 1 174192402 1 174223264 EFO_0002506 Osteoarthritis osteoarthritis European=20883 GCST003044 8.37190434327122 GCST003044 26192919 drug Medium Ed Mountjoy Cyclooxygenase-2 inhibitor drug CELECOXIB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000073756 at this locus (225905bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000073756 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 1 186875459 1 186906327 EFO_0000384 Crohn's disease [EA] Crohn's disease European=1030836 GCST006414 19.006828394969236 GCST006414 30061737 drug Low Ed Mountjoy Adenosine A1 receptor partial agonist drug CAPADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (33568bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163485 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 1 203026214 1 203057086 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 24.221848749616356 GCST006061 29892015 drug Low Ed Mountjoy Adenosine A1 receptor partial agonist drug CAPADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (33568bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163485 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 1 203026214 1 203057086 EFO_0000275 Atrial fibrillation atrial fibrillation East Asian=36792 GCST004373 10.045757490560675 GCST004373 28416822 drug Low Ed Mountjoy Adenosine A1 receptor agonist drug SELODENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (33191bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163485 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 1 203026591 1 203057463 EFO_0000275 Atrial fibrillation atrial fibrillation European=395739 10.1038/s41588-018-0184-y 9.97061622231479 SAIGE_427_2 drug Low Ed Mountjoy Adenosine A1 receptor agonist drug TECADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (31072bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163485 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 1 203028711 1 203059583 EFO_0000275 Atrial fibrillation and flutter atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 18.0 GCST006061_3 29892015 drug Low Ed Mountjoy Adenosine A1 receptor agonist drug TECADENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (31072bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163485 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 1 203028711 1 203059583 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation East Asian=4372 GCST004352 8.698970004336019 GCST004352 28460022 drug Low Ed Mountjoy Adenosine A1 receptor agonist drug SELODENOSON is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000163485 at this locus (24876bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163485 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 1 203034906 1 203065778 EFO_0000275 Early onset atrial fibrillation atrial fibrillation European=360527 9.949848472659069 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163485 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 1 203091274 1 203122146 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=341215 GCST007798 10.045757490560675 GCST007798 30929738 drug Low Ed Mountjoy Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163485 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 1 203093201 1 203124073 EFO_0000270 Asthma asthma European=157242 GCST003987 8.0 GCST003987 27182965 drug Low Ed Mountjoy Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163485 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 1 203100504 1 203131376 EFO_0000270 Asthma asthma European=361141 9.000392345087638 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Adenosine A1 receptor antagonist drug PBF-680 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000163485 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163485 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II TA T 1 203103205 1 203134077 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=361141 8.172660456455034 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Potassium channel subfamily K member 2 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000082482 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082482 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T TATA 1 215304685 1 215131342 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=139274 GCST004988 8.408601448718752 GCST004988 29059683 drug Low Ed Mountjoy Estrogen-related receptor gamma antagonist drug AFIMOXIFENE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000196482 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196482 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 1 217220574 1 217047232 EFO_0000305 Breast cancer breast carcinoma European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811 GCST007692 8.154901959985743 GCST007692 30804561 drug High Ed Mountjoy Muscarinic acetylcholine receptor M3 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000133019 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000133019 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C G 1 239901006 1 239737706 EFO_0000341 Chronic obstructive pulmonary disease chronic obstructive pulmonary disease European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811 GCST007692 8.154901959985743 GCST007692 30804561 drug Low Ed Mountjoy Muscarinic acetylcholine receptor M3 antagonist drug AZD8683 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000133019 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000133019 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 1 239901006 1 239737706 EFO_0000341 Chronic obstructive pulmonary disease chronic obstructive pulmonary disease European=88583 GCST007505 7.698970004336019 GCST007505 30429480 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000134460 at this locus (268502bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 10 5784151 10 5742188 EFO_0000389 Nevus count or cutaneous melanoma skin melanoma European=20883 GCST003044 12.095825631715837 GCST003044 26192919 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 10 6081230 10 6039267 EFO_0000384 Crohn's disease [EA] Crohn's disease European=4421 GCST004290 9.0 GCST004290 28445677 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 10 6092346 10 6050383 EFO_0003885 Multiple sclerosis multiple sclerosis European=360527 14.096910013008056 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6093139 10 6051176 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=341215 GCST007798 17.69897000433602 GCST007798 30929738 drug Low Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6093139 10 6051176 EFO_0000270 Asthma asthma European=401837 10.1038/s41588-018-0184-y 8.749579997691106 SAIGE_495 drug Low Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6093139 10 6051176 EFO_0000270 Asthma asthma European=361141 13.823908740944319 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6093139 10 6051176 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=86475 GCST005537 15.0 GCST005537 26974007 drug Low Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6094697 10 6052734 EFO_0000729 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ulcerative colitis European=16179 GCST001394 8.301029995663981 GCST001394 22293688 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 10 6094697 10 6052734 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European, NR=40266 GCST004132 7.702896349850744 GCST004132 28067908 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6094697 10 6052734 EFO_0000384 Crohn's disease Crohn's disease European=86475 GCST005537 15.0 GCST005537 26974007 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6094697 10 6052734 EFO_0000384 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] Crohn's disease European=29652 GCST005536 38.54606892809315 GCST005536 25751624 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6094697 10 6052734 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=16179 GCST001394 8.301029995663981 GCST001394 22293688 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6094697 10 6052734 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=102453 GCST007563 11.397940008672037 GCST007563 29785011 drug Low Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6094697 10 6052734 EFO_0000270 Allergic disease (asthma, hay fever or eczema) asthma European=29652 GCST005536 38.54606892809315 GCST005536 25751624 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 10 6094697 10 6052734 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=20883 GCST003044 12.496209316942819 GCST003044 26192919 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6094697 10 6052734 EFO_0000384 Crohn's disease [EA] Crohn's disease European=116538 GCST007564 10.698970004336019 GCST007564 29785011 drug Low Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6094697 10 6052734 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European=19102 GCST001191 38.0 GCST001191 21829393 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 10 6097283 10 6055320 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=19102 GCST001191 38.0 GCST001191 21829393 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 10 6097283 10 6055320 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=16753 GCST003097 8.221848749616356 GCST003097 26301688 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6098949 10 6056986 EFO_0000384 Pediatric autoimmune diseases Crohn's disease European=16753 GCST003097 8.221848749616356 GCST003097 26301688 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6098949 10 6056986 EFO_0001359 Pediatric autoimmune diseases insulin-dependent diabetes mellitus European=16753 GCST003097 8.221848749616356 GCST003097 26301688 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 10 6098949 10 6056986 EFO_0001359 Pediatric autoimmune diseases insulin-dependent diabetes mellitus European=16753 GCST003097 8.221848749616356 GCST003097 26301688 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6098949 10 6056986 EFO_0002690 Pediatric autoimmune diseases systemic lupus erythematosus European=16753 GCST003097 8.221848749616356 GCST003097 26301688 drug Low Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6098949 10 6056986 EFO_0000729 Pediatric autoimmune diseases ulcerative colitis European=38582 GCST005531 22.11861534322943 GCST005531 24076602 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 10 6099045 10 6057082 EFO_0003885 Multiple sclerosis multiple sclerosis European=26621 GCST001198 8.68909437062386 GCST001198 21833088 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 10 6101713 10 6059750 EFO_0003885 Multiple sclerosis multiple sclerosis European=21389 GCST000879 8.522878745280337 GCST000879 21102463 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6102012 10 6060049 EFO_0000384 Crohn's disease Crohn's disease European=5224 GCST000062 7.522878745280337 GCST000062 17660530 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 10 6102012 10 6060049 EFO_0003885 Multiple sclerosis multiple sclerosis European=17698 GCST001341 7.3979400086720375 GCST001341 22190364 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 10 6102012 10 6060049 EFO_0003885 Multiple sclerosis multiple sclerosis European=29652 GCST005536 22.81702340982209 GCST005536 25751624 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (2219bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 10 6106552 10 6064589 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=29652 GCST005536 22.81702340982209 GCST005536 25751624 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (2219bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 10 6106552 10 6064589 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=38582 GCST005531 20.443697499232712 GCST005531 24076602 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (16953bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 10 6121286 10 6079323 EFO_0003885 Multiple sclerosis multiple sclerosis European=15283 GCST003566 8.397940008672037 GCST003566 27386562 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (18336bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 10 6122669 10 6080706 EFO_0003885 Multiple sclerosis multiple sclerosis European=16559 GCST000392 13.0 GCST000392 19430480 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (19162bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 10 6123495 10 6081532 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=16559 GCST000392 13.0 GCST000392 19430480 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (19162bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6123495 10 6081532 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=38582 GCST005531 17.190440285364733 GCST005531 24076602 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000134460 at this locus (19925bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 10 6124257 10 6082294 EFO_0003885 Multiple sclerosis multiple sclerosis European=29652 GCST005536 8.257205214388867 GCST005536 25751624 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (25311bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6129643 10 6087680 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=29652 GCST005536 8.257205214388867 GCST005536 25751624 drug Medium Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (25311bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 10 6129643 10 6087680 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=27432 GCST003045 8.018482423811946 GCST003045 26192919 drug Low Ed Mountjoy Interleukin-2 receptor inhibitor drug BASILIXIMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000134460 at this locus (71834bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 6176166 10 6134203 EFO_0000729 Ulcerative colitis [EA] ulcerative colitis European=8207 GCST000258 8.397940008672037 GCST000258 18978792 drug Low Ed Mountjoy Interleukin-2 receptor inhibitor drug DACLIZUMAB is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (286119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 10 6390450 10 6348488 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=8207 GCST000258 8.397940008672037 GCST000258 18978792 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000134460 at this locus (286119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000134460 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 6390450 10 6348488 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=18264|African American or Afro-Caribbean=5422|Hispanic or Latin American=3888 GCST005752 9.154901959985743 GCST005752 28714469 drug Low Ed Mountjoy c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (327251bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000107643 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 10 49974656 10 48766611 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus East Asian=5420 GCST003599 8.698970004336019 GCST003599 26663301 drug Low Ed Mountjoy c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000107643 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 50025396 10 48817351 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus European=14267 GCST003155 10.065299598284575 GCST003155 26502338 drug Low Ed Mountjoy c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000107643 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 50025396 10 48817351 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus East Asian=5057|European=10995 GCST003622 10.045757490560675 GCST003622_3 27399966 drug Low Ed Mountjoy c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000107643 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 50025396 10 48817351 EFO_0002690 Systemic lupus erythematosus [EA] systemic lupus erythematosus European=14267 GCST003156 10.065299598284575 GCST003156 26502338 drug Low Ed Mountjoy c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000107643 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 50025396 10 48817351 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus East Asian=1798 GCST000592 11.096910013008056 GCST000592 20169177 drug Low Ed Mountjoy c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (377992bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000107643 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 50025396 10 48817351 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus East Asian=5050 GCST001795 8.096910013008056 GCST001795 23273568 drug Low Ed Mountjoy c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (395547bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000107643 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 50042951 10 48834906 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus European=18264 GCST007400 8.0 GCST007400 28714469 drug Low Ed Mountjoy c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (454572bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000107643 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 50101977 10 48893932 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus East Asian=2252 GCST000507 11.154901959985743 GCST000507 19838193 drug Low Ed Mountjoy c-Jun N-terminal kinase 1 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000107643 at this locus (471650bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000107643 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 50119054 10 48911009 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus European=86475 GCST005537 10.522878745280337 GCST005537 26974007 drug Low Ed Mountjoy Cytochrome P450 26A1 inhibitor drug TALAROZOLE is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000095596 at this locus (401233bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000095596 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 10 94432000 10 92672243 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis European=22548 GCST001942 9.301029995663981 GCST001942 23535732 drug Medium Ed Mountjoy Cytochrome P450 17A1 inhibitor drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000148795 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 10 104414221 10 102654464 EFO_0001663 Prostate cancer prostate carcinoma European=22548 GCST001942 9.301029995663981 GCST001942 23535732 drug Medium Ed Mountjoy Cytochrome P450 17A1 inhibitor drug ORTERONEL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000148795 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 10 104414221 10 102654464 EFO_0001663 Prostate cancer prostate carcinoma European=140254 GCST006085 15.221848749616356 GCST006085 29892016 drug Medium Ed Mountjoy Cytochrome P450 17A1 inhibitor drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000148795 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 10 104414221 10 102654464 EFO_0001663 Prostate cancer prostate carcinoma European=140254 GCST006085 15.221848749616356 GCST006085 29892016 drug Medium Ed Mountjoy Cytochrome P450 17A1 inhibitor drug ORTERONEL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000148795 at this locus (176068bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000148795 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 10 104414221 10 102654464 EFO_0001663 Prostate cancer prostate carcinoma European=361141 8.399595651036623 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Beta-1 adrenergic receptor antagonist drug NADOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (80138bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000043591 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 10 115723678 10 113963919 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension East Asian=50792 GCST007707 8.698970004336019 GCST007707 30487518 drug High Ed Mountjoy Beta-1 adrenergic receptor antagonist drug ACEBUTOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (61988bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000043591 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 10 115741828 10 113982069 EFO_0000537 Hypertension [East Asian] hypertension European=91102|African American or Afro-Caribbean=21417|Asian unspecified=12365|Hispanic or Latin American=8471 GCST006434 19.69897000433602 GCST006434_9 29912962 drug Low Ed Mountjoy Beta-1 adrenergic receptor antagonist drug PROPRANOLOL is Phase II for the indiciation EFO_0004329 and targets the gene ENSG00000043591 at this locus (11754bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000043591 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 115792062 10 114032303 EFO_0004329 Systolic blood pressure x alcohol consumption interaction (2df test) [EA] alcohol drinking European=91110|African American or Afro-Caribbean=21416|Asian unspecified=12365|Hispanic or Latin American=8470 GCST006167 9.698970004336019 GCST006167_9 29912962 drug Low Ed Mountjoy Beta-1 adrenergic receptor antagonist drug PROPRANOLOL is Phase II for the indiciation EFO_0004329 and targets the gene ENSG00000043591 at this locus (11029bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000043591 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 115792787 10 114033028 EFO_0004329 Mean arterial pressure x alcohol consumption interaction (2df test) [EA] alcohol drinking European=361141 21.73008330295326 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Beta-1 adrenergic receptor antagonist drug METOPROLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (11029bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000043591 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 10 115792787 10 114033028 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=91099|African American or Afro-Caribbean=21416|Asian unspecified=12365|Hispanic or Latin American=8471 GCST006166 22.096910013008056 GCST006166_8 29912962 drug Low Ed Mountjoy Beta-1 adrenergic receptor antagonist drug PROPRANOLOL is Phase II for the indiciation EFO_0004329 and targets the gene ENSG00000043591 at this locus (11029bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000043591 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 115792787 10 114033028 EFO_0004329 Diastolic blood pressure x alcohol consumption interaction (2df test) [EA] alcohol drinking European=408089 10.1038/s41588-018-0184-y 14.522878745280337 SAIGE_401_1 drug High Ed Mountjoy Beta-1 adrenergic receptor antagonist drug NEBIVOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000043591 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C G 10 115805056 10 114045297 EFO_0000537 Essential hypertension hypertension European=408343 10.1038/s41588-018-0184-y 14.397940008672037 SAIGE_401 drug High Ed Mountjoy Beta-1 adrenergic receptor antagonist drug NEBIVOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000043591 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000043591 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C G 10 115805056 10 114045297 EFO_0000537 Hypertension hypertension European=459000 GCST007072 23.221848749616356 GCST007072 30595370 drug High Ed Mountjoy Beta-1 adrenergic receptor agonist drug DOPAMINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000043591 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000043591 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C G 10 115805056 10 114045297 EFO_0000319 Cardiovascular disease cardiovascular system disease European=22627 GCST001937 7.698970004336019 GCST001937 23535729 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (143947bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 123093901 10 121334387 EFO_0000305 Breast cancer breast carcinoma European=33864 GCST004950 8.096910013008056 GCST004950 25751625 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (143947bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 123093901 10 121334387 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 11.680685695909489 GCST004988 29059683 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (143858bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II GT G 10 123093991 10 121334477 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 43.678815972697684 GCST004988 29059683 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T A 10 123331467 10 121571953 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 190.37059040089727 GCST004988 29059683 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T A 10 123331690 10 121572176 EFO_0000305 Breast cancer breast carcinoma European=123671 GCST003588 34.096910013008056 GCST003588_2 27197191 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 123334930 10 121575416 EFO_0000305 Cancer (pleiotropy) [subset analysis] breast carcinoma European=123671 GCST003588 34.096910013008056 GCST003588_2 27197191 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug REGORAFENIB is Phase II for the indiciation EFO_0005842 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 123334930 10 121575416 EFO_0005842 Cancer (pleiotropy) [subset analysis] colorectal cancer European=123671 GCST003588 34.096910013008056 GCST003588_2 27197191 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug REGORAFENIB is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 123334930 10 121575416 EFO_0001075 Cancer (pleiotropy) [subset analysis] ovarian carcinoma European=8556 GCST000678 30.397940008672037 GCST000678 20453838 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 123337335 10 121577821 EFO_0000305 Breast cancer breast carcinoma European=2287 GCST000365 9.698970004336019 GCST000365 19330030 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 123337335 10 121577821 EFO_0000305 Breast cancer breast carcinoma European=22627 GCST001937 169.69897000433602 GCST001937 23535729 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 123337335 10 121577821 EFO_0000305 Breast cancer breast carcinoma East Asian=13905 GCST003520 10.522878745280337 GCST003520 27354352 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 123337335 10 121577821 EFO_0000305 Breast cancer breast carcinoma European=33864 GCST004950 163.22184874961636 GCST004950 25751625 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 123337335 10 121577821 EFO_0000305 Breast cancer breast carcinoma European=330828 30.844827992822484 NEALE2_20110_5 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 123338975 10 121579461 EFO_0000305 Breast cancer | illnesses of mother breast carcinoma East Asian=4741 GCST002234 12.0 GCST002234 24143190 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 10 123340311 10 121580797 EFO_0000305 Breast cancer breast carcinoma East Asian=4741 GCST002234 12.0 GCST002234 24143190 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 123340311 10 121580797 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 321.65300282934044 GCST004988 29059683 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G GC 10 123340431 10 121580917 EFO_0000305 Breast cancer breast carcinoma European=279478 14.096910013008056 NEALE2_20111_5 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 10 123343909 10 121584395 EFO_0000305 Breast cancer | illnesses of siblings breast carcinoma European=1703 GCST000846 8.0 GCST000846 21060860 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 123346116 10 121586602 EFO_0000305 Breast cancer in BRCA2 mutation carriers breast carcinoma European=401447 10.1038/s41588-018-0184-y 71.26440110030182 SAIGE_174 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 10 123346116 10 121586602 EFO_0000305 Breast cancer breast carcinoma European=6346 GCST000952 30.0 GCST000952 21263130 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 123346190 10 121586676 EFO_0000305 Breast cancer breast carcinoma East Asian=13905 GCST003520 8.221848749616356 GCST003520 27354352 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 123346190 10 121586676 EFO_0000305 Breast cancer breast carcinoma European=8428 GCST000811 12.698970004336019 GCST000811 20872241 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 123346190 10 121586676 EFO_0000305 Breast cancer breast carcinoma European=2287 GCST000036 10.0 GCST000036 17529973 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 123346190 10 121586676 EFO_0000305 Breast cancer breast carcinoma European=6225 GCST002346 26.522878745280337 GCST002346 24493630 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 10 123348662 10 121589148 EFO_0000305 Breast cancer (early onset) breast carcinoma European=139274 GCST004988 36.13804762507855 GCST004988 29059683 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T A 10 123349324 10 121589810 EFO_0000305 Breast cancer breast carcinoma European=359981 13.229147988357855 NEALE2_2453 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug REGORAFENIB is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 10 123350216 10 121590702 EFO_0000311 Cancer diagnosed by doctor cancer European=8211 GCST007302 13.698970004336019 GCST007302 23544012 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 10 123351324 10 121591810 EFO_0000305 Breast cancer in BRCA2 mutation carriers breast carcinoma European=5452 GCST003823 10.301029995663981 GCST003823 27764800 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 123352220 10 121592706 EFO_0000305 Estrogen receptor status in HER2 negative breast cancer breast carcinoma European=754 GCST000035 75.69897000433602 GCST000035 17529967 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 123352317 10 121592803 EFO_0000305 Breast cancer breast carcinoma East Asian=13905 GCST003520 7.698970004336019 GCST003520 27354352 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 10 123352317 10 121592803 EFO_0000305 Breast cancer breast carcinoma European=8727 GCST003821 11.221848749616356 GCST003821 27764800 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 10 123353869 10 121594355 EFO_0000305 Estrogen receptor status in breast cancer breast carcinoma European=139274 GCST004988 13.173925197299173 GCST004988 29059683 drug Low Ed Mountjoy Fibroblast growth factor receptor 2 inhibitor drug LUCITANIB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000066468 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000066468 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 10 123357561 10 121598047 EFO_0000305 Breast cancer breast carcinoma European=408089 10.1038/s41588-018-0184-y 15.0 SAIGE_401_1 drug Low Ed Mountjoy Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (311928bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180176 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 11 1873232 11 1852002 EFO_0000537 Essential hypertension hypertension European=408343 10.1038/s41588-018-0184-y 15.0 SAIGE_401 drug Low Ed Mountjoy Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (311928bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180176 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 11 1873232 11 1852002 EFO_0000537 Hypertension hypertension European=361141 16.29810490633703 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (308214bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180176 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 1876945 11 1855715 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension East Asian=50792 GCST007707 8.0 GCST007707_2 30487518 drug Low Ed Mountjoy Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (298091bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180176 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 11 1887068 11 1865838 EFO_0000537 Hypertension [Japanese] hypertension European=361141 26.22452645095722 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (296545bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180176 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 1888614 11 1867384 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=408089 10.1038/s41588-018-0184-y 19.518557371497696 SAIGE_401_1 drug Low Ed Mountjoy Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (296545bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180176 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 1888614 11 1867384 EFO_0000537 Essential hypertension hypertension European=408343 10.1038/s41588-018-0184-y 19.619788758288394 SAIGE_401 drug Low Ed Mountjoy Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (296545bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180176 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 1888614 11 1867384 EFO_0000537 Hypertension hypertension East Asian=50792 GCST007707 15.397940008672037 GCST007707 30487518 drug Low Ed Mountjoy Tyrosine 3-hydroxylase inhibitor drug METYROSINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000180176 at this locus (286496bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180176 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 11 1898664 11 1877434 EFO_0000537 Hypertension [East Asian] hypertension European=139274 GCST004988 37.01300446027562 GCST004988 29059683 drug Low Ed Mountjoy Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (251679bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000167244 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 11 1898664 11 1877434 EFO_0000305 Breast cancer breast carcinoma European=19291 GCST003845 8.045757490560675 GCST003845 27117709 drug Low Ed Mountjoy Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (248245bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000167244 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 1902097 11 1880867 EFO_0000305 Breast cancer breast carcinoma European=33864 GCST004950 12.698970004336019 GCST004950 25751625 drug Low Ed Mountjoy Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (241337bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000167244 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 11 1909006 11 1887776 EFO_0000305 Breast cancer breast carcinoma European=22627 GCST001937 10.698970004336019 GCST001937 23535729 drug Low Ed Mountjoy Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (241337bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000167244 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 11 1909006 11 1887776 EFO_0000305 Breast cancer breast carcinoma European=754 GCST000035 8.522878745280337 GCST000035 17529967 drug Low Ed Mountjoy Insulin-like growth factor II inhibitor drug DUSIGITUMAB is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000167244 at this locus (241337bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000167244 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 11 1909006 11 1887776 EFO_0000305 Breast cancer breast carcinoma European=407701 10.1038/s41588-018-0184-y 9.896196279044043 SAIGE_250_2 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 17408404 11 17386857 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033 GCST005047 10.494850021680094 GCST005047 22885922 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 10.522878745280337 GCST002352 24509480 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 19.69897000433602 GCST006867 30054458 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 13.096910013008056 GCST004894_2 28869590 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 20.0 GCST004894 28869590 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007518 21.30102999566398 GCST007518 29632382 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957 GCST007517 16.397940008672037 GCST007517 29632382 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=4862 GCST000025 10.301029995663981 GCST000025_2 17463249 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes [DGI+FUSION+WTCCC] type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 21.69897000433602 GCST007516 29632382 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 11 17409572 11 17388025 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=2931 GCST000028 10.154901959985743 GCST000028 17463246 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 11 17409572 11 17388025 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=4862 GCST000277 9.0 GCST000277 19056611 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 11 17409572 11 17388025 EFO_0001360 Type 2 diabetes [non-obese] type II diabetes mellitus European=2335 GCST000024 10.154901959985743 GCST000024_2 17463248 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 11 17409572 11 17388025 EFO_0001360 Type 2 diabetes [DGI+FUSION+WTCCC] type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 21.221848749616356 GCST007515 29632382 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 11 17409572 11 17388025 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 11.698970004336019 GCST007077 30595370 drug Low Ed Mountjoy Potassium channel, inwardly rectifying, subfamily J, member 11 opener drug DIAZOXIDE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000187486 at this locus (943bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187486 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 17411821 11 17390274 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=361141 13.853871964321762 NEALE2_20002_1093 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0003827 and targets the gene ENSG00000180210 at this locus (34991bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 11 46705739 11 46684189 EFO_0003827 Pulmonary embolism +/- dvt | non-cancer illness code, self-reported pulmonary embolism European=120158 GCST004256 8.096910013008056 GCST004256_2 28373160 drug Medium Ed Mountjoy Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 11 46760756 11 46739206 EFO_0004286 Venous thromboembolism [Conditioned on rs1799963] venous thromboembolism European=120158 GCST004256 8.096910013008056 GCST004256_2 28373160 drug High Ed Mountjoy Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 46760756 11 46739206 EFO_0004286 Venous thromboembolism [Conditioned on rs1799963] venous thromboembolism European=404271 10.1038/s41588-018-0184-y 12.829738284605043 SAIGE_459_9 drug High Ed Mountjoy Thrombin inhibitor drug ARGATROBAN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 46761055 11 46739505 EFO_0000319 Circulatory disease nec cardiovascular system disease European=258962 GCST003390 24.0 GCST003390 26908601 drug High Ed Mountjoy Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 46761055 11 46739505 EFO_0000712 Thrombosis cerebrovascular accident European=120158 GCST004256 12.301029995663981 GCST004256 28373160 drug High Ed Mountjoy Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 46761055 11 46739505 EFO_0004286 Venous thromboembolism venous thromboembolism European=404449 10.1038/s41588-018-0184-y 12.882728704344236 SAIGE_459 drug High Ed Mountjoy Thrombin inhibitor drug ARGATROBAN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 46761055 11 46739505 EFO_0000319 Other disorders of circulatory system cardiovascular system disease European=404449 10.1038/s41588-018-0184-y 12.882728704344236 SAIGE_459 drug Medium Ed Mountjoy Thrombin inhibitor drug BIVALIRUDIN is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 11 46761055 11 46739505 EFO_0000319 Other disorders of circulatory system cardiovascular system disease European=258962 GCST003390 24.0 GCST003390 26908601 drug Medium Ed Mountjoy Thrombin inhibitor drug ARGATROBAN is Phase III for the indiciation HP_0002140 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 11 46761055 11 46739505 HP_0002140 Thrombosis Ischemic stroke European=360527 19.56919957537582 NEALE2_6152_5 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Thrombin inhibitor drug DESIRUDIN is Phase IV for the indiciation EFO_0003907 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 46761055 11 46739505 EFO_0003907 Blood clot in the leg (dvt) | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor deep vein thrombosis European=60139 GCST002808 8.698970004336019 GCST002808 25772935 drug High Ed Mountjoy Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 46761055 11 46739505 EFO_0004286 Venous thromboembolism venous thromboembolism European=258962 GCST003390 24.0 GCST003390 26908601 drug High Ed Mountjoy Thrombin inhibitor drug DABIGATRAN is Phase IV for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 46761055 11 46739505 EFO_0004286 Thrombosis venous thromboembolism European=120158 GCST004256 12.301029995663981 GCST004256 28373160 drug Medium Ed Mountjoy Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 11 46761055 11 46739505 EFO_0004286 Venous thromboembolism venous thromboembolism European=258962 GCST003390 24.0 GCST003390 26908601 drug High Ed Mountjoy Thrombin inhibitor drug DESIRUDIN is Phase IV for the indiciation EFO_0003907 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 46761055 11 46739505 EFO_0003907 Thrombosis deep vein thrombosis European=404271 10.1038/s41588-018-0184-y 12.829738284605043 SAIGE_459_9 drug Medium Ed Mountjoy Thrombin inhibitor drug BIVALIRUDIN is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 11 46761055 11 46739505 EFO_0000319 Circulatory disease nec cardiovascular system disease European=60139 GCST002808 8.698970004336019 GCST002808 25772935 drug Medium Ed Mountjoy Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 11 46761055 11 46739505 EFO_0004286 Venous thromboembolism venous thromboembolism European=258962 GCST003390 24.0 GCST003390 26908601 drug High Ed Mountjoy Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0003827 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 46761055 11 46739505 EFO_0003827 Thrombosis pulmonary embolism European=361141 20.081541349622885 NEALE2_20002_1094 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Thrombin inhibitor drug DESIRUDIN is Phase IV for the indiciation EFO_0003907 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 46761055 11 46739505 EFO_0003907 Deep venous thrombosis (dvt) | non-cancer illness code, self-reported deep vein thrombosis European=360527 12.362510270487489 NEALE2_6152_7 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase IV for the indiciation EFO_0003827 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 46761055 11 46739505 EFO_0003827 Blood clot in the lung | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor pulmonary embolism European=258962 GCST003390 24.0 GCST003390 26908601 drug Medium Ed Mountjoy Thrombin inhibitor drug DABIGATRAN ETEXILATE is Phase III for the indiciation EFO_0004286 and targets the gene ENSG00000180210 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180210 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 11 46761055 11 46739505 EFO_0004286 Thrombosis venous thromboembolism European=360527 8.413929430513312 NEALE2_6152_9 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy G protein-coupled receptor 44 antagonist drug SETIPIPRANT is Phase III for the indiciation EFO_0003956 and targets the gene ENSG00000183134 at this locus (170226bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183134 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 11 60793648 11 61026176 EFO_0003956 Hayfever, allergic rhinitis or eczema | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor seasonal allergic rhinitis European=360527 8.413929430513312 NEALE2_6152_9 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy G protein-coupled receptor 44 antagonist drug QAV680 is Phase II for the indiciation EFO_0003956 and targets the gene ENSG00000183134 at this locus (170226bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183134 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 60793648 11 61026176 EFO_0003956 Hayfever, allergic rhinitis or eczema | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor seasonal allergic rhinitis European=1951 GCST001737 26.0 GCST001737_2 23144326 drug Low Ed Mountjoy Muscarinic acetylcholine receptor M1 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (489610bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168539 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 62186542 11 62419070 EFO_0000341 Chronic obstructive pulmonary disease-related biomarkers [CC16] chronic obstructive pulmonary disease European=1951 GCST001737 26.0 GCST001737_2 23144326 drug Low Ed Mountjoy Muscarinic acetylcholine receptor M1 antagonist drug ASM-024 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (489610bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168539 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 11 62186542 11 62419070 EFO_0000341 Chronic obstructive pulmonary disease-related biomarkers [CC16] chronic obstructive pulmonary disease European=1951 GCST001737 13.698970004336019 GCST001737_2 23144326 drug Low Ed Mountjoy Muscarinic acetylcholine receptor M1 antagonist drug ASM-024 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (478724bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168539 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 11 62197427 11 62429955 EFO_0000341 Chronic obstructive pulmonary disease-related biomarkers [CC16] chronic obstructive pulmonary disease European=1951 GCST001737 13.698970004336019 GCST001737_2 23144326 drug Low Ed Mountjoy Muscarinic acetylcholine receptor M1 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (478724bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168539 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 11 62197427 11 62429955 EFO_0000341 Chronic obstructive pulmonary disease-related biomarkers [CC16] chronic obstructive pulmonary disease European=1951 GCST001737 9.0 GCST001737_2 23144326 drug Low Ed Mountjoy Muscarinic acetylcholine receptor M1 antagonist drug ASM-024 is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (476334bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168539 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 11 62199817 11 62432345 EFO_0000341 Chronic obstructive pulmonary disease-related biomarkers [CC16] chronic obstructive pulmonary disease European=1951 GCST001737 9.0 GCST001737_2 23144326 drug Low Ed Mountjoy Muscarinic acetylcholine receptor M1 antagonist drug GLYCOPYRRONIUM is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000168539 at this locus (476334bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168539 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 11 62199817 11 62432345 EFO_0000341 Chronic obstructive pulmonary disease-related biomarkers [CC16] chronic obstructive pulmonary disease European=408393 10.1038/s41588-018-0184-y 7.543633966870957 SAIGE_274_1 drug Low Ed Mountjoy Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (23999bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197891 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 64334114 11 64566642 EFO_0004274 Gout gout European=408393 10.1038/s41588-018-0184-y 7.543633966870957 SAIGE_274_1 drug High Ed Mountjoy Solute carrier family 22 member 12 inhibitor drug LESINURAD is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (23999bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197891 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 64334114 11 64566642 EFO_0004274 Gout gout European=408393 10.1038/s41588-018-0184-y 7.543633966870957 SAIGE_274_1 drug High Ed Mountjoy Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168065 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 64334114 11 64566642 EFO_0004274 Gout gout European=361141 15.066630665946775 NEALE2_20002_1466 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (9456bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168065 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 11 64349802 11 64582330 EFO_0004274 Gout | non-cancer illness code, self-reported gout European=361141 15.066630665946775 NEALE2_20002_1466 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (8311bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197891 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 11 64349802 11 64582330 EFO_0004274 Gout | non-cancer illness code, self-reported gout European=361141 15.066630665946775 NEALE2_20002_1466 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Solute carrier family 22 member 12 inhibitor drug SULFINPYRAZONE is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (8311bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197891 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 11 64349802 11 64582330 EFO_0004274 Gout | non-cancer illness code, self-reported gout European=361141 23.07433525192862 NEALE2_20002_1466 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Solute carrier family 22 member 12 inhibitor drug LESINURAD is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (6050bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197891 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 11 64352063 11 64584591 EFO_0004274 Gout | non-cancer illness code, self-reported gout European=361141 23.07433525192862 NEALE2_20002_1466 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (6050bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197891 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 11 64352063 11 64584591 EFO_0004274 Gout | non-cancer illness code, self-reported gout European=361141 23.07433525192862 NEALE2_20002_1466 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (11717bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168065 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 11 64352063 11 64584591 EFO_0004274 Gout | non-cancer illness code, self-reported gout East Asian=2158 GCST003925 10.301029995663981 GCST003925_2 27899376 drug High Ed Mountjoy Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (95559bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168065 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 64435906 11 64668434 EFO_0004274 Gout [Japanese] gout East Asian=1832 GCST003926 9.045757490560675 GCST003926 27899376 drug Low Ed Mountjoy Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197891 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 64435906 11 64668434 EFO_0004274 Renal underexcretion gout gout East Asian=1832 GCST003926 9.045757490560675 GCST003926 27899376 drug High Ed Mountjoy Solute carrier family 22 member 11 inhibitor drug PROBENECID is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000168065 at this locus (95559bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168065 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 64435906 11 64668434 EFO_0004274 Renal underexcretion gout gout East Asian=2158 GCST003925 10.301029995663981 GCST003925_2 27899376 drug Low Ed Mountjoy Solute carrier family 22 member 12 inhibitor drug ARHALOFENATE is Phase II for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197891 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 64435906 11 64668434 EFO_0004274 Gout [Japanese] gout East Asian=1832 GCST003926 9.045757490560675 GCST003926 27899376 drug High Ed Mountjoy Solute carrier family 22 member 12 inhibitor drug BENZBROMARONE is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197891 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 64435906 11 64668434 EFO_0004274 Renal underexcretion gout gout East Asian=2158 GCST003925 10.301029995663981 GCST003925_2 27899376 drug High Ed Mountjoy Solute carrier family 22 member 12 inhibitor drug BENZBROMARONE is Phase IV for the indiciation EFO_0004274 and targets the gene ENSG00000197891 at this locus (66081bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197891 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 64435906 11 64668434 EFO_0004274 Gout [Japanese] gout European=688809 GCST006477 9.0 GCST006477 29942085 drug Low Ed Mountjoy Metabotropic glutamate receptor 5 modulator drug BASIMGLURANT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000168959 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168959 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 11 88695846 11 88962678 EFO_0003761 Depression unipolar depression NR=361315|European=446238 GCST007342 24.522878745280337 GCST007342 30718901 drug Low Ed Mountjoy Metabotropic glutamate receptor 5 modulator drug BASIMGLURANT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000168959 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168959 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 11 88744425 11 89011257 EFO_0003761 Depression unipolar depression European=322580 GCST005902 10.171997842193115 GCST005902 29662059 drug Low Ed Mountjoy Metabotropic glutamate receptor 5 modulator drug BASIMGLURANT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000168959 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000168959 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 11 88748162 11 89014994 EFO_0003761 Depression (broad) unipolar depression East Asian=50792 GCST007707 12.0 GCST007707 30487518 drug Low Ed Mountjoy Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (318127bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082175 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 11 100582228 11 100711497 EFO_0000537 Hypertension [East Asian] hypertension East Asian=50792 GCST007707 9.301029995663981 GCST007707_2 30487518 drug Low Ed Mountjoy Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (306817bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082175 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 11 100593538 11 100722807 EFO_0000537 Hypertension [Japanese] hypertension European, NR=58918|European=458554 GCST007611 46.69897000433602 GCST007611 30940143 drug Low Ed Mountjoy Progesterone receptor agonist drug MEGESTROL ACETATE is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000082175 at this locus (306817bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082175 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 11 100593538 11 100722807 EFO_0000341 Chronic obstructive pulmonary disease or high blood pressure (pleiotropy) chronic obstructive pulmonary disease European=69395 GCST001238 10.301029995663981 GCST001238 21909115 drug Low Ed Mountjoy Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (306817bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082175 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 11 100593538 11 100722807 EFO_0000537 Hypertension hypertension European, NR=58918|European=458554 GCST007611 46.69897000433602 GCST007611 30940143 drug Low Ed Mountjoy Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (306817bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082175 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 11 100593538 11 100722807 EFO_0000537 Chronic obstructive pulmonary disease or high blood pressure (pleiotropy) hypertension European=408458 10.1038/s41588-018-0184-y 8.14206473528057 SAIGE_411 drug Low Ed Mountjoy Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (306817bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082175 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 11 100593538 11 100722807 EFO_0000378 Ischemic heart disease coronary artery disease European=459000 GCST007072 39.096910013008056 GCST007072 30595370 drug Low Ed Mountjoy Progesterone receptor agonist drug DROSPIRENONE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000082175 at this locus (289809bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082175 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 11 100610546 11 100739815 EFO_0000319 Cardiovascular disease cardiovascular system disease NR=547261 GCST005195 9.55284196865778 GCST005195 29212778 drug Low Ed Mountjoy Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (289809bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082175 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 11 100610546 11 100739815 EFO_0000378 Coronary artery disease coronary artery disease European=408089 10.1038/s41588-018-0184-y 20.34008379993015 SAIGE_401_1 drug Low Ed Mountjoy Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (289809bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082175 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 11 100610546 11 100739815 EFO_0000537 Essential hypertension hypertension European=408343 10.1038/s41588-018-0184-y 20.27490547891853 SAIGE_401 drug Low Ed Mountjoy Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (289809bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082175 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 11 100610546 11 100739815 EFO_0000537 Hypertension hypertension European=361141 38.813874644838485 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Progesterone receptor agonist drug DROSPIRENONE is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000082175 at this locus (289809bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082175 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 11 100610546 11 100739815 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension NR=250736 GCST005196 8.522878745280337 GCST005196 29212778 drug Low Ed Mountjoy Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (275756bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082175 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 11 100624599 11 100753868 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 10.168322150808534 GCST005194 29212778 drug Low Ed Mountjoy Progesterone receptor agonist drug PROGESTERONE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000082175 at this locus (268448bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000082175 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 11 100631908 11 100761177 EFO_0000378 Coronary artery disease coronary artery disease NR=574 GCST002665 43.69897000433602 GCST002665_5 25340798 drug Medium Ed Mountjoy Matrix metalloproteinase 13 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000137745 at this locus (96747bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137745 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 11 102716980 11 102846249 EFO_0000249 Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3] Alzheimer's disease NR=574 GCST002665 43.69897000433602 GCST002665_5 25340798 drug Medium Ed Mountjoy Matrix metalloproteinase 8 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000118113 at this locus (119199bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000118113 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 11 102716980 11 102846249 EFO_0000249 Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3] Alzheimer's disease NR=574 GCST002665 43.69897000433602 GCST002665_5 25340798 drug Medium Ed Mountjoy Matrix metalloproteinase-1 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000196611 at this locus (48090bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196611 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 11 102716980 11 102846249 EFO_0000249 Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3] Alzheimer's disease NR=574 GCST002665 43.69897000433602 GCST002665_5 25340798 drug Low Ed Mountjoy Matrix metalloproteinase 7 inhibitor drug DOXYCYCLINE is Phase III for the indiciation EFO_0000249 and targets the gene ENSG00000137673 at this locus (315500bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137673 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 11 102716980 11 102846249 EFO_0000249 Cerebrospinal fluid levels of Alzheimer's disease-related proteins [Matrix metalloproteinase-3] Alzheimer's disease European=7100|African American or Afro-Caribbean=2570 GCST002350 8.522878745280337 GCST002350 24621683 drug Low Ed Mountjoy Matrix metalloproteinase 7 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000137673 at this locus (319465bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137673 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 102720945 11 102850214 EFO_0000341 Chronic obstructive pulmonary disease (severe) chronic obstructive pulmonary disease European=7100|African American or Afro-Caribbean=2570 GCST002350 8.522878745280337 GCST002350 24621683 drug High Ed Mountjoy Matrix metalloproteinase-1 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000196611 at this locus (52055bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196611 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 102720945 11 102850214 EFO_0000341 Chronic obstructive pulmonary disease (severe) chronic obstructive pulmonary disease European=7100|African American or Afro-Caribbean=2570 GCST002350 8.522878745280337 GCST002350 24621683 drug High Ed Mountjoy Matrix metalloproteinase 13 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000137745 at this locus (92782bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137745 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 102720945 11 102850214 EFO_0000341 Chronic obstructive pulmonary disease (severe) chronic obstructive pulmonary disease European=7100|African American or Afro-Caribbean=2570 GCST002350 8.522878745280337 GCST002350 24621683 drug Medium Ed Mountjoy Matrix metalloproteinase 8 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000118113 at this locus (123164bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000118113 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 102720945 11 102850214 EFO_0000341 Chronic obstructive pulmonary disease (severe) chronic obstructive pulmonary disease European=459000 GCST007072 7.522878745280337 GCST007072 30595370 drug Low Ed Mountjoy Matrix metalloproteinase-1 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000196611 at this locus (284087bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196611 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 11 102952976 11 103082247 EFO_0000319 Cardiovascular disease cardiovascular system disease European=459000 GCST007072 7.522878745280337 GCST007072 30595370 drug Low Ed Mountjoy Matrix metalloproteinase 8 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000118113 at this locus (355197bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000118113 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 11 102952976 11 103082247 EFO_0000319 Cardiovascular disease cardiovascular system disease European=459000 GCST007072 7.522878745280337 GCST007072 30595370 drug Medium Ed Mountjoy Matrix metalloproteinase 13 inhibitor drug DOXYCYCLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000137745 at this locus (126515bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137745 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 11 102952976 11 103082247 EFO_0000319 Cardiovascular disease cardiovascular system disease European=348219 GCST006478 9.0 GCST006478 29942085 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug PALIPERIDONE is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (452613bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 11 112827715 11 112956992 EFO_0005230 Worry anxiety European=348219 GCST006478 9.0 GCST006478 29942085 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug QUETIAPINE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (452613bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 11 112827715 11 112956992 EFO_0005230 Worry anxiety European=357957 GCST006475 8.487182241435127 GCST006475 29942085 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug CLOZAPINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (430609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G HG305_PATCH 112849719 11 112978997 EFO_0003761 Depressed affect unipolar depression European=357957 GCST006475 8.487182241435127 GCST006475 29942085 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug ILOPERIDONE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (430609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G HG305_PATCH 112849719 11 112978997 EFO_0003761 Depressed affect unipolar depression European=357957 GCST006475 8.487182241435127 GCST006475 29942085 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug QUETIAPINE is Phase III for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (430609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G HG305_PATCH 112849719 11 112978997 EFO_0004247 Depressed affect mood disorder European=357957 GCST006475 8.487182241435127 GCST006475 29942085 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug ZIPRASIDONE is Phase IV for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (430609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G HG305_PATCH 112849719 11 112978997 EFO_0004247 Depressed affect mood disorder East Asian=45528 GCST007201 7.698970004336019 GCST007201 30285260 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (64405bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G HG305_PATCH 113215923 11 113345201 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 7.698970004336019 GCST007201 30285260 drug High Ed Mountjoy Dopamine D2 receptor modulator drug CARIPRAZINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (64405bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G HG305_PATCH 113215923 11 113345201 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 7.698970004336019 GCST007201 30285260 drug Medium Ed Mountjoy Dopamine D2 receptor antagonist drug TRIMIPRAMINE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (64405bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G HG305_PATCH 113215923 11 113345201 EFO_0000692 Schizophrenia schizophrenia European=348219 GCST006478 9.0 GCST006478 29942085 drug High Ed Mountjoy Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (18235bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 11 113364647 11 113493925 EFO_0005230 Worry anxiety European=348219 GCST006478 9.0 GCST006478 29942085 drug Medium Ed Mountjoy Dopamine D2 receptor antagonist drug BROMPERIDOL is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000149295 at this locus (18235bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 11 113364647 11 113493925 EFO_0005230 Worry anxiety NR=361315|European=446238 GCST007342 38.39794000867204 GCST007342 30718901 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000166736 at this locus (474846bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 113370758 11 113500036 EFO_0003761 Depression unipolar depression NR=361315|European=446238 GCST007342 38.39794000867204 GCST007342 30718901 drug High Ed Mountjoy Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (24346bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 113370758 11 113500036 EFO_0003761 Depression unipolar depression NR=361315|European=446238 GCST007342 38.39794000867204 GCST007342 30718901 drug Medium Ed Mountjoy Dopamine D2 receptor modulator drug CARIPRAZINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (24346bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 11 113370758 11 113500036 EFO_0003761 Depression unipolar depression European=357957 GCST006475 12.761953896871205 GCST006475 29942085 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000166736 at this locus (459256bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 11 113386347 11 113515625 EFO_0003761 Depressed affect unipolar depression European=357957 GCST006475 12.761953896871205 GCST006475 29942085 drug Medium Ed Mountjoy Dopamine D2 receptor antagonist drug QUETIAPINE is Phase III for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (39935bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 11 113386347 11 113515625 EFO_0004247 Depressed affect mood disorder European=357957 GCST006475 12.761953896871205 GCST006475 29942085 drug Medium Ed Mountjoy Dopamine D2 receptor antagonist drug PERPHENAZINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (39935bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 11 113386347 11 113515625 EFO_0003761 Depressed affect unipolar depression European=357957 GCST006475 12.761953896871205 GCST006475 29942085 drug High Ed Mountjoy Dopamine D2 receptor antagonist drug ZIPRASIDONE is Phase IV for the indiciation EFO_0004247 and targets the gene ENSG00000149295 at this locus (39935bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 11 113386347 11 113515625 EFO_0004247 Depressed affect mood disorder European=357957 GCST006475 12.761953896871205 GCST006475 29942085 drug High Ed Mountjoy Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000149295 at this locus (39935bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 11 113386347 11 113515625 EFO_0003761 Depressed affect unipolar depression East Asian=26026|European=82315 GCST004946 10.301029995663981 GCST004946 28991256 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia East Asian=26026|European=82315 GCST004946 10.301029995663981 GCST004946 28991256 drug Medium Ed Mountjoy Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia European=82315|East Asian=5219 GCST002539 10.522878745280337 GCST002539 25056061 drug Medium Ed Mountjoy Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia European=82315|East Asian=5219 GCST002539 10.522878745280337 GCST002539 25056061 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 10.0 GCST007201 30285260 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia Other=1097|NR=150064 GCST003048 9.698970004336019 GCST003048 26198764 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia East Asian=26026|European=82315 GCST004946 10.301029995663981 GCST004946 28991256 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 9.301029995663981 GCST007201_2 30285260 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia [EA] schizophrenia East Asian=45528 GCST007201 9.301029995663981 GCST007201_2 30285260 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia [EA] schizophrenia East Asian=45528 GCST007201 10.0 GCST007201 30285260 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 10.0 GCST007201 30285260 drug Medium Ed Mountjoy Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia East Asian=26026|European=82315 GCST004946 10.301029995663981 GCST004946 28991256 drug High Ed Mountjoy Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia European=82315|East Asian=5219 GCST002539 10.522878745280337 GCST002539 25056061 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia European=105318 GCST006803 11.698970004336019 GCST006803 29483656 drug Medium Ed Mountjoy Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 9.301029995663981 GCST007201_2 30285260 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia [EA] schizophrenia Other=1097|NR=150064 GCST003048 9.698970004336019 GCST003048 26198764 drug Medium Ed Mountjoy Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia Other=1097|NR=150064 GCST003048 9.698970004336019 GCST003048 26198764 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 9.301029995663981 GCST007201_2 30285260 drug High Ed Mountjoy Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia [EA] schizophrenia Other=1097|NR=150064 GCST003048 9.698970004336019 GCST003048 26198764 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia European=105318 GCST006803 11.698970004336019 GCST006803 29483656 drug High Ed Mountjoy Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia European=82315|East Asian=5219 GCST002539 10.522878745280337 GCST002539 25056061 drug High Ed Mountjoy Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia European=82315|East Asian=5219 GCST002539 10.522878745280337 GCST002539 25056061 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 10.0 GCST007201 30285260 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia European=105318 GCST006803 11.698970004336019 GCST006803 29483656 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia East Asian=26026|European=82315 GCST004946 10.301029995663981 GCST004946 28991256 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia Other=1097|NR=150064 GCST003048 9.698970004336019 GCST003048 26198764 drug High Ed Mountjoy Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 9.301029995663981 GCST007201_2 30285260 drug Medium Ed Mountjoy Dopamine D2 receptor antagonist drug CHLORPROTHIXENE is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia [EA] schizophrenia European=105318 GCST006803 11.698970004336019 GCST006803 29483656 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (452609bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 10.0 GCST007201 30285260 drug High Ed Mountjoy Dopamine D2 receptor antagonist drug FLUPHENAZINE DECANOATE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia European=105318 GCST006803 11.698970004336019 GCST006803 29483656 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (46582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 11 113392994 11 113522272 EFO_0000692 Schizophrenia schizophrenia European=13574|NR=2380 GCST004521 8.301029995663981 GCST004521 28540026 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug SB-773812 is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (66031bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 11 113412443 11 113541721 EFO_0000692 Autism spectrum disorder or schizophrenia schizophrenia European=13574|NR=2380 GCST004521 8.301029995663981 GCST004521 28540026 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (433161bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 11 113412443 11 113541721 EFO_0000692 Autism spectrum disorder or schizophrenia schizophrenia European=13574|NR=2380 GCST004521 8.301029995663981 GCST004521 28540026 drug High Ed Mountjoy Dopamine D2 receptor partial agonist drug ARIPIPRAZOLE is Phase IV for the indiciation EFO_0003756 and targets the gene ENSG00000149295 at this locus (66031bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 11 113412443 11 113541721 EFO_0003756 Autism spectrum disorder or schizophrenia autism spectrum disorder European=13574|NR=2380 GCST004521 8.301029995663981 GCST004521 28540026 drug High Ed Mountjoy Dopamine D2 receptor antagonist drug ASENAPINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (66031bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 11 113412443 11 113541721 EFO_0000692 Autism spectrum disorder or schizophrenia schizophrenia European=13574|NR=2380 GCST004521 8.301029995663981 GCST004521 28540026 drug Medium Ed Mountjoy Dopamine D2 receptor partial agonist drug BIFEPRUNOX is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000149295 at this locus (66031bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 11 113412443 11 113541721 EFO_0000692 Autism spectrum disorder or schizophrenia schizophrenia European=13574|NR=2380 GCST004521 8.301029995663981 GCST004521 28540026 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug VORTIOXETINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000166736 at this locus (433161bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 11 113412443 11 113541721 EFO_0000692 Autism spectrum disorder or schizophrenia schizophrenia European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080 GCST002606 7.522878745280337 GCST002606_3 25217961 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug METOCLOPRAMIDE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000149295 at this locus (460768bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 113807181 11 113936459 EFO_0001663 Prostate cancer [EA] prostate carcinoma European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080 GCST002606 7.301029995663981 GCST002606 25217961 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug METOCLOPRAMIDE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000149295 at this locus (460768bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 113807181 11 113936459 EFO_0001663 Prostate cancer prostate carcinoma European=140254 GCST006085 14.397940008672037 GCST006085 29892016 drug Low Ed Mountjoy Dopamine D2 receptor antagonist drug METOCLOPRAMIDE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000149295 at this locus (460768bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000149295 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 113807181 11 113936459 EFO_0001663 Prostate cancer prostate carcinoma European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080 GCST002606 7.522878745280337 GCST002606_3 25217961 drug High Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000166736 at this locus (38422bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 113807181 11 113936459 EFO_0001663 Prostate cancer [EA] prostate carcinoma European=140254 GCST006085 14.397940008672037 GCST006085 29892016 drug High Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000166736 at this locus (38422bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 113807181 11 113936459 EFO_0001663 Prostate cancer prostate carcinoma European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080 GCST002606 7.301029995663981 GCST002606 25217961 drug High Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug ONDANSETRON is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000166736 at this locus (38422bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 113807181 11 113936459 EFO_0001663 Prostate cancer prostate carcinoma European=9799 GCST003227 10.221848749616356 GCST003227 26424050 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug GRANISETRON is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000166736 at this locus (169764bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 11 114030799 11 114160077 EFO_0000326 Non-glioblastoma glioma central nervous system cancer European=24009 GCST004348 11.301029995663981 GCST004348 28346443 drug Low Ed Mountjoy Serotonin 3a (5-HT3a) receptor antagonist drug GRANISETRON is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000166736 at this locus (169764bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 11 114030799 11 114160077 EFO_0000326 Non-glioblastoma glioma central nervous system cancer European=5548 GCST000439 8.0 GCST000439 19578367 drug Low Ed Mountjoy T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (290477bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198851 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 11 118477367 11 118606652 EFO_0000326 Glioma central nervous system cancer European=11582 GCST001058 10.301029995663981 GCST001058 21531791 drug Low Ed Mountjoy T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (290477bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198851 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 11 118477367 11 118606652 EFO_0000326 Glioma central nervous system cancer European=9799 GCST003227 24.397940008672037 GCST003227 26424050 drug Low Ed Mountjoy T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198851 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 11 118480115 11 118609400 EFO_0000326 Non-glioblastoma glioma central nervous system cancer European=24009 GCST004348 42.221848749616356 GCST004348 28346443 drug Low Ed Mountjoy T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198851 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 11 118480115 11 118609400 EFO_0000326 Non-glioblastoma glioma central nervous system cancer European=11582 GCST003228 15.698970004336019 GCST003228 26424050 drug Low Ed Mountjoy T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198851 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 11 118480115 11 118609400 EFO_0000326 Glioma central nervous system cancer European=30659 GCST004347 15.0 GCST004347 28346443 drug Low Ed Mountjoy T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000198851 at this locus (293225bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198851 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 11 118480115 11 118609400 EFO_0000326 Glioma central nervous system cancer European=38053 GCST000987 12.0 GCST000987 21383967 drug Low Ed Mountjoy T cell surface glycoprotein CD3 inhibitor drug MUROMONAB-CD3 is Phase IV for the indiciation EFO_0000540 and targets the gene ENSG00000198851 at this locus (424897bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198851 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 11 118611781 11 118741072 EFO_0000540 Celiac disease or Rheumatoid arthritis immune system disease European=459000 GCST007072 12.096910013008056 GCST007072 30595370 drug Low Ed Mountjoy Phosphodiesterase 3A inhibitor drug MILRINONE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000172572 at this locus (361012bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000172572 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 12 20161168 12 20008234 EFO_0000319 Cardiovascular disease cardiovascular system disease NR=250736 GCST005196 13.096910013008056 GCST005196 29212778 drug Low Ed Mountjoy Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000172572 at this locus (302146bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000172572 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 12 20220033 12 20067099 EFO_0000378 Coronary artery disease coronary artery disease NR=547261 GCST005195 8.2839966563652 GCST005195 29212778 drug Low Ed Mountjoy Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000172572 at this locus (302146bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000172572 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 12 20220033 12 20067099 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 13.537602002101044 GCST005194 29212778 drug Low Ed Mountjoy Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000172572 at this locus (302146bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000172572 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 12 20220033 12 20067099 EFO_0000378 Coronary artery disease coronary artery disease European=459000 GCST007072 8.698970004336019 GCST007072 30595370 drug Medium Ed Mountjoy Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000172572 at this locus (161851bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000172572 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 12 20360328 12 20207394 EFO_0000319 Cardiovascular disease cardiovascular system disease European=440328|East Asian=45564|South Asian=9144|African American or Afro-Caribbean=20687|Asian unspecified=555|Hispanic or Latin American=1247 GCST005843 7.301029995663981 GCST005843 29531354 drug High Ed Mountjoy Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation HP_0002140 and targets the gene ENSG00000172572 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000172572 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 12 20577593 12 20424659 HP_0002140 Ischemic stroke Ischemic stroke European=440328|East Asian=45564|South Asian=9144|African American or Afro-Caribbean=20687|Asian unspecified=555|Hispanic or Latin American=1247 GCST005843 7.301029995663981 GCST005843 29531354 drug High Ed Mountjoy Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation HP_0002140 and targets the gene ENSG00000172572 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000172572 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 12 20577593 12 20424659 HP_0002140 Ischemic stroke Ischemic stroke European=17565|African American or Afro-Caribbean=375|South Asian=4710 GCST003322 7.522878745280337 GCST003322_2 26732560 drug Low Ed Mountjoy Phosphodiesterase 3A inhibitor drug CILOSTAZOL is Phase IV for the indiciation HP_0002140 and targets the gene ENSG00000172572 at this locus (486296bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000172572 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 12 21323611 12 21170677 HP_0002140 Ischemic stroke (large artery atherosclerosis) [EA] Ischemic stroke European=361141 8.267891037697892 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (48757bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 12 48186563 12 47792780 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=361141 8.267891037697892 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (48757bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 12 48186563 12 47792780 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=360838 GCST005038 10.941953769604718 GCST005038 29083406 drug Low Ed Mountjoy Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase II for the indiciation EFO_0003785 and targets the gene ENSG00000111424 at this locus (39448bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 12 48195873 12 47802090 EFO_0003785 Allergic disease (asthma, hay fever or eczema) allergy European, NR=58918|European=458554 GCST007611 10.154901959985743 GCST007611 30940143 drug High Ed Mountjoy Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (30821bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 12 48204499 12 47810716 EFO_0000537 Chronic obstructive pulmonary disease or high blood pressure (pleiotropy) hypertension European, NR=58918|European=458554 GCST007611 10.154901959985743 GCST007611 30940143 drug High Ed Mountjoy Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000111424 at this locus (30821bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 12 48204499 12 47810716 EFO_0000341 Chronic obstructive pulmonary disease or high blood pressure (pleiotropy) chronic obstructive pulmonary disease European, NR=58918|European=458554 GCST007611 10.154901959985743 GCST007611 30940143 drug Low Ed Mountjoy Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (30821bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 12 48204499 12 47810716 EFO_0000537 Chronic obstructive pulmonary disease or high blood pressure (pleiotropy) hypertension European=86475 GCST005537 8.221848749616356 GCST005537 26974007 drug Medium Ed Mountjoy Vitamin D receptor agonist drug PEFCALCITOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000111424 at this locus (26953bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 12 48208368 12 47814585 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis European=86475 GCST005537 8.221848749616356 GCST005537 26974007 drug Low Ed Mountjoy Vitamin D receptor agonist drug DOXERCALCIFEROL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000111424 at this locus (26953bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 12 48208368 12 47814585 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis European=86475 GCST005537 8.221848749616356 GCST005537 26974007 drug Medium Ed Mountjoy Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000111424 at this locus (26953bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 12 48208368 12 47814585 EFO_0000729 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ulcerative colitis European=86475 GCST005537 8.221848749616356 GCST005537 26974007 drug High Ed Mountjoy Vitamin D receptor agonist drug CALCITRIOL is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000111424 at this locus (26953bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 12 48208368 12 47814585 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis European=86475 GCST005537 8.221848749616356 GCST005537 26974007 drug High Ed Mountjoy Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000111424 at this locus (26953bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 12 48208368 12 47814585 EFO_0000384 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] Crohn's disease European=361141 12.517126416391246 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 12 48254353 12 47860570 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=459000 GCST007072 9.301029995663981 GCST007072 30595370 drug Medium Ed Mountjoy Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000111424 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A T 12 48254353 12 47860570 EFO_0000319 Cardiovascular disease cardiovascular system disease European=361141 12.517126416391246 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 12 48254353 12 47860570 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=2062 GCST007843 11.522878745280337 GCST007843 30891314 drug High Ed Mountjoy Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000111424 at this locus (78926bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 12 48415757 12 48021974 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080 GCST002606 8.698970004336019 GCST002606 25217961 drug Medium Ed Mountjoy Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 12 48419618 12 48025835 EFO_0001663 Prostate cancer prostate carcinoma European=140254 GCST006085 10.698970004336019 GCST006085 29892016 drug Medium Ed Mountjoy Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 12 48419618 12 48025835 EFO_0001663 Prostate cancer prostate carcinoma European=140254 GCST006085 10.698970004336019 GCST006085 29892016 drug Low Ed Mountjoy Vitamin D receptor agonist drug PARICALCITOL is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 12 48419618 12 48025835 EFO_0001663 Prostate cancer prostate carcinoma European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080 GCST002606 7.3979400086720375 GCST002606_3 25217961 drug Low Ed Mountjoy Vitamin D receptor agonist drug PARICALCITOL is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 12 48419618 12 48025835 EFO_0001663 Prostate cancer [EA] prostate carcinoma European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080 GCST002606 8.698970004336019 GCST002606 25217961 drug Low Ed Mountjoy Vitamin D receptor agonist drug PARICALCITOL is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 12 48419618 12 48025835 EFO_0001663 Prostate cancer prostate carcinoma European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080 GCST002606 7.3979400086720375 GCST002606_3 25217961 drug Medium Ed Mountjoy Vitamin D receptor agonist drug ERGOCALCIFEROL is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000111424 at this locus (82787bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 12 48419618 12 48025835 EFO_0001663 Prostate cancer [EA] prostate carcinoma European=459000 GCST007072 9.301029995663981 GCST007072 30595370 drug Low Ed Mountjoy Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase III for the indiciation EFO_0000319 and targets the gene ENSG00000111424 at this locus (260223bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 12 48597053 12 48203270 EFO_0000319 Cardiovascular disease cardiovascular system disease European=361141 9.53863955699212 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Vitamin D receptor agonist drug CALCITRIOL is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (278452bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T A 12 48615283 12 48221500 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=361141 9.53863955699212 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Vitamin D receptor agonist drug CHOLECALCIFEROL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000111424 at this locus (278452bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111424 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 12 48615283 12 48221500 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=58284|East Asian=22515 GCST002318 10.0 GCST002318 24390342 drug Low Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000110944 at this locus (333004bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 12 56394954 12 56001170 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis European=58284|East Asian=22515 GCST002318 7.698970004336019 GCST002318_2 24390342 drug Low Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000110944 at this locus (333004bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 12 56394954 12 56001170 EFO_0000685 Rheumatoid arthritis [EA] rheumatoid arthritis African American or Afro-Caribbean=2308 GCST006959 9.0 GCST006959 30423114 drug Low Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000110944 at this locus (333004bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 12 56394954 12 56001170 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis European=16753 GCST003097 8.397940008672037 GCST003097 26301688 drug Low Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000110944 at this locus (331190bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 12 56396768 12 56002984 EFO_0000384 Pediatric autoimmune diseases Crohn's disease European=16753 GCST003097 8.397940008672037 GCST003097 26301688 drug Low Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000110944 at this locus (331190bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 12 56396768 12 56002984 EFO_0000729 Pediatric autoimmune diseases ulcerative colitis European=16753 GCST003097 8.397940008672037 GCST003097 26301688 drug Low Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (331190bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C G 12 56396768 12 56002984 EFO_0000676 Pediatric autoimmune diseases psoriasis European=16753 GCST003097 8.397940008672037 GCST003097 26301688 drug Low Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (331190bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 12 56396768 12 56002984 EFO_0000676 Pediatric autoimmune diseases psoriasis European=16753 GCST003097 8.397940008672037 GCST003097 26301688 drug Low Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug BRAZIKUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000110944 at this locus (331190bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 12 56396768 12 56002984 EFO_0000384 Pediatric autoimmune diseases Crohn's disease European=2759 GCST000322 9.0 GCST000322 19169254 drug High Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 12 56737973 12 56344189 EFO_0000676 Psoriasis psoriasis European=12244 GCST002738 9.221848749616356 GCST002738 25574825 drug Medium Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 12 56737973 12 56344189 EFO_0000676 Psoriasis psoriasis European=12244 GCST002738 9.221848749616356 GCST002738 25574825 drug High Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 12 56737973 12 56344189 EFO_0000676 Psoriasis psoriasis European=2759 GCST000322 9.0 GCST000322 19169254 drug Medium Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (3779bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 12 56737973 12 56344189 EFO_0000676 Psoriasis psoriasis East Asian=5134|European=8682 GCST002874 11.301029995663981 GCST002874 25903422 drug Medium Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 12 56740682 12 56346898 EFO_0000676 Psoriasis psoriasis East Asian=5134|European=8682 GCST002874 10.0 GCST002874_8 25903422 drug High Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 12 56740682 12 56346898 EFO_0000676 Psoriasis [EA] psoriasis East Asian=5134|European=8682 GCST002874 11.301029995663981 GCST002874 25903422 drug High Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 12 56740682 12 56346898 EFO_0000676 Psoriasis psoriasis East Asian=5134|European=8682 GCST002874 10.0 GCST002874_8 25903422 drug Medium Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (6489bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 12 56740682 12 56346898 EFO_0000676 Psoriasis [EA] psoriasis European=287323 GCST004346 24.397940008672037 GCST004346 28537254 drug High Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (7034bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 12 56741228 12 56347444 EFO_0000676 Psoriasis psoriasis European=287323 GCST004346 24.397940008672037 GCST004346 28537254 drug Medium Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (7034bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 12 56741228 12 56347444 EFO_0000676 Psoriasis psoriasis European=18190 GCST002740 11.698970004336019 GCST002740_4 25574825 drug High Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (10082bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 12 56744276 12 56350492 EFO_0000676 Inflammatory skin disease [Psoriasis] psoriasis European=18190 GCST002740 11.698970004336019 GCST002740_4 25574825 drug Medium Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug TILDRAKIZUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000110944 at this locus (10082bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 12 56744276 12 56350492 EFO_0000676 Inflammatory skin disease [Psoriasis] psoriasis European=8941 GCST003268 14.397940008672037 GCST003268 26626624 drug High Ed Mountjoy Interleukin-23 subunit alpha inhibitor drug GUSELKUMAB is Phase IV for the indiciation EFO_1001494 and targets the gene ENSG00000110944 at this locus (16011bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000110944 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 12 56750204 12 56356420 EFO_1001494 Psoriasis vulgaris psoriasis vulgaris European=58284|East Asian=22515 GCST002318 8.154901959985743 GCST002318_2 24390342 drug Low Ed Mountjoy MAP kinase-activated protein kinase 5 inhibitor drug GLPG-0259 is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000089022 at this locus (446244bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000089022 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 12 111833788 12 111395984 EFO_0000685 Rheumatoid arthritis [EA] rheumatoid arthritis East Asian=314 GCST002293 7.301029995663981 GCST002293 24277619 drug High Ed Mountjoy Aldehyde dehydrogenase inhibitor drug DISULFIRAM is Phase IV for the indiciation EFO_0003829 and targets the gene ENSG00000111275 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000111275 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 12 112241766 12 111803962 EFO_0003829 Alcohol dependence alcohol dependence NR=7046|European=7320|NR, Hispanic or Latin American, African unspecified, Asian unspecified=636 GCST002991 10.045757490560675 GCST002991 26098869 drug Medium Ed Mountjoy Tyrosine-protein kinase receptor FLT3 inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (100433bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122025 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 13 28476978 13 27902841 EFO_0002618 Pancreatic cancer pancreatic carcinoma NR=7046|European=7320|NR, Hispanic or Latin American, African unspecified, Asian unspecified=636 GCST002991 10.045757490560675 GCST002991 26098869 drug Low Ed Mountjoy Tyrosine-protein kinase receptor FLT3 inhibitor drug ENMD-981693 is Phase II for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (100433bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122025 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 13 28476978 13 27902841 EFO_0002618 Pancreatic cancer pancreatic carcinoma European=21536 GCST005434 13.301029995663981 GCST005434 29422604 drug Medium Ed Mountjoy Tyrosine-protein kinase receptor FLT3 inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122025 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 13 28493997 13 27919860 EFO_0002618 Pancreatic cancer pancreatic carcinoma European=21536 GCST005434 13.301029995663981 GCST005434 29422604 drug Low Ed Mountjoy Tyrosine-protein kinase receptor FLT3 inhibitor drug ENMD-981693 is Phase II for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122025 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 13 28493997 13 27919860 EFO_0002618 Pancreatic cancer pancreatic carcinoma European=6785 GCST002553 8.698970004336019 GCST002553 25086665 drug Medium Ed Mountjoy Tyrosine-protein kinase receptor FLT3 inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122025 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 13 28493997 13 27919860 EFO_0002618 Pancreatic cancer pancreatic carcinoma European=6785 GCST002553 8.698970004336019 GCST002553 25086665 drug Low Ed Mountjoy Tyrosine-protein kinase receptor FLT3 inhibitor drug ENMD-981693 is Phase II for the indiciation EFO_0002618 and targets the gene ENSG00000122025 at this locus (83414bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122025 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 13 28493997 13 27919860 EFO_0002618 Pancreatic cancer pancreatic carcinoma European=459000 GCST007072 11.698970004336019 GCST007072 30595370 drug High Ed Mountjoy Relaxin receptor 2 activator drug SERELAXIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000133105 at this locus (67851bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000133105 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 13 32245813 13 31671676 EFO_0000319 Cardiovascular disease cardiovascular system disease European=361141 11.549904924128398 NEALE2_20002_1309 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Tumor necrosis factor ligand superfamily member 11 inhibitor drug DENOSUMAB is Phase IV for the indiciation EFO_0003882 and targets the gene ENSG00000120659 at this locus (184727bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000120659 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 13 42952145 13 42378009 EFO_0003882 Osteoporosis | non-cancer illness code, self-reported osteoporosis NR=250736 GCST005196 11.096910013008056 GCST005196 29212778 drug Medium Ed Mountjoy Coagulation factor X inhibitor drug EDOXABAN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000126218 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 13 113631780 13 112977466 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 11.085445301482366 GCST005194 29212778 drug Medium Ed Mountjoy Coagulation factor X inhibitor drug EDOXABAN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000126218 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 13 113631780 13 112977466 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 11.096910013008056 GCST005196 29212778 drug Medium Ed Mountjoy Coagulation factor X inhibitor drug RIVAROXABAN is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000126218 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 13 113631780 13 112977466 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 11.085445301482366 GCST005194 29212778 drug Medium Ed Mountjoy Coagulation factor X inhibitor drug RIVAROXABAN is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000126218 at this locus (145349bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000126218 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 13 113631780 13 112977466 EFO_0000378 Coronary artery disease coronary artery disease European=8071 GCST001209 7.698970004336019 GCST001209 21871595 drug High Ed Mountjoy Coagulation factor X inhibitor drug RIVAROXABAN is Phase IV for the indiciation EFO_0002506 and targets the gene ENSG00000126218 at this locus (82619bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000126218 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 13 113694509 13 113040195 EFO_0002506 Osteoarthritis osteoarthritis European=1030836 GCST006414 7.860750782428393 GCST006414 30061737 drug Low Ed Mountjoy Coagulation factor X inhibitor drug BETRIXABAN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000126218 at this locus (68870bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000126218 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 13 113872712 13 113218398 EFO_0000275 Atrial fibrillation atrial fibrillation European=1030836 GCST006414 7.860750782428393 GCST006414 30061737 drug High Ed Mountjoy Coagulation factor X inhibitor drug RIVAROXABAN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000126218 at this locus (68870bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000126218 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 13 113872712 13 113218398 EFO_0000275 Atrial fibrillation atrial fibrillation European=1030836 GCST006414 7.860750782428393 GCST006414 30061737 drug Medium Ed Mountjoy Coagulation factor X inhibitor drug IDRAPARINUX is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000126218 at this locus (68870bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000126218 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 13 113872712 13 113218398 EFO_0000275 Atrial fibrillation atrial fibrillation European=140254 GCST006085 7.698970004336019 GCST006085 29892016 drug Low Ed Mountjoy 26S proteosome inhibitor drug CARFILZOMIB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000100804 at this locus (180104bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100804 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 14 23305649 14 22836440 EFO_0001663 Prostate cancer prostate carcinoma European=140254 GCST006085 7.698970004336019 GCST006085 29892016 drug Low Ed Mountjoy Apoptosis regulator Bcl-W inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000258643 at this locus (470396bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258643 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 14 23305649 14 22836440 EFO_0001663 Prostate cancer prostate carcinoma European=140254 GCST006085 7.698970004336019 GCST006085 29892016 drug Low Ed Mountjoy Apoptosis regulator Bcl-W inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000129473 at this locus (462350bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000129473 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 14 23305649 14 22836440 EFO_0001663 Prostate cancer prostate carcinoma African American or Afro-Caribbean=1452|European=2358|Hispanic or Latin American=1313 GCST001912 11.045757490560675 GCST001912 23512250 drug Medium Ed Mountjoy 26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (80894bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100804 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 14 23585333 14 23116124 EFO_0000220 Acute lymphoblastic leukemia (childhood) acute lymphoblastic leukemia European=4735|Hispanic or Latin American=10533|African American or Afro-Caribbean=3972 GCST005315 12.154901959985743 GCST005315 29348612 drug Medium Ed Mountjoy 26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (84619bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100804 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 14 23589057 14 23119848 EFO_0000220 Acute lymphoblastic leukemia (childhood) acute lymphoblastic leukemia European=893 GCST001320 7.698970004336019 GCST001320_3 22076464 drug Medium Ed Mountjoy 26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (84619bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100804 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 14 23589057 14 23119848 EFO_0000220 Acute lymphoblastic leukemia (childhood) [ETV6-RUNX1 positive] acute lymphoblastic leukemia European=6381 GCST002158 16.0 GCST002158 23996088 drug Low Ed Mountjoy 26S proteosome inhibitor drug BORTEZOMIB is Phase II for the indiciation EFO_0000094 and targets the gene ENSG00000100804 at this locus (84619bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100804 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 14 23589057 14 23119848 EFO_0000094 Acute lymphoblastic leukemia (B-cell precursor) B-cell acute lymphoblastic leukemia European=893 GCST001320 9.397940008672037 GCST001320 22076464 drug Medium Ed Mountjoy 26S proteosome inhibitor drug BORTEZOMIB is Phase III for the indiciation EFO_0000220 and targets the gene ENSG00000100804 at this locus (84619bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100804 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 14 23589057 14 23119848 EFO_0000220 Acute lymphoblastic leukemia (childhood) acute lymphoblastic leukemia European=17051 GCST005832 13.301029995663981 GCST005832 29632299 drug Low Ed Mountjoy 26S proteosome inhibitor drug BORTEZOMIB is Phase II for the indiciation EFO_0000094 and targets the gene ENSG00000100804 at this locus (84619bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100804 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 14 23589057 14 23119848 EFO_0000094 Acute lymphoblastic leukemia in childhood (B cell precursor) B-cell acute lymphoblastic leukemia European=480359 GCST005839 9.096910013008056 GCST005839 29700475 drug High Ed Mountjoy Estrogen receptor beta modulator drug RALOXIFENE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000140009 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000140009 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 14 64686207 14 64219489 EFO_0003761 Depression unipolar depression East Asian=7394 GCST003148 9.221848749616356 GCST003148 26443449 drug Medium Ed Mountjoy Estrogen receptor beta modulator drug ESTRAMUSTINE PHOSPHATE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000140009 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000140009 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 14 64693912 14 64227194 EFO_0001663 Prostate cancer prostate carcinoma NR=361315|European=446238 GCST007342 11.397940008672037 GCST007342 30718901 drug High Ed Mountjoy Estrogen receptor beta modulator drug RALOXIFENE is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000140009 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000140009 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 14 64697037 14 64230319 EFO_0003761 Depression unipolar depression European=408961 10.1038/s41588-018-0184-y 9.172630726946174 SAIGE_366 drug Low Ed Mountjoy GABA-A receptor; anion channel positive allosteric modulator drug MIDAZOLAM is Phase IV for the indiciation EFO_0001059 and targets the gene ENSG00000182256 at this locus (443188bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000182256 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 15 28230318 15 27985172 EFO_0001059 Cataract cataract European=11756 GCST003524 12.301029995663981 GCST003524 27135401 drug Medium Ed Mountjoy Cytochrome P450 19A1 inhibitor drug LETROZOLE is Phase III for the indiciation EFO_1001512 and targets the gene ENSG00000137869 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137869 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 15 51537806 15 51245609 EFO_1001512 Endometrial cancer endometrial carcinoma European=121885 GCST006464 13.522878745280337 GCST006464 30093612 drug Medium Ed Mountjoy Cytochrome P450 19A1 inhibitor drug LETROZOLE is Phase III for the indiciation EFO_1001512 and targets the gene ENSG00000137869 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137869 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 15 51553909 15 51261712 EFO_1001512 Endometrial cancer endometrial carcinoma European=54884 GCST006465 9.698970004336019 GCST006465 30093612 drug Medium Ed Mountjoy Cytochrome P450 19A1 inhibitor drug LETROZOLE is Phase III for the indiciation EFO_1001512 and targets the gene ENSG00000137869 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137869 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 15 51553909 15 51261712 EFO_1001512 Endometrial cancer (endometrioid histology) endometrial carcinoma European=20926|African American or Afro-Caribbean=2895 GCST000675 8.0 GCST000675_2 20445134 drug High Ed Mountjoy Carbonic anhydrase XII inhibitor drug ACETAZOLAMIDE is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000074410 at this locus (63881bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000074410 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 15 63737925 15 63445726 EFO_0003144 Heart failure [EA] heart failure European, NR=58918|European=458969 GCST007656 12.0 GCST007656 30940143 drug Low Ed Mountjoy Carbonic anhydrase XII inhibitor drug ACETAZOLAMIDE is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000074410 at this locus (314720bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000074410 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 15 63988765 15 63696566 EFO_0000341 Chronic obstructive pulmonary disease or resting heart rate (pleiotropy) chronic obstructive pulmonary disease European=59133 GCST001499 16.522878745280337 GCST001499 22544366 drug High Ed Mountjoy Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138622 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 15 73652174 15 73359833 EFO_0000275 Atrial fibrillation atrial fibrillation European=59133 GCST001499 16.522878745280337 GCST001499 22544366 drug Medium Ed Mountjoy Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138622 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 15 73652174 15 73359833 EFO_0000275 Atrial fibrillation atrial fibrillation European=1030836 GCST006414 35.32039042822024 GCST006414 30061737 drug Medium Ed Mountjoy Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138622 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 15 73667255 15 73374914 EFO_0000275 Atrial fibrillation atrial fibrillation European=1030836 GCST006414 35.32039042822024 GCST006414 30061737 drug High Ed Mountjoy Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138622 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 15 73667255 15 73374914 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 26.69897000433602 GCST006061_3 29892015 drug Medium Ed Mountjoy Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138622 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 15 73667255 15 73374914 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 26.69897000433602 GCST006061_3 29892015 drug High Ed Mountjoy Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (5956bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138622 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 15 73667255 15 73374914 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=395739 10.1038/s41588-018-0184-y 14.522878745280337 SAIGE_427_2 drug Medium Ed Mountjoy Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (6748bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138622 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 15 73668046 15 73375705 EFO_0000275 Atrial fibrillation and flutter atrial fibrillation European=395739 10.1038/s41588-018-0184-y 14.522878745280337 SAIGE_427_2 drug High Ed Mountjoy Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (6748bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138622 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 15 73668046 15 73375705 EFO_0000275 Atrial fibrillation and flutter atrial fibrillation European=118755 GCST004297 11.096910013008056 GCST004297 28416818 drug Medium Ed Mountjoy Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (7708bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138622 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 15 73669006 15 73376665 EFO_0000275 Atrial fibrillation atrial fibrillation European=118755 GCST004297 11.096910013008056 GCST004297 28416818 drug High Ed Mountjoy Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (7708bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138622 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 15 73669006 15 73376665 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 27.0 GCST006061 29892015 drug Medium Ed Mountjoy Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug IVABRADINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (15966bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138622 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 15 73677264 15 73384923 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 27.0 GCST006061 29892015 drug High Ed Mountjoy Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000138622 at this locus (15966bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138622 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 15 73677264 15 73384923 EFO_0000275 Atrial fibrillation atrial fibrillation European=13574|NR=2380 GCST004521 8.698970004336019 GCST004521 28540026 drug Low Ed Mountjoy Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183454 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 16 9900057 16 9806200 EFO_0000692 Autism spectrum disorder or schizophrenia schizophrenia European=13574|NR=2380 GCST004521 8.698970004336019 GCST004521 28540026 drug Low Ed Mountjoy Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0003756 and targets the gene ENSG00000183454 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183454 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 16 9900057 16 9806200 EFO_0003756 Autism spectrum disorder or schizophrenia autism spectrum disorder European=105318 GCST006803 8.221848749616356 GCST006803 29483656 drug Low Ed Mountjoy Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183454 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 16 9900057 16 9806200 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 7.698970004336019 GCST007201 30285260 drug Low Ed Mountjoy Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183454 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 16 9946319 16 9852462 EFO_0000692 Schizophrenia schizophrenia Other=1097|NR=150064 GCST003048 8.698970004336019 GCST003048 26198764 drug Low Ed Mountjoy Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183454 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 16 9946319 16 9852462 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 8.221848749616356 GCST007201_2 30285260 drug Low Ed Mountjoy Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183454 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 16 9946319 16 9852462 EFO_0000692 Schizophrenia [EA] schizophrenia European=82315|East Asian=5219 GCST002539 8.0 GCST002539 25056061 drug Low Ed Mountjoy Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183454 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 16 9946319 16 9852462 EFO_0000692 Schizophrenia schizophrenia East Asian=26026|European=82315 GCST004946 8.522878745280337 GCST004946 28991256 drug Low Ed Mountjoy Glutamate [NMDA] receptor subunit epsilon 1 antagonist drug DEXTROMETHORPHAN is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000183454 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183454 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 16 9946319 16 9852462 EFO_0000692 Schizophrenia schizophrenia European=28835 GCST007797 8.301029995663981 GCST007797 30929738 drug Medium Ed Mountjoy Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000077238 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 16 27349168 16 27337847 EFO_0000270 Asthma onset (childhood vs adult) asthma European=361141 11.676747899828312 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000077238 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 16 27349168 16 27337847 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=459000 GCST007076 15.301029995663981 GCST007076 30595370 drug Low Ed Mountjoy Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase II for the indiciation EFO_0000684 and targets the gene ENSG00000077238 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000077238 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 16 27349168 16 27337847 EFO_0000684 Respiratory diseases respiratory system disease European=360527 12.204815410317575 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000077238 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 16 27349168 16 27337847 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=401837 10.1038/s41588-018-0184-y 9.97061622231479 SAIGE_495 drug Medium Ed Mountjoy Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000077238 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 16 27349438 16 27338117 EFO_0000270 Asthma asthma European=401837 10.1038/s41588-018-0184-y 8.866461091629782 SAIGE_495 drug Medium Ed Mountjoy Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000077238 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 16 27355849 16 27344528 EFO_0000270 Asthma asthma European=341215 GCST007798 19.397940008672037 GCST007798 30929738 drug Medium Ed Mountjoy Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000077238 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 16 27369502 16 27358181 EFO_0000270 Asthma asthma European=361141 12.795880017344075 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000077238 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 16 27371424 16 27360103 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=360527 13.721246399047171 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000077238 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000077238 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 16 27371424 16 27360103 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=459000 GCST007075 8.096910013008056 GCST007075 30595370 drug High Ed Mountjoy Interleukin-4 receptor subunit alpha antagonist drug DUPILUMAB is Phase IV for the indiciation HP_0000964 and targets the gene ENSG00000077238 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000077238 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 16 27371539 16 27360218 HP_0000964 Eczema Eczema European=86475 GCST005537 29.397940008672037 GCST005537 26974007 drug Low Ed Mountjoy Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (312964bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000005844 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G GT 16 30171015 16 30159694 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis East Asian=2252 GCST000507 7.522878745280337 GCST000507 19838193 drug Low Ed Mountjoy Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000005844 at this locus (108362bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000005844 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 16 30642867 16 30631546 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus European=33394 GCST005527 7.607581136972331 GCST005527 23143594 drug Low Ed Mountjoy Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (269751bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000005844 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 16 30804257 16 30792936 EFO_0000676 Psoriasis psoriasis NR=4377 GCST000834 9.045757490560675 GCST000834 20953189 drug Low Ed Mountjoy Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (408120bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000005844 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 16 30942625 16 30931304 EFO_0000676 Psoriasis psoriasis European=86475 GCST005537 10.0 GCST005537 26974007 drug Low Ed Mountjoy Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (436435bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000005844 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 16 30970941 16 30959620 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis East Asian=5134|European=8682 GCST002874 7.698970004336019 GCST002874 25903422 drug Low Ed Mountjoy Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (466304bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000005844 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 16 31000809 16 30989488 EFO_0000676 Psoriasis psoriasis European=287323 GCST004346 15.0 GCST004346 28537254 drug Low Ed Mountjoy Integrin alpha-L/beta-2 (LFA-1) inhibitor drug EFALIZUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000005844 at this locus (486572bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000005844 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 16 31021078 16 31009757 EFO_0000676 Psoriasis psoriasis European=361141 9.289274371510311 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Sodium/glucose cotransporter 2 inhibitor drug DAPAGLIFLOZIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000140675 at this locus (345181bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000140675 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 16 31149142 16 31137821 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=459000 GCST007072 12.0 GCST007072 30595370 drug Low Ed Mountjoy Sodium/glucose cotransporter 2 inhibitor drug EMPAGLIFLOZIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000140675 at this locus (345181bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000140675 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 16 31149142 16 31137821 EFO_0000319 Cardiovascular disease cardiovascular system disease European=22161 GCST001003 8.045757490560675 GCST001003 21386085 drug High Ed Mountjoy Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (38282bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000070915 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 16 56988044 16 56954132 EFO_0000195 Metabolic syndrome metabolic syndrome European=22161 GCST001007 16.0 GCST001007_4 21386085 drug High Ed Mountjoy Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (38282bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000070915 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 16 56988044 16 56954132 EFO_0000195 Metabolic syndrome (bivariate traits) [HDLC-WC] metabolic syndrome European=9618 GCST004045 149.0 GCST004045 27790247 drug Medium Ed Mountjoy Cholesteryl ester transfer protein inhibitor drug ANACETRAPIB is Phase III for the indiciation EFO_0001645 and targets the gene ENSG00000087237 at this locus (5120bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000087237 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 16 56990716 16 56956804 EFO_0001645 Age-related diseases, mortality and associated endophenotypes coronary heart disease European=9618 GCST004045 149.0 GCST004045 27790247 drug High Ed Mountjoy Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000070915 at this locus (40954bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000070915 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 16 56990716 16 56956804 EFO_0000400 Age-related diseases, mortality and associated endophenotypes diabetes mellitus European=9618 GCST004045 149.0 GCST004045 27790247 drug High Ed Mountjoy Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000070915 at this locus (40954bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000070915 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 16 56990716 16 56956804 EFO_0003144 Age-related diseases, mortality and associated endophenotypes heart failure European=10564 GCST001436 59.045757490560675 GCST001436_2 22399527 drug High Ed Mountjoy Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (40954bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000070915 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 16 56990716 16 56956804 EFO_0000195 Metabolic syndrome [HDL] metabolic syndrome European=22161 GCST001007 12.522878745280337 GCST001007_2 21386085 drug High Ed Mountjoy Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (43562bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000070915 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 16 56993324 16 56959412 EFO_0000195 Metabolic syndrome (bivariate traits) [BP-HDLC] metabolic syndrome South Asian=2554 GCST000753 48.0 GCST000753_3 20694148 drug High Ed Mountjoy Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (43562bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000070915 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 16 56993324 16 56959412 EFO_0000195 Metabolic syndrome [HDL] metabolic syndrome European=22161 GCST001007 11.154901959985743 GCST001007_3 21386085 drug High Ed Mountjoy Thiazide-sensitive sodium-chloride cotransporter inhibitor drug HYDROCHLOROTHIAZIDE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000070915 at this locus (52971bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000070915 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 16 57002732 16 56968820 EFO_0000195 Metabolic syndrome (bivariate traits) [HDLC-GLUC] metabolic syndrome European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080 GCST002606 7.522878745280337 GCST002606 25217961 drug Low Ed Mountjoy Dihydroorotate dehydrogenase inhibitor drug LEFLUNOMIDE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000102967 at this locus (351162bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000102967 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 16 71691329 16 71657426 EFO_0001663 Prostate cancer prostate carcinoma European=455221 GCST007093 9.698970004336019 GCST007093 30664745 drug Low Ed Mountjoy Tubulin inhibitor drug COLCHICINE is Phase II for the indiciation EFO_0002506 and targets the gene ENSG00000258947 at this locus (283436bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 16 89704365 16 89637957 EFO_0002506 Osteoarthritis osteoarthritis European=361141 33.803837637410474 NEALE2_20001_1059 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (251643bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 16 89736157 16 89669749 EFO_0000756 Malignant melanoma | cancer code, self-reported melanoma European=61457 GCST003327 20.0 GCST003327_3 26829030 drug Low Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (251643bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 16 89736157 16 89669749 EFO_0000707 Squamous cell carcinoma [adjusted for rs4268748] squamous cell carcinoma European=361141 33.803837637410474 NEALE2_20001_1059 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (251643bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 16 89736157 16 89669749 EFO_0000756 Malignant melanoma | cancer code, self-reported melanoma European=61457 GCST003327 20.0 GCST003327_3 26829030 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (251643bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 16 89736157 16 89669749 EFO_0000707 Squamous cell carcinoma [adjusted for rs4268748] squamous cell carcinoma European=10422 GCST001267 26.522878745280337 GCST001267 21983787 drug Medium Ed Mountjoy Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 16 89755903 16 89689495 EFO_0000756 Melanoma melanoma European=291407 GCST004142 26.522878745280337 GCST004142 28212542 drug Medium Ed Mountjoy Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 16 89755903 16 89689495 EFO_0000756 Melanoma melanoma European=291407 GCST004142 26.522878745280337 GCST004142 28212542 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 16 89755903 16 89689495 EFO_0000756 Melanoma melanoma European=6122 GCST002514 8.698970004336019 GCST002514 24980573 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 16 89755903 16 89689495 EFO_0000756 Melanoma melanoma European=5456 GCST000437 26.522878745280337 GCST000437 19578364 drug Medium Ed Mountjoy Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 16 89755903 16 89689495 EFO_0000756 Melanoma melanoma European=5456 GCST000437 26.522878745280337 GCST000437 19578364 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 16 89755903 16 89689495 EFO_0000756 Melanoma melanoma European=10422 GCST001267 26.522878745280337 GCST001267 21983787 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 16 89755903 16 89689495 EFO_0000756 Melanoma melanoma European=6122 GCST002514 8.698970004336019 GCST002514 24980573 drug Medium Ed Mountjoy Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (231898bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 16 89755903 16 89689495 EFO_0000756 Melanoma melanoma European=58607 11.396639075651619 NEALE2_40009 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (141123bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 16 89846677 16 89780269 EFO_0000311 Reported occurrences of cancer cancer European=88583 GCST007505 44.69897000433602 GCST007505 30429480 drug Low Ed Mountjoy Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (141123bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 16 89846677 16 89780269 EFO_0000389 Nevus count or cutaneous melanoma skin melanoma European=58607 11.396639075651619 NEALE2_40009 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Tubulin inhibitor drug ERIBULIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (141123bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 16 89846677 16 89780269 EFO_0000311 Reported occurrences of cancer cancer European=88583 GCST007505 44.69897000433602 GCST007505 30429480 drug Medium Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (141123bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 16 89846677 16 89780269 EFO_0000389 Nevus count or cutaneous melanoma skin melanoma European=58607 11.396639075651619 NEALE2_40009 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (141123bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C G 16 89846677 16 89780269 EFO_0000311 Reported occurrences of cancer cancer European=361141 12.303643611266669 NEALE2_20001_1059 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (36274bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 16 89951527 16 89885119 EFO_0000756 Malignant melanoma | cancer code, self-reported melanoma European=361141 12.303643611266669 NEALE2_20001_1059 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (36274bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 16 89951527 16 89885119 EFO_0000756 Malignant melanoma | cancer code, self-reported melanoma European=406033 10.1038/s41588-018-0184-y 14.698970004336019 SAIGE_702_1 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0002496 and targets the gene ENSG00000258947 at this locus (1683bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 16 89986117 16 89919709 EFO_0002496 Actinic keratosis actinic keratosis European=397762 10.1038/s41588-018-0184-y 28.661543506395397 SAIGE_172_11 drug Low Ed Mountjoy Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 16 89986117 16 89919709 EFO_0000389 Melanomas of skin skin melanoma European=291407 GCST004142 36.39794000867204 GCST004142 28212542 drug Medium Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (1683bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 16 89986117 16 89919709 EFO_0000756 Melanoma melanoma European=291407 GCST004142 36.39794000867204 GCST004142 28212542 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (1683bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 16 89986117 16 89919709 EFO_0000756 Melanoma melanoma European=287137 GCST003655 38.045757490560675 GCST003655 27424798 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_1001927 and targets the gene ENSG00000258947 at this locus (1683bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 16 89986117 16 89919709 EFO_1001927 Cutaneous squamous cell carcinoma cutaneous squamous cell carcinoma European=397762 10.1038/s41588-018-0184-y 28.661543506395397 SAIGE_172_11 drug Medium Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 16 89986117 16 89919709 EFO_0000389 Melanomas of skin skin melanoma European=397762 10.1038/s41588-018-0184-y 28.661543506395397 SAIGE_172_1 drug Medium Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 16 89986117 16 89919709 EFO_0000389 Melanomas of skin, dx or hx skin melanoma European=397762 10.1038/s41588-018-0184-y 28.661543506395397 SAIGE_172_1 drug Low Ed Mountjoy Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (1683bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 16 89986117 16 89919709 EFO_0000389 Melanomas of skin, dx or hx skin melanoma European=397762 10.1038/s41588-018-0184-y 9.339134521996131 SAIGE_172_11 drug Medium Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 16 89990843 16 89924435 EFO_0000389 Melanomas of skin skin melanoma European=397762 10.1038/s41588-018-0184-y 9.339134521996131 SAIGE_172_11 drug Low Ed Mountjoy Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 16 89990843 16 89924435 EFO_0000389 Melanomas of skin skin melanoma European=397762 10.1038/s41588-018-0184-y 9.339134521996131 SAIGE_172_1 drug Low Ed Mountjoy Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 16 89990843 16 89924435 EFO_0000389 Melanomas of skin, dx or hx skin melanoma European=397762 10.1038/s41588-018-0184-y 9.339134521996131 SAIGE_172_1 drug Medium Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000258947 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 16 89990843 16 89924435 EFO_0000389 Melanomas of skin, dx or hx skin melanoma European=359981 12.515700160653214 NEALE2_2453 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (19038bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 16 90024206 16 89957798 EFO_0000311 Cancer diagnosed by doctor cancer European=359981 12.515700160653214 NEALE2_2453 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (19038bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 16 90024206 16 89957798 EFO_0000311 Cancer diagnosed by doctor cancer European=359981 12.515700160653214 NEALE2_2453 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000311 and targets the gene ENSG00000258947 at this locus (19038bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 16 90024206 16 89957798 EFO_0000311 Cancer diagnosed by doctor cancer European=61457 GCST003327 43.69897000433602 GCST003327 26829030 drug Medium Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (21343bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 16 90026512 16 89960104 EFO_0000707 Squamous cell carcinoma squamous cell carcinoma European=61457 GCST003327 43.69897000433602 GCST003327 26829030 drug High Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (21343bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 16 90026512 16 89960104 EFO_0000707 Squamous cell carcinoma squamous cell carcinoma European=13550 GCST003422 8.698970004336019 GCST003422 26908436 drug High Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (22458bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 16 90027626 16 89961218 EFO_0000707 Squamous cell carcinoma squamous cell carcinoma European=13550 GCST003422 8.698970004336019 GCST003422 26908436 drug Medium Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000258947 at this locus (22458bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T A 16 90027626 16 89961218 EFO_0000707 Squamous cell carcinoma squamous cell carcinoma European=291407 GCST004142 21.221848749616356 GCST004142 28212542 drug Medium Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 16 90066936 16 90000528 EFO_0000756 Melanoma melanoma European=5456 GCST000437 21.221848749616356 GCST000437 19578364 drug Medium Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 16 90066936 16 90000528 EFO_0000756 Melanoma melanoma European=291407 GCST004142 21.221848749616356 GCST004142 28212542 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 16 90066936 16 90000528 EFO_0000756 Melanoma melanoma European=5456 GCST000437 21.221848749616356 GCST000437 19578364 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000258947 at this locus (61767bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000258947 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 16 90066936 16 90000528 EFO_0000756 Melanoma melanoma European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 10.096910013008056 GCST007515 29632382 drug Low Ed Mountjoy Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (434940bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196689 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 17 3947644 17 4044350 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 10.096910013008056 GCST007515 29632382 drug Low Ed Mountjoy Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (434940bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196689 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 17 3947644 17 4044350 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007517 10.045757490560675 GCST007517 29632382 drug Low Ed Mountjoy Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196689 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 17 3953102 17 4049808 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007518 8.096910013008056 GCST007518 29632382 drug Low Ed Mountjoy Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196689 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 17 3953102 17 4049808 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957 GCST007518 8.096910013008056 GCST007518 29632382 drug Low Ed Mountjoy Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196689 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 17 3953102 17 4049808 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957 GCST007517 10.045757490560675 GCST007517 29632382 drug Low Ed Mountjoy Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (440397bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196689 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 17 3953102 17 4049808 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=361141 8.644381843915278 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000196689 at this locus (467788bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196689 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 17 3980493 17 4077199 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=655666|South Asian=3650 GCST006867 13.397940008672037 GCST006867 30054458 drug Low Ed Mountjoy Vanilloid receptor opener drug ACETAMINOPHEN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (473159bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196689 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 17 3985864 17 4082570 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 13.397940008672037 GCST006867 30054458 drug Low Ed Mountjoy Vanilloid receptor antagonist drug XEN-D0501 is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000196689 at this locus (473159bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196689 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 17 3985864 17 4082570 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=5704 GCST001364 10.045757490560675 GCST001364 22197929 drug Low Ed Mountjoy Tumor necrosis factor ligand superfamily member 13 inhibitor drug ATACICEPT is Phase II for the indiciation EFO_0004194 and targets the gene ENSG00000161955 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000161955 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 17 7462969 17 7559652 EFO_0004194 IgA nephropathy IGA glomerulonephritis East Asian=5704 GCST001364 9.397940008672037 GCST001364 22197929 drug Low Ed Mountjoy Tumor necrosis factor ligand superfamily member 13 inhibitor drug ATACICEPT is Phase II for the indiciation EFO_0004194 and targets the gene ENSG00000161955 at this locus (26251bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000161955 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 17 7491177 17 7587859 EFO_0004194 IgA nephropathy IGA glomerulonephritis European=86475 GCST005537 20.30102999566398 GCST005537 26974007 drug Low Ed Mountjoy Eotaxin inhibitor drug BERTILIMUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000172156 at this locus (42141bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000172156 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 17 32570547 17 34243528 EFO_0000729 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ulcerative colitis East Asian=4392 GCST002082 9.045757490560675 GCST002082 23817570 drug Low Ed Mountjoy DNA topoisomerase II alpha inhibitor drug DOXORUBICIN is Phase II for the indiciation EFO_0001061 and targets the gene ENSG00000131747 at this locus (493430bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000131747 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 17 38051348 17 39895095 EFO_0001061 Cervical cancer [Matched] cervical carcinoma East Asian=4392 GCST002082 9.045757490560675 GCST002082 23817570 drug Low Ed Mountjoy Receptor protein-tyrosine kinase erbB-2 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0001061 and targets the gene ENSG00000141736 at this locus (164669bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000141736 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 17 38051348 17 39895095 EFO_0001061 Cervical cancer [Matched] cervical carcinoma European=4735|Hispanic or Latin American=10533|African American or Afro-Caribbean=3972 GCST005315 9.0 GCST005315 29348612 drug Low Ed Mountjoy DNA topoisomerase II alpha inhibitor drug ETOPOSIDE PHOSPHATE is Phase II for the indiciation EFO_0000220 and targets the gene ENSG00000131747 at this locus (478539bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000131747 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 17 38066240 17 39909987 EFO_0000220 Acute lymphoblastic leukemia (childhood) acute lymphoblastic leukemia European=4735|Hispanic or Latin American=10533|African American or Afro-Caribbean=3972 GCST005315 9.0 GCST005315 29348612 drug Low Ed Mountjoy DNA topoisomerase II alpha inhibitor drug DAUNORUBICIN is Phase IV for the indiciation EFO_0000220 and targets the gene ENSG00000131747 at this locus (478539bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000131747 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 17 38066240 17 39909987 EFO_0000220 Acute lymphoblastic leukemia (childhood) acute lymphoblastic leukemia European=359241 12.11747546204512 NEALE2_2463 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Sclerostin inhibitor drug ROMOSOZUMAB is Phase II for the indiciation EFO_0003931 and targets the gene ENSG00000167941 at this locus (37925bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000167941 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C CT 17 41793182 17 43715814 EFO_0003931 Fractured/broken bones in last 5 years bone fracture European=426795 GCST006980 40.30102999566398 GCST006980 30598549 drug Low Ed Mountjoy Sclerostin inhibitor drug ROMOSOZUMAB is Phase II for the indiciation EFO_0003931 and targets the gene ENSG00000167941 at this locus (32252bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000167941 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 17 41798855 17 43721487 EFO_0003931 Fractures bone fracture East Asian=800|European=264173 GCST006423 24.522878745280337 GCST006423 30158200 drug Low Ed Mountjoy Sclerostin inhibitor drug ROMOSOZUMAB is Phase II for the indiciation EFO_0003931 and targets the gene ENSG00000167941 at this locus (4268bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000167941 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 17 41826839 17 43749471 EFO_0003931 Fractures bone fracture NR=171776 GCST005835 10.522878745280337 GCST005835 29559929 drug Low Ed Mountjoy Corticotropin releasing factor receptor 1 antagonist drug VERUCERFONT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000120088 at this locus (297425bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000120088 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 17 43564222 17 45486856 EFO_0003761 Remission after SSRI treatment in MDD or neuroticism unipolar depression European=357957 GCST006475 21.624885315307775 GCST006475 29942085 drug Low Ed Mountjoy Corticotropin releasing factor receptor 1 antagonist drug VERUCERFONT is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000120088 at this locus (5007bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000120088 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 17 43856639 17 45779273 EFO_0003761 Depressed affect unipolar depression European=38582 GCST005531 15.265200170411154 GCST005531 24076602 drug Low Ed Mountjoy Carbonic anhydrase IV inhibitor drug TOPIRAMATE is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000167434 at this locus (410546bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000167434 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 17 57816757 17 59739396 EFO_0003885 Multiple sclerosis multiple sclerosis European=459000 GCST007072 24.154901959985743 GCST007072 30595370 drug High Ed Mountjoy Angiotensin-converting enzyme inhibitor drug FOSINOPRIL is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000159640 at this locus (5504bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159640 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 17 61548918 17 63471557 EFO_0000319 Cardiovascular disease cardiovascular system disease European=459000 GCST007072 24.154901959985743 GCST007072 30595370 drug Low Ed Mountjoy Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000007314 at this locus (466997bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000007314 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 17 61548918 17 63471557 EFO_0000319 Cardiovascular disease cardiovascular system disease European=361141 19.50811606596098 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Angiotensin-converting enzyme inhibitor drug CAPTOPRIL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (5474bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159640 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 17 61548948 17 63471587 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=361141 19.50811606596098 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (5474bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159640 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 17 61548948 17 63471587 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=361141 19.50811606596098 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Sodium channel protein type IV alpha subunit blocker drug BUPIVACAINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000007314 at this locus (466967bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000007314 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 17 61548948 17 63471587 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=408343 10.1038/s41588-018-0184-y 10.26440110030182 SAIGE_401 drug High Ed Mountjoy Angiotensin-converting enzyme inhibitor drug LISINOPRIL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159640 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 17 61556298 17 63478937 EFO_0000537 Hypertension hypertension European=408343 10.1038/s41588-018-0184-y 10.26440110030182 SAIGE_401 drug Medium Ed Mountjoy Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159640 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 17 61556298 17 63478937 EFO_0000537 Hypertension hypertension European=408343 10.1038/s41588-018-0184-y 10.26440110030182 SAIGE_401 drug Low Ed Mountjoy Sodium channel protein type IV alpha subunit blocker drug LEVOBUPIVACAINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000007314 at this locus (459618bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000007314 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 17 61556298 17 63478937 EFO_0000537 Hypertension hypertension European=408089 10.1038/s41588-018-0184-y 10.172630726946174 SAIGE_401_1 drug Medium Ed Mountjoy Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159640 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 17 61556298 17 63478937 EFO_0000537 Essential hypertension hypertension European=408089 10.1038/s41588-018-0184-y 10.172630726946174 SAIGE_401_1 drug High Ed Mountjoy Angiotensin-converting enzyme inhibitor drug LISINOPRIL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000159640 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159640 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 17 61556298 17 63478937 EFO_0000537 Essential hypertension hypertension European=408089 10.1038/s41588-018-0184-y 10.172630726946174 SAIGE_401_1 drug Low Ed Mountjoy Sodium channel protein type IV alpha subunit blocker drug LEVOBUPIVACAINE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000007314 at this locus (459618bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000007314 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 17 61556298 17 63478937 EFO_0000537 Essential hypertension hypertension European=655666|South Asian=3650 GCST006867 7.3979400086720375 GCST006867 30054458 drug Medium Ed Mountjoy Angiotensin-converting enzyme inhibitor drug ENALAPRILAT is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000159640 at this locus (111860bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159640 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 17 61687600 17 63610240 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 7.3979400086720375 GCST006867 30054458 drug Medium Ed Mountjoy Angiotensin-converting enzyme inhibitor drug PERINDOPRIL is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000159640 at this locus (111860bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000159640 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 17 61687600 17 63610240 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 7.3979400086720375 GCST006867 30054458 drug Low Ed Mountjoy Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000007314 at this locus (328315bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000007314 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 17 61687600 17 63610240 EFO_0001360 Type 2 diabetes type II diabetes mellitus NR=250736 GCST005196 10.096910013008056 GCST005196 29212778 drug Low Ed Mountjoy Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000007314 at this locus (336814bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000007314 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 17 62387091 17 64309731 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 10.20210951694165 GCST005194 29212778 drug Low Ed Mountjoy Sodium channel protein type IV alpha subunit blocker drug RANOLAZINE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000007314 at this locus (351688bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000007314 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 17 62401965 17 64324605 EFO_0000378 Coronary artery disease coronary artery disease European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 10.0 GCST006061 29892015 drug Medium Ed Mountjoy Inward rectifier potassium channel 2 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000123700 at this locus (160996bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000123700 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 17 68337185 17 70341044 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 8.522878745280337 GCST006061_3 29892015 drug Medium Ed Mountjoy Inward rectifier potassium channel 2 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000123700 at this locus (171150bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000123700 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 17 68347338 17 70351197 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 8.522878745280337 GCST006061_3 29892015 drug Medium Ed Mountjoy Inward rectifier potassium channel 2 blocker drug DRONEDARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000123700 at this locus (171150bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000123700 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 17 68347338 17 70351197 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation East Asian=9299|European=45790 GCST006048 7.522878745280337 GCST006048 24532676 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000176014 at this locus (453375bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000176014 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 18 12797694 18 12797695 EFO_0000685 Rheumatoid arthritis (ACPA-positive) rheumatoid arthritis East Asian=20965 GCST001454 7.698970004336019 GCST001454 22446963 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000176014 at this locus (453375bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000176014 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 18 12797694 18 12797695 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis East Asian=4075 GCST001674 10.698970004336019 GCST001674 22960999 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000707 and targets the gene ENSG00000176014 at this locus (477275bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000176014 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 18 12821593 18 12821594 EFO_0000707 Esophageal cancer (squamous cell) squamous cell carcinoma East Asian=4075 GCST001674 10.698970004336019 GCST001674 22960999 drug Low Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000707 and targets the gene ENSG00000176014 at this locus (477275bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000176014 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 18 12821593 18 12821594 EFO_0000707 Esophageal cancer (squamous cell) squamous cell carcinoma East Asian=4075 GCST001674 10.698970004336019 GCST001674 22960999 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0002916 and targets the gene ENSG00000176014 at this locus (477275bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000176014 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 18 12821593 18 12821594 EFO_0002916 Esophageal cancer (squamous cell) esophageal carcinoma European=2258 GCST000663 10.221848749616356 GCST000663 20421936 drug Medium Ed Mountjoy Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (226313bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166603 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 18 57811982 18 60144750 EFO_0001073 Obesity (early onset extreme) obesity European=204498 GCST001953 35.69897000433602 GCST001953_4 23563607 drug Medium Ed Mountjoy Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187873bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166603 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 18 57850422 18 60183189 EFO_0001073 Obesity [Obesity class I] obesity European=2796 GCST000317 7.698970004336019 GCST000317_3 19151714 drug Medium Ed Mountjoy Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187199bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166603 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 18 57851097 18 60183864 EFO_0001073 Obesity [children] obesity European=2796 GCST000317 14.301029995663981 GCST000317 19151714 drug Medium Ed Mountjoy Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187199bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166603 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 18 57851097 18 60183864 EFO_0001073 Obesity obesity European=2796 GCST000317 8.397940008672037 GCST000317_2 19151714 drug Medium Ed Mountjoy Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (187199bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166603 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 18 57851097 18 60183864 EFO_0001073 Obesity [adults] obesity European=204498 GCST001953 26.69897000433602 GCST001953_5 23563607 drug Medium Ed Mountjoy Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (186533bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166603 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 18 57851763 18 60184530 EFO_0001073 Obesity [Overweight] obesity European=408792 10.1038/s41588-018-0184-y 11.251037138743838 SAIGE_278_1 drug Medium Ed Mountjoy Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185708bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166603 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 18 57852587 18 60185354 EFO_0001073 Obesity obesity European=6889 GCST001957 13.045757490560675 GCST001957 23563609 drug Medium Ed Mountjoy Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185708bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166603 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 18 57852587 18 60185354 EFO_0001073 Obesity (early onset extreme) obesity European=408961 10.1038/s41588-018-0184-y 11.126098402135538 SAIGE_278 drug Medium Ed Mountjoy Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185708bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166603 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 18 57852587 18 60185354 EFO_0001073 Overweight, obesity and other hyperalimentation obesity European=204498 GCST001953 21.522878745280337 GCST001953_3 23563607 drug Medium Ed Mountjoy Melanocortin receptor 4 agonist drug SETMELANOTIDE is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000166603 at this locus (185347bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000166603 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 18 57852948 18 60185715 EFO_0001073 Obesity [Obesity class II] obesity European=10486 GCST002643 9.096910013008056 GCST002643 25279986 drug Low Ed Mountjoy Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase II for the indiciation EFO_0000096 and targets the gene ENSG00000171791 at this locus (7369bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171791 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 18 60783211 18 63115978 EFO_0000096 Follicular lymphoma neoplasm of mature B-cells European=17691 GCST004146 10.698970004336019 GCST004146 28165464 drug Low Ed Mountjoy Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (1834bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171791 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 18 60788745 18 63121512 EFO_0000095 Chronic lymphocytic leukemia chronic lymphocytic leukemia European=17691 GCST004146 10.698970004336019 GCST004146 28165464 drug High Ed Mountjoy Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (1834bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171791 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 18 60788745 18 63121512 EFO_0000095 Chronic lymphocytic leukemia chronic lymphocytic leukemia European=10767 GCST003468 10.397940008672037 GCST003468 26956414 drug Low Ed Mountjoy Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171791 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 18 60793494 18 63126261 EFO_0000095 Chronic lymphocytic leukemia chronic lymphocytic leukemia European=10767 GCST003468 10.397940008672037 GCST003468 26956414 drug High Ed Mountjoy Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171791 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 18 60793494 18 63126261 EFO_0000095 Chronic lymphocytic leukemia chronic lymphocytic leukemia European=8400 GCST002073 11.522878745280337 GCST002073 23770605 drug Low Ed Mountjoy Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171791 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 18 60793549 18 63126316 EFO_0000095 Chronic lymphocytic leukemia chronic lymphocytic leukemia European=8400 GCST002073 11.522878745280337 GCST002073 23770605 drug High Ed Mountjoy Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171791 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 18 60793549 18 63126316 EFO_0000095 Chronic lymphocytic leukemia chronic lymphocytic leukemia European=8400 GCST002073 10.096910013008056 GCST002073 23770605 drug Low Ed Mountjoy Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171791 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 18 60793921 18 63126688 EFO_0000095 Chronic lymphocytic leukemia chronic lymphocytic leukemia European=8400 GCST002073 10.096910013008056 GCST002073 23770605 drug High Ed Mountjoy Apoptosis regulator Bcl-2 inhibitor drug VENETOCLAX is Phase IV for the indiciation EFO_0000095 and targets the gene ENSG00000171791 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171791 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 18 60793921 18 63126688 EFO_0000095 Chronic lymphocytic leukemia chronic lymphocytic leukemia European=140254 GCST006085 8.0 GCST006085 29892016 drug Low Ed Mountjoy Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000171791 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171791 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II CT C 18 60961193 18 63293960 EFO_0001663 Prostate cancer prostate carcinoma European=140254 GCST006085 8.0 GCST006085 29892016 drug Low Ed Mountjoy Apoptosis regulator Bcl-2 inhibitor drug NAVITOCLAX is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000171791 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171791 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C CT 18 60961193 18 63293960 EFO_0001663 Prostate cancer prostate carcinoma European=33976 GCST003219 7.522878745280337 GCST003219_2 26691988 drug Medium Ed Mountjoy Complement factor D inhibitor drug LAMPALIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000197766 at this locus (167810bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197766 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 19 1031438 19 1031439 EFO_0001365 Advanced age-related macular degeneration [EA] age-related macular degeneration European=17691 GCST004146 7.301029995663981 GCST004146 28165464 drug Low Ed Mountjoy Elongation factor 2 inhibitor drug DENILEUKIN DIFTITOX is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000167658 at this locus (83658bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000167658 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 19 4069119 19 4069121 EFO_0000095 Chronic lymphocytic leukemia chronic lymphocytic leukemia European=1043 GCST005934 8.522878745280337 GCST005934 29884837 drug Low Ed Mountjoy Insulin receptor inhibitor drug LINSITINIB is Phase II for the indiciation EFO_0006859 and targets the gene ENSG00000171105 at this locus (340047bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171105 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 19 7699347 19 7634461 EFO_0006859 Neuropathic pain in head and neck cancer head and neck malignant neoplasia European=86475 GCST005537 21.69897000433602 GCST005537 26974007 drug Medium Ed Mountjoy Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (169080bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000079999 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A T 19 10427721 19 10317045 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis European=287323 GCST004346 42.52287874528034 GCST004346 28537254 drug Medium Ed Mountjoy Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (133684bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000079999 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 19 10463118 19 10352442 EFO_0000676 Psoriasis psoriasis European=361141 11.517984423549288 NEALE2_20002_1453 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (133684bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000079999 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 19 10463118 19 10352442 EFO_0000676 Psoriasis | non-cancer illness code, self-reported psoriasis European=33394 GCST005527 13.045757490560675 GCST005527 23143594 drug Medium Ed Mountjoy Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (133684bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000079999 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 19 10463118 19 10352442 EFO_0000676 Psoriasis psoriasis European=7353 GCST000833 10.397940008672037 GCST000833 20953190 drug Medium Ed Mountjoy Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (126826bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000079999 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 19 10469975 19 10359299 EFO_0000676 Psoriasis psoriasis European=7353 GCST000833 8.397940008672037 GCST000833 20953190 drug Medium Ed Mountjoy Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (123868bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000079999 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 19 10472933 19 10362257 EFO_0000676 Psoriasis psoriasis European=18190 GCST002740 13.522878745280337 GCST002740_4 25574825 drug Medium Ed Mountjoy Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (18959bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000079999 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 19 10577843 19 10467167 EFO_0000676 Inflammatory skin disease [Psoriasis] psoriasis European=38582 GCST005531 9.019088062223156 GCST005531 24076602 drug Medium Ed Mountjoy Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase IV for the indiciation EFO_0003885 and targets the gene ENSG00000079999 at this locus (127936bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000079999 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 19 10742170 19 10631494 EFO_0003885 Multiple sclerosis multiple sclerosis European=38582 GCST005531 9.019088062223156 GCST005531 24076602 drug Medium Ed Mountjoy Sphingosine 1-phosphate receptor Edg-8 agonist drug SIPONIMOD is Phase III for the indiciation EFO_0003885 and targets the gene ENSG00000180739 at this locus (113564bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180739 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 19 10742170 19 10631494 EFO_0003885 Multiple sclerosis multiple sclerosis European=33394 GCST005527 9.378437388797577 GCST005527 23143594 drug Medium Ed Mountjoy Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (203859bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000079999 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 19 10818092 19 10707416 EFO_0000676 Psoriasis psoriasis European=287323 GCST004346 9.698970004336019 GCST004346 28537254 drug Low Ed Mountjoy Kelch-like ECH-associated protein 1 inhibitor drug DIMETHYL FUMARATE is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000079999 at this locus (271972bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000079999 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 19 10886206 19 10775530 EFO_0000676 Psoriasis psoriasis European=6042 GCST000340 8.698970004336019 GCST000340 19198609 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (324283bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 19 11163601 19 11052925 EFO_0000612 Myocardial infarction (early onset) myocardial infarction NR=123388 GCST002287 11.522878745280337 GCST002287 24262325 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000712 and targets the gene ENSG00000187266 at this locus (324283bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 19 11163601 19 11052925 EFO_0000712 Coronary artery disease or ischemic stroke cerebrovascular accident European=6042 GCST000340 8.698970004336019 GCST000340 19198609 drug Low Ed Mountjoy Erythropoietin receptor agonist drug DARBEPOETIN ALFA is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (324283bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 19 11163601 19 11052925 EFO_0000612 Myocardial infarction (early onset) myocardial infarction European=446696|East Asian=45564|South Asian=9144|African American or Afro-Caribbean=20695|Asian unspecified=698|Hispanic or Latin American=1557 GCST005838 7.522878745280337 GCST005838 29531354 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000712 and targets the gene ENSG00000187266 at this locus (312949bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 19 11174935 19 11064259 EFO_0000712 Stroke cerebrovascular accident African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630 GCST003117 7.522878745280337 GCST003117 26343387 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299730bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 19 11188153 19 11077477 EFO_0000612 Myocardial infarction myocardial infarction African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630 GCST003117 7.522878745280337 GCST003117 26343387 drug Low Ed Mountjoy Erythropoietin receptor agonist drug DARBEPOETIN ALFA is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299730bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 19 11188153 19 11077477 EFO_0000612 Myocardial infarction myocardial infarction European=388806 10.1038/s41588-018-0184-y 8.777283528852417 SAIGE_411_2 drug Low Ed Mountjoy Erythropoietin receptor agonist drug DARBEPOETIN ALFA is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299720bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 19 11188164 19 11077488 EFO_0000612 Myocardial infarction myocardial infarction European=388806 10.1038/s41588-018-0184-y 8.777283528852417 SAIGE_411_2 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000612 and targets the gene ENSG00000187266 at this locus (299720bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 19 11188164 19 11077488 EFO_0000612 Myocardial infarction myocardial infarction NR=296525 GCST005194 35.71175077442801 GCST005194 29212778 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (299637bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 19 11188247 19 11077571 EFO_0000378 Coronary artery disease coronary artery disease European=408458 10.1038/s41588-018-0184-y 12.602059991327963 SAIGE_411 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (299637bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 19 11188247 19 11077571 EFO_0000378 Ischemic heart disease coronary artery disease European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323 GCST003116 14.397940008672037 GCST003116 26343387 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (299637bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 19 11188247 19 11077571 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 40.30102999566398 GCST005196 29212778 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (285577bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 19 11202306 19 11091630 EFO_0000378 Coronary artery disease coronary artery disease European, NR=63731 GCST004787 21.096910013008056 GCST004787 28714975 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (285577bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 19 11202306 19 11091630 EFO_0000378 Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) coronary artery disease NR=547261 GCST005195 23.4089353929735 GCST005195 29212778 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (285577bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 19 11202306 19 11091630 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 7.705313375720557 GCST005194 29212778 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (263618bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 19 11224265 19 11113589 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 7.698970004336019 GCST005196 29212778 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (184329bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 19 11303554 19 11192878 EFO_0000378 Coronary artery disease coronary artery disease European=87827 GCST005077 8.154901959985743 GCST005077 29058716 drug Medium Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000187266 at this locus (64180bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 19 11423703 19 11313027 EFO_0000305 Breast cancer breast carcinoma NR=547261 GCST005195 8.2518119729938 GCST005195 29212778 drug Low Ed Mountjoy Erythropoietin receptor agonist drug EPOETIN ALFA is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000187266 at this locus (1963bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000187266 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 19 11496981 19 11386305 EFO_0000378 Coronary artery disease coronary artery disease European=66756 GCST004744 9.045757490560675 GCST004744 28604730 drug Low Ed Mountjoy Tyrosine-protein kinase receptor UFO inhibitor drug R428 is Phase II for the indiciation EFO_0000571 and targets the gene ENSG00000167601 at this locus (372022bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000167601 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 19 41353107 19 40847202 EFO_0000571 Lung adenocarcinoma lung adenocarcinoma European=140254 GCST006085 8.045757490560675 GCST006085 29892016 drug Low Ed Mountjoy Sodium/potassium-transporting ATPase inhibitor drug DIGOXIN is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000105409 at this locus (199298bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000105409 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 19 42700947 19 42196795 EFO_0001663 Prostate cancer prostate carcinoma European=22548 GCST001942 7.522878745280337 GCST001942 23535732 drug Low Ed Mountjoy Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (462229bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000115758 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 10117868 2 9977740 EFO_0001663 Prostate cancer prostate carcinoma European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080 GCST002606 7.698970004336019 GCST002606_3 25217961 drug Low Ed Mountjoy Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (122277bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000115758 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 10710730 2 10570604 EFO_0001663 Prostate cancer [EA] prostate carcinoma European=140254 GCST006085 16.221848749616356 GCST006085 29892016 drug Low Ed Mountjoy Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (122277bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000115758 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 10710730 2 10570604 EFO_0001663 Prostate cancer prostate carcinoma European=67543|Sub-Saharan African, African American or Afro-Caribbean=10463|East Asian=6954|Hispanic or Latin American=2080 GCST002606 7.522878745280337 GCST002606 25217961 drug Low Ed Mountjoy Ornithine decarboxylase inhibitor drug EFLORNITHINE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000115758 at this locus (122277bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000115758 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 10710730 2 10570604 EFO_0001663 Prostate cancer prostate carcinoma European=241704 GCST004483 16.0 GCST004483 27363682 drug Low Ed Mountjoy DNA (cytosine-5)-methyltransferase 3A inhibitor drug AZACITIDINE is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000119772 at this locus (47687bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000119772 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 2 25613146 2 25390277 EFO_0001378 Multiple myeloma multiple myeloma European=14421 GCST004099 9.221848749616356 GCST004099 28112199 drug Low Ed Mountjoy DNA (cytosine-5)-methyltransferase 3A inhibitor drug AZACITIDINE is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000119772 at this locus (63979bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000119772 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 2 25629438 2 25406569 EFO_0001378 B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy) multiple myeloma European=14421 GCST004099 9.221848749616356 GCST004099 28112199 drug Low Ed Mountjoy DNA (cytosine-5)-methyltransferase 3A inhibitor drug AZACITIDINE is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000119772 at this locus (63979bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000119772 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 2 25629438 2 25406569 EFO_0000095 B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy) chronic lymphocytic leukemia European=408089 10.1038/s41588-018-0184-y 35.59516628338006 SAIGE_401_1 drug High Ed Mountjoy Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (1194bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171303 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 2 26914364 2 26691496 EFO_0000537 Essential hypertension hypertension European=361141 39.522019692388156 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (1194bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171303 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 2 26914364 2 26691496 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension East Asian=50792 GCST007707 13.301029995663981 GCST007707_2 30487518 drug High Ed Mountjoy Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171303 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 2 26920025 2 26697157 EFO_0000537 Hypertension [Japanese] hypertension European=408343 10.1038/s41588-018-0184-y 35.37263414340727 SAIGE_401 drug High Ed Mountjoy Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171303 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 2 26923568 2 26700700 EFO_0000537 Hypertension hypertension East Asian=50792 GCST007707 17.69897000433602 GCST007707 30487518 drug High Ed Mountjoy Potassium channel subfamily K member 3 opener drug SEVOFLURANE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000171303 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171303 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 2 26930411 2 26707543 EFO_0000537 Hypertension [East Asian] hypertension European=17500 GCST003983 14.698970004336019 GCST003983 27182965 drug High Ed Mountjoy Steroid 5-alpha-reductase 2 inhibitor drug FINASTERIDE is Phase IV for the indiciation EFO_0004191 and targets the gene ENSG00000277893 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000277893 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 2 31805826 2 31580756 EFO_0004191 Male-pattern baldness androgenetic alopecia European=43590 GCST005116 25.69897000433602 GCST005116 29146897 drug Low Ed Mountjoy Steroid 5-alpha-reductase 2 inhibitor drug FINASTERIDE is Phase IV for the indiciation EFO_0004191 and targets the gene ENSG00000277893 at this locus (375418bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000277893 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 2 32181424 2 31956355 EFO_0004191 Male-pattern baldness androgenetic alopecia East Asian=5255 GCST001634 8.397940008672037 GCST001634 22885925 drug Low Ed Mountjoy Luteinizing hormone/Choriogonadotropin receptor agonist drug CHORIOGONADOTROPIN ALFA is Phase II for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138039 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 2 48978159 2 48751020 EFO_0000660 Polycystic ovary syndrome polycystic ovary syndrome East Asian=1639 GCST000914 20.096910013008056 GCST000914 21151128 drug High Ed Mountjoy Luteinizing hormone/Choriogonadotropin receptor agonist drug GONADOTROPIN, CHORIONIC is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138039 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 2 48978159 2 48751020 EFO_0000660 Polycystic ovary syndrome polycystic ovary syndrome East Asian=5255 GCST001634 8.397940008672037 GCST001634 22885925 drug Medium Ed Mountjoy Follicle stimulating hormone receptor agonist drug MENOTROPINS is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000170820 at this locus (211138bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000170820 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 2 48978159 2 48751020 EFO_0000660 Polycystic ovary syndrome polycystic ovary syndrome East Asian=5255 GCST001634 8.397940008672037 GCST001634 22885925 drug High Ed Mountjoy Luteinizing hormone/Choriogonadotropin receptor agonist drug GONADOTROPIN, CHORIONIC is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138039 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 2 48978159 2 48751020 EFO_0000660 Polycystic ovary syndrome polycystic ovary syndrome East Asian=1639 GCST000914 20.096910013008056 GCST000914 21151128 drug Low Ed Mountjoy Luteinizing hormone/Choriogonadotropin receptor agonist drug CHORIOGONADOTROPIN ALFA is Phase II for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138039 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 2 48978159 2 48751020 EFO_0000660 Polycystic ovary syndrome polycystic ovary syndrome East Asian=1639 GCST000914 20.096910013008056 GCST000914 21151128 drug Medium Ed Mountjoy Follicle stimulating hormone receptor agonist drug MENOTROPINS is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000170820 at this locus (211138bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000170820 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 2 48978159 2 48751020 EFO_0000660 Polycystic ovary syndrome polycystic ovary syndrome East Asian=5255 GCST001634 12.0 GCST001634 22885925 drug Medium Ed Mountjoy Luteinizing hormone/Choriogonadotropin receptor agonist drug LH (MENOTROPINS) is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (218743bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138039 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 2 49201612 2 48974473 EFO_0000660 Polycystic ovary syndrome polycystic ovary syndrome East Asian=5255 GCST001634 12.0 GCST001634 22885925 drug Low Ed Mountjoy Luteinizing hormone/Choriogonadotropin receptor agonist drug CHORIOGONADOTROPIN ALFA is Phase II for the indiciation EFO_0000660 and targets the gene ENSG00000138039 at this locus (218743bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138039 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 49201612 2 48974473 EFO_0000660 Polycystic ovary syndrome polycystic ovary syndrome East Asian=5255 GCST001634 12.0 GCST001634 22885925 drug High Ed Mountjoy Follicle stimulating hormone receptor agonist drug HUMAN FSH is Phase IV for the indiciation EFO_0000660 and targets the gene ENSG00000170820 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000170820 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 2 49201612 2 48974473 EFO_0000660 Polycystic ovary syndrome polycystic ovary syndrome European=407052 10.1038/s41588-018-0184-y 7.52432881167557 SAIGE_420_2 drug Medium Ed Mountjoy Interleukin-1 beta inhibitor drug RILONACEPT is Phase III for the indiciation EFO_0007427 and targets the gene ENSG00000125538 at this locus (15088bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000125538 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 2 113609568 2 112851991 EFO_0007427 Pericarditis pericarditis European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811 GCST007692 7.698970004336019 GCST007692 30804561 drug Low Ed Mountjoy Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000115159 at this locus (278767bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000115159 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 2 157013035 2 156156523 EFO_0000341 Chronic obstructive pulmonary disease chronic obstructive pulmonary disease NR=361315|European=446238 GCST007342 17.522878745280337 GCST007342 30718901 drug Medium Ed Mountjoy Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000115159 at this locus (180489bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000115159 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 2 157111313 2 156254801 EFO_0003761 Depression unipolar depression European=480359 GCST005839 7.698970004336019 GCST005839 29700475 drug Medium Ed Mountjoy Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000115159 at this locus (180489bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000115159 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 2 157111313 2 156254801 EFO_0003761 Depression unipolar depression European=357957 GCST006475 7.4889191544608815 GCST006475 29942085 drug Medium Ed Mountjoy Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor drug METFORMIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000115159 at this locus (134654bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000115159 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 2 157157148 2 156300636 EFO_0003761 Depressed affect unipolar depression European=361141 8.54284051026846 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000197635 at this locus (367302bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 2 162481453 2 161624943 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=408343 10.1038/s41588-018-0184-y 7.732828271596986 SAIGE_401 drug Low Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000197635 at this locus (265252bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 2 162583504 2 161726994 EFO_0000537 Hypertension hypertension European=408089 10.1038/s41588-018-0184-y 7.580044251510242 SAIGE_401_1 drug Low Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000197635 at this locus (265252bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 2 162583504 2 161726994 EFO_0000537 Essential hypertension hypertension European=82315|East Asian=5219 GCST002539 7.301029995663981 GCST002539 25056061 drug High Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug LINAGLIPTIN is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000197635 at this locus (2901bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 2 162845855 2 161989345 EFO_0000692 Schizophrenia schizophrenia European=86475 GCST005537 12.522878745280337 GCST005537 26974007 drug Low Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (179811bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 2 163110536 2 162254026 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis European=18190 GCST002740 11.698970004336019 GCST002740_4 25574825 drug Low Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (179811bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 2 163110536 2 162254026 EFO_0000676 Inflammatory skin disease [Psoriasis] psoriasis European=29652 GCST005536 17.418639958543828 GCST005536 25751624 drug Medium Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (179811bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 2 163110536 2 162254026 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=29652 GCST005536 17.418639958543828 GCST005536 25751624 drug Medium Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (179811bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 2 163110536 2 162254026 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=33394 GCST005527 7.709543459425466 GCST005527 23143594 drug Low Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (193326bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 163124051 2 162267541 EFO_0000676 Psoriasis psoriasis European=19102 GCST001191 13.698970004336019 GCST001191 21829393 drug Medium Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SAXAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 2 163124051 2 162267541 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus East Asian=5134|European=8682 GCST002874 8.0 GCST002874 25903422 drug Low Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (193326bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 163124051 2 162267541 EFO_0000676 Psoriasis psoriasis European=5000 GCST000038 10.698970004336019 GCST000038 17554260 drug Medium Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SAXAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 2 163124051 2 162267541 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=16559 GCST000392 8.154901959985743 GCST000392 19430480 drug Medium Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SAXAGLIPTIN is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 2 163124051 2 162267541 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=16559 GCST000392 8.154901959985743 GCST000392 19430480 drug Medium Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 2 163124051 2 162267541 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=5000 GCST000038 10.698970004336019 GCST000038 17554260 drug Medium Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 2 163124051 2 162267541 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=19102 GCST001191 13.698970004336019 GCST001191 21829393 drug Medium Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug VILDAGLIPTIN is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000197635 at this locus (193326bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 2 163124051 2 162267541 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus East Asian=5134|European=8682 GCST002874 10.522878745280337 GCST002874_5 25903422 drug Low Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (198100bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 2 163128824 2 162272314 EFO_0000676 Psoriasis [EA, conditional on rs1990760] psoriasis East Asian=5134|European=8682 GCST002874 18.0 GCST002874_9 25903422 drug Low Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (198100bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 2 163128824 2 162272314 EFO_0000676 Psoriasis [conditional on rs1990760] psoriasis European=287323 GCST004346 24.0 GCST004346 28537254 drug Low Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (237021bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 2 163167746 2 162311236 EFO_0000676 Psoriasis psoriasis European=12244 GCST002738 8.522878745280337 GCST002738 25574825 drug Low Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (329966bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 2 163260691 2 162404181 EFO_0000676 Psoriasis psoriasis European=7353 GCST000833 13.0 GCST000833 20953190 drug Low Ed Mountjoy Dipeptidyl peptidase IV inhibitor drug SITAGLIPTIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000197635 at this locus (329966bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000197635 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 2 163260691 2 162404181 EFO_0000676 Psoriasis psoriasis European, NR=40266 GCST004132 10.012333735073724 GCST004132 28067908 drug High Ed Mountjoy Integrin alpha-4/beta-1 inhibitor drug NATALIZUMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000115232 at this locus (13578bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000115232 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 2 182308352 2 181443625 EFO_0000384 Crohn's disease Crohn's disease East Asian=4325 GCST001457 13.045757490560675 GCST001457 22452962 drug Low Ed Mountjoy Receptor protein-tyrosine kinase erbB-4 inhibitor drug BMS-690514 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000178568 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000178568 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 2 213296863 2 212432139 EFO_0000305 Breast cancer breast carcinoma European, NR=58918|European=458969 GCST007656 8.698970004336019 GCST007656 30940143 drug Low Ed Mountjoy Interleukin-8 receptor A antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000163464 at this locus (360196bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163464 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 2 218667372 2 217802649 EFO_0000341 Chronic obstructive pulmonary disease or resting heart rate (pleiotropy) chronic obstructive pulmonary disease European, NR=58918|European=458969 GCST007656 8.698970004336019 GCST007656 30940143 drug Low Ed Mountjoy Interleukin-8 receptor B antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000180871 at this locus (322641bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180871 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 2 218667372 2 217802649 EFO_0000341 Chronic obstructive pulmonary disease or resting heart rate (pleiotropy) chronic obstructive pulmonary disease European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811 GCST007692 11.522878745280337 GCST007692 30804561 drug Low Ed Mountjoy Interleukin-8 receptor A antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000163464 at this locus (344415bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163464 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 2 218683154 2 217818431 EFO_0000341 Chronic obstructive pulmonary disease chronic obstructive pulmonary disease European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811 GCST007692 11.522878745280337 GCST007692 30804561 drug Low Ed Mountjoy Interleukin-8 receptor B antagonist drug DANIRIXIN is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000180871 at this locus (306858bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180871 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 2 218683154 2 217818431 EFO_0000341 Chronic obstructive pulmonary disease chronic obstructive pulmonary disease European=139274 GCST004988 9.466355021201236 GCST004988 29059683 drug Low Ed Mountjoy Interleukin-8 receptor A modulator drug REPARIXIN is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000163464 at this locus (304113bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163464 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 2 218723455 2 217858732 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 9.466355021201236 GCST004988 29059683 drug Low Ed Mountjoy Interleukin-8 receptor B modulator drug REPARIXIN is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000180871 at this locus (266557bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180871 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 2 218723455 2 217858732 EFO_0000305 Breast cancer breast carcinoma European=27432 GCST003045 8.682610761959468 GCST003045 26192919 drug Low Ed Mountjoy Interleukin-8 receptor B antagonist drug ELUBRIXIN is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000180871 at this locus (8173bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180871 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 219010146 2 218145423 EFO_0000729 Ulcerative colitis [EA] ulcerative colitis European=86475 GCST005537 10.698970004336019 GCST005537 26974007 drug Low Ed Mountjoy Interleukin-8 receptor B antagonist drug ELUBRIXIN is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000180871 at this locus (8173bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180871 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 219010146 2 218145423 EFO_0000729 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ulcerative colitis European=26405 GCST000964 8.056505484093897 GCST000964 21297633 drug Low Ed Mountjoy Interleukin-8 receptor B antagonist drug ELUBRIXIN is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000180871 at this locus (8173bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180871 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 219010146 2 218145423 EFO_0000729 Ulcerative colitis ulcerative colitis European=86475 GCST005537 10.698970004336019 GCST005537 26974007 drug Low Ed Mountjoy Interleukin-8 receptor B antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000180871 at this locus (8173bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000180871 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 219010146 2 218145423 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis European=86475 GCST005537 10.698970004336019 GCST005537 26974007 drug Low Ed Mountjoy Interleukin-8 receptor A antagonist drug NAVARIXIN is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000163464 at this locus (17422bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163464 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 219010146 2 218145423 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis European=17691 GCST004146 11.045757490560675 GCST004146 28165464 drug Low Ed Mountjoy Programmed cell death protein 1 inhibitor drug NIVOLUMAB is Phase II for the indiciation EFO_0000095 and targets the gene ENSG00000188389 at this locus (494386bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000188389 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 2 242294913 2 241355498 EFO_0000095 Chronic lymphocytic leukemia chronic lymphocytic leukemia European=140254 GCST006085 14.0 GCST006085 29892016 drug Low Ed Mountjoy Programmed cell death protein 1 inhibitor drug PEMBROLIZUMAB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000188389 at this locus (406436bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000188389 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 242382864 2 241443449 EFO_0001663 Prostate cancer prostate carcinoma European=22548 GCST001942 8.301029995663981 GCST001942 23535732 drug Low Ed Mountjoy Programmed cell death protein 1 inhibitor drug PEMBROLIZUMAB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000188389 at this locus (406436bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000188389 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 2 242382864 2 241443449 EFO_0001663 Prostate cancer prostate carcinoma European=16559 GCST000392 11.0 GCST000392 19430480 drug Medium Ed Mountjoy FK506-binding protein 1A inhibitor drug SIROLIMUS is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (236734bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000088832 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 20 1610551 20 1629905 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=16559 GCST000392 11.0 GCST000392 19430480 drug Medium Ed Mountjoy FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (236734bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000088832 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 20 1610551 20 1629905 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=29652 GCST005536 9.526299949462304 GCST005536 25751624 drug Medium Ed Mountjoy FK506-binding protein 1A inhibitor drug SIROLIMUS is Phase IV for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (242388bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000088832 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 20 1616206 20 1635560 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=29652 GCST005536 9.526299949462304 GCST005536 25751624 drug Medium Ed Mountjoy FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000088832 at this locus (242388bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000088832 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 20 1616206 20 1635560 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=20883 GCST003044 54.01739783478714 GCST003044 26192919 drug Low Ed Mountjoy FK506-binding protein 1A inhibitor drug SIROLIMUS is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000088832 at this locus (308219bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000088832 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 20 1682037 20 1701391 EFO_0000384 Crohn's disease [EA] Crohn's disease European=27432 GCST003045 41.87573133737034 GCST003045 26192919 drug Low Ed Mountjoy FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000088832 at this locus (308219bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000088832 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 20 1682037 20 1701391 EFO_0000729 Ulcerative colitis [EA] ulcerative colitis European=20883 GCST003044 54.01739783478714 GCST003044 26192919 drug Low Ed Mountjoy FK506-binding protein 1A inhibitor drug TACROLIMUS is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000088832 at this locus (308219bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000088832 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 20 1682037 20 1701391 EFO_0000384 Crohn's disease [EA] Crohn's disease European=89677 GCST007236 7.4634655452861525 GCST007236 25751625 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (408100bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 20 44229447 20 45600808 EFO_0000305 Breast cancer breast carcinoma European, NR=40266 GCST004132 10.576918041702768 GCST004132 28067908 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100985 at this locus (2636bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 20 44634912 20 46006273 EFO_0000384 Crohn's disease Crohn's disease European=89677 GCST007236 7.402641632544848 GCST007236 25751625 drug Medium Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (48698bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 20 44693897 20 46065258 EFO_0000305 Breast cancer breast carcinoma European=43327 GCST005568 9.0 GCST005568 23143596 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (89110bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 20 44734310 20 46105671 EFO_0000685 Rheumatoid arthritis (ACPA-positive) rheumatoid arthritis European=20883 GCST003044 11.569280112136719 GCST003044 26192919 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100985 at this locus (94996bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 20 44740196 20 46111557 EFO_0000384 Crohn's disease [EA] Crohn's disease European=86475 GCST005537 11.397940008672037 GCST005537 26974007 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000100985 at this locus (101782bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 20 44746982 20 46118343 EFO_0000729 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ulcerative colitis European=86475 GCST005537 11.397940008672037 GCST005537 26974007 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100985 at this locus (101782bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 20 44746982 20 46118343 EFO_0000384 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] Crohn's disease East Asian=9299|European=45790 GCST006048 12.698970004336019 GCST006048 24532676 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (101782bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 20 44746982 20 46118343 EFO_0000685 Rheumatoid arthritis (ACPA-positive) rheumatoid arthritis European=25708 GCST000679 8.244874758392445 GCST000679 20453842 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (102748bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 20 44747947 20 46119308 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis European=15853 GCST000232 8.096910013008056 GCST000232 18794853 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (102748bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 20 44747947 20 46119308 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis European=43327 GCST005568 10.045757490560675 GCST005568 23143596 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (102748bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 20 44747947 20 46119308 EFO_0000685 Rheumatoid arthritis (ACPA-positive) rheumatoid arthritis African American or Afro-Caribbean=2308 GCST006959 13.522878745280337 GCST006959 30423114 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 20 44749251 20 46120612 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis European=58284|East Asian=22515 GCST002318 17.397940008672037 GCST002318 24390342 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 20 44749251 20 46120612 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis African American or Afro-Caribbean=2308 GCST006959 13.397940008672037 GCST006959_3 30423114 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 20 44749251 20 46120612 EFO_0000685 Rheumatoid arthritis [EA] rheumatoid arthritis European=58284|East Asian=22515 GCST002318 16.0 GCST002318_2 24390342 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug ANDECALIXIMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000100985 at this locus (104051bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 20 44749251 20 46120612 EFO_0000685 Rheumatoid arthritis [EA] rheumatoid arthritis European=89677 GCST007236 7.61253898367965 GCST007236 25751625 drug Medium Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (229958bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 20 44875157 20 46246518 EFO_0000305 Breast cancer breast carcinoma European=89677 GCST007236 7.818633826857316 GCST007236 25751625 drug Low Ed Mountjoy Matrix metalloproteinase 9 inhibitor drug MARIMASTAT is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000100985 at this locus (391013bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100985 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 20 45036213 20 46407574 EFO_0000305 Breast cancer breast carcinoma European=89677 GCST007236 8.34338536184194 GCST007236 25751625 drug Medium Ed Mountjoy Tubulin inhibitor drug TRASTUZUMAB EMTANSINE is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (226411bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000101162 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 20 57367899 20 58792844 EFO_0000305 Breast cancer breast carcinoma European=89677 GCST007236 8.34338536184194 GCST007236 25751625 drug Low Ed Mountjoy Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (226411bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000101162 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 20 57367899 20 58792844 EFO_0000305 Breast cancer breast carcinoma East Asian=70506 GCST007552 7.698970004336019 GCST007552 30529582 drug Low Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0005842 and targets the gene ENSG00000101162 at this locus (119118bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000101162 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 20 57475191 20 58900136 EFO_0005842 Colorectal cancer colorectal cancer European=89677 GCST007236 7.5130894413060085 GCST007236 25751625 drug Low Ed Mountjoy Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (57416bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000101162 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 20 57659124 20 59084069 EFO_0000305 Breast cancer breast carcinoma European=89677 GCST007236 7.5130894413060085 GCST007236 25751625 drug High Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (57416bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000101162 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 20 57659124 20 59084069 EFO_0000305 Breast cancer breast carcinoma NR=296525 GCST005194 9.099086932262331 GCST005194 29212778 drug Medium Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000101162 at this locus (112317bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000101162 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 20 57714025 20 59138970 EFO_0000378 Coronary artery disease coronary artery disease European=86475 GCST005537 11.397940008672037 GCST005537 26974007 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000101162 at this locus (222600bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000101162 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 20 57824309 20 59249254 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis European=89677 GCST007236 7.339507340775082 GCST007236 25751625 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (369395bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000101162 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 20 57971104 20 59396049 EFO_0000305 Breast cancer breast carcinoma European=89677 GCST007236 7.339507340775082 GCST007236 25751625 drug Low Ed Mountjoy Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000101162 at this locus (369395bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000101162 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 20 57971104 20 59396049 EFO_0000305 Breast cancer breast carcinoma European=140254 GCST006085 17.522878745280337 GCST006085 29892016 drug Low Ed Mountjoy Tyrosine-protein kinase BRK inhibitor drug VANDETANIB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000101213 at this locus (193836bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000101213 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 20 62362563 20 63731211 EFO_0001663 Prostate cancer prostate carcinoma European=22548 GCST001942 15.397940008672037 GCST001942 23535732 drug Low Ed Mountjoy Tyrosine-protein kinase BRK inhibitor drug VANDETANIB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000101213 at this locus (193836bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000101213 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 20 62362563 20 63731211 EFO_0001663 Prostate cancer prostate carcinoma European=58284|East Asian=22515 GCST002318 7.522878745280337 GCST002318_2 24390342 drug Low Ed Mountjoy Interferon-alpha/beta receptor alpha chain antagonist drug ANIFROLUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000142166 at this locus (32118bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142166 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 21 34764288 21 33391982 EFO_0000685 Rheumatoid arthritis [EA] rheumatoid arthritis European, NR=63731 GCST004787 9.154901959985743 GCST004787 28714975 drug Medium Ed Mountjoy Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (154989bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000128271 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 22 24658858 22 24262890 EFO_0000378 Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) coronary artery disease European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323 GCST003116 9.698970004336019 GCST003116_2 26343387 drug Medium Ed Mountjoy Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (154989bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000128271 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 22 24658858 22 24262890 EFO_0000378 Coronary artery disease [additive model] coronary artery disease NR=250736 GCST005196 9.045757490560675 GCST005196 29212778 drug Medium Ed Mountjoy Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (151677bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000128271 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 22 24662171 22 24266203 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 8.428291168191313 GCST005194 29212778 drug Medium Ed Mountjoy Adenosine A2a receptor agonist drug REGADENOSON is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000128271 at this locus (141129bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000128271 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 22 24672718 22 24276750 EFO_0000378 Coronary artery disease coronary artery disease European, NR=40266 GCST004132 7.7544873321858505 GCST004132 28067908 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000100385 at this locus (263382bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100385 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 22 37258503 22 36862461 EFO_0000384 Crohn's disease Crohn's disease European=29652 GCST005536 7.748198311221298 GCST005536 25751624 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000100385 at this locus (16018bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100385 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 22 37587111 22 37191071 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus European=8207 GCST000258 7.698970004336019 GCST000258 18978792 drug Low Ed Mountjoy Interleukin-2 receptor agonist drug ALDESLEUKIN is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000100385 at this locus (20224bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000100385 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 22 37591318 22 37195278 EFO_0001359 Type 1 diabetes insulin-dependent diabetes mellitus NR=237 GCST004105 7.3979400086720375 GCST004105 28044437 drug Medium Ed Mountjoy Interleukin-5 receptor subunit alpha inhibitor drug BENRALIZUMAB is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000091181 at this locus (122868bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091181 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 3 2985142 3 2943458 EFO_0000341 Body mass index (change over time) in chronic obstructive pulmonary disease chronic obstructive pulmonary disease European=459000 GCST007072 10.0 GCST007072 30595370 drug Medium Ed Mountjoy Histamine H1 receptor agonist drug TOLAZOLINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000196639 at this locus (203935bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196639 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 3 11508965 3 11467491 EFO_0000319 Cardiovascular disease cardiovascular system disease European=688809 GCST006477 7.301029995663981 GCST006477 29942085 drug Low Ed Mountjoy Histamine H1 receptor antagonist drug HYDROXYZINE is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000196639 at this locus (285721bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196639 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 3 11590751 3 11549277 EFO_0003761 Depression unipolar depression European=688809 GCST006477 7.301029995663981 GCST006477 29942085 drug Low Ed Mountjoy Histamine H1 receptor agonist drug BETAHISTINE is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000196639 at this locus (285721bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196639 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 3 11590751 3 11549277 EFO_0003761 Depression unipolar depression European=688809 GCST006477 7.301029995663981 GCST006477 29942085 drug Low Ed Mountjoy Histamine H1 receptor antagonist drug DIBENZEPIN is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000196639 at this locus (285721bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196639 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 3 11590751 3 11549277 EFO_0003761 Depression unipolar depression European=459000 GCST007077 11.0 GCST007077 30595370 drug Medium Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 3 12329783 3 12288284 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=360192 7.5486127463375 NEALE2_2443 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug PIOGLITAZONE is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 3 12329783 3 12288284 EFO_0000400 Diabetes diagnosed by doctor diabetes mellitus European=459000 GCST007077 11.0 GCST007077 30595370 drug Low Ed Mountjoy Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 3 12329783 3 12288284 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 11.0 GCST007077 30595370 drug High Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 3 12329783 3 12288284 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=360192 7.5486127463375 NEALE2_2443 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0000400 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 3 12329783 3 12288284 EFO_0000400 Diabetes diagnosed by doctor diabetes mellitus European=69033 GCST005047 8.795880017344075 GCST005047 22885922 drug Low Ed Mountjoy Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 3 12392272 3 12350773 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033 GCST005047 8.795880017344075 GCST005047 22885922 drug Medium Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 3 12392272 3 12350773 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033 GCST005047 8.795880017344075 GCST005047 22885922 drug High Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 3 12392272 3 12350773 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007517 11.301029995663981 GCST007517 29632382 drug Low Ed Mountjoy Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 13.698970004336019 GCST004894_2 28869590 drug High Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 18.522878745280337 GCST007516 29632382 drug Low Ed Mountjoy Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957 GCST007518 16.0 GCST007518 29632382 drug Medium Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 9.221848749616356 GCST002352 24509480 drug High Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 13.698970004336019 GCST004894_2 28869590 drug Medium Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 18.522878745280337 GCST007516 29632382 drug Medium Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 18.69897000433602 GCST004894 28869590 drug High Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 9.221848749616356 GCST002352 24509480 drug Medium Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 9.221848749616356 GCST002352 24509480 drug Low Ed Mountjoy Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 17.0 GCST007515 29632382 drug Low Ed Mountjoy Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007517 11.301029995663981 GCST007517 29632382 drug High Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 18.522878745280337 GCST007516 29632382 drug High Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 17.0 GCST007515 29632382 drug Medium Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 18.69897000433602 GCST004894 28869590 drug Low Ed Mountjoy Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007518 16.0 GCST007518 29632382 drug Low Ed Mountjoy Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957 GCST007517 11.301029995663981 GCST007517 29632382 drug Medium Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 18.69897000433602 GCST004894 28869590 drug Medium Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 13.698970004336019 GCST004894_2 28869590 drug Low Ed Mountjoy Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus European=298957 GCST007518 16.0 GCST007518 29632382 drug High Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 17.0 GCST007515 29632382 drug High Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 23.69897000433602 GCST006867 30054458 drug Medium Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 3 12394840 3 12353341 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 23.69897000433602 GCST006867 30054458 drug High Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 3 12394840 3 12353341 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 23.69897000433602 GCST006867 30054458 drug Low Ed Mountjoy Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 3 12394840 3 12353341 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=70127 GCST005413 15.357832365595055 GCST005413 29358691 drug Low Ed Mountjoy Peroxisome proliferator-activated receptor gamma modulator drug ARHALOFENATE is Phase II for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 3 12396913 3 12355414 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=70127 GCST005413 15.357832365595055 GCST005413 29358691 drug High Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug ROSIGLITAZONE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 3 12396913 3 12355414 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=70127 GCST005413 15.357832365595055 GCST005413 29358691 drug Medium Ed Mountjoy Peroxisome proliferator-activated receptor gamma agonist drug MURAGLITAZAR is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000132170 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000132170 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 3 12396913 3 12355414 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 7.698970004336019 GCST006061_3 29892015 drug Medium Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 3 38634142 3 38592651 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 7.698970004336019 GCST006061_3 29892015 drug Low Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 3 38634142 3 38592651 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 7.698970004336019 GCST006061_3 29892015 drug High Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 3 38634142 3 38592651 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=1030836 GCST006414 15.12010167566999 GCST006414 30061737 drug High Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 3 38710315 3 38668824 EFO_0000275 Atrial fibrillation atrial fibrillation European=1030836 GCST006414 15.12010167566999 GCST006414 30061737 drug Medium Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 3 38710315 3 38668824 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 13.154901959985743 GCST006061_3 29892015 drug Low Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 3 38710315 3 38668824 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 13.154901959985743 GCST006061_3 29892015 drug High Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 3 38710315 3 38668824 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 13.154901959985743 GCST006061_3 29892015 drug Medium Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 3 38710315 3 38668824 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=1030836 GCST006414 15.12010167566999 GCST006414 30061737 drug Low Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (19151bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 3 38710315 3 38668824 EFO_0000275 Atrial fibrillation atrial fibrillation European=395739 10.1038/s41588-018-0184-y 7.87942606879415 SAIGE_427_2 drug Medium Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (75512bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 3 38766675 3 38725184 EFO_0000275 Atrial fibrillation and flutter atrial fibrillation European=395739 10.1038/s41588-018-0184-y 7.87942606879415 SAIGE_427_2 drug High Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (75512bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 3 38766675 3 38725184 EFO_0000275 Atrial fibrillation and flutter atrial fibrillation European=395739 10.1038/s41588-018-0184-y 7.87942606879415 SAIGE_427_2 drug Low Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (75512bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 3 38766675 3 38725184 EFO_0000275 Atrial fibrillation and flutter atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 17.397940008672037 GCST006061 29892015 drug Medium Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 3 38771925 3 38730434 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 14.221848749616356 GCST006061_3 29892015 drug Medium Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 3 38771925 3 38730434 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=1030836 GCST006414 19.619607839942972 GCST006414 30061737 drug Low Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 3 38771925 3 38730434 EFO_0000275 Atrial fibrillation atrial fibrillation European=1030836 GCST006414 19.619607839942972 GCST006414 30061737 drug Medium Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug RANOLAZINE is Phase III for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 3 38771925 3 38730434 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 14.221848749616356 GCST006061_3 29892015 drug Low Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 3 38771925 3 38730434 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 17.397940008672037 GCST006061 29892015 drug Low Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug AZD1305 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 3 38771925 3 38730434 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 14.221848749616356 GCST006061_3 29892015 drug High Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 3 38771925 3 38730434 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=1030836 GCST006414 19.619607839942972 GCST006414 30061737 drug High Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 3 38771925 3 38730434 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 17.397940008672037 GCST006061 29892015 drug High Ed Mountjoy Sodium channel protein type V alpha subunit blocker drug FLECAINIDE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000183873 at this locus (80761bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000183873 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 3 38771925 3 38730434 EFO_0000275 Atrial fibrillation atrial fibrillation European=361141 10.553695886048077 NEALE2_20002_1456 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (247604bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000173585 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 3 46192270 3 46150778 EFO_0001060 Malabsorption/coeliac disease | non-cancer illness code, self-reported celiac disease European=23649|South Asian=620 GCST005523 8.045757490560675 GCST005523_7 22057235 drug Low Ed Mountjoy C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (261019bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000173585 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 3 46205686 3 46164194 EFO_0001060 Celiac disease [conditioned on rs2097282] celiac disease European=15283 GCST000612 10.597222930389652 GCST000612 20190752 drug Low Ed Mountjoy C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (290535bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000173585 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 3 46235201 3 46193709 EFO_0001060 Celiac disease celiac disease European=4634 GCST002520 7.3979400086720375 GCST002520 24999842 drug Low Ed Mountjoy C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (337078bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000173585 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 3 46281744 3 46240253 EFO_0001060 Celiac disease celiac disease European=23649|South Asian=620 GCST005523 20.0 GCST005523 22057235 drug Low Ed Mountjoy C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0001060 and targets the gene ENSG00000173585 at this locus (433359bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000173585 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 3 46378025 3 46336534 EFO_0001060 Celiac disease celiac disease European=86475 GCST005537 7.698970004336019 GCST005537 26974007 drug Low Ed Mountjoy C-C chemokine receptor type 2 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0004268 and targets the gene ENSG00000121807 at this locus (26239bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000121807 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 3 46428658 3 46387167 EFO_0004268 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] sclerosing cholangitis European=86475 GCST005537 7.698970004336019 GCST005537 26974007 drug Low Ed Mountjoy C-C chemokine receptor type 5 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0004268 and targets the gene ENSG00000160791 at this locus (10962bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160791 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 3 46428658 3 46387167 EFO_0004268 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] sclerosing cholangitis European=86475 GCST005537 7.698970004336019 GCST005537 26974007 drug Low Ed Mountjoy C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000173585 at this locus (483992bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000173585 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 3 46428658 3 46387167 EFO_0000384 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] Crohn's disease European=86475 GCST005537 7.698970004336019 GCST005537 26974007 drug Low Ed Mountjoy C-C chemokine receptor type 9 antagonist drug VERCIRNON is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000173585 at this locus (483992bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000173585 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 3 46428658 3 46387167 EFO_0000729 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ulcerative colitis European=6315 GCST003183 18.69897000433602 GCST003183 26553974 drug Low Ed Mountjoy C-C chemokine receptor type 2 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0000180 and targets the gene ENSG00000121807 at this locus (49262bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000121807 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 3 46451680 3 46410189 EFO_0000180 Setpoint viral load in HIV-1 infection HIV-1 infection European=6315 GCST003183 18.69897000433602 GCST003183 26553974 drug Low Ed Mountjoy C-C chemokine receptor type 5 antagonist drug CENICRIVIROC is Phase II for the indiciation EFO_0000180 and targets the gene ENSG00000160791 at this locus (33984bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160791 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 3 46451680 3 46410189 EFO_0000180 Setpoint viral load in HIV-1 infection HIV-1 infection European=6315 GCST003183 18.69897000433602 GCST003183 26553974 drug High Ed Mountjoy C-C chemokine receptor type 5 antagonist drug MARAVIROC is Phase IV for the indiciation EFO_0000180 and targets the gene ENSG00000160791 at this locus (33984bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000160791 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 3 46451680 3 46410189 EFO_0000180 Setpoint viral load in HIV-1 infection HIV-1 infection European=13574|NR=2380 GCST004521 7.3979400086720375 GCST004521 28540026 drug Medium Ed Mountjoy Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (220268bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000010322 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 3 52268866 3 52234850 EFO_0000692 Autism spectrum disorder or schizophrenia schizophrenia Other=1097|NR=150064 GCST003048 8.522878745280337 GCST003048 26198764 drug Medium Ed Mountjoy Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (201667bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000010322 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 3 52287468 3 52253452 EFO_0000692 Schizophrenia schizophrenia European=398213 10.1038/s41588-018-0184-y 7.847711655616943 SAIGE_740_1 drug Medium Ed Mountjoy Toll-like receptor 9 antagonist drug HYDROXYCHLOROQUINE is Phase III for the indiciation EFO_0002506 and targets the gene ENSG00000239732 at this locus (196795bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000239732 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 3 52456973 3 52422957 EFO_0002506 Osteoarthritis; localized osteoarthritis East Asian=45528 GCST007201 12.698970004336019 GCST007201 30285260 drug Medium Ed Mountjoy Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (100972bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000010322 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 3 52628056 3 52594040 EFO_0000692 Schizophrenia schizophrenia East Asian=26026|European=82315 GCST004946 12.301029995663981 GCST004946 28991256 drug Medium Ed Mountjoy Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (100972bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000010322 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 3 52628056 3 52594040 EFO_0000692 Schizophrenia schizophrenia European=18419 GCST001592 8.301029995663981 GCST001592 22763110 drug Low Ed Mountjoy Toll-like receptor 9 antagonist drug HYDROXYCHLOROQUINE is Phase III for the indiciation EFO_0002506 and targets the gene ENSG00000239732 at this locus (461126bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000239732 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 3 52721305 3 52687289 EFO_0002506 Osteoarthritis osteoarthritis European=417596 GCST007092 9.698970004336019 GCST007092 30664745 drug Low Ed Mountjoy Toll-like receptor 9 antagonist drug HYDROXYCHLOROQUINE is Phase II for the indiciation EFO_0004616 and targets the gene ENSG00000239732 at this locus (468625bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000239732 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 3 52728804 3 52694788 EFO_0004616 Osteoarthritis of the hip or knee osteoarthritis, knee NR, African American or Afro-Caribbean, European, African unspecified, Asian unspecified, Other=48070 GCST002254 7.522878745280337 GCST002254 24166486 drug Low Ed Mountjoy Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (288821bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000010322 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 3 52815905 3 52781889 EFO_0000692 Schizophrenia, schizoaffective disorder or bipolar disorder schizophrenia European=61220 GCST001877 11.522878745280337 GCST001877 23453885 drug Low Ed Mountjoy Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306136bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000010322 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 3 52833219 3 52799203 EFO_0000692 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) schizophrenia NR=150064|European=70017 GCST007257 10.698970004336019 GCST007257 30626913 drug Low Ed Mountjoy Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306136bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000010322 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 3 52833219 3 52799203 EFO_0000692 Broad depression or schizophrenia schizophrenia European=105318 GCST006803 11.0 GCST006803 29483656 drug Low Ed Mountjoy Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306721bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000010322 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 3 52833805 3 52799789 EFO_0000692 Schizophrenia schizophrenia European=13574|NR=2380 GCST004521 11.522878745280337 GCST004521 28540026 drug Low Ed Mountjoy Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306721bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000010322 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 3 52833805 3 52799789 EFO_0000692 Autism spectrum disorder or schizophrenia schizophrenia East Asian=45528 GCST007201 10.0 GCST007201_2 30285260 drug Low Ed Mountjoy Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (306721bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000010322 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 3 52833805 3 52799789 EFO_0000692 Schizophrenia [EA] schizophrenia European=11244|NR=20899 GCST002149 8.0 GCST002149 23974872 drug Low Ed Mountjoy Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (311318bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000010322 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 3 52838402 3 52804386 EFO_0000692 Schizophrenia schizophrenia European=82315|East Asian=5219 GCST002539 10.397940008672037 GCST002539 25056061 drug Low Ed Mountjoy Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (318021bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000010322 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 3 52845105 3 52811089 EFO_0000692 Schizophrenia schizophrenia Other=1097|NR=150064 GCST003048 10.698970004336019 GCST003048 26198764 drug Low Ed Mountjoy Nischarin agonist drug MOXONIDINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000010322 at this locus (318021bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000010322 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 3 52845105 3 52811089 EFO_0000692 Schizophrenia schizophrenia East Asian=5158 GCST004302 12.522878745280337 GCST004302 28425483 drug High Ed Mountjoy T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (93052bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000121594 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 3 119150089 3 119431242 EFO_1001486 Primary biliary cholangitis primary biliary cirrhosis European=18264|African American or Afro-Caribbean=5422|Hispanic or Latin American=3888 GCST005752 11.0 GCST005752 28714469 drug Low Ed Mountjoy T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (68758bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000121594 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 3 119174383 3 119455536 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus European=13239 GCST003129 14.397940008672037 GCST003129 26394269 drug High Ed Mountjoy T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (23206bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000121594 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 3 119219934 3 119501087 EFO_1001486 Primary biliary cholangitis primary biliary cirrhosis European=26621 GCST001198 8.96738123914928 GCST001198 21833088 drug Low Ed Mountjoy T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000121594 at this locus (23206bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000121594 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 3 119219934 3 119501087 EFO_0003885 Multiple sclerosis multiple sclerosis European=11375 GCST005581 15.16526148109616 GCST005581 22961000 drug High Ed Mountjoy T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (23206bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000121594 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 3 119219934 3 119501087 EFO_1001486 Primary biliary cirrhosis primary biliary cirrhosis East Asian=3574 GCST007036 8.221848749616356 GCST007036 30643196 drug High Ed Mountjoy T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase IV for the indiciation EFO_1001486 and targets the gene ENSG00000121594 at this locus (23206bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000121594 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 3 119219934 3 119501087 EFO_1001486 Primary biliary cholangitis primary biliary cirrhosis European=18264 GCST007400 9.0 GCST007400 28714469 drug Low Ed Mountjoy T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (20684bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000121594 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 3 119222456 3 119503609 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus European=38582 GCST005531 14.397940008672037 GCST005531 24076602 drug Low Ed Mountjoy T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000121594 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000121594 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 3 119244593 3 119525746 EFO_0003885 Multiple sclerosis multiple sclerosis East Asian=5050 GCST001795 15.522878745280337 GCST001795 23273568 drug Low Ed Mountjoy T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000121594 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 3 119260944 3 119542097 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus East Asian=5050 GCST002845 7.301029995663981 GCST002845 25862617 drug Low Ed Mountjoy T-lymphocyte activation antigen CD80 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000121594 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000121594 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 3 119272391 3 119553544 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus European=38582 GCST005531 14.154901959985743 GCST005531 24076602 drug Low Ed Mountjoy T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (230632bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000114013 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 3 121543577 3 121824730 EFO_0003885 Multiple sclerosis multiple sclerosis NR=215725 GCST007124 7.3979400086720375 GCST007124 26920376 drug Low Ed Mountjoy T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (113546bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000114013 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 3 121660664 3 121941817 EFO_0003885 Multiple sclerosis and HDL levels (pleiotropy) multiple sclerosis European=341215 GCST007798 8.154901959985743 GCST007798 30929738 drug Low Ed Mountjoy T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000114013 at this locus (58039bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000114013 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 3 121716171 3 121997324 EFO_0000270 Asthma asthma European=15283 GCST003566 9.0 GCST003566 27386562 drug Low Ed Mountjoy T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (4687bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000114013 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 3 121769522 3 122050675 EFO_0003885 Multiple sclerosis multiple sclerosis NR=3599|Hispanic or Latin American=1956|European=17698 GCST003340 7.301029995663981 GCST003340 26819262 drug Low Ed Mountjoy T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (3670bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000114013 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 3 121770539 3 122051692 EFO_0003885 Epstein Barr virus nuclear antigen 1 IgG levels or multiple sclerosis multiple sclerosis European=38582 GCST005531 12.273272790973428 GCST005531 24076602 drug Low Ed Mountjoy T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (3670bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000114013 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 3 121770539 3 122051692 EFO_0003885 Multiple sclerosis multiple sclerosis European=26621 GCST001198 8.811915626285062 GCST001198 21833088 drug Low Ed Mountjoy T-lymphocyte activation antigen CD86 inhibitor drug ABATACEPT is Phase II for the indiciation EFO_0003885 and targets the gene ENSG00000114013 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000114013 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 3 121796768 3 122077921 EFO_0003885 Multiple sclerosis multiple sclerosis European=41199 GCST000639 11.0 GCST000639 20348956 drug Low Ed Mountjoy Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (60781bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000068078 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 4 1734239 4 1732512 EFO_0000292 Urinary bladder cancer bladder carcinoma European=6206 GCST002240 24.154901959985743 GCST002240 24163127 drug Low Ed Mountjoy Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (60781bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000068078 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 4 1734239 4 1732512 EFO_0000292 Bladder cancer bladder carcinoma European=8652 GCST000842 12.397940008672037 GCST000842 20972438 drug Low Ed Mountjoy Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (60781bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000068078 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 4 1734239 4 1732512 EFO_0000292 Bladder cancer bladder carcinoma European=361141 7.692944898477948 NEALE2_20001_1035 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Fibroblast growth factor receptor 3 inhibitor drug DOVITINIB is Phase II for the indiciation EFO_0000292 and targets the gene ENSG00000068078 at this locus (25584bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000068078 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 1769436 4 1767709 EFO_0000292 Bladder cancer | cancer code, self-reported bladder carcinoma African American or Afro-Caribbean=1541|European=1436 GCST004955 7.522878745280337 GCST004955 28990359 drug Low Ed Mountjoy GABA-A receptor; anion channel positive allosteric modulator drug LORAZEPAM is Phase IV for the indiciation EFO_0003829 and targets the gene ENSG00000163285 at this locus (490719bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163285 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 4 45547068 4 45545051 EFO_0003829 Risky sexual behaviors in alcohol dependence [AA] alcohol dependence African American or Afro-Caribbean=1541|European=1436 GCST004955 7.522878745280337 GCST004955 28990359 drug Low Ed Mountjoy GABA-A receptor; anion channel allosteric antagonist drug FLUMAZENIL is Phase II for the indiciation EFO_0003829 and targets the gene ENSG00000163285 at this locus (490719bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163285 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 4 45547068 4 45545051 EFO_0003829 Risky sexual behaviors in alcohol dependence [AA] alcohol dependence African American or Afro-Caribbean=1541|European=1436 GCST004955 7.522878745280337 GCST004955 28990359 drug Low Ed Mountjoy GABA-A receptor; anion channel positive allosteric modulator drug CHLORDIAZEPOXIDE is Phase III for the indiciation EFO_0003829 and targets the gene ENSG00000163285 at this locus (490719bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163285 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 4 45547068 4 45545051 EFO_0003829 Risky sexual behaviors in alcohol dependence [AA] alcohol dependence European=3524 GCST003427 9.0 GCST003427 26830138 drug Low Ed Mountjoy GABA-A receptor; anion channel inverse agonist drug RESEQUINIL is Phase II for the indiciation EFO_0000249 and targets the gene ENSG00000163285 at this locus (288042bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163285 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 46414112 4 46412095 EFO_0000249 Alzheimer disease and age of onset [between families] Alzheimer's disease European=3524 GCST003427 9.0 GCST003427 26830138 drug Low Ed Mountjoy GABA-A receptor; anion channel inverse agonist drug RESEQUINIL is Phase II for the indiciation EFO_0000249 and targets the gene ENSG00000151834 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000151834 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 46414112 4 46412095 EFO_0000249 Alzheimer disease and age of onset [between families] Alzheimer's disease European=26405 GCST000964 8.872895201635192 GCST000964 21297633 drug High Ed Mountjoy GABA-A receptor; anion channel positive allosteric modulator drug MIDAZOLAM is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000151834 at this locus (66059bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000151834 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 4 46543306 4 46541289 EFO_0000729 Ulcerative colitis ulcerative colitis European=26405 GCST000964 8.872895201635192 GCST000964 21297633 drug Low Ed Mountjoy GABA-A receptor; anion channel positive allosteric modulator drug MIDAZOLAM is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000163285 at this locus (417235bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000163285 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 4 46543306 4 46541289 EFO_0000729 Ulcerative colitis ulcerative colitis European=3524 GCST003427 9.0 GCST003427 26830138 drug Low Ed Mountjoy GABA-A receptor; anion channel inverse agonist drug RESEQUINIL is Phase II for the indiciation EFO_0000249 and targets the gene ENSG00000151834 at this locus (213998bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000151834 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 4 46691244 4 46689227 EFO_0000249 Alzheimer disease and age of onset [between families] Alzheimer's disease East Asian=4275 GCST001384 8.096910013008056 GCST001384 22291604 drug Low Ed Mountjoy c-Jun N-terminal kinase 3 inhibitor drug TANZISERTIB is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000109339 at this locus (442619bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000109339 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 87958395 4 87037243 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus European=361141 9.056494107508188 NEALE2_20002_1262 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (25518bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II TA T 4 90619732 4 89698581 EFO_0002508 Parkinsons disease | non-cancer illness code, self-reported Parkinson's disease European=334141 GCST003984 56.0 GCST003984 27182965 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (19139bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 90626111 4 89704960 EFO_0002508 Parkinson's disease Parkinson's disease European=108990 GCST002544 72.39794000867204 GCST002544 25064009 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (19139bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 90626111 4 89704960 EFO_0002508 Parkinson's disease Parkinson's disease European=417508 GCST004902 122.30102999566398 GCST004902 28892059 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (19139bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 90626111 4 89704960 EFO_0002508 Parkinson's disease Parkinson's disease NR=4258 GCST001445 64.22184874961636 GCST001445_2 22438815 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (7650bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 90637601 4 89716450 EFO_0002508 Parkinson's disease [EA] Parkinson's disease European=17352 GCST000959 46.69897000433602 GCST000959 21292315 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (7650bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 90637601 4 89716450 EFO_0002508 Parkinson's disease Parkinson's disease East Asian=3509 GCST000530 16.154901959985743 GCST000530 19915576 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (5735bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 4 90639515 4 89718364 EFO_0002508 Parkinson's disease Parkinson's disease European=33050 GCST001126 18.69897000433602 GCST001126 21738487 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 4 90641340 4 89720189 EFO_0002508 Parkinson's disease Parkinson's disease European=3986 GCST002353 9.0 GCST002353_3 24511991 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 4 90641340 4 89720189 EFO_0002508 Parkinson's disease [Sporadic] Parkinson's disease European=8477 GCST001430 34.096910013008056 GCST001430 22451204 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 4 90641340 4 89720189 EFO_0002508 Parkinson's disease Parkinson's disease European=3986 GCST000772 10.522878745280337 GCST000772 20711177 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 4 90641340 4 89720189 EFO_0002508 Parkinson's disease Parkinson's disease European=6880 GCST000855 15.045757490560675 GCST000855 21044948 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 4 90641340 4 89720189 EFO_0002508 Parkinson's disease Parkinson's disease European=3023 GCST000874 7.522878745280337 GCST000874 21084426 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 4 90641340 4 89720189 EFO_0002508 Parkinson's disease Parkinson's disease European=3986 GCST002353 10.522878745280337 GCST002353 24511991 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (3911bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 4 90641340 4 89720189 EFO_0002508 Parkinson's disease Parkinson's disease East Asian=14006 GCST003922 32.0 GCST003922 28011712 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (797bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 4 90644454 4 89723303 EFO_0002508 Parkinson's disease Parkinson's disease NR=17996 GCST007780 11.698970004336019 GCST007780 30957308 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 4 90666041 4 89744890 EFO_0002508 Parkinson's disease (age of onset) Parkinson's disease European=5691 GCST000528 15.698970004336019 GCST000528 19915575 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 90678541 4 89757390 EFO_0002508 Parkinson's disease Parkinson's disease NR=4258 GCST001445 10.301029995663981 GCST001445 22438815 drug Low Ed Mountjoy Alpha-synuclein inhibitor drug BIIB054 is Phase II for the indiciation EFO_0002508 and targets the gene ENSG00000145335 at this locus (21437bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145335 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 4 90780902 4 89859751 EFO_0002508 Parkinson's disease [Asian] Parkinson's disease European=459000 GCST007072 14.096910013008056 GCST007072 30595370 drug Medium Ed Mountjoy Microsomal triglyceride transfer protein inhibitor drug LOMITAPIDE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000138823 at this locus (245600bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000138823 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 4 100239319 4 99318162 EFO_0000319 Cardiovascular disease cardiovascular system disease East Asian=4168 GCST003154 8.301029995663981 GCST003154 26488411 drug Low Ed Mountjoy Endothelin receptor ET-A antagonist drug ZIBOTENTAN is Phase II for the indiciation EFO_0004265 and targets the gene ENSG00000151617 at this locus (1251bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000151617 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 4 148400819 4 147479667 EFO_0004265 Peripheral artery disease peripheral arterial disease European=1030836 GCST006414 10.878440155812498 GCST006414 30061737 drug High Ed Mountjoy Mineralocorticoid receptor antagonist drug SPIRONOLACTONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000151623 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 4 148937537 4 148016386 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 13.221848749616356 GCST006061 29892015 drug High Ed Mountjoy Mineralocorticoid receptor antagonist drug SPIRONOLACTONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000151623 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 4 148937537 4 148016386 EFO_0000275 Atrial fibrillation atrial fibrillation European=1030836 GCST006414 10.878440155812498 GCST006414 30061737 drug Low Ed Mountjoy Mineralocorticoid receptor antagonist drug EPLERENONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000151623 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 4 148937537 4 148016386 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 13.221848749616356 GCST006061 29892015 drug Low Ed Mountjoy Mineralocorticoid receptor antagonist drug EPLERENONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (62377bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000151623 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 4 148937537 4 148016386 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 12.154901959985743 GCST006061_3 29892015 drug High Ed Mountjoy Mineralocorticoid receptor antagonist drug CANRENONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (53224bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000151623 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 4 148946690 4 148025539 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 12.154901959985743 GCST006061_3 29892015 drug Low Ed Mountjoy Mineralocorticoid receptor antagonist drug EPLERENONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000151623 at this locus (53224bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000151623 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 4 148946690 4 148025539 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=459000 GCST007072 10.698970004336019 GCST007072 30595370 drug Low Ed Mountjoy Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000061918 at this locus (259540bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 4 156420605 4 155499453 EFO_0000319 Cardiovascular disease cardiovascular system disease European=361141 8.636910992288339 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (246836bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 156433308 4 155512156 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=361141 8.636910992288339 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Soluble guanylate cyclase activator drug SODIUM NITROPRUSSIDE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (246836bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 4 156433308 4 155512156 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension NR=296525 GCST005194 9.962972120244226 GCST005194 29212778 drug Low Ed Mountjoy Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243638bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 156436507 4 155515355 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 9.962972120244226 GCST005194 29212778 drug Medium Ed Mountjoy Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243638bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 4 156436507 4 155515355 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 9.962972120244226 GCST005194 29212778 drug Medium Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243638bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 4 156436507 4 155515355 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 10.0 GCST005196 29212778 drug Medium Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243628bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 4 156436517 4 155515365 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 10.0 GCST005196 29212778 drug Low Ed Mountjoy Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243628bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 4 156436517 4 155515365 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 10.0 GCST005196 29212778 drug Medium Ed Mountjoy Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (243628bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 4 156436517 4 155515365 EFO_0000378 Coronary artery disease coronary artery disease NR=547261 GCST005195 14.0 GCST005195 29212778 drug Low Ed Mountjoy Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (65960bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 4 156614184 4 155693032 EFO_0000378 Coronary artery disease coronary artery disease NR=547261 GCST005195 14.0 GCST005195 29212778 drug High Ed Mountjoy Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (65960bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 4 156614184 4 155693032 EFO_0000378 Coronary artery disease coronary artery disease NR=547261 GCST005195 14.0 GCST005195 29212778 drug Medium Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (65960bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 4 156614184 4 155693032 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 22.476643793345207 GCST005194 29212778 drug Low Ed Mountjoy Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 156635309 4 155714157 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 21.397940008672037 GCST005196 29212778 drug Low Ed Mountjoy Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 4 156635309 4 155714157 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 21.397940008672037 GCST005196 29212778 drug Medium Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 4 156635309 4 155714157 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 21.397940008672037 GCST005196 29212778 drug High Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 4 156635309 4 155714157 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 22.476643793345207 GCST005194 29212778 drug Medium Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 4 156635309 4 155714157 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 22.476643793345207 GCST005194 29212778 drug High Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (44835bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 4 156635309 4 155714157 EFO_0000378 Coronary artery disease coronary artery disease European, NR=63731 GCST004787 9.0 GCST004787 28714975 drug Low Ed Mountjoy Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (41572bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 4 156638573 4 155717421 EFO_0000378 Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) coronary artery disease European, NR=63731 GCST004787 9.0 GCST004787 28714975 drug High Ed Mountjoy Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (41572bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 4 156638573 4 155717421 EFO_0000378 Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) coronary artery disease European, NR=63731 GCST004787 9.0 GCST004787 28714975 drug Medium Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (41572bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 4 156638573 4 155717421 EFO_0000378 Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) coronary artery disease European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323 GCST003116 8.221848749616356 GCST003116 26343387 drug Medium Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (40257bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 4 156639888 4 155718736 EFO_0000378 Coronary artery disease coronary artery disease European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323 GCST003116 8.221848749616356 GCST003116 26343387 drug High Ed Mountjoy Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (40257bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 4 156639888 4 155718736 EFO_0000378 Coronary artery disease coronary artery disease European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323 GCST003116 8.221848749616356 GCST003116 26343387 drug Low Ed Mountjoy Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (40257bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 4 156639888 4 155718736 EFO_0000378 Coronary artery disease coronary artery disease African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630 GCST003117 7.698970004336019 GCST003117 26343387 drug High Ed Mountjoy Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000061918 at this locus (40257bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 4 156639888 4 155718736 EFO_0000612 Myocardial infarction myocardial infarction European=408343 10.1038/s41588-018-0184-y 16.378823718224965 SAIGE_401 drug High Ed Mountjoy Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 4 156642884 4 155721732 EFO_0000537 Hypertension hypertension European=408089 10.1038/s41588-018-0184-y 16.32513885926219 SAIGE_401_1 drug High Ed Mountjoy Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 4 156642884 4 155721732 EFO_0000537 Essential hypertension hypertension European=408343 10.1038/s41588-018-0184-y 16.378823718224965 SAIGE_401 drug Low Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 4 156642884 4 155721732 EFO_0000537 Hypertension hypertension European=408089 10.1038/s41588-018-0184-y 16.32513885926219 SAIGE_401_1 drug Low Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (37260bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 4 156642884 4 155721732 EFO_0000537 Essential hypertension hypertension European=408458 10.1038/s41588-018-0184-y 9.669586226650809 SAIGE_411 drug High Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (34631bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 4 156645513 4 155724361 EFO_0000378 Ischemic heart disease coronary artery disease European=408458 10.1038/s41588-018-0184-y 9.669586226650809 SAIGE_411 drug Medium Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (34631bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 4 156645513 4 155724361 EFO_0000378 Ischemic heart disease coronary artery disease European=408458 10.1038/s41588-018-0184-y 9.669586226650809 SAIGE_411 drug Low Ed Mountjoy Soluble guanylate cyclase activator drug NITRIC OXIDE is Phase II for the indiciation EFO_0000378 and targets the gene ENSG00000061918 at this locus (34631bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 4 156645513 4 155724361 EFO_0000378 Ischemic heart disease coronary artery disease European=459000 GCST007072 19.69897000433602 GCST007072 30595370 drug High Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE DINITRATE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000061918 at this locus (33805bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 4 156646340 4 155725188 EFO_0000319 Cardiovascular disease cardiovascular system disease European=361141 15.293624498063002 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Soluble guanylate cyclase activator drug NITROGLYCERIN is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (33805bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 4 156646340 4 155725188 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=361141 15.293624498063002 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (33805bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 4 156646340 4 155725188 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension East Asian=50792 GCST007707 8.698970004336019 GCST007707 30487518 drug Low Ed Mountjoy Soluble guanylate cyclase activator drug ISOSORBIDE MONONITRATE is Phase II for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (13153bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T A 4 156666991 4 155745839 EFO_0000537 Hypertension [East Asian] hypertension East Asian=50792 GCST007707 8.698970004336019 GCST007707 30487518 drug High Ed Mountjoy Soluble guanylate cyclase activator drug SODIUM NITROPRUSSIDE is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000061918 at this locus (13153bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000061918 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 4 156666991 4 155745839 EFO_0000537 Hypertension [East Asian] hypertension European=30659 GCST004347 65.52287874528034 GCST004347 28346443 drug Medium Ed Mountjoy Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 1279790 5 1279675 EFO_0000326 Glioma central nervous system cancer African American or Afro-Caribbean=3749|European=5388 GCST001298 10.0 GCST001298 22037553 drug Low Ed Mountjoy Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164362 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000305 Breast cancer breast carcinoma European=33864 GCST004950 8.0 GCST004950 25751625 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000305 Breast cancer breast carcinoma European=24381 GCST004349 73.09691001300806 GCST004349 28346443 drug Medium Ed Mountjoy Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 1279790 5 1279675 EFO_0000326 Glioblastoma central nervous system cancer European=24381 GCST004349 73.09691001300806 GCST004349 28346443 drug Low Ed Mountjoy Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000326 Glioblastoma central nervous system cancer European=24009 GCST004348 16.0 GCST004348 28346443 drug Low Ed Mountjoy Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000326 Non-glioblastoma glioma central nervous system cancer European=22627 GCST001937 8.154901959985743 GCST001937 23535729 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000305 Breast cancer breast carcinoma European=15566 GCST005075 15.397940008672037 GCST005075 29058716 drug Low Ed Mountjoy Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164362 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000305 Breast Cancer in BRCA1 mutation carriers breast carcinoma European=24009 GCST004348 16.0 GCST004348 28346443 drug Medium Ed Mountjoy Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 1279790 5 1279675 EFO_0000326 Non-glioblastoma glioma central nervous system cancer European=30659 GCST004347 65.52287874528034 GCST004347 28346443 drug Low Ed Mountjoy Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000326 Glioma central nervous system cancer European=139274 GCST004988 16.10874138309586 GCST004988 29059683 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000305 Breast cancer breast carcinoma European=11582 GCST003228 19.397940008672037 GCST003228 26424050 drug Low Ed Mountjoy Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000326 Glioma central nervous system cancer European=22627 GCST001937 8.154901959985743 GCST001937 23535729 drug Low Ed Mountjoy Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164362 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000305 Breast cancer breast carcinoma European=63347 GCST004415 7.522878745280337 GCST004415 28346442 drug Low Ed Mountjoy Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0001075 Invasive epithelial ovarian cancer ovarian carcinoma European=39387 GCST001930 11.301029995663981 GCST001930 23535733 drug Low Ed Mountjoy Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164362 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000305 Breast cancer breast carcinoma European=39387 GCST001930 11.301029995663981 GCST001930 23535733 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 16.10874138309586 GCST004988 29059683 drug Low Ed Mountjoy Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164362 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000305 Breast cancer breast carcinoma European=15566 GCST005075 15.397940008672037 GCST005075 29058716 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000305 Breast Cancer in BRCA1 mutation carriers breast carcinoma European=11582 GCST003228 19.397940008672037 GCST003228 26424050 drug Medium Ed Mountjoy Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 1279790 5 1279675 EFO_0000326 Glioma central nervous system cancer European=33864 GCST004950 8.0 GCST004950 25751625 drug Low Ed Mountjoy Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164362 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000305 Breast cancer breast carcinoma African American or Afro-Caribbean=3749|European=5388 GCST001298 10.0 GCST001298 22037553 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (113119bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1279790 5 1279675 EFO_0000305 Breast cancer breast carcinoma European=140254 GCST006085 51.39794000867204 GCST006085 29892016 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (112882bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 1280028 5 1279913 EFO_0001663 Prostate cancer prostate carcinoma European=19291 GCST003845 27.096910013008056 GCST003845 27117709 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (112882bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 1280028 5 1279913 EFO_0000305 Breast cancer breast carcinoma European=19291 GCST003845 27.096910013008056 GCST003845 27117709 drug Low Ed Mountjoy Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164362 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 1280028 5 1279913 EFO_0000305 Breast cancer breast carcinoma European=13560 GCST001148 23.522878745280337 GCST001148 21743467 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (112882bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 1280028 5 1279913 EFO_0001663 Prostate cancer prostate carcinoma European=407770 10.1038/s41588-018-0184-y 8.411168274405792 SAIGE_191_1 drug Low Ed Mountjoy Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (112079bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 5 1280830 5 1280715 EFO_0000326 Cancer of brain and nervous system central nervous system cancer European=407770 10.1038/s41588-018-0184-y 8.411168274405792 SAIGE_191_1 drug Medium Ed Mountjoy Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (112079bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 5 1280830 5 1280715 EFO_0000326 Cancer of brain and nervous system central nervous system cancer European=19291 GCST003845 7.522878745280337 GCST003845 27117709 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (110590bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 1282319 5 1282204 EFO_0000305 Breast cancer breast carcinoma European=19291 GCST003845 7.522878745280337 GCST003845 27117709 drug Low Ed Mountjoy Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164362 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 1282319 5 1282204 EFO_0000305 Breast cancer breast carcinoma European=123671 GCST003588 9.698970004336019 GCST003588_2 27197191 drug Low Ed Mountjoy Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000142319 at this locus (110495bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 1282414 5 1282299 EFO_0001075 Cancer (pleiotropy) [subset analysis] ovarian carcinoma European=123671 GCST003588 9.698970004336019 GCST003588_2 27197191 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (110495bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 1282414 5 1282299 EFO_0001663 Cancer (pleiotropy) [subset analysis] prostate carcinoma European=123671 GCST003588 9.698970004336019 GCST003588_2 27197191 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (110495bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 1282414 5 1282299 EFO_0000305 Cancer (pleiotropy) [subset analysis] breast carcinoma European=123671 GCST003588 9.698970004336019 GCST003588_2 27197191 drug Medium Ed Mountjoy Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (110495bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 1282414 5 1282299 EFO_0001071 Cancer (pleiotropy) [subset analysis] lung carcinoma European=123671 GCST003588 9.698970004336019 GCST003588_2 27197191 drug Low Ed Mountjoy Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164362 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 1282414 5 1282299 EFO_0000305 Cancer (pleiotropy) [subset analysis] breast carcinoma European=7541 GCST002890 10.522878745280337 GCST002890 25939597 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (110495bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 1282414 5 1282299 EFO_0001663 Prostate cancer prostate carcinoma European=291407 GCST004142 11.154901959985743 GCST004142 28212542 drug Low Ed Mountjoy Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000142319 at this locus (108257bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 1284653 5 1284538 EFO_0000756 Melanoma melanoma European=63347 GCST004415 9.154901959985743 GCST004415 28346442 drug Low Ed Mountjoy Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000142319 at this locus (106936bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 1285974 5 1285859 EFO_0001075 Invasive epithelial ovarian cancer ovarian carcinoma European=361141 7.383947958952672 NEALE2_20002_1438 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Telomerase reverse transcriptase inhibitor drug IMETELSTAT is Phase II for the indiciation EFO_0002429 and targets the gene ENSG00000164362 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164362 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 1285974 5 1285859 EFO_0002429 Polycythaemia vera | non-cancer illness code, self-reported polycythemia vera East Asian=5408 GCST001140 27.0 GCST001140 21725308 drug Medium Ed Mountjoy Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (106394bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 1286516 5 1286401 EFO_0001071 Lung cancer lung carcinoma European=4773 GCST001194 8.154901959985743 GCST001194 21827660 drug Medium Ed Mountjoy Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 1286516 5 1286401 EFO_0000326 Glioma central nervous system cancer European=11582 GCST001058 14.0 GCST001058 21531791 drug Low Ed Mountjoy Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 1286516 5 1286401 EFO_0000326 Glioma central nervous system cancer European=7608 GCST002474 15.0 GCST002474 24908248 drug Low Ed Mountjoy Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 1286516 5 1286401 EFO_0000326 Glioma (high-grade) central nervous system cancer European=5548 GCST000439 16.69897000433602 GCST000439 19578367 drug Medium Ed Mountjoy Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 1286516 5 1286401 EFO_0000326 Glioma central nervous system cancer East Asian=10054 GCST001740 26.397940008672037 GCST001740 23143601 drug Medium Ed Mountjoy Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (106394bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 1286516 5 1286401 EFO_0001071 Lung cancer lung carcinoma European=4773 GCST001194 8.154901959985743 GCST001194 21827660 drug Low Ed Mountjoy Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 1286516 5 1286401 EFO_0000326 Glioma central nervous system cancer European=6811 GCST001633 8.397940008672037 GCST001633 22886559 drug Low Ed Mountjoy Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 1286516 5 1286401 EFO_0000326 Glioma central nervous system cancer European=7608 GCST002474 15.0 GCST002474 24908248 drug Medium Ed Mountjoy Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 1286516 5 1286401 EFO_0000326 Glioma (high-grade) central nervous system cancer European=5548 GCST000439 16.69897000433602 GCST000439 19578367 drug Low Ed Mountjoy Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 1286516 5 1286401 EFO_0000326 Glioma central nervous system cancer European=11582 GCST001058 14.0 GCST001058 21531791 drug Medium Ed Mountjoy Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 1286516 5 1286401 EFO_0000326 Glioma central nervous system cancer European=6811 GCST001633 8.397940008672037 GCST001633 22886559 drug Medium Ed Mountjoy Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (106394bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 1286516 5 1286401 EFO_0000326 Glioma central nervous system cancer African American or Afro-Caribbean=5339 GCST003775 8.522878745280337 GCST003775 27393504 drug Medium Ed Mountjoy Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (105715bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 1287194 5 1287079 EFO_0001071 Lung cancer lung carcinoma European=5548 GCST000439 13.397940008672037 GCST000439 19578367 drug Medium Ed Mountjoy Dopamine transporter releasing agent drug DEXTROAMPHETAMINE is Phase III for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (104363bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 1288547 5 1288432 EFO_0000326 Glioma central nervous system cancer European=5548 GCST000439 13.397940008672037 GCST000439 19578367 drug Low Ed Mountjoy Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000142319 at this locus (104363bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 1288547 5 1288432 EFO_0000326 Glioma central nervous system cancer European=139274 GCST004988 20.392866795608434 GCST004988 29059683 drug Low Ed Mountjoy Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (166bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164362 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 1295349 5 1295234 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 20.392866795608434 GCST004988 29059683 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (97561bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 1295349 5 1295234 EFO_0000305 Breast cancer breast carcinoma European=19291 GCST003845 13.522878745280337 GCST003845 27117709 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (95422bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1297488 5 1297373 EFO_0000305 Breast cancer breast carcinoma European=33864 GCST004950 8.698970004336019 GCST004950 25751625 drug Low Ed Mountjoy Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (2305bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164362 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1297488 5 1297373 EFO_0000305 Breast cancer breast carcinoma European=33864 GCST004950 8.698970004336019 GCST004950 25751625 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000142319 at this locus (95422bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1297488 5 1297373 EFO_0000305 Breast cancer breast carcinoma European=19291 GCST003845 13.522878745280337 GCST003845 27117709 drug Low Ed Mountjoy Telomerase reverse transcriptase inhibitor drug IMETELSTAT SODIUM is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000164362 at this locus (2305bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164362 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1297488 5 1297373 EFO_0000305 Breast cancer breast carcinoma European=3390 GCST000459 8.522878745280337 GCST000459 19654303 drug Medium Ed Mountjoy Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (77250bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 1315660 5 1315545 EFO_0001071 Lung cancer lung carcinoma European=40187 GCST004749 16.522878745280337 GCST004749 28604730 drug Medium Ed Mountjoy Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (72773bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 1320136 5 1320021 EFO_0001071 Lung cancer in ever smokers lung carcinoma European=85716 GCST004748 31.69897000433602 GCST004748 28604730 drug Medium Ed Mountjoy Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (72663bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 1320247 5 1320132 EFO_0001071 Lung cancer lung carcinoma European=10422 GCST001267 7.522878745280337 GCST001267 21983787 drug Low Ed Mountjoy Dopamine transporter inhibitor drug MODAFINIL is Phase II for the indiciation EFO_0000756 and targets the gene ENSG00000142319 at this locus (70822bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1322087 5 1321972 EFO_0000756 Melanoma melanoma European=10295 GCST000257 8.096910013008056 GCST000257 18978787 drug Medium Ed Mountjoy Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (70822bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 1322087 5 1321972 EFO_0001071 Lung cancer lung carcinoma European=314072 10.406891232219362 NEALE2_20107_3 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Dopamine transporter inhibitor drug BUPROPION is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000142319 at this locus (53019bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 5 1339890 5 1339775 EFO_0001071 Lung cancer | illnesses of father lung carcinoma European=360738 7.9587810673873625 NEALE2_1200 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Dopamine transporter inhibitor drug MODAFINIL is Phase IV for the indiciation EFO_0004698 and targets the gene ENSG00000142319 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 5 1442979 5 1442864 EFO_0004698 Sleeplessness / insomnia insomnia European=360738 7.9587810673873625 NEALE2_1200 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Dopamine transporter inhibitor drug ARMODAFINIL is Phase II for the indiciation EFO_0004698 and targets the gene ENSG00000142319 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1442979 5 1442864 EFO_0004698 Sleeplessness / insomnia insomnia East Asian=4969 GCST000750 17.397940008672037 GCST000750 20676098 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (450275bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1895829 5 1895715 EFO_0001663 Prostate cancer prostate carcinoma East Asian=7394 GCST003148 11.698970004336019 GCST003148 26443449 drug Low Ed Mountjoy Dopamine transporter inhibitor drug METHYLPHENIDATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000142319 at this locus (450275bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000142319 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 1895829 5 1895715 EFO_0001663 Prostate cancer prostate carcinoma European, NR=45975 GCST004133 8.104080454689985 GCST004133 28067908 drug Low Ed Mountjoy Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (332548bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171522 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 40347469 5 40347367 EFO_0000729 Ulcerative colitis ulcerative colitis European=27432 GCST003045 11.43486084803021 GCST003045 26192919 drug Low Ed Mountjoy Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (265131bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171522 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 40414886 5 40414784 EFO_0000729 Ulcerative colitis [EA] ulcerative colitis European=86475 GCST005537 74.0 GCST005537 26974007 drug Low Ed Mountjoy Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (265029bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171522 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 40414989 5 40414887 EFO_0000729 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ulcerative colitis European=16753 GCST003097 10.096910013008056 GCST003097 26301688 drug Low Ed Mountjoy Prostanoid EP4 receptor agonist drug RIVENPROST is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000171522 at this locus (192747bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000171522 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 40487270 5 40487168 EFO_0000729 Pediatric autoimmune diseases ulcerative colitis European=83129 GCST006983 7.522878745280337 GCST006983 30610198 drug Low Ed Mountjoy Growth hormone receptor agonist drug SOMATROPIN is Phase IV for the indiciation EFO_0003888 and targets the gene ENSG00000112964 at this locus (332768bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112964 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 5 43054747 5 43054645 EFO_0003888 Attention deficit hyperactivity disorder or cannabis use attention deficit hyperactivity disorder European=459000 GCST007072 7.3979400086720375 GCST007072 30595370 drug Low Ed Mountjoy Serotonin 1a (5-HT1a) receptor agonist drug ERGOLOID is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000178394 at this locus (478140bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000178394 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 5 63736474 5 64440647 EFO_0000319 Cardiovascular disease cardiovascular system disease European=408878 10.1038/s41588-018-0184-y 15.436518914605589 SAIGE_272_1 drug High Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0003774 and targets the gene ENSG00000113161 at this locus (26934bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 74605220 5 75309395 EFO_0003774 Hyperlipidemia hyperlipidemia European=406276 10.1038/s41588-018-0184-y 14.154901959985743 SAIGE_272_11 drug High Ed Mountjoy HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000113161 at this locus (26934bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 74605220 5 75309395 HP_0003124 Hypercholesterolemia Hypercholesterolemia European=408961 10.1038/s41588-018-0184-y 15.410050398674292 SAIGE_272 drug High Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation Orphanet_309005 and targets the gene ENSG00000113161 at this locus (26934bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 74605220 5 75309395 Orphanet_309005 Disorders of lipoid metabolism Disorder of lipid metabolism European=408961 10.1038/s41588-018-0184-y 15.410050398674292 SAIGE_272 drug Medium Ed Mountjoy HMG-CoA reductase inhibitor drug LOVASTATIN is Phase III for the indiciation Orphanet_309005 and targets the gene ENSG00000113161 at this locus (26934bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 74605220 5 75309395 Orphanet_309005 Disorders of lipoid metabolism Disorder of lipid metabolism European=9618 GCST004045 11.045757490560675 GCST004045 27790247 drug Low Ed Mountjoy HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (6667bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 74625487 5 75329662 EFO_0000275 Age-related diseases, mortality and associated endophenotypes atrial fibrillation European=9618 GCST004045 11.045757490560675 GCST004045 27790247 drug High Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000113161 at this locus (6667bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 5 74625487 5 75329662 EFO_0000712 Age-related diseases, mortality and associated endophenotypes cerebrovascular accident European=9618 GCST004045 11.045757490560675 GCST004045 27790247 drug High Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (6667bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 5 74625487 5 75329662 EFO_0000275 Age-related diseases, mortality and associated endophenotypes atrial fibrillation European=9618 GCST004045 11.045757490560675 GCST004045 27790247 drug Low Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000113161 at this locus (6667bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 74625487 5 75329662 EFO_0000311 Age-related diseases, mortality and associated endophenotypes cancer European=9618 GCST004045 11.045757490560675 GCST004045 27790247 drug High Ed Mountjoy HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000113161 at this locus (6667bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 5 74625487 5 75329662 EFO_0003144 Age-related diseases, mortality and associated endophenotypes heart failure European=9618 GCST004045 11.045757490560675 GCST004045 27790247 drug High Ed Mountjoy HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000113161 at this locus (6667bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 5 74625487 5 75329662 EFO_0000400 Age-related diseases, mortality and associated endophenotypes diabetes mellitus European=9618 GCST004045 11.045757490560675 GCST004045 27790247 drug High Ed Mountjoy HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001645 and targets the gene ENSG00000113161 at this locus (6667bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 5 74625487 5 75329662 EFO_0001645 Age-related diseases, mortality and associated endophenotypes coronary heart disease European=459000 GCST007072 8.301029995663981 GCST007072 30595370 drug High Ed Mountjoy HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000113161 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 74656539 5 75360714 EFO_0000319 Cardiovascular disease cardiovascular system disease European=361141 42.19124767849288 NEALE2_20002_1473 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000113161 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 74656539 5 75360714 HP_0003124 High cholesterol | non-cancer illness code, self-reported Hypercholesterolemia European=9618 GCST004045 7.698970004336019 GCST004045 27790247 drug Low Ed Mountjoy HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (101258bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 5 74759183 5 75463358 EFO_0000275 Age-related diseases, mortality and associated endophenotypes atrial fibrillation European=9618 GCST004045 7.698970004336019 GCST004045 27790247 drug Medium Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0001645 and targets the gene ENSG00000113161 at this locus (101258bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 5 74759183 5 75463358 EFO_0001645 Age-related diseases, mortality and associated endophenotypes coronary heart disease European=9618 GCST004045 7.698970004336019 GCST004045 27790247 drug Medium Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (101258bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 5 74759183 5 75463358 EFO_0000275 Age-related diseases, mortality and associated endophenotypes atrial fibrillation European=9618 GCST004045 7.698970004336019 GCST004045 27790247 drug Medium Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000113161 at this locus (101258bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 5 74759183 5 75463358 EFO_0000400 Age-related diseases, mortality and associated endophenotypes diabetes mellitus European=9618 GCST004045 7.698970004336019 GCST004045 27790247 drug Medium Ed Mountjoy HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000113161 at this locus (101258bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 5 74759183 5 75463358 EFO_0000712 Age-related diseases, mortality and associated endophenotypes cerebrovascular accident European=9618 GCST004045 7.698970004336019 GCST004045 27790247 drug Medium Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000113161 at this locus (101258bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 5 74759183 5 75463358 EFO_0003144 Age-related diseases, mortality and associated endophenotypes heart failure European=9618 GCST004045 7.698970004336019 GCST004045 27790247 drug Low Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000113161 at this locus (101258bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 5 74759183 5 75463358 EFO_0000311 Age-related diseases, mortality and associated endophenotypes cancer European=9618 GCST004045 7.522878745280337 GCST004045 27790247 drug Medium Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0001645 and targets the gene ENSG00000113161 at this locus (221964bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 74879890 5 75584065 EFO_0001645 Age-related diseases, mortality and associated endophenotypes coronary heart disease European=9618 GCST004045 7.522878745280337 GCST004045 27790247 drug Medium Ed Mountjoy HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (221964bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 74879890 5 75584065 EFO_0000275 Age-related diseases, mortality and associated endophenotypes atrial fibrillation European=9618 GCST004045 7.522878745280337 GCST004045 27790247 drug Medium Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000113161 at this locus (221964bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 74879890 5 75584065 EFO_0000712 Age-related diseases, mortality and associated endophenotypes cerebrovascular accident European=9618 GCST004045 7.522878745280337 GCST004045 27790247 drug Low Ed Mountjoy HMG-CoA reductase inhibitor drug SIMVASTATIN is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113161 at this locus (221964bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 74879890 5 75584065 EFO_0000275 Age-related diseases, mortality and associated endophenotypes atrial fibrillation European=9618 GCST004045 7.522878745280337 GCST004045 27790247 drug Medium Ed Mountjoy HMG-CoA reductase inhibitor drug PRAVASTATIN is Phase IV for the indiciation EFO_0003144 and targets the gene ENSG00000113161 at this locus (221964bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 74879890 5 75584065 EFO_0003144 Age-related diseases, mortality and associated endophenotypes heart failure European=9618 GCST004045 7.522878745280337 GCST004045 27790247 drug Low Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase II for the indiciation EFO_0000311 and targets the gene ENSG00000113161 at this locus (221964bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 74879890 5 75584065 EFO_0000311 Age-related diseases, mortality and associated endophenotypes cancer European=9618 GCST004045 7.522878745280337 GCST004045 27790247 drug Medium Ed Mountjoy HMG-CoA reductase inhibitor drug ATORVASTATIN is Phase IV for the indiciation EFO_0000400 and targets the gene ENSG00000113161 at this locus (221964bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 74879890 5 75584065 EFO_0000400 Age-related diseases, mortality and associated endophenotypes diabetes mellitus European=655666|South Asian=3650 GCST006867 7.522878745280337 GCST006867 30054458 drug Low Ed Mountjoy HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000113161 at this locus (345752bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 75003678 5 75707853 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 14.698970004336019 GCST007515 29632382 drug Low Ed Mountjoy HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000113161 at this locus (345752bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 75003678 5 75707853 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007517 11.301029995663981 GCST007517 29632382 drug Low Ed Mountjoy HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000113161 at this locus (345752bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 75003678 5 75707853 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=204498 GCST001953 11.522878745280337 GCST001953_4 23563607 drug Low Ed Mountjoy HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000113161 at this locus (345752bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 75003678 5 75707853 EFO_0001073 Obesity [Obesity class I] obesity European=204498 GCST001953 8.397940008672037 GCST001953_3 23563607 drug Low Ed Mountjoy HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000113161 at this locus (357316bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 5 75015242 5 75719417 EFO_0001073 Obesity [Obesity class II] obesity European=204498 GCST001953 8.0 GCST001953_5 23563607 drug Low Ed Mountjoy HMG-CoA reductase inhibitor drug ROSUVASTATIN is Phase III for the indiciation EFO_0001073 and targets the gene ENSG00000113161 at this locus (357316bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113161 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 5 75015242 5 75719417 EFO_0001073 Obesity [Overweight] obesity European=116538 GCST007564 19.0 GCST007564 29785011 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 5 110142816 5 110807116 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European=116538 GCST007564 19.0 GCST007564 29785011 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 110142816 5 110807116 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European=102453 GCST007563 19.69897000433602 GCST007563 29785011 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 5 110142816 5 110807116 EFO_0000270 Allergic disease (asthma, hay fever or eczema) asthma European=102453 GCST007563 19.69897000433602 GCST007563 29785011 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (262947bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 110142816 5 110807116 EFO_0000270 Allergic disease (asthma, hay fever or eczema) asthma European=401837 10.1038/s41588-018-0184-y 7.835647144215563 SAIGE_495 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (246917bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 5 110158844 5 110823145 EFO_0000270 Asthma asthma European=401837 10.1038/s41588-018-0184-y 7.835647144215563 SAIGE_495 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (246917bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 110158844 5 110823145 EFO_0000270 Asthma asthma European=91787 7.755663492560309 NEALE2_22127 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II CA C 5 110161473 5 110825774 EFO_0000270 Doctor diagnosed asthma asthma European=91787 7.755663492560309 NEALE2_22127 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III CA C 5 110161473 5 110825774 EFO_0000270 Doctor diagnosed asthma asthma European=361141 17.72690377259096 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II CA C 5 110161473 5 110825774 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=361141 17.72690377259096 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III CA C 5 110161473 5 110825774 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=360527 19.160999247384563 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II CA C 5 110161473 5 110825774 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=72232 8.280520382028882 NEALE2_3761_raw http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000145777 at this locus (244289bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II CA C 5 110161473 5 110825774 EFO_0000274 Age hay fever, rhinitis or eczema diagnosed atopic eczema European=360527 19.160999247384563 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (244289bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III CA C 5 110161473 5 110825774 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=127669 GCST006862 10.097453220686008 GCST006862 29273806 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (207647bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 110198114 5 110862415 EFO_0000270 Asthma asthma European=127669 GCST006862 10.097453220686008 GCST006862 29273806 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (207647bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 110198114 5 110862415 EFO_0000270 Asthma asthma European=36955 7.8621333944441085 NEALE2_3786_raw http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Age asthma diagnosed asthma European=127669 GCST006862 20.97469413473523 GCST006862 29273806 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma European=360527 36.21098861481695 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=157242 GCST003987 30.522878745280337 GCST003987 27182965 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma European=90853 GCST007562 19.69897000433602 GCST007562 29785011 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma European=36955 7.8621333944441085 NEALE2_3786_raw http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Age asthma diagnosed asthma European=90853 GCST007562 19.69897000433602 GCST007562 29785011 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma European=157242 GCST003987 30.522878745280337 GCST003987 27182965 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma African American or Afro-Caribbean=1612|European=2088|Hispanic or Latin American=1688 GCST001182 14.0 GCST001182 21804549 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma European=361141 37.65559397059892 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma African American or Afro-Caribbean=1612|European=2088|Hispanic or Latin American=1688 GCST001182 14.0 GCST001182 21804549 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma European=91787 21.00267741002066 NEALE2_22127 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Doctor diagnosed asthma asthma European=116538 GCST007564 20.397940008672037 GCST007564 29785011 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European=401837 10.1038/s41588-018-0184-y 26.016373712875467 SAIGE_495 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma European=127669 GCST006862 20.97469413473523 GCST006862 29273806 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma European=116538 GCST007564 20.397940008672037 GCST007564 29785011 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European=341215 GCST007798 41.0 GCST007798 30929738 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma European=20776 GCST002322 9.0 GCST002322 24388013 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Asthma and hay fever asthma European=361141 37.65559397059892 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=341215 GCST007798 41.0 GCST007798 30929738 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma European=30810 GCST006911 21.69897000433602 GCST006911 30552067 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Asthma (moderate or severe) asthma European=20776 GCST002322 9.0 GCST002322 24388013 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Asthma and hay fever asthma East Asian=4836 GCST001183 16.0 GCST001183 21804548 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma European=28835 GCST007797 14.301029995663981 GCST007797 30929738 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Asthma onset (childhood vs adult) asthma East Asian=4836 GCST001183 16.0 GCST001183 21804548 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma European=401837 10.1038/s41588-018-0184-y 26.016373712875467 SAIGE_495 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Asthma asthma European=30810 GCST006911 21.69897000433602 GCST006911 30552067 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Asthma (moderate or severe) asthma European=91787 21.00267741002066 NEALE2_22127 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Doctor diagnosed asthma asthma European=360527 36.21098861481695 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 110401872 5 111066174 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=28835 GCST007797 14.301029995663981 GCST007797 30929738 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (3888bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 110401872 5 111066174 EFO_0000270 Asthma onset (childhood vs adult) asthma African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398 GCST005212 25.045757490560675 GCST005212 29273806 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 110404999 5 111069301 EFO_0000270 Asthma asthma African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398 GCST005212 25.045757490560675 GCST005212 29273806 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 5 110404999 5 111069301 EFO_0000270 Asthma asthma European=127669 GCST006862 24.692503962086786 GCST006862 29273806 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 110404999 5 111069301 EFO_0000270 Asthma asthma European=127669 GCST006862 24.692503962086786 GCST006862 29273806 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (762bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 5 110404999 5 111069301 EFO_0000270 Asthma asthma European=361141 18.959010211096686 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 110406742 5 111071044 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=361141 18.959010211096686 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 110406742 5 111071044 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=360527 20.137288556960716 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 110406742 5 111071044 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=360527 20.137288556960716 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 110406742 5 111071044 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=20776 GCST002322 10.522878745280337 GCST002322 24388013 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 110467499 5 111131801 EFO_0000270 Asthma and hay fever asthma European=30810 GCST006911 12.522878745280337 GCST006911 30552067 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 110467499 5 111131801 EFO_0000270 Asthma (moderate or severe) asthma European=30810 GCST006911 12.522878745280337 GCST006911 30552067 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 110467499 5 111131801 EFO_0000270 Asthma (moderate or severe) asthma European=102453 GCST007563 19.30102999566398 GCST007563 29785011 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 110467499 5 111131801 EFO_0000270 Allergic disease (asthma, hay fever or eczema) asthma European=102453 GCST007563 19.30102999566398 GCST007563 29785011 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 110467499 5 111131801 EFO_0000270 Allergic disease (asthma, hay fever or eczema) asthma European=20776 GCST002322 10.522878745280337 GCST002322 24388013 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (53775bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 110467499 5 111131801 EFO_0000270 Asthma and hay fever asthma European=401837 10.1038/s41588-018-0184-y 18.149353764816933 SAIGE_495 drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug AMG-157 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (56414bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 110470137 5 111134439 EFO_0000270 Asthma asthma European=401837 10.1038/s41588-018-0184-y 18.149353764816933 SAIGE_495 drug Medium Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000145777 at this locus (56414bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 110470137 5 111134439 EFO_0000270 Asthma asthma European=72232 8.814540009081632 NEALE2_3761_raw http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Thymic stromal lymphopoietin inhibitor drug TEZEPELUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000145777 at this locus (57494bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145777 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 110471218 5 111135520 EFO_0000274 Age hay fever, rhinitis or eczema diagnosed atopic eczema East Asian=20965 GCST001454 9.522878745280337 GCST001454 22446963 drug Low Ed Mountjoy Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000164400 at this locus (18255bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164400 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 131430118 5 132094425 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis European=27432 GCST003045 25.175982286576183 GCST003045 26192919 drug Low Ed Mountjoy Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (322795bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 5 131669161 5 132333468 EFO_0000729 Ulcerative colitis [EA] ulcerative colitis European=20883 GCST003044 46.705144404319334 GCST003044 26192919 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (322795bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 5 131669161 5 132333468 EFO_0000384 Crohn's disease [EA] Crohn's disease European=719047 GCST007443 8.0 GCST007443 30643255 drug Low Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase II for the indiciation EFO_1000391 and targets the gene ENSG00000113525 at this locus (200819bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 131676320 5 132340627 EFO_1000391 Nasal polyps Nasal Cavity Polyp European=393356 10.1038/s41588-018-0184-y 9.707743928643524 SAIGE_471 drug Low Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase II for the indiciation EFO_1000391 and targets the gene ENSG00000113525 at this locus (166739bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 131710399 5 132374707 EFO_1000391 Nasal polyps Nasal Cavity Polyp European=20883 GCST003044 25.162379159732975 GCST003044 26192919 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (259500bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 5 131732456 5 132396764 EFO_0000384 Crohn's disease [EA] Crohn's disease European, NR=40266 GCST004132 35.25274360255786 GCST004132 28067908 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (221151bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 131770805 5 132435113 EFO_0000384 Crohn's disease Crohn's disease European=9541 GCST000207 17.69897000433602 GCST000207 18587394 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (221151bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 131770805 5 132435113 EFO_0000384 Crohn's disease Crohn's disease European=86475 GCST005537 54.69897000433602 GCST005537 26974007 drug Low Ed Mountjoy Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (213503bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131778452 5 132442760 EFO_0000729 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ulcerative colitis European=86475 GCST005537 54.69897000433602 GCST005537 26974007 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (213503bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131778452 5 132442760 EFO_0000384 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] Crohn's disease European=86475 GCST005537 54.69897000433602 GCST005537 26974007 drug Low Ed Mountjoy Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000164400 at this locus (366590bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164400 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131778452 5 132442760 EFO_0003898 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ankylosing spondylitis European=86475 GCST005537 54.69897000433602 GCST005537 26974007 drug Low Ed Mountjoy Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000164400 at this locus (366590bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164400 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131778452 5 132442760 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis European=21389 GCST000879 20.0 GCST000879 21102463 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (207562bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 5 131784393 5 132448701 EFO_0000384 Crohn's disease Crohn's disease European=34366 GCST001729 19.496209316942817 GCST001729 23128233 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (207562bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 5 131784393 5 132448701 EFO_0000384 Crohn's disease Crohn's disease European=27432 GCST003045 10.237794241945119 GCST003045 26192919 drug Low Ed Mountjoy Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (195033bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 131796922 5 132461230 EFO_0000729 Ulcerative colitis [EA] ulcerative colitis European=127669 GCST006862 10.667561540084394 GCST006862 29273806 drug High Ed Mountjoy Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (79591bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 5 131797547 5 132461855 EFO_0000270 Asthma asthma European=127669 GCST006862 10.667561540084394 GCST006862 29273806 drug Low Ed Mountjoy Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (194409bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131797547 5 132461855 EFO_0000270 Asthma asthma European=127669 GCST006862 10.667561540084394 GCST006862 29273806 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (194409bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 5 131797547 5 132461855 EFO_0000270 Asthma asthma European=127669 GCST006862 10.667561540084394 GCST006862 29273806 drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (212132bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131797547 5 132461855 EFO_0000270 Asthma asthma European=33394 GCST005527 7.620391669707774 GCST005527 23143594 drug Low Ed Mountjoy Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000164400 at this locus (387511bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164400 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 5 131799373 5 132463681 EFO_0000676 Psoriasis psoriasis European=30810 GCST006911 13.221848749616356 GCST006911 30552067 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131799626 5 132463934 EFO_0000270 Asthma (moderate or severe) asthma European=360527 26.061318695302564 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 131799626 5 132463934 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=401837 10.1038/s41588-018-0184-y 9.563837352959244 SAIGE_495 drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131799626 5 132463934 EFO_0000270 Asthma asthma European=360527 26.061318695302564 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131799626 5 132463934 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=30810 GCST006911 13.221848749616356 GCST006911 30552067 drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131799626 5 132463934 EFO_0000270 Asthma (moderate or severe) asthma European=360527 26.061318695302564 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131799626 5 132463934 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=30810 GCST006911 13.221848749616356 GCST006911 30552067 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 131799626 5 132463934 EFO_0000270 Asthma (moderate or severe) asthma European=401837 10.1038/s41588-018-0184-y 9.563837352959244 SAIGE_495 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 131799626 5 132463934 EFO_0000270 Asthma asthma European=401837 10.1038/s41588-018-0184-y 9.563837352959244 SAIGE_495 drug High Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 131799626 5 132463934 EFO_0000270 Asthma asthma European=361141 27.398007329534234 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 131799626 5 132463934 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=361141 27.398007329534234 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 131799626 5 132463934 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=361141 27.398007329534234 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (210052bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131799626 5 132463934 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=30810 GCST006911 13.221848749616356 GCST006911 30552067 drug High Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 131799626 5 132463934 EFO_0000270 Asthma (moderate or severe) asthma European=361141 27.398007329534234 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131799626 5 132463934 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=401837 10.1038/s41588-018-0184-y 9.563837352959244 SAIGE_495 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (192330bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131799626 5 132463934 EFO_0000270 Asthma asthma European=360527 26.061318695302564 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (77511bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 131799626 5 132463934 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=116538 GCST007564 9.301029995663981 GCST007564 29785011 drug High Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (68469bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 5 131808668 5 132472976 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European=116538 GCST007564 9.301029995663981 GCST007564 29785011 drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (201010bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131808668 5 132472976 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European=116538 GCST007564 9.301029995663981 GCST007564 29785011 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (183287bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 5 131808668 5 132472976 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European=116538 GCST007564 9.301029995663981 GCST007564 29785011 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (183287bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131808668 5 132472976 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European=16753 GCST003097 8.698970004336019 GCST003097 26301688 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000169194 at this locus (180773bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 131811182 5 132475490 EFO_0000384 Pediatric autoimmune diseases Crohn's disease European=16753 GCST003097 8.698970004336019 GCST003097 26301688 drug Low Ed Mountjoy Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000169194 at this locus (180773bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 131811182 5 132475490 EFO_0000729 Pediatric autoimmune diseases ulcerative colitis European=16753 GCST003097 8.698970004336019 GCST003097 26301688 drug Low Ed Mountjoy Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0003898 and targets the gene ENSG00000164400 at this locus (399320bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164400 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 131811182 5 132475490 EFO_0003898 Pediatric autoimmune diseases ankylosing spondylitis European=16753 GCST003097 8.698970004336019 GCST003097 26301688 drug Low Ed Mountjoy Granulocyte-macrophage colony-stimulating factor inhibitor drug NAMILUMAB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000164400 at this locus (399320bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164400 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 131811182 5 132475490 EFO_0000676 Pediatric autoimmune diseases psoriasis European=91787 11.05858795962645 NEALE2_22127 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (50815bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 131826322 5 132490630 EFO_0000270 Doctor diagnosed asthma asthma European=91787 11.05858795962645 NEALE2_22127 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (165633bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 131826322 5 132490630 EFO_0000270 Doctor diagnosed asthma asthma European=91787 11.05858795962645 NEALE2_22127 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (183357bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 131826322 5 132490630 EFO_0000270 Doctor diagnosed asthma asthma European=91787 11.05858795962645 NEALE2_22127 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (165633bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 131826322 5 132490630 EFO_0000270 Doctor diagnosed asthma asthma European=30810 GCST006911 14.698970004336019 GCST006911 30552067 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (103970bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 131887986 5 132552294 EFO_0000270 Asthma (moderate or severe) asthma European=30810 GCST006911 14.698970004336019 GCST006911 30552067 drug Low Ed Mountjoy Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (103970bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 131887986 5 132552294 EFO_0000270 Asthma (moderate or severe) asthma European=30810 GCST006911 14.698970004336019 GCST006911 30552067 drug High Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 5 131887986 5 132552294 EFO_0000270 Asthma (moderate or severe) asthma European=30810 GCST006911 14.698970004336019 GCST006911 30552067 drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (121692bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 131887986 5 132552294 EFO_0000270 Asthma (moderate or severe) asthma European=157242 GCST003987 15.698970004336019 GCST003987 27182965 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (90730bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 5 131901225 5 132565533 EFO_0000270 Asthma asthma European=157242 GCST003987 15.698970004336019 GCST003987 27182965 drug High Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (8696bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 5 131901225 5 132565533 EFO_0000270 Asthma asthma European=157242 GCST003987 15.698970004336019 GCST003987 27182965 drug Low Ed Mountjoy Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (90730bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131901225 5 132565533 EFO_0000270 Asthma asthma European=157242 GCST003987 15.698970004336019 GCST003987 27182965 drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (108454bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131901225 5 132565533 EFO_0000270 Asthma asthma European=341215 GCST007798 31.154901959985743 GCST007798 30929738 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 5 131916940 5 132581248 EFO_0000270 Asthma asthma European=361141 26.939774475605834 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 131916940 5 132581248 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=360527 28.044273294785736 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 5 131916940 5 132581248 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=341215 GCST007798 31.154901959985743 GCST007798 30929738 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 131916940 5 132581248 EFO_0000270 Asthma asthma European=360527 28.044273294785736 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 131916940 5 132581248 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=341215 GCST007798 31.154901959985743 GCST007798 30929738 drug High Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 5 131916940 5 132581248 EFO_0000270 Asthma asthma European=361141 26.939774475605834 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 131916940 5 132581248 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=28835 GCST007797 8.154901959985743 GCST007797 30929738 drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 131916940 5 132581248 EFO_0000270 Asthma onset (childhood vs adult) asthma European=360527 28.044273294785736 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 5 131916940 5 132581248 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=361141 26.939774475605834 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 5 131916940 5 132581248 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=28835 GCST007797 8.154901959985743 GCST007797 30929738 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 5 131916940 5 132581248 EFO_0000270 Asthma onset (childhood vs adult) asthma European=28835 GCST007797 8.154901959985743 GCST007797 30929738 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 131916940 5 132581248 EFO_0000270 Asthma onset (childhood vs adult) asthma European=28835 GCST007797 8.154901959985743 GCST007797 30929738 drug High Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (24411bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 5 131916940 5 132581248 EFO_0000270 Asthma onset (childhood vs adult) asthma European=360527 28.044273294785736 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 131916940 5 132581248 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma European=361141 26.939774475605834 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (75015bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 5 131916940 5 132581248 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=341215 GCST007798 31.154901959985743 GCST007798 30929738 drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (92738bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 131916940 5 132581248 EFO_0000270 Asthma asthma European=90853 GCST007562 11.0 GCST007562 29785011 drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (84491bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131925187 5 132589495 EFO_0000270 Asthma asthma European=90853 GCST007562 11.0 GCST007562 29785011 drug Low Ed Mountjoy Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (66768bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131925187 5 132589495 EFO_0000270 Asthma asthma European=90853 GCST007562 11.0 GCST007562 29785011 drug High Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (32657bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 131925187 5 132589495 EFO_0000270 Asthma asthma European=90853 GCST007562 11.0 GCST007562 29785011 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (66768bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 131925187 5 132589495 EFO_0000270 Asthma asthma European=18190 GCST002740 17.69897000433602 GCST002740_3 25574825 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (39733bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 131952222 5 132616530 EFO_0000274 Inflammatory skin disease [Opposed] atopic eczema European=18190 GCST002740 17.69897000433602 GCST002740_3 25574825 drug Low Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (39733bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131952222 5 132616530 EFO_0000274 Inflammatory skin disease [Opposed] atopic eczema NR, European=212120 GCST006409 8.698970004336019 GCST006409 30013184 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 5 131955577 5 132619885 EFO_0005854 Allergic rhinitis allergic rhinitis NR, European=212120 GCST006409 8.698970004336019 GCST006409 30013184 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II TATATATATATAG T 5 131955577 5 132619885 EFO_0005854 Allergic rhinitis allergic rhinitis NR, European=212120 GCST006409 8.698970004336019 GCST006409 30013184 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II TAGAG T 5 131955577 5 132619885 EFO_0005854 Allergic rhinitis allergic rhinitis NR, European=212120 GCST006409 8.698970004336019 GCST006409 30013184 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II TAG T 5 131955577 5 132619885 EFO_0005854 Allergic rhinitis allergic rhinitis NR, European=212120 GCST006409 8.698970004336019 GCST006409 30013184 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0005854 and targets the gene ENSG00000169194 at this locus (36379bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II TAA T 5 131955577 5 132619885 EFO_0005854 Allergic rhinitis allergic rhinitis European=103066|Hispanic or Latin American=1892|African American or Afro-Caribbean=1266|East Asian=9438|NR=1201 GCST003184 16.397940008672037 GCST003184 26482879 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (871bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 131991085 5 132655393 EFO_0000274 Atopic dermatitis [EA, fixed effects] atopic eczema European=103066|Hispanic or Latin American=1892|African American or Afro-Caribbean=1266|East Asian=9438|NR=1201 GCST003184 16.397940008672037 GCST003184 26482879 drug Low Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (871bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131991085 5 132655393 EFO_0000274 Atopic dermatitis [EA, fixed effects] atopic eczema European=401837 10.1038/s41588-018-0184-y 15.5654310959658 SAIGE_495 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (74bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 131991881 5 132656189 EFO_0000270 Asthma asthma European=401837 10.1038/s41588-018-0184-y 15.5654310959658 SAIGE_495 drug High Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (99351bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 5 131991881 5 132656189 EFO_0000270 Asthma asthma European=401837 10.1038/s41588-018-0184-y 15.5654310959658 SAIGE_495 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (74bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 131991881 5 132656189 EFO_0000270 Asthma asthma European=401837 10.1038/s41588-018-0184-y 15.5654310959658 SAIGE_495 drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (17797bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 131991881 5 132656189 EFO_0000270 Asthma asthma European=5617 GCST002100 16.69897000433602 GCST002100 23886662 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 131995843 5 132660151 EFO_0000274 Atopic dermatitis atopic eczema European=5946 GCST002737 8.301029995663981 GCST002737 25574825 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 131995843 5 132660151 EFO_0000274 Atopic dermatitis atopic eczema European=5617 GCST002100 16.69897000433602 GCST002100 23886662 drug Low Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131995843 5 132660151 EFO_0000274 Atopic dermatitis atopic eczema European=5946 GCST002737 8.301029995663981 GCST002737 25574825 drug Low Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 131995843 5 132660151 EFO_0000274 Atopic dermatitis atopic eczema African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398 GCST005212 15.301029995663981 GCST005212 29273806 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131995964 5 132660272 EFO_0000270 Asthma asthma African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398 GCST005212 15.301029995663981 GCST005212 29273806 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 5 131995964 5 132660272 EFO_0000270 Asthma asthma European=127669 GCST006862 13.853871964321762 GCST006862 29273806 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 5 131995964 5 132660272 EFO_0000270 Asthma asthma European=127669 GCST006862 13.853871964321762 GCST006862 29273806 drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (13714bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131995964 5 132660272 EFO_0000270 Asthma asthma African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398 GCST005212 15.301029995663981 GCST005212 29273806 drug Medium Ed Mountjoy Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (103434bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 5 131995964 5 132660272 EFO_0000270 Asthma asthma European=127669 GCST006862 13.853871964321762 GCST006862 29273806 drug Low Ed Mountjoy Interleukin-13 inhibitor drug QAX-576 is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131995964 5 132660272 EFO_0000270 Asthma asthma African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398 GCST005212 15.301029995663981 GCST005212 29273806 drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (13714bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 131995964 5 132660272 EFO_0000270 Asthma asthma European=127669 GCST006862 13.853871964321762 GCST006862 29273806 drug Medium Ed Mountjoy Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (103434bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 5 131995964 5 132660272 EFO_0000270 Asthma asthma European=7565 GCST004866 8.301029995663981 GCST004866 25608926 drug Low Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase II for the indiciation EFO_0004192 and targets the gene ENSG00000169194 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 131996500 5 132660808 EFO_0004192 Alopecia areata alopecia areata European=103066|Hispanic or Latin American=1892|African American or Afro-Caribbean=1266|East Asian=9438|NR=1201 GCST003184 11.154901959985743 GCST003184_2 26482879 drug Low Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (32057bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 132028858 5 132693166 EFO_0000274 Atopic dermatitis [conditional on rs6419573] atopic eczema European=103066|Hispanic or Latin American=1892|African American or Afro-Caribbean=1266|East Asian=9438|NR=1201 GCST003184 11.154901959985743 GCST003184_2 26482879 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (32057bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 132028858 5 132693166 EFO_0000274 Atopic dermatitis [conditional on rs6419573] atopic eczema European=11181 GCST003180 7.301029995663981 GCST003180 26542096 drug Low Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (33866bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 5 132030667 5 132694975 EFO_0000274 Atopic march atopic eczema European=11181 GCST003180 7.301029995663981 GCST003180 26542096 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (33866bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 5 132030667 5 132694975 EFO_0000274 Atopic march atopic eczema European=103066|Hispanic or Latin American=1892|African American or Afro-Caribbean=1266|East Asian=9438|NR=1201 GCST003184 10.0 GCST003184 26482879 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 132049027 5 132713335 EFO_0000274 Atopic dermatitis [EA, fixed effects] atopic eczema European=26171 GCST001363 7.3979400086720375 GCST001363 22197932 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 132049027 5 132713335 EFO_0000274 Atopic dermatitis atopic eczema European=103066|Hispanic or Latin American=1892|African American or Afro-Caribbean=1266|East Asian=9438|NR=1201 GCST003184 10.0 GCST003184 26482879 drug Low Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 132049027 5 132713335 EFO_0000274 Atopic dermatitis [EA, fixed effects] atopic eczema European=26171 GCST001363 7.3979400086720375 GCST001363 22197932 drug Low Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000169194 at this locus (52225bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 132049027 5 132713335 EFO_0000274 Atopic dermatitis atopic eczema European=36955 8.737359096244738 NEALE2_3786_raw http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-13 inhibitor drug TRALOKINUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (60072bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 5 132056874 5 132721182 EFO_0000270 Age asthma diagnosed asthma European=36955 8.737359096244738 NEALE2_3786_raw http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (60072bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 132056874 5 132721182 EFO_0000270 Age asthma diagnosed asthma European=36955 8.737359096244738 NEALE2_3786_raw http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (38505bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 132056874 5 132721182 EFO_0000270 Age asthma diagnosed asthma European=36955 8.737359096244738 NEALE2_3786_raw http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-5 inhibitor drug MEPOLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (164345bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 5 132056874 5 132721182 EFO_0000270 Age asthma diagnosed asthma European=116538 GCST007564 9.698970004336019 GCST007564 29785011 drug Medium Ed Mountjoy Interleukin-5 inhibitor drug RESLIZUMAB is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000113525 at this locus (168054bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113525 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 5 132060583 5 132724891 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European=116538 GCST007564 9.698970004336019 GCST007564 29785011 drug Low Ed Mountjoy Interleukin-4 inhibitor drug PASCOLIZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000113520 at this locus (42213bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 132060583 5 132724891 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European=116538 GCST007564 9.698970004336019 GCST007564 29785011 drug Low Ed Mountjoy Interleukin-13 inhibitor drug ANRUKINZUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (63781bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 132060583 5 132724891 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European=116538 GCST007564 9.698970004336019 GCST007564 29785011 drug Medium Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase III for the indiciation EFO_0000270 and targets the gene ENSG00000169194 at this locus (63781bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 132060583 5 132724891 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811 GCST007692 7.698970004336019 GCST007692 30804561 drug Low Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169194 at this locus (442208bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 5 132439010 5 133103318 EFO_0000341 Chronic obstructive pulmonary disease chronic obstructive pulmonary disease European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811 GCST007692 7.698970004336019 GCST007692 30804561 drug Low Ed Mountjoy Interleukin-13 inhibitor drug LEBRIKIZUMAB is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169194 at this locus (442208bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 132439010 5 133103318 EFO_0000341 Chronic obstructive pulmonary disease chronic obstructive pulmonary disease European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 10.221848749616356 GCST006061_3 29892015 drug Low Ed Mountjoy Glucocorticoid receptor agonist drug HYDROCORTISONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113580 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 142650404 5 143270839 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 11.0 GCST006061 29892015 drug Low Ed Mountjoy Glucocorticoid receptor agonist drug HYDROCORTISONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113580 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 5 142650404 5 143270839 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 11.0 GCST006061 29892015 drug High Ed Mountjoy Glucocorticoid receptor agonist drug PREDNISONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113580 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 142650404 5 143270839 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 10.221848749616356 GCST006061_3 29892015 drug High Ed Mountjoy Glucocorticoid receptor agonist drug PREDNISONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (7093bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113580 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 142650404 5 143270839 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=1030836 GCST006414 16.716472635138306 GCST006414 30061737 drug High Ed Mountjoy Glucocorticoid receptor agonist drug METHYLPREDNISOLONE HEMISUCCINATE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (65455bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113580 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C G 5 142880532 5 143500967 EFO_0000275 Atrial fibrillation atrial fibrillation European=1030836 GCST006414 16.716472635138306 GCST006414 30061737 drug Low Ed Mountjoy Glucocorticoid receptor agonist drug HYDROCORTISONE is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000113580 at this locus (65455bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113580 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 5 142880532 5 143500967 EFO_0000275 Atrial fibrillation atrial fibrillation European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811 GCST007692 32.52287874528034 GCST007692 30804561 drug Low Ed Mountjoy Beta-2 adrenergic receptor agonist drug FENOTEROL is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (349839bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169252 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 147854970 5 148475407 EFO_0000341 Chronic obstructive pulmonary disease chronic obstructive pulmonary disease European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811 GCST007692 32.52287874528034 GCST007692 30804561 drug Low Ed Mountjoy Beta-2 adrenergic receptor partial agonist drug CELIPROLOL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (349839bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169252 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 5 147854970 5 148475407 EFO_0000341 Chronic obstructive pulmonary disease chronic obstructive pulmonary disease European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811 GCST007692 32.52287874528034 GCST007692 30804561 drug Low Ed Mountjoy Beta-2 adrenergic receptor agonist drug CARMOTEROL is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (349839bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169252 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 147854970 5 148475407 EFO_0000341 Chronic obstructive pulmonary disease chronic obstructive pulmonary disease European, NR=58918|European=458554 GCST007611 13.0 GCST007611 30940143 drug Low Ed Mountjoy Beta-2 adrenergic receptor agonist drug SALMETEROL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169252 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 147856333 5 148476770 EFO_0000341 Chronic obstructive pulmonary disease or high blood pressure (pleiotropy) chronic obstructive pulmonary disease European, NR=58918|European=458554 GCST007611 13.0 GCST007611 30940143 drug Low Ed Mountjoy Beta-2 adrenergic receptor agonist drug FENOTEROL is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169252 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 147856333 5 148476770 EFO_0000341 Chronic obstructive pulmonary disease or high blood pressure (pleiotropy) chronic obstructive pulmonary disease European, NR=58918|European=458554 GCST007611 13.0 GCST007611 30940143 drug Low Ed Mountjoy Beta-2 adrenergic receptor agonist drug CARMOTEROL is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169252 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 147856333 5 148476770 EFO_0000341 Chronic obstructive pulmonary disease or high blood pressure (pleiotropy) chronic obstructive pulmonary disease African American or Afro-Caribbean=3522|Hispanic or Latin American=600|European=47856|East Asian=6940 GCST004147 25.30102999566398 GCST004147 28166215 drug Low Ed Mountjoy Beta-2 adrenergic receptor agonist drug FENOTEROL is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169252 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 147856333 5 148476770 EFO_0000341 Chronic obstructive pulmonary disease chronic obstructive pulmonary disease African American or Afro-Caribbean=3522|Hispanic or Latin American=600|European=47856|East Asian=6940 GCST004147 25.30102999566398 GCST004147 28166215 drug Low Ed Mountjoy Beta-2 adrenergic receptor agonist drug CARMOTEROL is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169252 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 147856333 5 148476770 EFO_0000341 Chronic obstructive pulmonary disease chronic obstructive pulmonary disease European, NR=58918|European=458554 GCST007611 13.0 GCST007611 30940143 drug Low Ed Mountjoy Beta-2 adrenergic receptor antagonist drug PROPRANOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000169252 at this locus (348475bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169252 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 147856333 5 148476770 EFO_0000537 Chronic obstructive pulmonary disease or high blood pressure (pleiotropy) hypertension African American or Afro-Caribbean=3522|Hispanic or Latin American=600|European=47856|East Asian=6940 GCST004147 25.30102999566398 GCST004147 28166215 drug Low Ed Mountjoy Beta-2 adrenergic receptor agonist drug SALMETEROL is Phase IV for the indiciation EFO_0000341 and targets the gene ENSG00000169252 at this locus (348475bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169252 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 147856333 5 148476770 EFO_0000341 Chronic obstructive pulmonary disease chronic obstructive pulmonary disease European=361141 8.715497077748008 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Beta-2 adrenergic receptor antagonist drug NEBIVOLOL is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000169252 at this locus (139293bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169252 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 148347543 5 148967980 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=88583 GCST007505 8.698970004336019 GCST007505 30429480 drug Low Ed Mountjoy Macrophage colony stimulating factor receptor inhibitor drug VATALANIB is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000182578 at this locus (236621bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000182578 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 5 149196234 5 149816671 EFO_0000389 Nevus count or cutaneous melanoma skin melanoma European=88583 GCST007505 8.698970004336019 GCST007505 30429480 drug Low Ed Mountjoy Platelet-derived growth factor receptor beta inhibitor drug DASATINIB is Phase II for the indiciation EFO_0000389 and targets the gene ENSG00000113721 at this locus (297168bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113721 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 5 149196234 5 149816671 EFO_0000389 Nevus count or cutaneous melanoma skin melanoma European=88583 GCST007505 8.698970004336019 GCST007505 30429480 drug Low Ed Mountjoy Platelet-derived growth factor receptor beta inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0000389 and targets the gene ENSG00000113721 at this locus (297168bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113721 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 5 149196234 5 149816671 EFO_0000389 Nevus count or cutaneous melanoma skin melanoma European=33394 GCST005527 10.388393510619363 GCST005527 23143594 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71878bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 158669913 5 159242905 EFO_0000676 Psoriasis psoriasis European=33394 GCST005527 10.388393510619363 GCST005527 23143594 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71878bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 5 158669913 5 159242905 EFO_0000676 Psoriasis psoriasis European=2759 GCST000322 27.69897000433602 GCST000322 19169254 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 158717789 5 159290781 EFO_0000676 Psoriasis psoriasis European=6297 GCST003269 13.0 GCST003269 26626624 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 158717789 5 159290781 EFO_0000676 Cutaneous psoriasis psoriasis European=2759 GCST000322 27.69897000433602 GCST000322 19169254 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 158717789 5 159290781 EFO_0000676 Psoriasis psoriasis European=6297 GCST003269 13.0 GCST003269 26626624 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (24003bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 158717789 5 159290781 EFO_0000676 Cutaneous psoriasis psoriasis East Asian=5134|European=8682 GCST002874 9.301029995663981 GCST002874_10 25903422 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 5 158749088 5 159322080 EFO_0000676 Psoriasis [conditional on rs7709212, rs4921493] psoriasis East Asian=5134|European=8682 GCST002874 9.301029995663981 GCST002874_10 25903422 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 5 158749088 5 159322080 EFO_0000676 Psoriasis [conditional on rs7709212, rs4921493] psoriasis East Asian=5134|European=8682 GCST002874 7.698970004336019 GCST002874_6 25903422 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 5 158749088 5 159322080 EFO_0000676 Psoriasis [EA, conditional on rs7709212, rs4921493] psoriasis East Asian=5134|European=8682 GCST002874 7.698970004336019 GCST002874_6 25903422 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 5 158749088 5 159322080 EFO_0000676 Psoriasis [EA, conditional on rs7709212, rs4921493] psoriasis European=7353 GCST000833 10.301029995663981 GCST000833 20953190 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 5 158750769 5 159323761 EFO_0000676 Psoriasis psoriasis East Asian=2271 GCST000321 25.522878745280337 GCST000321 19169255 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 5 158750769 5 159323761 EFO_0000676 Psoriasis psoriasis European=7353 GCST000833 10.301029995663981 GCST000833 20953190 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 158750769 5 159323761 EFO_0000676 Psoriasis psoriasis East Asian=2271 GCST000321 25.522878745280337 GCST000321 19169255 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 158750769 5 159323761 EFO_0000676 Psoriasis psoriasis European=398907 10.1038/s41588-018-0184-y 8.0268721464003 SAIGE_696_42 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 158755845 5 159328837 EFO_0003778 Psoriatic arthropathy psoriatic arthritis European=18190 GCST002740 34.52287874528034 GCST002740_4 25574825 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 5 158759900 5 159332892 EFO_0000676 Inflammatory skin disease [Psoriasis] psoriasis European=1618 GCST000836 20.0 GCST000836 20953188 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 5 158759900 5 159332892 EFO_0000676 Psoriasis psoriasis European=1618 GCST000836 20.0 GCST000836 20953188 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 5 158759900 5 159332892 EFO_0000676 Psoriasis psoriasis European=18190 GCST002740 34.52287874528034 GCST002740_4 25574825 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (2006bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 5 158759900 5 159332892 EFO_0000676 Inflammatory skin disease [Psoriasis] psoriasis East Asian=5134|European=8682 GCST002874 19.522878745280337 GCST002874_8 25903422 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 158764177 5 159337169 EFO_0000676 Psoriasis [EA] psoriasis East Asian=5134|European=8682 GCST002874 11.0 GCST002874_3 25903422 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 158764177 5 159337169 EFO_0000676 Psoriasis [Chinese] psoriasis East Asian=5134|European=8682 GCST002874 8.301029995663981 GCST002874_2 25903422 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 158764177 5 159337169 EFO_0000676 Psoriasis [Chinese, conditional on rs1990760] psoriasis East Asian=5134|European=8682 GCST002874 11.0 GCST002874_3 25903422 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 158764177 5 159337169 EFO_0000676 Psoriasis [Chinese] psoriasis East Asian=5134|European=8682 GCST002874 19.522878745280337 GCST002874_8 25903422 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 158764177 5 159337169 EFO_0000676 Psoriasis [EA] psoriasis East Asian=5134|European=8682 GCST002874 29.69897000433602 GCST002874 25903422 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 158764177 5 159337169 EFO_0000676 Psoriasis psoriasis East Asian=5134|European=8682 GCST002874 8.301029995663981 GCST002874_2 25903422 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 158764177 5 159337169 EFO_0000676 Psoriasis [Chinese, conditional on rs1990760] psoriasis East Asian=5134|European=8682 GCST002874 29.69897000433602 GCST002874 25903422 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (6282bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 158764177 5 159337169 EFO_0000676 Psoriasis psoriasis European=6880 GCST003270 24.0 GCST003270 26626624 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (6584bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 158764478 5 159337470 EFO_0003778 Psoriatic arthritis psoriatic arthritis European=361141 22.400348322298537 NEALE2_20002_1453 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (8128bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 5 158766022 5 159339014 EFO_0000676 Psoriasis | non-cancer illness code, self-reported psoriasis European=361141 22.400348322298537 NEALE2_20002_1453 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (8128bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 158766022 5 159339014 EFO_0000676 Psoriasis | non-cancer illness code, self-reported psoriasis European=2198 GCST007043 9.045757490560675 GCST007043 30552173 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (10470bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 5 158768365 5 159341357 EFO_0003778 Psoriatic arthritis psoriatic arthritis European=20883 GCST003044 33.5271134750456 GCST003044 26192919 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (13443bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 158771337 5 159344329 EFO_0000384 Crohn's disease [EA] Crohn's disease European=20883 GCST003044 33.5271134750456 GCST003044 26192919 drug Low Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (13443bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 158771337 5 159344329 EFO_0000384 Crohn's disease [EA] Crohn's disease European=27432 GCST003045 16.91802094893202 GCST003045 26192919 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (17070bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 158774965 5 159347957 EFO_0000729 Ulcerative colitis [EA] ulcerative colitis European, NR=45975 GCST004133 19.67571754470231 GCST004133 28067908 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (17070bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 158774965 5 159347957 EFO_0000729 Ulcerative colitis ulcerative colitis European=21389 GCST000879 13.301029995663981 GCST000879 21102463 drug Low Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (29491bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 5 158787385 5 159360377 EFO_0000384 Crohn's disease Crohn's disease European=21389 GCST000879 13.301029995663981 GCST000879 21102463 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (29491bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 5 158787385 5 159360377 EFO_0000384 Crohn's disease Crohn's disease European, NR=40266 GCST004132 19.061080187755227 GCST004132 28067908 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (40181bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 5 158798075 5 159371067 EFO_0000384 Crohn's disease Crohn's disease European, NR=40266 GCST004132 19.061080187755227 GCST004132 28067908 drug Low Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (40181bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 5 158798075 5 159371067 EFO_0000384 Crohn's disease Crohn's disease European=361141 20.03839715731701 NEALE2_20002_1453 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (52898bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 158810793 5 159383785 EFO_0000676 Psoriasis | non-cancer illness code, self-reported psoriasis European=361141 20.03839715731701 NEALE2_20002_1453 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (52898bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 158810793 5 159383785 EFO_0000676 Psoriasis | non-cancer illness code, self-reported psoriasis European=9541 GCST000207 12.397940008672037 GCST000207 18587394 drug Low Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (56638bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 5 158814533 5 159387525 EFO_0000384 Crohn's disease Crohn's disease European=9541 GCST000207 12.397940008672037 GCST000207 18587394 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (56638bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 5 158814533 5 159387525 EFO_0000384 Crohn's disease Crohn's disease European=11802 GCST001149 7.698970004336019 GCST001149 21743469 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (60850bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 5 158818745 5 159391737 EFO_0003898 Ankylosing spondylitis ankylosing spondylitis European=400436 10.1038/s41588-018-0184-y 13.292429823902063 SAIGE_696_4 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (62166bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 158820061 5 159393053 EFO_0000676 Psoriasis psoriasis European=400436 10.1038/s41588-018-0184-y 13.292429823902063 SAIGE_696_4 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (62166bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 158820061 5 159393053 EFO_0000676 Psoriasis psoriasis European=33394 GCST005527 13.017728766960431 GCST005527 23143594 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (64023bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 5 158821917 5 159394909 EFO_0000676 Psoriasis psoriasis European=33394 GCST005527 13.017728766960431 GCST005527 23143594 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (64023bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 5 158821917 5 159394909 EFO_0000676 Psoriasis psoriasis European=400492 10.1038/s41588-018-0184-y 20.714442690992225 SAIGE_696 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (68416bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C G 5 158826310 5 159399302 EFO_0000676 Psoriasis and related disorders psoriasis European=400492 10.1038/s41588-018-0184-y 20.714442690992225 SAIGE_696 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (68416bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 5 158826310 5 159399302 EFO_0000676 Psoriasis and related disorders psoriasis European=22647|East Asian=3117 GCST005529 7.522878745280337 GCST005529 23749187 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (68897bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 158826792 5 159399784 EFO_0003898 Ankylosing spondylitis ankylosing spondylitis European, NR=45975 GCST004133 23.22951619056889 GCST004133 28067908 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (68897bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 158826792 5 159399784 EFO_0000729 Ulcerative colitis ulcerative colitis European=26405 GCST000964 7.991399828238082 GCST000964 21297633 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (68897bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 158826792 5 159399784 EFO_0000729 Ulcerative colitis ulcerative colitis European=27432 GCST003045 26.13838459401752 GCST003045 26192919 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (69875bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 158827769 5 159400761 EFO_0000729 Ulcerative colitis [EA] ulcerative colitis European=86475 GCST005537 42.52287874528034 GCST005537 26974007 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (69875bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 158827769 5 159400761 EFO_0000729 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ulcerative colitis European=20883 GCST003044 40.64029045008325 GCST003044 26192919 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 158827769 5 159400761 EFO_0000384 Crohn's disease [EA] Crohn's disease European=20883 GCST003044 40.64029045008325 GCST003044 26192919 drug Low Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 158827769 5 159400761 EFO_0000384 Crohn's disease [EA] Crohn's disease European=86475 GCST005537 42.52287874528034 GCST005537 26974007 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (69875bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 5 158827769 5 159400761 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis European=86475 GCST005537 42.52287874528034 GCST005537 26974007 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 158827769 5 159400761 EFO_0000384 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] Crohn's disease European=86475 GCST005537 42.52287874528034 GCST005537 26974007 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (69875bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 158827769 5 159400761 EFO_0003898 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ankylosing spondylitis European=86475 GCST005537 42.52287874528034 GCST005537 26974007 drug Low Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (69875bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 158827769 5 159400761 EFO_0000384 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] Crohn's disease European=86475 GCST005537 42.52287874528034 GCST005537 26974007 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (69875bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 5 158827769 5 159400761 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis European=400436 10.1038/s41588-018-0184-y 19.950781977329818 SAIGE_696_4 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71395bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 5 158829289 5 159402281 EFO_0000676 Psoriasis psoriasis European=400436 10.1038/s41588-018-0184-y 19.950781977329818 SAIGE_696_4 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71395bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 5 158829289 5 159402281 EFO_0000676 Psoriasis psoriasis European=16753 GCST003097 9.698970004336019 GCST003097 26301688 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000729 and targets the gene ENSG00000113302 at this locus (71399bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 158829294 5 159402286 EFO_0000729 Pediatric autoimmune diseases ulcerative colitis European=16753 GCST003097 9.698970004336019 GCST003097 26301688 drug Low Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 158829294 5 159402286 EFO_0000384 Pediatric autoimmune diseases Crohn's disease European=16753 GCST003097 9.698970004336019 GCST003097 26301688 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 158829294 5 159402286 EFO_0000384 Pediatric autoimmune diseases Crohn's disease European=16753 GCST003097 9.698970004336019 GCST003097 26301688 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0003898 and targets the gene ENSG00000113302 at this locus (71399bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 158829294 5 159402286 EFO_0003898 Pediatric autoimmune diseases ankylosing spondylitis European=16753 GCST003097 9.698970004336019 GCST003097 26301688 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71399bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 5 158829294 5 159402286 EFO_0000676 Pediatric autoimmune diseases psoriasis European=16753 GCST003097 9.698970004336019 GCST003097 26301688 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71399bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 158829294 5 159402286 EFO_0000676 Pediatric autoimmune diseases psoriasis European, NR=40266 GCST004132 28.860120913598763 GCST004132 28067908 drug Low Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase II for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 158829294 5 159402286 EFO_0000384 Crohn's disease Crohn's disease European=16753 GCST003097 9.698970004336019 GCST003097 26301688 drug Low Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000113302 at this locus (71399bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 5 158829294 5 159402286 EFO_0001359 Pediatric autoimmune diseases insulin-dependent diabetes mellitus European=16753 GCST003097 9.698970004336019 GCST003097 26301688 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0002690 and targets the gene ENSG00000113302 at this locus (71399bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 158829294 5 159402286 EFO_0002690 Pediatric autoimmune diseases systemic lupus erythematosus European, NR=40266 GCST004132 28.860120913598763 GCST004132 28067908 drug Medium Ed Mountjoy Interleukin-23 inhibitor drug USTEKINUMAB is Phase III for the indiciation EFO_0000384 and targets the gene ENSG00000113302 at this locus (71399bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 5 158829294 5 159402286 EFO_0000384 Crohn's disease Crohn's disease European=361141 32.77779353908738 NEALE2_20002_1453 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T A 5 158829527 5 159402519 EFO_0000676 Psoriasis | non-cancer illness code, self-reported psoriasis European=1460 GCST000835 16.154901959985743 GCST000835 20953186 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (71632bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 5 158829527 5 159402519 EFO_0003778 Psoriatic arthritis psoriatic arthritis European=361141 32.77779353908738 NEALE2_20002_1453 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 5 158829527 5 159402519 EFO_0000676 Psoriasis | non-cancer illness code, self-reported psoriasis European=287323 GCST004346 83.52287874528034 GCST004346 28537254 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 5 158829527 5 159402519 EFO_0000676 Psoriasis psoriasis European=33394 GCST005527 12.669586226650809 GCST005527 23143594 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T A 5 158829527 5 159402519 EFO_0000676 Psoriasis psoriasis European=33394 GCST005527 12.669586226650809 GCST005527 23143594 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 5 158829527 5 159402519 EFO_0000676 Psoriasis psoriasis European=361141 11.735654492949907 NEALE2_20002_1477 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (71632bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 5 158829527 5 159402519 EFO_0003778 Psoriatic arthropathy | non-cancer illness code, self-reported psoriatic arthritis European=287323 GCST004346 83.52287874528034 GCST004346 28537254 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (71632bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T A 5 158829527 5 159402519 EFO_0000676 Psoriasis psoriasis European=398907 10.1038/s41588-018-0184-y 10.665546248849068 SAIGE_696_42 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000113302 at this locus (71632bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 5 158829527 5 159402519 EFO_0003778 Psoriatic arthropathy psoriatic arthritis European=7208 GCST005538 8.698970004336019 GCST005538 26051272 drug Low Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase II for the indiciation Orphanet_797 and targets the gene ENSG00000113302 at this locus (74382bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 5 158832277 5 159405269 Orphanet_797 Sarcoidosis [EA] Sarcoidosis East Asian=5134|European=8682 GCST002874 12.154901959985743 GCST002874_11 25903422 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 158836107 5 159409099 EFO_0000676 Psoriasis [conditional on rs7709212] psoriasis East Asian=5134|European=8682 GCST002874 10.522878745280337 GCST002874_7 25903422 drug High Ed Mountjoy Interleukin-12 inhibitor drug USTEKINUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 5 158836107 5 159409099 EFO_0000676 Psoriasis [EA, conditional on rs7709212] psoriasis East Asian=5134|European=8682 GCST002874 12.154901959985743 GCST002874_11 25903422 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 158836107 5 159409099 EFO_0000676 Psoriasis [conditional on rs7709212] psoriasis East Asian=5134|European=8682 GCST002874 10.522878745280337 GCST002874_7 25903422 drug Medium Ed Mountjoy Interleukin-12 subunit beta inhibitor drug BRIAKINUMAB is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000113302 at this locus (78212bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113302 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 5 158836107 5 159409099 EFO_0000676 Psoriasis [EA, conditional on rs7709212] psoriasis European=351833 8.322648589788734 NEALE2_1980 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy GABA-A receptor; anion channel agonist drug MEPROBAMATE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000145863 at this locus (281691bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145863 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C CA 5 161411289 5 161984283 EFO_0005230 Worrier / anxious feelings anxiety European=351833 8.322648589788734 NEALE2_1980 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy GABA-A receptor; anion channel positive allosteric modulator drug ALPRAZOLAM is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000022355 at this locus (84303bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000022355 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C CA 5 161411289 5 161984283 EFO_0005230 Worrier / anxious feelings anxiety European=351833 8.322648589788734 NEALE2_1980 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy GABA-A receptor; anion channel agonist drug MEPROBAMATE is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000145864 at this locus (435239bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145864 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C CA 5 161411289 5 161984283 EFO_0005230 Worrier / anxious feelings anxiety European=351833 8.322648589788734 NEALE2_1980 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy GABA-A receptor; anion channel positive allosteric modulator drug TRIAZOLAM is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000022355 at this locus (84303bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000022355 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C CA 5 161411289 5 161984283 EFO_0005230 Worrier / anxious feelings anxiety European=351833 8.322648589788734 NEALE2_1980 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy GABA-A receptor; anion channel positive allosteric modulator drug TRIAZOLAM is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000113327 at this locus (15775bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113327 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C CA 5 161411289 5 161984283 EFO_0005230 Worrier / anxious feelings anxiety European=351833 8.322648589788734 NEALE2_1980 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy GABA-A receptor; anion channel positive allosteric modulator drug CLORAZEPIC ACID is Phase IV for the indiciation EFO_0005230 and targets the gene ENSG00000113327 at this locus (15775bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000113327 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C CA 5 161411289 5 161984283 EFO_0005230 Worrier / anxious feelings anxiety European=351833 8.322648589788734 NEALE2_1980 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy GABA-A receptor; anion channel positive allosteric modulator drug CLOMETHIAZOLE is Phase III for the indiciation EFO_0005230 and targets the gene ENSG00000145864 at this locus (435239bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000145864 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C CA 5 161411289 5 161984283 EFO_0005230 Worrier / anxious feelings anxiety European=10767 GCST003468 7.698970004336019 GCST003468 26956414 drug Low Ed Mountjoy Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000095 and targets the gene ENSG00000137285 at this locus (255233bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137285 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 2969278 6 2969044 EFO_0000095 Chronic lymphocytic leukemia chronic lymphocytic leukemia European=10767 GCST003468 7.698970004336019 GCST003468 26956414 drug Medium Ed Mountjoy Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000095 and targets the gene ENSG00000137267 at this locus (184622bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137267 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 2969278 6 2969044 EFO_0000095 Chronic lymphocytic leukemia chronic lymphocytic leukemia East Asian=7321 GCST007728 8.045757490560675 GCST007728_9 30898391 drug Low Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137285 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A T 6 3581089 6 3580855 EFO_0001075 Epithelial ovarian cancer [serous] ovarian carcinoma East Asian=7321 GCST007728 8.045757490560675 GCST007728_9 30898391 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137285 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 6 3581089 6 3580855 EFO_0001075 Epithelial ovarian cancer [serous] ovarian carcinoma East Asian=7321 GCST007728 8.045757490560675 GCST007728_9 30898391 drug Low Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137267 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A T 6 3581089 6 3580855 EFO_0001075 Epithelial ovarian cancer [serous] ovarian carcinoma East Asian=7321 GCST007728 8.045757490560675 GCST007728_9 30898391 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137267 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 6 3581089 6 3580855 EFO_0001075 Epithelial ovarian cancer [serous] ovarian carcinoma East Asian=7321 GCST007728 7.3979400086720375 GCST007728_2 30898391 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137285 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 6 3581089 6 3580855 EFO_0001075 Epithelial ovarian cancer [HGSOC] ovarian carcinoma East Asian=7321 GCST007728 7.3979400086720375 GCST007728_2 30898391 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137285 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 6 3581089 6 3580855 EFO_0001075 Epithelial ovarian cancer [HGSOC] ovarian carcinoma East Asian=7321 GCST007728 8.045757490560675 GCST007728_9 30898391 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137285 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 6 3581089 6 3580855 EFO_0001075 Epithelial ovarian cancer [serous] ovarian carcinoma East Asian=7321 GCST007728 8.045757490560675 GCST007728_9 30898391 drug Low Ed Mountjoy Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137267 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 6 3581089 6 3580855 EFO_0001075 Epithelial ovarian cancer [serous] ovarian carcinoma East Asian=7321 GCST007728 7.3979400086720375 GCST007728_2 30898391 drug Low Ed Mountjoy Tubulin inhibitor drug CABAZITAXEL is Phase II for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137267 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 6 3581089 6 3580855 EFO_0001075 Epithelial ovarian cancer [HGSOC] ovarian carcinoma East Asian=7321 GCST007728 7.3979400086720375 GCST007728_2 30898391 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137267 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 6 3581089 6 3580855 EFO_0001075 Epithelial ovarian cancer [HGSOC] ovarian carcinoma East Asian=7321 GCST007728 7.3979400086720375 GCST007728_2 30898391 drug Low Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137267 at this locus (423311bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137267 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A T 6 3581089 6 3580855 EFO_0001075 Epithelial ovarian cancer [HGSOC] ovarian carcinoma East Asian=7321 GCST007728 7.3979400086720375 GCST007728_2 30898391 drug Low Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001075 and targets the gene ENSG00000137285 at this locus (349126bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000137285 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A T 6 3581089 6 3580855 EFO_0001075 Epithelial ovarian cancer [HGSOC] ovarian carcinoma European=40187 GCST004749 12.154901959985743 GCST004749 28604730 drug Low Ed Mountjoy Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (345376bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 30342753 6 30374976 EFO_0001071 Lung cancer in ever smokers lung carcinoma European=40187 GCST004749 12.154901959985743 GCST004749 28604730 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (345376bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 30342753 6 30374976 EFO_0001071 Lung cancer in ever smokers lung carcinoma European=63053 GCST004750 13.522878745280337 GCST004750 28604730 drug Low Ed Mountjoy Tubulin inhibitor drug VINORELBINE is Phase III for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (336782bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 30351348 6 30383571 EFO_0000708 Squamous cell lung carcinoma squamous cell lung carcinoma European=63053 GCST004750 13.522878745280337 GCST004750 28604730 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase IV for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (336782bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 30351348 6 30383571 EFO_0000708 Squamous cell lung carcinoma squamous cell lung carcinoma European=85716 GCST004748 17.397940008672037 GCST004748 28604730 drug Low Ed Mountjoy Tubulin inhibitor drug VINORELBINE is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (330836bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 30357294 6 30389517 EFO_0001071 Lung cancer lung carcinoma European=85716 GCST004748 17.397940008672037 GCST004748 28604730 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (330836bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 30357294 6 30389517 EFO_0001071 Lung cancer lung carcinoma European=140254 GCST006085 8.221848749616356 GCST006085 29892016 drug Medium Ed Mountjoy Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (86897bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 6 30601232 6 30633455 EFO_0001663 Prostate cancer prostate carcinoma European=140254 GCST006085 8.221848749616356 GCST006085 29892016 drug High Ed Mountjoy Tubulin inhibitor drug CABAZITAXEL is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (86897bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 6 30601232 6 30633455 EFO_0001663 Prostate cancer prostate carcinoma European=140254 GCST006085 8.221848749616356 GCST006085 29892016 drug Low Ed Mountjoy Tubulin inhibitor drug ERIBULIN is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (86897bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 30601232 6 30633455 EFO_0001663 Prostate cancer prostate carcinoma European=85716 GCST004748 18.154901959985743 GCST004748 28604730 drug Medium Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (171076bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 30864279 6 30896502 EFO_0001071 Lung cancer lung carcinoma European=85716 GCST004748 18.154901959985743 GCST004748 28604730 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (171076bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 30864279 6 30896502 EFO_0001071 Lung cancer lung carcinoma European=63053 GCST004750 15.522878745280337 GCST004750 28604730 drug Medium Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase IV for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (189213bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 30882415 6 30914638 EFO_0000708 Squamous cell lung carcinoma squamous cell lung carcinoma European=63053 GCST004750 15.522878745280337 GCST004750 28604730 drug Medium Ed Mountjoy Tubulin inhibitor drug VINORELBINE is Phase III for the indiciation EFO_0000708 and targets the gene ENSG00000196230 at this locus (189213bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 30882415 6 30914638 EFO_0000708 Squamous cell lung carcinoma squamous cell lung carcinoma European=287323 GCST004346 324.22184874961636 GCST004346 28537254 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000196230 at this locus (223056bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 30916259 6 30948482 EFO_0000676 Psoriasis psoriasis European=120184|East Asian=5294 GCST007856 8.045757490560675 GCST007856 30510241 drug Low Ed Mountjoy Tubulin inhibitor drug DOCETAXEL is Phase II for the indiciation EFO_0005842 and targets the gene ENSG00000196230 at this locus (316982bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 6 31010185 6 31042408 EFO_0005842 Colorectal cancer or advanced adenoma colorectal cancer European=1712|African American or Afro-Caribbean=1233|Hispanic or Latin American=677 GCST000863 8.0 GCST000863 21051598 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase III for the indiciation EFO_0000180 and targets the gene ENSG00000196230 at this locus (331606bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 6 31024808 6 31057031 EFO_0000180 HIV-1 control [AA] HIV-1 infection East Asian=1098 GCST001768 11.0 GCST001768 23001997 drug Low Ed Mountjoy Tubulin inhibitor drug COLCHICINE is Phase II for the indiciation EFO_0003780 and targets the gene ENSG00000196230 at this locus (364975bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 6 31058178 6 31090401 EFO_0003780 Behcet's disease Behcet's syndrome East Asian=1098 GCST001768 11.0 GCST001768 23001997 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0003780 and targets the gene ENSG00000232810 at this locus (485164bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 31058178 6 31090401 EFO_0003780 Behcet's disease Behcet's syndrome European=781 GCST000448 10.301029995663981 GCST000448 19620980 drug Low Ed Mountjoy Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000096 and targets the gene ENSG00000196230 at this locus (380827bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 6 31074030 6 31106253 EFO_0000096 Follicular lymphoma neoplasm of mature B-cells European=1048 GCST005541 26.096910013008056 GCST005541 26651848 drug Low Ed Mountjoy TNF-alpha inhibitor drug ADALIMUMAB is Phase II for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (463327bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 6 31080016 6 31112239 Orphanet_797 Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome) Sarcoidosis European=1048 GCST005541 26.096910013008056 GCST005541 26651848 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (463327bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 6 31080016 6 31112239 Orphanet_797 Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome) Sarcoidosis European=40187 GCST004749 15.301029995663981 GCST004749 28604730 drug Low Ed Mountjoy Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (388002bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 31081205 6 31113428 EFO_0001071 Lung cancer in ever smokers lung carcinoma European=40187 GCST004749 15.301029995663981 GCST004749 28604730 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000196230 at this locus (388002bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 6 31081205 6 31113428 EFO_0001071 Lung cancer in ever smokers lung carcinoma European=8970|African American or Afro-Caribbean=2025 GCST003833 10.698970004336019 GCST003833 27611488 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (455197bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 6 31088145 6 31120368 EFO_0000270 Adult asthma asthma Other=978|European=1112 GCST006575 9.698970004336019 GCST006575_3 25604533 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (453635bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 31089708 6 31121931 EFO_1001857 Takayasu arteritis [Turkish] Takayasu arteritis East Asian=1098 GCST001768 19.69897000433602 GCST001768 23001997 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0003780 and targets the gene ENSG00000232810 at this locus (443766bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 31099577 6 31131800 EFO_0003780 Behcet's disease Behcet's syndrome East Asian=1098 GCST001768 19.69897000433602 GCST001768 23001997 drug Low Ed Mountjoy Tubulin inhibitor drug COLCHICINE is Phase II for the indiciation EFO_0003780 and targets the gene ENSG00000196230 at this locus (406375bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 31099577 6 31131800 EFO_0003780 Behcet's disease Behcet's syndrome Other=1097|NR=150064 GCST003048 9.0 GCST003048 26198764 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (440378bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 6 31102964 6 31135187 EFO_0000692 Schizophrenia schizophrenia NR=150064|European=70017 GCST007257 9.698970004336019 GCST007257 30626913 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000232810 at this locus (437929bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 6 31105413 6 31137636 EFO_0003761 Broad depression or schizophrenia unipolar depression NR=150064|European=70017 GCST007257 9.698970004336019 GCST007257 30626913 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (437929bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 6 31105413 6 31137636 EFO_0000692 Broad depression or schizophrenia schizophrenia European=9641 GCST002140 10.0 GCST002140 23955597 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (414055bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 6 31107258 6 31139481 EFO_0001378 Multiple myeloma multiple myeloma European=9641 GCST002140 10.0 GCST002140 23955597 drug Low Ed Mountjoy Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (414055bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 31107258 6 31139481 EFO_0001378 Multiple myeloma multiple myeloma East Asian=1310 GCST000529 66.39794000867204 GCST000529 19915573 drug Low Ed Mountjoy TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (431987bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 31111356 6 31143579 EFO_0000729 Ulcerative colitis ulcerative colitis East Asian=1310 GCST000529 66.39794000867204 GCST000529 19915573 drug Low Ed Mountjoy TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (431987bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 31111356 6 31143579 EFO_0000729 Ulcerative colitis ulcerative colitis European=241704 GCST004483 16.522878745280337 GCST004483 27363682 drug Low Ed Mountjoy Tubulin inhibitor drug VINORELBINE is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (423324bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 31116526 6 31148749 EFO_0001378 Multiple myeloma multiple myeloma European=241704 GCST004483 16.522878745280337 GCST004483 27363682 drug Low Ed Mountjoy Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0001378 and targets the gene ENSG00000196230 at this locus (423324bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 6 31116526 6 31148749 EFO_0001378 Multiple myeloma multiple myeloma European=13560 GCST001148 7.522878745280337 GCST001148 21743467 drug Low Ed Mountjoy Tubulin inhibitor drug CABAZITAXEL is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (425308bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 6 31118511 6 31150734 EFO_0001663 Prostate cancer prostate carcinoma European=13560 GCST001148 7.522878745280337 GCST001148 21743467 drug Low Ed Mountjoy Tubulin inhibitor drug IXABEPILONE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (425308bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 6 31118511 6 31150734 EFO_0001663 Prostate cancer prostate carcinoma European=13560 GCST001148 7.522878745280337 GCST001148 21743467 drug Low Ed Mountjoy Tubulin inhibitor drug VINBLASTINE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000196230 at this locus (425308bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 6 31118511 6 31150734 EFO_0001663 Prostate cancer prostate carcinoma European=2305 GCST001181 7.698970004336019 GCST001181 21801394 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (406890bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 31136453 6 31168676 EFO_0004775 Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) toxic epidermal necrolysis European=2305 GCST001181 7.698970004336019 GCST001181 21801394 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (406890bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 6 31136453 6 31168676 EFO_0004276 Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) Stevens-Johnson syndrome European=2305 GCST001181 7.522878745280337 GCST001181 21801394 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (401097bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 6 31142245 6 31174468 EFO_0004276 Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) Stevens-Johnson syndrome European=2305 GCST001181 7.522878745280337 GCST001181 21801394 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (401097bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 6 31142245 6 31174468 EFO_0004775 Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) toxic epidermal necrolysis European=1712|African American or Afro-Caribbean=1233|Hispanic or Latin American=677 GCST000863 15.397940008672037 GCST000863_2 21051598 drug Low Ed Mountjoy Tubulin inhibitor drug VINCRISTINE is Phase III for the indiciation EFO_0000180 and targets the gene ENSG00000196230 at this locus (450379bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 6 31143582 6 31175805 EFO_0000180 HIV-1 control [EA] HIV-1 infection East Asian=2271 GCST000321 207.69897000433602 GCST000321 19169255 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (387557bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C G 6 31155785 6 31188008 EFO_0000676 Psoriasis psoriasis East Asian=2271 GCST000321 207.69897000433602 GCST000321 19169255 drug Low Ed Mountjoy TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (387557bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 6 31155785 6 31188008 EFO_0000676 Psoriasis psoriasis East Asian=2271 GCST000321 207.69897000433602 GCST000321 19169255 drug Low Ed Mountjoy Tubulin inhibitor drug PACLITAXEL is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000196230 at this locus (462582bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196230 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C G 6 31155785 6 31188008 EFO_0000676 Psoriasis psoriasis European=1951 GCST001737 9.698970004336019 GCST001737_7 23144326 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (302912bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 6 31240431 6 31272654 EFO_0000341 Chronic obstructive pulmonary disease-related biomarkers [SP-D] chronic obstructive pulmonary disease European=1951 GCST001737 9.698970004336019 GCST001737_7 23144326 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (302912bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 6 31240431 6 31272654 EFO_0000341 Chronic obstructive pulmonary disease-related biomarkers [SP-D] chronic obstructive pulmonary disease European=1460 GCST000835 71.69897000433602 GCST000835 20953186 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (302233bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 31241109 6 31273332 EFO_0003778 Psoriatic arthritis psoriatic arthritis European=1460 GCST000835 71.69897000433602 GCST000835 20953186 drug Low Ed Mountjoy TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (302233bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 31241109 6 31273332 EFO_0003778 Psoriatic arthritis psoriatic arthritis Other=978|European=1112 GCST006575 9.0 GCST006575_2 25604533 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (301152bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 31242191 6 31274414 EFO_1001857 Takayasu arteritis [EA] Takayasu arteritis European=2759 GCST000322 100.0 GCST000322 19169254 drug Low Ed Mountjoy TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 31252925 6 31285148 EFO_0000676 Psoriasis psoriasis European=6880 GCST003270 98.69897000433602 GCST003270 26626624 drug Low Ed Mountjoy TNF-alpha inhibitor drug GOLIMUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (290418bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 31252925 6 31285148 EFO_0003778 Psoriatic arthritis psoriatic arthritis European=2759 GCST000322 100.0 GCST000322 19169254 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 31252925 6 31285148 EFO_0000676 Psoriasis psoriasis European=1618 GCST000836 31.397940008672037 GCST000836 20953188 drug Low Ed Mountjoy TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 31252925 6 31285148 EFO_0000676 Psoriasis psoriasis European=1618 GCST000836 31.397940008672037 GCST000836 20953188 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (290418bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 31252925 6 31285148 EFO_0000676 Psoriasis psoriasis European=6880 GCST003270 98.69897000433602 GCST003270 26626624 drug Low Ed Mountjoy TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (290418bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 31252925 6 31285148 EFO_0003778 Psoriatic arthritis psoriatic arthritis East Asian=2546 GCST000692 32.69897000433602 GCST000692 20526339 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0004208 and targets the gene ENSG00000232810 at this locus (284506bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 31258837 6 31291060 EFO_0004208 Vitiligo Vitiligo European=2198 GCST007043 36.0 GCST007043 30552173 drug Low Ed Mountjoy TNF-alpha inhibitor drug GOLIMUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (277590bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 31265752 6 31297975 EFO_0003778 Psoriatic arthritis psoriatic arthritis European=2198 GCST007043 36.0 GCST007043 30552173 drug Low Ed Mountjoy TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (277590bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 31265752 6 31297975 EFO_0003778 Psoriatic arthritis psoriatic arthritis European=8941 GCST003268 311.69897000433605 GCST003268 26626624 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_1001494 and targets the gene ENSG00000232810 at this locus (277252bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 31266090 6 31298313 EFO_1001494 Psoriasis vulgaris psoriasis vulgaris East Asian=2644 GCST003360 22.045757490560675 GCST003360 26891255 drug Low Ed Mountjoy TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000232810 at this locus (273649bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 31269693 6 31301916 EFO_0000384 Crohn's disease Crohn's disease European=7353 GCST000833 213.39794000867204 GCST000833 20953190 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 31274555 6 31306778 EFO_0000676 Psoriasis psoriasis European=7353 GCST000833 213.39794000867204 GCST000833 20953190 drug Low Ed Mountjoy TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 31274555 6 31306778 EFO_0000676 Psoriasis psoriasis European=6297 GCST003269 206.39794000867204 GCST003269 26626624 drug Low Ed Mountjoy TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 31274555 6 31306778 EFO_0000676 Cutaneous psoriasis psoriasis European=737 GCST000173 38.69897000433602 GCST000173 18369459 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 31274555 6 31306778 EFO_0000676 Psoriasis psoriasis European=737 GCST000173 38.69897000433602 GCST000173 18369459 drug Low Ed Mountjoy TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 31274555 6 31306778 EFO_0000676 Psoriasis psoriasis European=6297 GCST003269 206.39794000867204 GCST003269 26626624 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (268787bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 31274555 6 31306778 EFO_0000676 Cutaneous psoriasis psoriasis East Asian=2569 GCST006984 33.39794000867204 GCST006984 30498034 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (263125bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 6 31280218 6 31312441 EFO_1001857 Takayasu arteritis Takayasu arteritis European=606 GCST000165 9.0 GCST000165 18364390 drug Medium Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (231017bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 6 31312326 6 31344549 EFO_0000676 Psoriasis psoriasis European=606 GCST000165 9.0 GCST000165 18364390 drug Medium Ed Mountjoy TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (231017bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 6 31312326 6 31344549 EFO_0000676 Psoriasis psoriasis Other=1097|NR=150064 GCST003048 19.096910013008056 GCST003048 26198764 drug Medium Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (222075bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 6 31321267 6 31353490 EFO_0000692 Schizophrenia schizophrenia Other=1828|Greater Middle Eastern (Middle Eastern / North African / Persian)=1176 GCST007844 119.22184874961636 GCST007844_4 30946743 drug Medium Ed Mountjoy TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (221214bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 6 31322129 6 31354352 EFO_0003898 Ankylosing spondylitis [Turkish] ankylosing spondylitis European=157242 GCST003987 16.0 GCST003987 27182965 drug Low Ed Mountjoy TNF-alpha inhibitor drug ADALIMUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (221145bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 6 31322197 6 31354420 EFO_0000270 Asthma asthma European=341215 GCST007798 59.69897000433602 GCST007798 30929738 drug Low Ed Mountjoy TNF-alpha inhibitor drug ADALIMUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (221145bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 6 31322197 6 31354420 EFO_0000270 Asthma asthma Other=1828|Greater Middle Eastern (Middle Eastern / North African / Persian)=1176 GCST007844 90.04575749056067 GCST007844_3 30946743 drug Medium Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (217409bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 31325933 6 31358156 EFO_0003898 Ankylosing spondylitis [Iranian] ankylosing spondylitis European=4806 GCST000961 8.0 GCST000961 21254220 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000289 and targets the gene ENSG00000232810 at this locus (215641bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 6 31327701 6 31359924 EFO_0000289 Bipolar disorder [addtive] bipolar disorder European=7193 GCST000563 303.30102999566395 GCST000563 20062062 drug Medium Ed Mountjoy TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (207242bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 6 31336100 6 31368323 EFO_0003898 Ankylosing spondylitis ankylosing spondylitis East Asian=1098 GCST001768 9.698970004336019 GCST001768 23001997 drug Medium Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0003780 and targets the gene ENSG00000232810 at this locus (206925bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 31336418 6 31368641 EFO_0003780 Behcet's disease Behcet's syndrome European=22647|East Asian=3117 GCST005529 100.0 GCST005529_3 23749187 drug Medium Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (198427bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 31344916 6 31377139 EFO_0003898 Ankylosing spondylitis [EA] ankylosing spondylitis European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811 GCST007692 15.698970004336019 GCST007692_13 30804561 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (194823bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 31348519 6 31380742 EFO_0000341 Chronic obstructive pulmonary disease [conditional on rs2284174] chronic obstructive pulmonary disease European, East Asian, African American or Afro-Caribbean, Hispanic or Latin American, NR=257811 GCST007692 15.698970004336019 GCST007692_13 30804561 drug Medium Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation EFO_0000341 and targets the gene ENSG00000232810 at this locus (194823bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 6 31348519 6 31380742 EFO_0000341 Chronic obstructive pulmonary disease [conditional on rs2284174] chronic obstructive pulmonary disease Other=978|European=1112 GCST006575 7.698970004336019 GCST006575_3 25604533 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (192130bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 31351212 6 31383435 EFO_1001857 Takayasu arteritis [Turkish] Takayasu arteritis European=7156 GCST002357 8.045757490560675 GCST002357 24532677 drug Low Ed Mountjoy TNF-beta inhibitor drug PATECLIZUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000226979 at this locus (186502bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000226979 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 31353329 6 31385552 EFO_0000685 Rheumatoid arthritis (ACPA-negative) rheumatoid arthritis European=7156 GCST002357 8.045757490560675 GCST002357 24532677 drug Low Ed Mountjoy TNF-alpha inhibitor drug PLACULUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (190014bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 31353329 6 31385552 EFO_0000685 Rheumatoid arthritis (ACPA-negative) rheumatoid arthritis European=7156 GCST002357 8.045757490560675 GCST002357 24532677 drug Medium Ed Mountjoy TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (190014bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 31353329 6 31385552 EFO_0000685 Rheumatoid arthritis (ACPA-negative) rheumatoid arthritis Other=788|European=659 GCST006863 15.221848749616356 GCST006863 23830517 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (189105bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 31354238 6 31386461 EFO_1001857 Takayasu arteritis Takayasu arteritis Other=978|European=1112 GCST006575 14.522878745280337 GCST006575_2 25604533 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (189105bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 31354238 6 31386461 EFO_1001857 Takayasu arteritis [EA] Takayasu arteritis European=2930 GCST007361 17.30102999566398 GCST007361 25200001 drug Medium Ed Mountjoy TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (183053bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 6 31360289 6 31392512 EFO_0003898 Acute anterior uveitis in ankylosing spondylitis ankylosing spondylitis European=1073 GCST002876 22.0 GCST002876 25936594 drug Medium Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (178635bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 31364707 6 31396930 EFO_0001359 Type 1 diabetes and autoimmune thyroid diseases insulin-dependent diabetes mellitus European=1073 GCST002876 22.0 GCST002876 25936594 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (178635bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 31364707 6 31396930 EFO_0001359 Type 1 diabetes and autoimmune thyroid diseases insulin-dependent diabetes mellitus European=11802 GCST001149 200.0 GCST001149_2 21743469 drug Medium Ed Mountjoy TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0003898 and targets the gene ENSG00000232810 at this locus (177556bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 31365787 6 31398010 EFO_0003898 Ankylosing spondylitis [less than] ankylosing spondylitis European=2305 GCST001181 8.698970004336019 GCST001181 21801394 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (135514bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 6 31407828 6 31440051 EFO_0004775 Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) toxic epidermal necrolysis European=2305 GCST001181 8.698970004336019 GCST001181 21801394 drug Medium Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (135514bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 31407828 6 31440051 EFO_0004276 Drug-induced Stevens-Johnson syndrome or toxic epidermal necrolysis (SJS/TEN) Stevens-Johnson syndrome European=737 GCST000173 25.69897000433602 GCST000173 18369459 drug Medium Ed Mountjoy TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (111563bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 6 31431780 6 31464003 EFO_0000676 Psoriasis psoriasis European=737 GCST000173 25.69897000433602 GCST000173 18369459 drug Medium Ed Mountjoy TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase III for the indiciation EFO_0000676 and targets the gene ENSG00000232810 at this locus (111563bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 6 31431780 6 31464003 EFO_0000676 Psoriasis psoriasis European=6434 GCST003092 44.52287874528034 GCST003092 26291516 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (109011bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T A 6 31434331 6 31466554 EFO_0000783 Myositis myositis European=16582 GCST006052 75.22184874961636 GCST006052 26362759 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0003063 and targets the gene ENSG00000232810 at this locus (108976bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 31434366 6 31466589 EFO_0003063 Polymyositis polymyositis European=6434 GCST003092 44.69897000433602 GCST003092 26291516 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (108976bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 31434366 6 31466589 EFO_0000783 Myositis myositis European=6434 GCST003092 44.69897000433602 GCST003092 26291516 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (108721bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 31434621 6 31466844 EFO_0000783 Myositis myositis European=6434 GCST003092 42.52287874528034 GCST003092 26291516 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (100560bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 31442782 6 31475005 EFO_0000783 Myositis myositis South Asian=1225 GCST002453 14.698970004336019 GCST002453 24837172 drug High Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (94481bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 6 31448862 6 31481085 EFO_0000729 Ulcerative colitis ulcerative colitis South Asian=1225 GCST002453 14.698970004336019 GCST002453 24837172 drug Low Ed Mountjoy TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (94481bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 6 31448862 6 31481085 EFO_0000729 Ulcerative colitis ulcerative colitis European=6434 GCST003092 48.30102999566398 GCST003092 26291516 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (94366bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 6 31448976 6 31481199 EFO_0000783 Myositis myositis European=10564 GCST001436 7.698970004336019 GCST001436_2 22399527 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0000195 and targets the gene ENSG00000232810 at this locus (94366bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 6 31448976 6 31481199 EFO_0000195 Metabolic syndrome [HDL] metabolic syndrome European=6434 GCST003092 49.0 GCST003092 26291516 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (91507bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 6 31451836 6 31484059 EFO_0000783 Myositis myositis African unspecified, African American or Afro-Caribbean=8204|European=127669|East Asian=5215|Hispanic or Latin American=1398 GCST005212 11.045757490560675 GCST005212 29273806 drug Low Ed Mountjoy TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000232810 at this locus (70622bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 6 31472720 6 31504943 EFO_0000270 Asthma asthma European=6434 GCST003092 47.39794000867204 GCST003092 26291516 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (66885bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 6 31476458 6 31508681 EFO_0000783 Myositis myositis East Asian=1005 GCST001239 7.698970004336019 GCST001239 21912425 drug Medium Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0004276 and targets the gene ENSG00000232810 at this locus (37863bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 6 31505480 6 31537703 EFO_0004276 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) Stevens-Johnson syndrome European=6434 GCST003092 48.52287874528034 GCST003092 26291516 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (37863bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 31505480 6 31537703 EFO_0000783 Myositis myositis East Asian=1005 GCST001239 7.698970004336019 GCST001239 21912425 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0004775 and targets the gene ENSG00000232810 at this locus (37863bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 31505480 6 31537703 EFO_0004775 Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) toxic epidermal necrolysis European=6434 GCST003092 48.221848749616356 GCST003092 26291516 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0000783 and targets the gene ENSG00000232810 at this locus (29095bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 31514247 6 31546470 EFO_0000783 Myositis myositis European=21389 GCST000879 10.397940008672037 GCST000879 21102463 drug High Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000232810 at this locus (1034bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 31542308 6 31574531 EFO_0000384 Crohn's disease Crohn's disease European=1073 GCST002876 22.69897000433602 GCST002876 25936594 drug Low Ed Mountjoy TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (22356bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 31568469 6 31600692 EFO_0001359 Type 1 diabetes and autoimmune thyroid diseases insulin-dependent diabetes mellitus European=1073 GCST002876 22.69897000433602 GCST002876 25936594 drug Medium Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (22356bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 31568469 6 31600692 EFO_0001359 Type 1 diabetes and autoimmune thyroid diseases insulin-dependent diabetes mellitus Other=978|European=1112 GCST006575 9.0 GCST006575_3 25604533 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_1001857 and targets the gene ENSG00000232810 at this locus (24557bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 31570670 6 31602893 EFO_1001857 Takayasu arteritis [Turkish] Takayasu arteritis European=69395 GCST001238 10.0 GCST001238 21909115 drug High Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000232810 at this locus (70254bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 31616366 6 31648589 EFO_0000537 Hypertension hypertension East Asian=700 GCST001203 9.522878745280337 GCST001203 21844665 drug Low Ed Mountjoy TNF-alpha inhibitor drug OZORALIZUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (76494bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 6 31622606 6 31654829 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis East Asian=700 GCST001203 9.522878745280337 GCST001203 21844665 drug Low Ed Mountjoy TNF-beta inhibitor drug PATECLIZUMAB is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000226979 at this locus (80506bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000226979 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 6 31622606 6 31654829 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis East Asian=700 GCST001203 9.522878745280337 GCST001203 21844665 drug High Ed Mountjoy TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000685 and targets the gene ENSG00000232810 at this locus (76494bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 6 31622606 6 31654829 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis European=3037 GCST000142 51.69897000433602 GCST000142 18204446 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (174921bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 31721033 6 31753256 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus European=2734 GCST004053 8.301029995663981 GCST004053 28067912 drug Medium Ed Mountjoy TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000232810 at this locus (187838bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C CAG 6 31733950 6 31766173 EFO_0000384 Poor prognosis in Crohn's disease Crohn's disease European=1048 GCST005541 31.397940008672037 GCST005541 26651848 drug Low Ed Mountjoy TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (203029bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 31749142 6 31781365 Orphanet_797 Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome) Sarcoidosis European=1048 GCST005541 31.397940008672037 GCST005541 26651848 drug Medium Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase III for the indiciation Orphanet_797 and targets the gene ENSG00000232810 at this locus (203029bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 31749142 6 31781365 Orphanet_797 Sarcoidosis (Lofgren's syndrome vs non-Lofgren's syndrome) Sarcoidosis East Asian=45528 GCST007201 19.30102999566398 GCST007201_2 30285260 drug Medium Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (241055bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 31787167 6 31819390 EFO_0000692 Schizophrenia [EA] schizophrenia Other=1097|NR=150064 GCST003048 18.154901959985743 GCST003048 26198764 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (280592bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 31826705 6 31858928 EFO_0000692 Schizophrenia schizophrenia East Asian=2546 GCST000692 48.0 GCST000692 20526339 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0004208 and targets the gene ENSG00000232810 at this locus (290954bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 31837066 6 31869289 EFO_0004208 Vitiligo Vitiligo European=3163 GCST002463 20.096910013008056 GCST002463 24871463 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (324214bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 31870326 6 31902549 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus European=13574|NR=2380 GCST004521 15.698970004336019 GCST004521 28540026 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (335197bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 31881309 6 31913532 EFO_0000692 Autism spectrum disorder or schizophrenia schizophrenia European=3105 GCST004873 7.698970004336019 GCST004873 28881265 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase II for the indiciation EFO_0001065 and targets the gene ENSG00000232810 at this locus (337844bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 31883957 6 31916180 EFO_0001065 Endometriosis endometriosis South Asian=1225 GCST002453 13.301029995663981 GCST002453 24837172 drug Low Ed Mountjoy TNF-alpha inhibitor drug CERTOLIZUMAB PEGOL is Phase II for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (371428bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 6 31917540 6 31949763 EFO_0000729 Ulcerative colitis ulcerative colitis South Asian=1225 GCST002453 13.301029995663981 GCST002453 24837172 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000232810 at this locus (371428bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 31917540 6 31949763 EFO_0000729 Ulcerative colitis ulcerative colitis European=1073 GCST002876 24.30102999566398 GCST002876 25936594 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase III for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (372748bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 6 31918860 6 31951083 EFO_0001359 Type 1 diabetes and autoimmune thyroid diseases insulin-dependent diabetes mellitus European=1073 GCST002876 24.30102999566398 GCST002876 25936594 drug Low Ed Mountjoy TNF-alpha inhibitor drug GOLIMUMAB is Phase II for the indiciation EFO_0001359 and targets the gene ENSG00000232810 at this locus (372748bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 31918860 6 31951083 EFO_0001359 Type 1 diabetes and autoimmune thyroid diseases insulin-dependent diabetes mellitus European=2198 GCST007043 13.397940008672037 GCST007043 30552173 drug Low Ed Mountjoy TNF-alpha inhibitor drug ADALIMUMAB is Phase IV for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (389945bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 6 31936057 6 31968280 EFO_0003778 Psoriatic arthritis psoriatic arthritis European=2198 GCST007043 13.397940008672037 GCST007043 30552173 drug Low Ed Mountjoy TNF-alpha inhibitor drug ONERCEPT is Phase III for the indiciation EFO_0003778 and targets the gene ENSG00000232810 at this locus (389945bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 6 31936057 6 31968280 EFO_0003778 Psoriatic arthritis psoriatic arthritis NR=150064|European=70017 GCST007257 12.0 GCST007257 30626913 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000232810 at this locus (401348bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 6 31947460 6 31979683 EFO_0000692 Broad depression or schizophrenia schizophrenia NR=150064|European=70017 GCST007257 12.0 GCST007257 30626913 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000232810 at this locus (401348bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 6 31947460 6 31979683 EFO_0003761 Broad depression or schizophrenia unipolar depression East Asian=5057|European=10995 GCST003622 100.69897000433602 GCST003622_3 27399966 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (483092bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 32029205 6 32061428 EFO_0002690 Systemic lupus erythematosus [EA] systemic lupus erythematosus European=18264|African American or Afro-Caribbean=5422|Hispanic or Latin American=3888 GCST005752 116.22184874961636 GCST005752 28714469 drug Low Ed Mountjoy TNF-alpha inhibitor drug ETANERCEPT is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000232810 at this locus (492437bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 32038550 6 32070773 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus East Asian=9469 GCST002627 10.397940008672037 GCST002627 25249183 drug Low Ed Mountjoy TNF-alpha inhibitor drug INFLIXIMAB is Phase IV for the indiciation EFO_0000537 and targets the gene ENSG00000232810 at this locus (498738bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000232810 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 32044851 6 32077074 EFO_0000537 Hypertension hypertension African American or Afro-Caribbean=2308 GCST006959 7.3979400086720375 GCST006959_3 30423114 drug Low Ed Mountjoy MAP kinase p38 alpha inhibitor drug LOSMAPIMOD is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112062 at this locus (276642bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112062 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 6 36355654 6 36387877 EFO_0000685 Rheumatoid arthritis [EA] rheumatoid arthritis African American or Afro-Caribbean=2308 GCST006959 8.698970004336019 GCST006959 30423114 drug Low Ed Mountjoy MAP kinase p38 alpha inhibitor drug LOSMAPIMOD is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112062 at this locus (276642bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112062 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 6 36355654 6 36387877 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis East Asian=191764 GCST007847 13.397940008672037 GCST007847 30718926 drug High Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug DULAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV AAAAG A 6 39039140 6 39071364 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 13.397940008672037 GCST007847 30718926 drug Medium Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 6 39039140 6 39071364 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 13.397940008672037 GCST007847 30718926 drug Medium Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III AAAAG A 6 39039140 6 39071364 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 13.397940008672037 GCST007847 30718926 drug High Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug DULAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 6 39039140 6 39071364 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 13.397940008672037 GCST007847 30718926 drug High Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug DULAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV AG A 6 39039140 6 39071364 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 13.397940008672037 GCST007847 30718926 drug Medium Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III AG A 6 39039140 6 39071364 EFO_0001360 Type 2 diabetes type II diabetes mellitus African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630 GCST003117 7.522878745280337 GCST003117 26343387 drug High Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000112164 at this locus (65370bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 6 39124448 6 39156672 EFO_0000612 Myocardial infarction myocardial infarction European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323 GCST003116 7.698970004336019 GCST003116 26343387 drug Medium Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000112164 at this locus (75021bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 39134099 6 39166323 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 11.117418546445549 GCST005194 29212778 drug Medium Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000112164 at this locus (115843bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 39174922 6 39207146 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 11.522878745280337 GCST005196 29212778 drug Medium Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug EXENATIDE is Phase III for the indiciation EFO_0000378 and targets the gene ENSG00000112164 at this locus (115843bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 39174922 6 39207146 EFO_0000378 Coronary artery disease coronary artery disease East Asian=191764 GCST007847 9.0 GCST007847 30718926 drug Medium Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug LIXISENATIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (223292bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 39282371 6 39314595 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 9.0 GCST007847 30718926 drug Medium Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (223292bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 39282371 6 39314595 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=15000|South East Asian=2034|Asian unspecified=1783 GCST001351 7.698970004336019 GCST001351 22158537 drug Medium Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug TASPOGLUTIDE is Phase III for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (224972bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 6 39284050 6 39316274 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=15000|South East Asian=2034|Asian unspecified=1783 GCST001351 7.698970004336019 GCST001351 22158537 drug Medium Ed Mountjoy Glucagon-like peptide 1 receptor agonist drug LIRAGLUTIDE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000112164 at this locus (224972bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112164 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 6 39284050 6 39316274 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=140254 GCST006085 7.522878745280337 GCST006085 29892016 drug Low Ed Mountjoy Vascular endothelial growth factor A inhibitor drug BEVACIZUMAB is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000112715 at this locus (43324bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112715 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 6 43694598 6 43726861 EFO_0001663 Prostate cancer prostate carcinoma NR=296525 GCST005194 11.39848321634999 GCST005194 29212778 drug Low Ed Mountjoy Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000112759 at this locus (428369bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112759 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 43758873 6 43791136 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 11.698970004336019 GCST005196 29212778 drug Low Ed Mountjoy Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000112759 at this locus (428369bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112759 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 43758873 6 43791136 EFO_0000378 Coronary artery disease coronary artery disease NR=547261 GCST005195 8.3767507096021 GCST005195 29212778 drug Low Ed Mountjoy Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000112759 at this locus (428369bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112759 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 43758873 6 43791136 EFO_0000378 Coronary artery disease coronary artery disease European=33976 GCST003219 14.0 GCST003219_2 26691988 drug Medium Ed Mountjoy Vascular endothelial growth factor A inhibitor drug BROLUCIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112715 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 43826627 6 43858890 EFO_0001365 Advanced age-related macular degeneration [EA] age-related macular degeneration European=55115|South Asian=229|East Asian=4150 GCST001884 15.045757490560675 GCST001884 23455636 drug Medium Ed Mountjoy Vascular endothelial growth factor A inhibitor drug BROLUCIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112715 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 43826627 6 43858890 EFO_0001365 Age-related macular degeneration age-related macular degeneration European=33976 GCST003219 14.0 GCST003219_2 26691988 drug Medium Ed Mountjoy Vascular endothelial growth factor A inhibitor drug BEVACIZUMAB is Phase III for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (72403bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112715 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 43826627 6 43858890 EFO_0004683 Advanced age-related macular degeneration [EA] wet macular degeneration European=33976 GCST003219 14.0 GCST003219_2 26691988 drug High Ed Mountjoy Vascular endothelial growth factor A inhibitor drug RANIBIZUMAB is Phase IV for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (72403bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112715 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 43826627 6 43858890 EFO_0004683 Advanced age-related macular degeneration [EA] wet macular degeneration European=33976 GCST003219 14.0 GCST003219_2 26691988 drug High Ed Mountjoy Vascular endothelial growth factor A inhibitor drug RANIBIZUMAB is Phase IV for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112715 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 43826627 6 43858890 EFO_0001365 Advanced age-related macular degeneration [EA] age-related macular degeneration European=55115|South Asian=229|East Asian=4150 GCST001884 15.045757490560675 GCST001884 23455636 drug High Ed Mountjoy Vascular endothelial growth factor A inhibitor drug RANIBIZUMAB is Phase IV for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (72403bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112715 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 43826627 6 43858890 EFO_0001365 Age-related macular degeneration age-related macular degeneration European=6728 GCST001100 8.045757490560675 GCST001100 21665990 drug Medium Ed Mountjoy Vascular endothelial growth factor A inhibitor drug BROLUCIZUMAB is Phase III for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (74358bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112715 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 43828582 6 43860845 EFO_0001365 Age-related macular degeneration age-related macular degeneration European=6728 GCST001100 8.045757490560675 GCST001100 21665990 drug High Ed Mountjoy Vascular endothelial growth factor A inhibitor drug CONBERCEPT is Phase IV for the indiciation EFO_0001365 and targets the gene ENSG00000112715 at this locus (74358bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112715 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 43828582 6 43860845 EFO_0001365 Age-related macular degeneration age-related macular degeneration East Asian=7810 GCST002766 17.221848749616356 GCST002766 25629512 drug Medium Ed Mountjoy Vascular endothelial growth factor A inhibitor drug BEVACIZUMAB is Phase III for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (216603bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112715 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 43970827 6 44003090 EFO_0004683 Exudative age-related macular degeneration wet macular degeneration East Asian=7810 GCST002766 17.221848749616356 GCST002766 25629512 drug Medium Ed Mountjoy Vascular endothelial growth factor A inhibitor drug AFLIBERCEPT is Phase IV for the indiciation EFO_0004683 and targets the gene ENSG00000112715 at this locus (216603bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112715 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 43970827 6 44003090 EFO_0004683 Exudative age-related macular degeneration wet macular degeneration East Asian=5683 GCST001681 15.0 GCST001681 23028356 drug Low Ed Mountjoy Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (31032bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112759 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 44232920 6 44265183 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis East Asian=20965 GCST001454 18.221848749616356 GCST001454 22446963 drug Low Ed Mountjoy Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (31032bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112759 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 44232920 6 44265183 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis African American or Afro-Caribbean=2308 GCST006959 7.522878745280337 GCST006959_3 30423114 drug Low Ed Mountjoy Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112759 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 44233921 6 44266184 EFO_0000685 Rheumatoid arthritis [EA] rheumatoid arthritis African American or Afro-Caribbean=2308 GCST006959 18.69897000433602 GCST006959 30423114 drug Low Ed Mountjoy Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112759 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 44233921 6 44266184 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis European=58284|East Asian=22515 GCST002318 19.0 GCST002318 24390342 drug Low Ed Mountjoy Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112759 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 44233921 6 44266184 EFO_0000685 Rheumatoid arthritis rheumatoid arthritis European=58284|East Asian=22515 GCST002318 12.698970004336019 GCST002318_3 24390342 drug Low Ed Mountjoy Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112759 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 44233921 6 44266184 EFO_0000685 Rheumatoid arthritis [East Asian] rheumatoid arthritis European=58284|East Asian=22515 GCST002318 7.522878745280337 GCST002318_2 24390342 drug Low Ed Mountjoy Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112759 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 44233921 6 44266184 EFO_0000685 Rheumatoid arthritis [EA] rheumatoid arthritis African American or Afro-Caribbean=2308 GCST006959 12.045757490560675 GCST006959_4 30423114 drug Low Ed Mountjoy Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase II for the indiciation EFO_0000685 and targets the gene ENSG00000112759 at this locus (32034bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112759 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 44233921 6 44266184 EFO_0000685 Rheumatoid arthritis [East Asian] rheumatoid arthritis European=2406 GCST001659 7.301029995663981 GCST001659 22941190 drug Low Ed Mountjoy Equilibrative nucleoside transporter 1 inhibitor drug DIPYRIDAMOLE is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000112759 at this locus (392271bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112759 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 6 44594159 6 44626422 EFO_0000712 Stroke (ischemic) [LAA] cerebrovascular accident European, Asian unspecified, African American or Afro-Caribbean, Greater Middle Eastern (Middle Eastern / North African / Persian), Oceanian, Native American, Other admixed ancestry=22156 GCST004963 178.0 GCST004963 28753643 drug Medium Ed Mountjoy LDL-associated phospholipase A2 inhibitor drug DARAPLADIB is Phase III for the indiciation EFO_0005672 and targets the gene ENSG00000146070 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146070 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 6 46677098 6 46709361 EFO_0005672 Lipoprotein phospholipase A2 activity in cardiovascular disease acute coronary syndrome European, Asian unspecified, African American or Afro-Caribbean, Greater Middle Eastern (Middle Eastern / North African / Persian), Oceanian, Native American, Other admixed ancestry=10874 GCST004966 46.096910013008056 GCST004966 28753643 drug Medium Ed Mountjoy LDL-associated phospholipase A2 inhibitor drug DARAPLADIB is Phase III for the indiciation EFO_0005672 and targets the gene ENSG00000146070 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146070 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 6 46677098 6 46709361 EFO_0005672 Lipoprotein-associated phospholipase A2 activity change in response to darapladib treatment in cardiovascular disease acute coronary syndrome European=11181 GCST003180 7.698970004336019 GCST003180 26542096 drug Low Ed Mountjoy Interleukin 17A inhibitor drug SECUKINUMAB is Phase II for the indiciation EFO_0000274 and targets the gene ENSG00000112115 at this locus (236700bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112115 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 52292136 6 52427338 EFO_0000274 Atopic march atopic eczema European=204641|East Asian=4262 GCST004549 7.3979400086720375 GCST004549 28537267 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase IV for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (161816bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 151816011 6 151494876 EFO_0001065 Endometriosis endometriosis European=204641|East Asian=4262 GCST004549 7.3979400086720375 GCST004549 28537267 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (161816bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 151816011 6 151494876 EFO_0001065 Endometriosis endometriosis European=361141 8.287247628480976 NEALE2_20002_1065 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0000537 and targets the gene ENSG00000091831 at this locus (67422bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A AAC 6 151910404 6 151589269 EFO_0000537 Hypertension | non-cancer illness code, self-reported hypertension European=22627 GCST001937 20.69897000433602 GCST001937 23535729 drug Low Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (63714bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 151914113 6 151592978 EFO_0000305 Breast cancer breast carcinoma European=22627 GCST001937 20.69897000433602 GCST001937 23535729 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (63714bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 151914113 6 151592978 EFO_0000305 Breast cancer breast carcinoma European=22627 GCST001937 20.69897000433602 GCST001937 23535729 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (63714bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 151914113 6 151592978 EFO_0000305 Breast cancer breast carcinoma European=19291 GCST003845 19.0 GCST003845 27117709 drug Low Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 6 151918856 6 151597721 EFO_0000305 Breast cancer breast carcinoma European=33864 GCST004950 26.154901959985743 GCST004950 25751625 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 6 151918856 6 151597721 EFO_0000305 Breast cancer breast carcinoma European=33864 GCST004950 26.154901959985743 GCST004950 25751625 drug Low Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 6 151918856 6 151597721 EFO_0000305 Breast cancer breast carcinoma European=33864 GCST004950 26.154901959985743 GCST004950 25751625 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 6 151918856 6 151597721 EFO_0000305 Breast cancer breast carcinoma European=19291 GCST003845 19.0 GCST003845 27117709 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 6 151918856 6 151597721 EFO_0000305 Breast cancer breast carcinoma European=19291 GCST003845 19.0 GCST003845 27117709 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (58970bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 6 151918856 6 151597721 EFO_0000305 Breast cancer breast carcinoma European=688809 GCST006477 9.154901959985743 GCST006477 29942085 drug Low Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (52320bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 6 151925507 6 151604372 EFO_0003761 Depression unipolar depression European=688809 GCST006477 9.154901959985743 GCST006477 29942085 drug High Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (52320bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 6 151925507 6 151604372 EFO_0003761 Depression unipolar depression European=15566 GCST005075 11.522878745280337 GCST005075 29058716 drug Low Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (35633bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 6 151942194 6 151621059 EFO_0000305 Breast Cancer in BRCA1 mutation carriers breast carcinoma European=15566 GCST005075 11.522878745280337 GCST005075 29058716 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (35633bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 6 151942194 6 151621059 EFO_0000305 Breast Cancer in BRCA1 mutation carriers breast carcinoma European=15566 GCST005075 11.522878745280337 GCST005075 29058716 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (35633bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 6 151942194 6 151621059 EFO_0000305 Breast Cancer in BRCA1 mutation carriers breast carcinoma European=19291 GCST003845 27.397940008672037 GCST003845 27117709 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (31674bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A T 6 151946152 6 151625017 EFO_0000305 Breast cancer breast carcinoma European=19291 GCST003845 27.397940008672037 GCST003845 27117709 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (31674bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A T 6 151946152 6 151625017 EFO_0000305 Breast cancer breast carcinoma European=19291 GCST003845 27.397940008672037 GCST003845 27117709 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (31674bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A T 6 151946152 6 151625017 EFO_0000305 Breast cancer breast carcinoma European=39387 GCST001930 15.301029995663981 GCST001930 23535733 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 151948366 6 151627231 EFO_0000305 Breast cancer breast carcinoma European=39387 GCST001930 15.301029995663981 GCST001930 23535733 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 151948366 6 151627231 EFO_0000305 Breast cancer breast carcinoma East Asian=13905 GCST003520 14.154901959985743 GCST003520 27354352 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 151948366 6 151627231 EFO_0000305 Breast cancer breast carcinoma East Asian=13905 GCST003520 14.154901959985743 GCST003520 27354352 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 151948366 6 151627231 EFO_0000305 Breast cancer breast carcinoma East Asian=13905 GCST003520 14.154901959985743 GCST003520 27354352 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 151948366 6 151627231 EFO_0000305 Breast cancer breast carcinoma European=33864 GCST004950 23.221848749616356 GCST004950 25751625 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 151948366 6 151627231 EFO_0000305 Breast cancer breast carcinoma European=2727 GCST001916 8.301029995663981 GCST001916 23544013 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 151948366 6 151627231 EFO_0000305 Breast Cancer in BRCA1 mutation carriers breast carcinoma European=39387 GCST001930 15.301029995663981 GCST001930 23535733 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 151948366 6 151627231 EFO_0000305 Breast cancer breast carcinoma European=33864 GCST004950 23.221848749616356 GCST004950 25751625 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 151948366 6 151627231 EFO_0000305 Breast cancer breast carcinoma European=33864 GCST004950 23.221848749616356 GCST004950 25751625 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 151948366 6 151627231 EFO_0000305 Breast cancer breast carcinoma East Asian=3027 GCST000343 14.698970004336019 GCST000343 19219042 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 151948366 6 151627231 EFO_0000305 Breast cancer breast carcinoma East Asian=3027 GCST000343 14.698970004336019 GCST000343 19219042 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 151948366 6 151627231 EFO_0000305 Breast cancer breast carcinoma East Asian=3027 GCST000343 14.698970004336019 GCST000343 19219042 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 151948366 6 151627231 EFO_0000305 Breast cancer breast carcinoma European=2727 GCST001916 8.301029995663981 GCST001916 23544013 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 151948366 6 151627231 EFO_0000305 Breast Cancer in BRCA1 mutation carriers breast carcinoma European=2727 GCST001916 8.301029995663981 GCST001916 23544013 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (29461bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 151948366 6 151627231 EFO_0000305 Breast Cancer in BRCA1 mutation carriers breast carcinoma European=401447 10.1038/s41588-018-0184-y 15.344861565188618 SAIGE_174 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (28021bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 6 151949806 6 151628671 EFO_0000305 Breast cancer breast carcinoma European=401447 10.1038/s41588-018-0184-y 15.344861565188618 SAIGE_174 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (28021bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 6 151949806 6 151628671 EFO_0000305 Breast cancer breast carcinoma European=401447 10.1038/s41588-018-0184-y 15.344861565188618 SAIGE_174 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (28021bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 6 151949806 6 151628671 EFO_0000305 Breast cancer breast carcinoma European=330828 12.785156151952302 NEALE2_20110_5 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25495bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 151952332 6 151631197 EFO_0000305 Breast cancer | illnesses of mother breast carcinoma European=330828 12.785156151952302 NEALE2_20110_5 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25495bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 6 151952332 6 151631197 EFO_0000305 Breast cancer | illnesses of mother breast carcinoma European=330828 12.785156151952302 NEALE2_20110_5 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25495bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 151952332 6 151631197 EFO_0000305 Breast cancer | illnesses of mother breast carcinoma European=139274 GCST004988 7.895171596346344 GCST004988 29059683 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug SR16234 is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25181bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 6 151952645 6 151631510 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 7.895171596346344 GCST004988 29059683 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25181bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 6 151952645 6 151631510 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 7.895171596346344 GCST004988 29059683 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (25181bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 6 151952645 6 151631510 EFO_0000305 Breast cancer breast carcinoma Hispanic or Latin American=4710 GCST002662 17.045757490560675 GCST002662 25327703 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (22992bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 6 151954834 6 151633699 EFO_0000305 Breast cancer breast carcinoma Hispanic or Latin American=4710 GCST002662 17.045757490560675 GCST002662 25327703 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (22992bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 6 151954834 6 151633699 EFO_0000305 Breast cancer breast carcinoma Hispanic or Latin American=4710 GCST002662 17.045757490560675 GCST002662 25327703 drug Low Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (22992bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 151954834 6 151633699 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 53.54668165995296 GCST004988 29059683 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (21912bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 151955914 6 151634779 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 53.54668165995296 GCST004988 29059683 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (21912bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 6 151955914 6 151634779 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 53.54668165995296 GCST004988 29059683 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (21912bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 6 151955914 6 151634779 EFO_0000305 Breast cancer breast carcinoma European=32530|African American or Afro-Caribbean=3748 GCST001683 9.698970004336019 GCST001683 22976474 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 6 151987357 6 151666222 EFO_0000305 Breast cancer breast carcinoma European=32530|African American or Afro-Caribbean=3748 GCST001683 9.698970004336019 GCST001683 22976474 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 6 151987357 6 151666222 EFO_0000305 Breast cancer breast carcinoma European=32530|African American or Afro-Caribbean=3748 GCST001683 9.698970004336019 GCST001683 22976474 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 6 151987357 6 151666222 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 18.080451241031152 GCST004988 29059683 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C A 6 152020390 6 151699255 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 18.080451241031152 GCST004988 29059683 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C A 6 152020390 6 151699255 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 18.080451241031152 GCST004988 29059683 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C A 6 152020390 6 151699255 EFO_0000305 Breast cancer breast carcinoma European=401447 10.1038/s41588-018-0184-y 7.47755576649368 SAIGE_174 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 152034820 6 151713685 EFO_0000305 Breast cancer breast carcinoma European=401447 10.1038/s41588-018-0184-y 7.47755576649368 SAIGE_174 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 152034820 6 151713685 EFO_0000305 Breast cancer breast carcinoma European=401447 10.1038/s41588-018-0184-y 7.47755576649368 SAIGE_174 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 6 152034820 6 151713685 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 25.84893674664625 GCST004988 29059683 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 152432902 6 152111767 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 25.84893674664625 GCST004988 29059683 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 152432902 6 152111767 EFO_0000305 Breast cancer breast carcinoma European=139274 GCST004988 25.84893674664625 GCST004988 29059683 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C 6 152432902 6 152111767 EFO_0000305 Breast cancer breast carcinoma European=401447 10.1038/s41588-018-0184-y 12.767003889607846 SAIGE_174 drug High Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase IV for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 152437016 6 152115881 EFO_0000305 Breast cancer breast carcinoma European=401447 10.1038/s41588-018-0184-y 12.767003889607846 SAIGE_174 drug Low Ed Mountjoy Estrogen receptor alpha antagonist drug BRILANESTRANT is Phase II for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 6 152437016 6 152115881 EFO_0000305 Breast cancer breast carcinoma European=401447 10.1038/s41588-018-0184-y 12.767003889607846 SAIGE_174 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000091831 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 152437016 6 152115881 EFO_0000305 Breast cancer breast carcinoma European=204641|East Asian=4262 GCST004549 7.698970004336019 GCST004549 28537267 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase IV for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 6 152554014 6 152232879 EFO_0001065 Endometriosis endometriosis European=204641|East Asian=4262 GCST004549 7.698970004336019 GCST004549 28537267 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 6 152554014 6 152232879 EFO_0001065 Endometriosis endometriosis European=204641|East Asian=4262 GCST004549 7.698970004336019 GCST004549_2 28537267 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase IV for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 6 152554014 6 152232879 EFO_0001065 Endometriosis [EA] endometriosis European=204641|East Asian=4262 GCST004549 7.698970004336019 GCST004549_2 28537267 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0001065 and targets the gene ENSG00000091831 at this locus (103260bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 6 152554014 6 152232879 EFO_0001065 Endometriosis [EA] endometriosis European=539925 GCST006462 23.045757490560675 GCST006462 30194396 drug Medium Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase III for the indiciation EFO_0000731 and targets the gene ENSG00000091831 at this locus (111518bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 6 152562271 6 152241136 EFO_0000731 Uterine fibroids uterine fibroid European=33181 GCST003962 7.3979400086720375 GCST003962 28072414 drug Low Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase III for the indiciation EFO_0000289 and targets the gene ENSG00000091831 at this locus (263852bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 6 152714606 6 152393471 EFO_0000289 Bipolar disorder bipolar disorder European=61220 GCST001877 8.397940008672037 GCST001877_3 23453885 drug Low Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase II for the indiciation EFO_0000692 and targets the gene ENSG00000091831 at this locus (339820bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 6 152790573 6 152469438 EFO_0000692 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis] schizophrenia European=61220 GCST001877 8.397940008672037 GCST001877_3 23453885 drug Low Ed Mountjoy Estrogen receptor alpha modulator drug TAMOXIFEN is Phase III for the indiciation EFO_0000289 and targets the gene ENSG00000091831 at this locus (339820bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 6 152790573 6 152469438 EFO_0000289 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis] bipolar disorder European=61220 GCST001877 8.397940008672037 GCST001877_3 23453885 drug Low Ed Mountjoy Estrogen receptor alpha agonist drug ESTRADIOL is Phase IV for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (339820bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 6 152790573 6 152469438 EFO_0003761 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis] unipolar depression European=61220 GCST001877 8.397940008672037 GCST001877_3 23453885 drug Low Ed Mountjoy Estrogen receptor alpha agonist drug ETHINYL ESTRADIOL is Phase II for the indiciation EFO_0003761 and targets the gene ENSG00000091831 at this locus (339820bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000091831 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 6 152790573 6 152469438 EFO_0003761 Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined) [Modelling analysis] unipolar depression European=1027|African American or Afro-Caribbean=383 GCST004136 7.522878745280337 GCST004136 28115739 drug Low Ed Mountjoy Mu opioid receptor agonist drug MORPHINE is Phase IV for the indiciation EFO_0005611 and targets the gene ENSG00000112038 at this locus (306493bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112038 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 154025139 6 153704004 EFO_0005611 Methadone dose in opioid dependence [AA] opioid dependence European=1027|African American or Afro-Caribbean=383 GCST004136 7.522878745280337 GCST004136 28115739 drug Low Ed Mountjoy Mu opioid receptor agonist drug TRAMADOL is Phase III for the indiciation EFO_0005611 and targets the gene ENSG00000112038 at this locus (306493bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112038 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 154025139 6 153704004 EFO_0005611 Methadone dose in opioid dependence [AA] opioid dependence European=1027|African American or Afro-Caribbean=383 GCST004136 7.522878745280337 GCST004136 28115739 drug Low Ed Mountjoy Mu opioid receptor antagonist drug NALDEMEDINE is Phase II for the indiciation EFO_0005611 and targets the gene ENSG00000112038 at this locus (306493bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000112038 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T 6 154025139 6 153704004 EFO_0005611 Methadone dose in opioid dependence [AA] opioid dependence NR=296525 GCST005194 88.32422165832591 GCST005194 29212778 drug Low Ed Mountjoy Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (371740bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 6 160751531 6 160330499 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 30.522878745280337 GCST005196 29212778 drug Medium Ed Mountjoy Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 160911596 6 160490564 EFO_0000378 Coronary artery disease coronary artery disease European=408458 10.1038/s41588-018-0184-y 19.416801226031378 SAIGE_411 drug Medium Ed Mountjoy Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 160911596 6 160490564 EFO_0000378 Ischemic heart disease coronary artery disease European=388806 10.1038/s41588-018-0184-y 11.869666231504993 SAIGE_411_2 drug Medium Ed Mountjoy Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (211675bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 6 160911596 6 160490564 EFO_0000612 Myocardial infarction myocardial infarction European=388806 10.1038/s41588-018-0184-y 11.869666231504993 SAIGE_411_2 drug Medium Ed Mountjoy Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (211675bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 160911596 6 160490564 EFO_0000612 Myocardial infarction myocardial infarction NR=296525 GCST005194 31.75870261289001 GCST005194 29212778 drug Medium Ed Mountjoy Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 160911596 6 160490564 EFO_0000378 Coronary artery disease coronary artery disease NR=547261 GCST005195 28.657577319177793 GCST005195 29212778 drug Medium Ed Mountjoy Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (211675bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 160911596 6 160490564 EFO_0000378 Coronary artery disease coronary artery disease European=15666 GCST006405 11.522878745280337 GCST006405 30003307 drug Medium Ed Mountjoy Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (126153bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T A 6 160997118 6 160576086 EFO_0000378 Coronary artery disease in diabetes coronary artery disease European=361141 28.71524000401907 NEALE2_20002_1075 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 161005610 6 160584578 EFO_0000612 Heart attack/myocardial infarction | non-cancer illness code, self-reported myocardial infarction NR=296525 GCST005194 153.0096611452124 GCST005194 29212778 drug Medium Ed Mountjoy Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 161005610 6 160584578 EFO_0000378 Coronary artery disease coronary artery disease European=408458 10.1038/s41588-018-0184-y 61.367542707815275 SAIGE_411 drug Medium Ed Mountjoy Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 161005610 6 160584578 EFO_0000378 Ischemic heart disease coronary artery disease European=361141 28.71524000401907 NEALE2_20002_1075 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 161005610 6 160584578 EFO_0000612 Heart attack/myocardial infarction | non-cancer illness code, self-reported myocardial infarction European=388806 10.1038/s41588-018-0184-y 40.28149831113272 SAIGE_411_2 drug Medium Ed Mountjoy Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 161005610 6 160584578 EFO_0000612 Myocardial infarction myocardial infarction NR=547261 GCST005195 119.20065945054642 GCST005195 29212778 drug Medium Ed Mountjoy Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 161005610 6 160584578 EFO_0000378 Coronary artery disease coronary artery disease European=388806 10.1038/s41588-018-0184-y 40.28149831113272 SAIGE_411_2 drug Medium Ed Mountjoy Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (117660bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 161005610 6 160584578 EFO_0000612 Myocardial infarction myocardial infarction NR=250736 GCST005196 153.52287874528034 GCST005196 29212778 drug Medium Ed Mountjoy Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 161005610 6 160584578 EFO_0000378 Coronary artery disease coronary artery disease European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323 GCST003116 38.30102999566398 GCST003116 26343387 drug Medium Ed Mountjoy Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117660bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 161005610 6 160584578 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 10.522878745280337 GCST005196 29212778 drug Medium Ed Mountjoy Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117194bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 161006077 6 160585045 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 10.522878745280337 GCST005196 29212778 drug Medium Ed Mountjoy Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (117194bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 6 161006077 6 160585045 EFO_0000378 Coronary artery disease coronary artery disease African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630 GCST003117 26.045757490560675 GCST003117 26343387 drug Medium Ed Mountjoy Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 6 161010118 6 160589086 EFO_0000612 Myocardial infarction myocardial infarction African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630 GCST003117 26.045757490560675 GCST003117 26343387 drug Medium Ed Mountjoy Plasminogen activator drug RETEPLASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 6 161010118 6 160589086 EFO_0000612 Myocardial infarction myocardial infarction European, NR=63731 GCST004787 48.69897000433602 GCST004787 28714975 drug Medium Ed Mountjoy Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (113152bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 6 161010118 6 160589086 EFO_0000378 Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) coronary artery disease NR=123388 GCST002287 11.698970004336019 GCST002287 24262325 drug Medium Ed Mountjoy Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000712 and targets the gene ENSG00000122194 at this locus (113152bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 6 161010118 6 160589086 EFO_0000712 Coronary artery disease or ischemic stroke cerebrovascular accident European=360420 27.967377210462196 NEALE2_6150_1 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Plasminogen activator drug RETEPLASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 6 161010118 6 160589086 EFO_0000612 Heart attack | vascular/heart problems diagnosed by doctor myocardial infarction European=360420 27.967377210462196 NEALE2_6150_1 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (113152bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 6 161010118 6 160589086 EFO_0000612 Heart attack | vascular/heart problems diagnosed by doctor myocardial infarction NR=123388 GCST002287 11.698970004336019 GCST002287 24262325 drug Low Ed Mountjoy Plasminogen activator drug RETEPLASE is Phase II for the indiciation EFO_0000712 and targets the gene ENSG00000122194 at this locus (113152bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 6 161010118 6 160589086 EFO_0000712 Coronary artery disease or ischemic stroke cerebrovascular accident NR=123388 GCST002287 11.698970004336019 GCST002287 24262325 drug Medium Ed Mountjoy Plasminogen activator drug DESMOTEPLASE is Phase III for the indiciation EFO_0000712 and targets the gene ENSG00000122194 at this locus (113152bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 6 161010118 6 160589086 EFO_0000712 Coronary artery disease or ischemic stroke cerebrovascular accident NR=547261 GCST005195 76.85387196432177 GCST005195 29212778 drug Medium Ed Mountjoy Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (110257bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 161013013 6 160591981 EFO_0000378 Coronary artery disease coronary artery disease European=388806 10.1038/s41588-018-0184-y 25.059981844992336 SAIGE_411_2 drug Medium Ed Mountjoy Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 161013013 6 160591981 EFO_0000612 Myocardial infarction myocardial infarction European=361141 17.90926593057954 NEALE2_20002_1075 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C T 6 161013013 6 160591981 EFO_0000612 Heart attack/myocardial infarction | non-cancer illness code, self-reported myocardial infarction European=361141 17.90926593057954 NEALE2_20002_1075 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 161013013 6 160591981 EFO_0000612 Heart attack/myocardial infarction | non-cancer illness code, self-reported myocardial infarction European=408458 10.1038/s41588-018-0184-y 42.36957212497498 SAIGE_411 drug Medium Ed Mountjoy Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (110257bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 161013013 6 160591981 EFO_0000378 Ischemic heart disease coronary artery disease European=388806 10.1038/s41588-018-0184-y 25.059981844992336 SAIGE_411_2 drug Medium Ed Mountjoy Plasminogen activator drug UROKINASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (110257bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 161013013 6 160591981 EFO_0000612 Myocardial infarction myocardial infarction NR=296525 GCST005194 9.409046764812015 GCST005194 29212778 drug Medium Ed Mountjoy Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (105907bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 6 161017363 6 160596331 EFO_0000378 Coronary artery disease coronary artery disease NR=250736 GCST005196 7.698970004336019 GCST005196 29212778 drug High Ed Mountjoy Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (35407bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 161087863 6 160666831 EFO_0000378 Coronary artery disease coronary artery disease African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630 GCST003117 23.69897000433602 GCST003117 26343387 drug High Ed Mountjoy Plasminogen activator drug TENECTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (15127bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A C 6 161108144 6 160687112 EFO_0000612 Myocardial infarction myocardial infarction African American or Afro-Caribbean=2908|Hispanic or Latin American=3615|South Asian=23156|Greater Middle Eastern (Middle Eastern / North African / Persian)=754|East Asian=9396|European=126630 GCST003117 23.69897000433602 GCST003117 26343387 drug Medium Ed Mountjoy Plasminogen activator drug RETEPLASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (15127bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A C 6 161108144 6 160687112 EFO_0000612 Myocardial infarction myocardial infarction European=360420 17.657683931817257 NEALE2_6150_1 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Plasminogen activator drug ALTEPLASE is Phase IV for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (11570bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 161111700 6 160690668 EFO_0000612 Heart attack | vascular/heart problems diagnosed by doctor myocardial infarction European=360420 17.657683931817257 NEALE2_6150_1 http://www.nealelab.is/uk-biobank drug Medium Ed Mountjoy Plasminogen activator drug STREPTOKINASE is Phase III for the indiciation EFO_0000612 and targets the gene ENSG00000122194 at this locus (11570bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C 6 161111700 6 160690668 EFO_0000612 Heart attack | vascular/heart problems diagnosed by doctor myocardial infarction NR=250736 GCST005196 91.30102999566398 GCST005196 29212778 drug High Ed Mountjoy Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (11570bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 161111700 6 160690668 EFO_0000378 Coronary artery disease coronary artery disease NR=296525 GCST005194 96.70114692359029 GCST005194 29212778 drug High Ed Mountjoy Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (11570bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 6 161111700 6 160690668 EFO_0000378 Coronary artery disease coronary artery disease European=141217|African American or Afro-Caribbean=3139|Hispanic or Latin American=4095|South Asian=25557|Greater Middle Eastern (Middle Eastern / North African / Persian)=2268|East Asian=11323 GCST003116 31.69897000433602 GCST003116 26343387 drug High Ed Mountjoy Plasminogen inhibitor drug TRANEXAMIC ACID is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000122194 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000122194 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 6 161123451 6 160702419 EFO_0000378 Coronary artery disease coronary artery disease European=361141 8.507692295087963 NEALE2_20002_1111 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-6 inhibitor drug SIRUKUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000136244 at this locus (11870bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000136244 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A AT 7 22783490 7 22743871 EFO_0000270 Asthma | non-cancer illness code, self-reported asthma European=360527 9.229103089046006 NEALE2_6152_8 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Interleukin-6 inhibitor drug SIRUKUMAB is Phase II for the indiciation EFO_0000270 and targets the gene ENSG00000136244 at this locus (11870bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000136244 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A AT 7 22783490 7 22743871 EFO_0000270 Asthma | blood clot, dvt, bronchitis, emphysema, asthma, rhinitis, eczema, allergy diagnosed by doctor asthma East Asian=191764 GCST007847 11.301029995663981 GCST007847 30718926 drug Low Ed Mountjoy Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (377278bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000015520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 7 44174857 7 44135258 EFO_0001360 Type 2 diabetes type II diabetes mellitus European, NR=735838 GCST007545 7.698970004336019 GCST007545 30525989 drug Low Ed Mountjoy Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000015520 at this locus (335997bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000015520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 7 44216137 7 44176538 EFO_0000378 Coronary artery disease and triglyceride levels (multivariate analysis) coronary artery disease East Asian=7696 GCST001965 9.522878745280337 GCST001965_2 23575436 drug Low Ed Mountjoy Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (323067bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000015520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 7 44229068 7 44189469 EFO_0001360 Glycemic traits [2-hPG] type II diabetes mellitus East Asian=7696 GCST001965 17.30102999566398 GCST001965_3 23575436 drug Low Ed Mountjoy Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (323067bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000015520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 7 44229068 7 44189469 EFO_0001360 Glycemic traits [FPG] type II diabetes mellitus East Asian=7696 GCST001965 8.522878745280337 GCST001965 23575436 drug Low Ed Mountjoy Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (323067bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000015520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 7 44229068 7 44189469 EFO_0001360 Glycemic traits [1-hPG] type II diabetes mellitus European=10564 GCST001436 12.397940008672037 GCST001436 22399527 drug Low Ed Mountjoy Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000015520 at this locus (320918bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000015520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G T 7 44231216 7 44191617 EFO_0000195 Metabolic syndrome [GLU] metabolic syndrome European=655666|South Asian=3650 GCST006867 8.397940008672037 GCST006867 30054458 drug Low Ed Mountjoy Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0001360 and targets the gene ENSG00000015520 at this locus (303306bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000015520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 7 44248828 7 44209229 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=10564 GCST001436 10.045757490560675 GCST001436 22399527 drug Low Ed Mountjoy Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000015520 at this locus (292263bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000015520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 7 44259871 7 44220272 EFO_0000195 Metabolic syndrome [GLU] metabolic syndrome European=10564 GCST001436 10.045757490560675 GCST001436 22399527 drug Low Ed Mountjoy Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000195 and targets the gene ENSG00000015520 at this locus (292263bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000015520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 7 44259871 7 44220272 EFO_0000195 Metabolic syndrome [GLU] metabolic syndrome European=459000 GCST007072 7.301029995663981 GCST007072 30595370 drug High Ed Mountjoy Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000015520 at this locus (1072bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000015520 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 7 44581986 7 44542387 EFO_0000319 Cardiovascular disease cardiovascular system disease European=459000 GCST007072 7.301029995663981 GCST007072 30595370 drug Low Ed Mountjoy Cyclophilin A modulator drug CYCLOSPORINE is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000196262 at this locus (254293bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196262 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 7 44581986 7 44542387 EFO_0000319 Cardiovascular disease cardiovascular system disease European=361141 14.154901959985743 NEALE2_20002_1473 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000015520 at this locus (3637bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000015520 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C G 7 44584551 7 44544952 HP_0003124 High cholesterol | non-cancer illness code, self-reported Hypercholesterolemia European=26405 GCST000964 9.097453220686008 GCST000964 21297633 drug Medium Ed Mountjoy Cyclophilin A modulator drug CYCLOSPORINE is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000196262 at this locus (224051bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000196262 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 7 44612229 7 44572630 EFO_0000729 Ulcerative colitis ulcerative colitis NR=296525 GCST005194 7.438898616350944 GCST005194 29212778 drug Low Ed Mountjoy Niemann-Pick C1-like protein 1 inhibitor drug EZETIMIBE is Phase IV for the indiciation EFO_0000378 and targets the gene ENSG00000015520 at this locus (497064bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000015520 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 7 45077978 7 45038379 EFO_0000378 Coronary artery disease coronary artery disease NR=15094 GCST006480 11.154901959985743 GCST006480_2 30152087 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 7 54916280 7 54848587 EFO_0000519 Glioblastoma (age-stratified) [Below median age-at-diagnosis] glioblastoma multiforme NR=15094 GCST006480 15.397940008672037 GCST006480 30152087 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 7 54916280 7 54848587 EFO_0000519 Glioblastoma (age-stratified) [Above median age-at-diagnosis] glioblastoma multiforme European=24381 GCST004349 33.30102999566398 GCST004349 28346443 drug Medium Ed Mountjoy Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 7 54916280 7 54848587 EFO_0000519 Glioblastoma glioblastoma multiforme NR=15094 GCST006480 11.154901959985743 GCST006480_2 30152087 drug Medium Ed Mountjoy Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 7 54916280 7 54848587 EFO_0000519 Glioblastoma (age-stratified) [Below median age-at-diagnosis] glioblastoma multiforme European=9218 GCST003220 10.221848749616356 GCST003220 26424050 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 7 54916280 7 54848587 EFO_0000519 Glioblastoma glioblastoma multiforme European=24381 GCST004349 33.30102999566398 GCST004349 28346443 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 7 54916280 7 54848587 EFO_0000519 Glioblastoma glioblastoma multiforme NR=15094 GCST006480 11.698970004336019 GCST006480_3 30152087 drug Medium Ed Mountjoy Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 7 54916280 7 54848587 EFO_0000519 Glioblastoma (age-stratified) [Median age-at-diagnosis] glioblastoma multiforme European=24381 GCST004349 33.30102999566398 GCST004349 28346443 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 7 54916280 7 54848587 EFO_0000326 Glioblastoma central nervous system cancer European=24009 GCST004348 7.698970004336019 GCST004348 28346443 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 7 54916280 7 54848587 EFO_0000326 Non-glioblastoma glioma central nervous system cancer NR=15094 GCST006480 15.397940008672037 GCST006480 30152087 drug Medium Ed Mountjoy Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 7 54916280 7 54848587 EFO_0000519 Glioblastoma (age-stratified) [Above median age-at-diagnosis] glioblastoma multiforme NR=15094 GCST006480 11.698970004336019 GCST006480_3 30152087 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug LAPATINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 7 54916280 7 54848587 EFO_0000519 Glioblastoma (age-stratified) [Median age-at-diagnosis] glioblastoma multiforme European=11582 GCST003228 10.698970004336019 GCST003228 26424050 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 7 54916280 7 54848587 EFO_0000326 Glioma central nervous system cancer European=30659 GCST004347 26.397940008672037 GCST004347 28346443 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug MAB-425 is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G T 7 54916280 7 54848587 EFO_0000326 Glioma central nervous system cancer European=9218 GCST003220 10.221848749616356 GCST003220 26424050 drug Medium Ed Mountjoy Epidermal growth factor receptor erbB1 binding agent drug DEPATUXIZUMAB MAFODOTIN is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (170431bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G T 7 54916280 7 54848587 EFO_0000519 Glioblastoma glioblastoma multiforme NR=15094 GCST006480 8.698970004336019 GCST006480_3 30152087 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 7 55134872 7 55067179 EFO_0000519 Glioblastoma (age-stratified) [Median age-at-diagnosis] glioblastoma multiforme European=24381 GCST004349 22.30102999566398 GCST004349 28346443 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 7 55134872 7 55067179 EFO_0000519 Glioblastoma glioblastoma multiforme European=24381 GCST004349 22.30102999566398 GCST004349 28346443 drug Medium Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 7 55134872 7 55067179 EFO_0000519 Glioblastoma glioblastoma multiforme NR=15094 GCST006480 10.698970004336019 GCST006480 30152087 drug Medium Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 7 55134872 7 55067179 EFO_0000519 Glioblastoma (age-stratified) [Above median age-at-diagnosis] glioblastoma multiforme NR=15094 GCST006480 10.698970004336019 GCST006480 30152087 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 7 55134872 7 55067179 EFO_0000519 Glioblastoma (age-stratified) [Above median age-at-diagnosis] glioblastoma multiforme European=24381 GCST004349 22.30102999566398 GCST004349 28346443 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000326 and targets the gene ENSG00000146648 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 7 55134872 7 55067179 EFO_0000326 Glioblastoma central nervous system cancer NR=15094 GCST006480 8.698970004336019 GCST006480_3 30152087 drug Medium Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 7 55134872 7 55067179 EFO_0000519 Glioblastoma (age-stratified) [Median age-at-diagnosis] glioblastoma multiforme NR=15094 GCST006480 9.698970004336019 GCST006480 30152087 drug Low Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug GEFITINIB is Phase II for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 7 55159349 7 55091656 EFO_0000519 Glioblastoma (age-stratified) [Above median age-at-diagnosis] glioblastoma multiforme NR=15094 GCST006480 9.698970004336019 GCST006480 30152087 drug Medium Ed Mountjoy Epidermal growth factor receptor erbB1 inhibitor drug NIMOTUZUMAB is Phase III for the indiciation EFO_0000519 and targets the gene ENSG00000146648 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000146648 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 7 55159349 7 55091656 EFO_0000519 Glioblastoma (age-stratified) [Above median age-at-diagnosis] glioblastoma multiforme NR=361315|European=446238 GCST007342 13.045757490560675 GCST007342 30718901 drug Low Ed Mountjoy Voltage-gated calcium channel modulator drug PREGABALIN is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000153956 at this locus (381311bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000153956 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 7 82454404 7 82825088 EFO_0003761 Depression unipolar depression European=6507 GCST004486 7.522878745280337 GCST004486 28540843 drug Low Ed Mountjoy Voltage-gated calcium channel modulator drug PREGABALIN is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000153956 at this locus (395281bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000153956 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T A 7 82468374 7 82839058 EFO_0003761 Major depressive disorder unipolar depression European=6507 GCST004486 7.522878745280337 GCST004486 28540843 drug Low Ed Mountjoy Voltage-gated calcium channel modulator drug PREGABALIN is Phase III for the indiciation EFO_0003761 and targets the gene ENSG00000153956 at this locus (395281bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000153956 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G A 7 82468374 7 82839058 EFO_0003761 Major depressive disorder unipolar depression Other=1097|NR=150064 GCST003048 10.154901959985743 GCST003048 26198764 drug Medium Ed Mountjoy Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198822 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 7 86427626 7 86798310 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 9.397940008672037 GCST007201 30285260 drug Medium Ed Mountjoy Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198822 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 7 86427626 7 86798310 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 9.522878745280337 GCST007201_2 30285260 drug Medium Ed Mountjoy Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198822 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 7 86427626 7 86798310 EFO_0000692 Schizophrenia [EA] schizophrenia European=105318 GCST006803 13.397940008672037 GCST006803 29483656 drug Medium Ed Mountjoy Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198822 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 7 86427626 7 86798310 EFO_0000692 Schizophrenia schizophrenia European=82315|East Asian=5219 GCST002539 9.522878745280337 GCST002539 25056061 drug Medium Ed Mountjoy Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198822 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 7 86427626 7 86798310 EFO_0000692 Schizophrenia schizophrenia European=13574|NR=2380 GCST004521 10.0 GCST004521 28540026 drug Medium Ed Mountjoy Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198822 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 7 86427626 7 86798310 EFO_0000692 Autism spectrum disorder or schizophrenia schizophrenia East Asian=26026|European=82315 GCST004946 9.522878745280337 GCST004946 28991256 drug Medium Ed Mountjoy Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198822 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 7 86427626 7 86798310 EFO_0000692 Schizophrenia schizophrenia East Asian=45528 GCST007201 7.522878745280337 GCST007201 30285260 drug Low Ed Mountjoy Metabotropic glutamate receptor 3 agonist drug POMAGLUMETAD METHIONIL is Phase III for the indiciation EFO_0000692 and targets the gene ENSG00000198822 at this locus (305241bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000198822 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A T 7 86799441 7 87170125 EFO_0000692 Schizophrenia schizophrenia African unspecified=224|European=367 GCST005028 8.0 GCST005028_2 29064472 drug Medium Ed Mountjoy Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000087085 at this locus (200123bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000087085 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 7 100287495 7 100689872 EFO_0000692 Pursuit maintenance gain in psychotic disorders [African] schizophrenia African unspecified=224|European=367 GCST005028 8.0 GCST005028_2 29064472 drug Low Ed Mountjoy Acetylcholinesterase inhibitor drug GALANTAMINE is Phase II for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (200123bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000087085 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 7 100287495 7 100689872 EFO_0005411 Pursuit maintenance gain in psychotic disorders [African] schizoaffective disorder African unspecified=224|European=367 GCST005028 8.0 GCST005028_2 29064472 drug Medium Ed Mountjoy Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000289 and targets the gene ENSG00000087085 at this locus (200123bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000087085 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 7 100287495 7 100689872 EFO_0000289 Pursuit maintenance gain in psychotic disorders [African] bipolar disorder African unspecified=224|European=367 GCST005028 8.0 GCST005028_2 29064472 drug Medium Ed Mountjoy Acetylcholinesterase inhibitor drug DONEPEZIL is Phase IV for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (200123bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000087085 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 7 100287495 7 100689872 EFO_0005411 Pursuit maintenance gain in psychotic disorders [African] schizoaffective disorder African unspecified=224|European=367 GCST005028 8.0 GCST005028_2 29064472 drug Low Ed Mountjoy Acetylcholinesterase inhibitor drug GALANTAMINE is Phase II for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (188633bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000087085 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A 7 100298984 7 100701361 EFO_0005411 Pursuit maintenance gain in psychotic disorders [African] schizoaffective disorder African unspecified=224|European=367 GCST005028 8.0 GCST005028_2 29064472 drug Medium Ed Mountjoy Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000692 and targets the gene ENSG00000087085 at this locus (188633bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000087085 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 7 100298984 7 100701361 EFO_0000692 Pursuit maintenance gain in psychotic disorders [African] schizophrenia African unspecified=224|European=367 GCST005028 8.0 GCST005028_2 29064472 drug Medium Ed Mountjoy Acetylcholinesterase inhibitor drug GALANTAMINE is Phase IV for the indiciation EFO_0000289 and targets the gene ENSG00000087085 at this locus (188633bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000087085 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 7 100298984 7 100701361 EFO_0000289 Pursuit maintenance gain in psychotic disorders [African] bipolar disorder African unspecified=224|European=367 GCST005028 8.0 GCST005028_2 29064472 drug Medium Ed Mountjoy Acetylcholinesterase inhibitor drug DONEPEZIL is Phase IV for the indiciation EFO_0005411 and targets the gene ENSG00000087085 at this locus (188633bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000087085 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G A 7 100298984 7 100701361 EFO_0005411 Pursuit maintenance gain in psychotic disorders [African] schizoaffective disorder European=139274 GCST004988 15.979638717352293 GCST004988 29059683 drug Low Ed Mountjoy Serine/threonine-protein kinase B-raf inhibitor drug SORAFENIB is Phase III for the indiciation EFO_0000305 and targets the gene ENSG00000157764 at this locus (476824bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000157764 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III A G 7 139942304 7 140242504 EFO_0000305 Breast cancer breast carcinoma European=1030836 GCST006414 10.674484336636851 GCST006414 30061737 drug High Ed Mountjoy HERG blocker drug AMIODARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000055118 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 7 150661409 7 150964321 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 10.045757490560675 GCST006061_3 29892015 drug Low Ed Mountjoy HERG blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000055118 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 7 150661409 7 150964321 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 9.154901959985743 GCST006061 29892015 drug High Ed Mountjoy HERG blocker drug AMIODARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000055118 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 7 150661409 7 150964321 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 9.154901959985743 GCST006061 29892015 drug Low Ed Mountjoy HERG blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000055118 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 7 150661409 7 150964321 EFO_0000275 Atrial fibrillation atrial fibrillation European=1030836 GCST006414 10.674484336636851 GCST006414 30061737 drug Low Ed Mountjoy HERG blocker drug AZD7009 is Phase II for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000055118 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 7 150661409 7 150964321 EFO_0000275 Atrial fibrillation atrial fibrillation European=537409|East Asian=36792|African American or Afro-Caribbean=8967|Hispanic or Latin American=5022 GCST006061 10.045757490560675 GCST006061_3 29892015 drug High Ed Mountjoy HERG blocker drug AMIODARONE is Phase IV for the indiciation EFO_0000275 and targets the gene ENSG00000055118 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000055118 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 7 150661409 7 150964321 EFO_0000275 Atrial fibrillation [EA] atrial fibrillation European=459000 GCST007072 48.69897000433602 GCST007072 30595370 drug High Ed Mountjoy HERG blocker drug SOTALOL is Phase IV for the indiciation EFO_0000319 and targets the gene ENSG00000055118 at this locus (14774bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000055118 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 7 150690176 7 150993088 EFO_0000319 Cardiovascular disease cardiovascular system disease European=241704 GCST004483 8.0 GCST004483 27363682 drug Low Ed Mountjoy Cyclin-dependent kinase 5 inhibitor drug DINACICLIB is Phase II for the indiciation EFO_0001378 and targets the gene ENSG00000164885 at this locus (195958bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000164885 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G 7 150950940 7 151253854 EFO_0001378 Multiple myeloma multiple myeloma European=33394 GCST005527 7.481235531320022 GCST005527 23143594 drug Low Ed Mountjoy Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000096968 at this locus (12463bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000096968 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 9 4971927 9 4971927 EFO_0000676 Psoriasis psoriasis European=86475 GCST005537 42.30102999566398 GCST005537 26974007 drug Low Ed Mountjoy Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase II for the indiciation EFO_0000676 and targets the gene ENSG00000096968 at this locus (2788bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000096968 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C 9 4981602 9 4981602 EFO_0000676 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] psoriasis East Asian=5057|European=10995 GCST003622 16.69897000433602 GCST003622 27399966 drug Medium Ed Mountjoy Tyrosine-protein kinase JAK2 inhibitor drug BARICITINIB is Phase III for the indiciation EFO_0002690 and targets the gene ENSG00000096968 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000096968 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 9 4984530 9 4984530 EFO_0002690 Systemic lupus erythematosus systemic lupus erythematosus East Asian=5057|European=10995 GCST003622 13.397940008672037 GCST003622_2 27399966 drug Medium Ed Mountjoy Tyrosine-protein kinase JAK2 inhibitor drug BARICITINIB is Phase III for the indiciation EFO_0002690 and targets the gene ENSG00000096968 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000096968 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III C G 9 4984530 9 4984530 EFO_0002690 Systemic lupus erythematosus [Chinese] systemic lupus erythematosus European=401535 10.1038/s41588-018-0184-y 16.707743928643524 SAIGE_200_1 drug High Ed Mountjoy Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase IV for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000096968 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 9 5049092 9 5049092 EFO_0002429 Polycythemia vera polycythemia vera European=401535 10.1038/s41588-018-0184-y 16.707743928643524 SAIGE_200_1 drug Low Ed Mountjoy Tyrosine-protein kinase JAK2 inhibitor drug LESTAURTINIB is Phase II for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000096968 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 9 5049092 9 5049092 EFO_0002429 Polycythemia vera polycythemia vera European=361141 19.559482903933304 NEALE2_20002_1438 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase IV for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000096968 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T G 9 5049092 9 5049092 EFO_0002429 Polycythaemia vera | non-cancer illness code, self-reported polycythemia vera European=361141 19.559482903933304 NEALE2_20002_1438 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Tyrosine-protein kinase JAK2 inhibitor drug LESTAURTINIB is Phase II for the indiciation EFO_0002429 and targets the gene ENSG00000096968 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000096968 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 9 5049092 9 5049092 EFO_0002429 Polycythaemia vera | non-cancer illness code, self-reported polycythemia vera European=3198 GCST002840 10.0 GCST002840 25849990 drug Low Ed Mountjoy Tyrosine-protein kinase JAK2 inhibitor drug PACRITINIB is Phase II for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000096968 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T G 9 5063296 9 5063296 EFO_0004251 Myeloproliferative neoplasms myeloproliferative disorder European=3198 GCST002840 10.0 GCST002840 25849990 drug Medium Ed Mountjoy Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase III for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000096968 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T G 9 5063296 9 5063296 EFO_0004251 Myeloproliferative neoplasms myeloproliferative disorder European=3323 GCST000357 19.397940008672037 GCST000357 19287384 drug Medium Ed Mountjoy Tyrosine-protein kinase JAK2 inhibitor drug RUXOLITINIB is Phase III for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000096968 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III G C 9 5070831 9 5070831 EFO_0004251 Myeloproliferative neoplasms myeloproliferative disorder European=3323 GCST000357 19.397940008672037 GCST000357 19287384 drug Low Ed Mountjoy Tyrosine-protein kinase JAK2 inhibitor drug PACRITINIB is Phase II for the indiciation EFO_0004251 and targets the gene ENSG00000096968 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000096968 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G C 9 5070831 9 5070831 EFO_0004251 Myeloproliferative neoplasms myeloproliferative disorder European=86475 GCST005537 8.221848749616356 GCST005537 26974007 drug High Ed Mountjoy Sigma opioid receptor agonist drug DEXTROMETHORPHAN is Phase IV for the indiciation EFO_0000729 and targets the gene ENSG00000147955 at this locus (72455bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000147955 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 9 34710260 9 34710263 EFO_0000729 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] ulcerative colitis European=86475 GCST005537 8.221848749616356 GCST005537 26974007 drug High Ed Mountjoy Sigma opioid receptor agonist drug DEXTROMETHORPHAN is Phase IV for the indiciation EFO_0000384 and targets the gene ENSG00000147955 at this locus (72455bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000147955 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV A G 9 34710260 9 34710263 EFO_0000384 Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy) [subset analysis] Crohn's disease European=116538 GCST007564 10.096910013008056 GCST007564 29785011 drug Low Ed Mountjoy Sigma opioid receptor agonist drug DEXTROMETHORPHAN is Phase IV for the indiciation EFO_0000270 and targets the gene ENSG00000147955 at this locus (251638bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000147955 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C G 9 34889444 9 34889447 EFO_0000270 Asthma or allergic disease (pleiotropy) asthma European=361141 14.698970004336019 NEALE2_20002_1473 http://www.nealelab.is/uk-biobank drug High Ed Mountjoy ATP-binding cassette sub-family A member 1 inhibitor drug PROBUCOL is Phase IV for the indiciation HP_0003124 and targets the gene ENSG00000165029 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000165029 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C 9 107664301 9 104902020 HP_0003124 High cholesterol | non-cancer illness code, self-reported Hypercholesterolemia European=408878 10.1038/s41588-018-0184-y 7.73754891026957 SAIGE_272_1 drug High Ed Mountjoy ATP-binding cassette sub-family A member 1 inhibitor drug PROBUCOL is Phase IV for the indiciation EFO_0003774 and targets the gene ENSG00000165029 at this locus (0bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000165029 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV G C 9 107665978 9 104903697 EFO_0003774 Hyperlipidemia hyperlipidemia European=38053 GCST000987 10.397940008672037 GCST000987 21383967 drug High Ed Mountjoy Complement C5 inhibitor drug ECULIZUMAB is Phase IV for the indiciation EFO_0000540 and targets the gene ENSG00000106804 at this locus (74113bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000106804 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV C T 9 123640500 9 120878222 EFO_0000540 Celiac disease or Rheumatoid arthritis immune system disease European=314072 7.955550400347374 NEALE2_20107_3 http://www.nealelab.is/uk-biobank drug Low Ed Mountjoy Tyrosine-protein kinase ABL inhibitor drug IMATINIB is Phase II for the indiciation EFO_0001071 and targets the gene ENSG00000097007 at this locus (238206bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000097007 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G GT 9 133351128 9 130475741 EFO_0001071 Lung cancer | illnesses of father lung carcinoma European=1125 GCST000250 10.301029995663981 GCST000250 18849991 drug Low Ed Mountjoy Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (252890bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169083 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A G X 66510984 X 67291142 EFO_0004191 Male-pattern baldness androgenetic alopecia European=1198 GCST001297 21.522878745280337 GCST001297 22032556 drug Low Ed Mountjoy Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (200857bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169083 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T X 66563018 X 67343176 EFO_0004191 Male-pattern baldness androgenetic alopecia European=12806 GCST001548 90.69897000433602 GCST001548 22693459 drug Low Ed Mountjoy Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (200857bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169083 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T X 66563018 X 67343176 EFO_0004191 Male-pattern baldness androgenetic alopecia European=13560 GCST001148 8.0 GCST001148 21743467 drug Medium Ed Mountjoy Androgen Receptor antagonist drug CYPROTERONE ACETATE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169083 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C X 67021550 X 67801708 EFO_0001663 Prostate cancer prostate carcinoma European=13560 GCST001148 8.0 GCST001148 21743467 drug High Ed Mountjoy Androgen Receptor antagonist drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169083 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C X 67021550 X 67801708 EFO_0001663 Prostate cancer prostate carcinoma European=13560 GCST001148 8.0 GCST001148 21743467 drug Low Ed Mountjoy Androgen Receptor agonist drug TESTOSTERONE ENANTHATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169083 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C X 67021550 X 67801708 EFO_0001663 Prostate cancer prostate carcinoma European=140254 GCST006085 9.0 GCST006085 29892016 drug High Ed Mountjoy Androgen Receptor antagonist drug ABIRATERONE is Phase IV for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169083 High Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_IV Ed Mountjoy drug|ChEMBL|ChEMBL_IV T C X 67021550 X 67801708 EFO_0001663 Prostate cancer prostate carcinoma European=140254 GCST006085 9.0 GCST006085 29892016 drug Low Ed Mountjoy Androgen Receptor agonist drug TESTOSTERONE ENANTHATE is Phase II for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169083 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II T C X 67021550 X 67801708 EFO_0001663 Prostate cancer prostate carcinoma European=140254 GCST006085 9.0 GCST006085 29892016 drug Medium Ed Mountjoy Androgen Receptor antagonist drug CYPROTERONE ACETATE is Phase III for the indiciation EFO_0001663 and targets the gene ENSG00000169083 at this locus (71090bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169083 Medium Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_III Ed Mountjoy drug|ChEMBL|ChEMBL_III T C X 67021550 X 67801708 EFO_0001663 Prostate cancer prostate carcinoma European=43590 GCST005116 34.52287874528034 GCST005116 29146897 drug Low Ed Mountjoy Androgen Receptor antagonist drug CB-03-01 is Phase II for the indiciation EFO_0004191 and targets the gene ENSG00000169083 at this locus (413341bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000169083 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II G A X 67363801 X 68143959 EFO_0004191 Male-pattern baldness androgenetic alopecia European=16753 GCST003097 8.0 GCST003097 26301688 drug Low Ed Mountjoy CD40 ligand inhibitor drug DAPIROLIZUMAB PEGOL is Phase II for the indiciation EFO_0002690 and targets the gene ENSG00000102245 at this locus (64575bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000102245 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II A C X 135665778 X 136583619 EFO_0002690 Pediatric autoimmune diseases systemic lupus erythematosus European=258962 GCST003390 12.154901959985743 GCST003390 26908601 drug Low Ed Mountjoy Coagulation factor VIII inhibitor drug DROTRECOGIN ALFA (ACTIVATED) is Phase II for the indiciation EFO_0003827 and targets the gene ENSG00000185010 at this locus (23583bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000185010 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T X 154278797 X 155050522 EFO_0003827 Thrombosis pulmonary embolism European=258962 GCST003390 12.154901959985743 GCST003390 26908601 drug Low Ed Mountjoy Coagulation factor VIII inhibitor drug TB-402 is Phase II for the indiciation EFO_0004286 and targets the gene ENSG00000185010 at this locus (23583bp away). ChEMBL - Open Targets Evidence 19.06 ENSG00000185010 Low Gold-standard derived from drug-indication pairs in ChEMBL 2019-07-29 Ed Mountjoy ChEMBL_II Ed Mountjoy drug|ChEMBL|ChEMBL_II C T X 154278797 X 155050522 EFO_0004286 Thrombosis venous thromboembolism European=407701 10.1038/s41588-018-0184-y 8.20690839982342 SAIGE_250_2 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000183049 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 10 12250620 10 12208621 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 26.096910013008056 GCST007847 30718926 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000183049 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 10 12302607 10 12260608 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 16.69897000433602 GCST006867 30054458 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000183049 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 12307894 10 12265895 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=70127 GCST005413 9.42712839779952 GCST005413 29358691 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000183049 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 12307894 10 12265895 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 13.397940008672037 GCST007077 30595370 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000183049 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 12307894 10 12265895 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=41646 GCST003400 12.0 GCST003400_2 26818947 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000183049 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 12307894 10 12265895 EFO_0001360 Type 2 diabetes [Japanese] type II diabetes mellitus East Asian=3712 GCST001666 8.154901959985743 GCST001666 22961080 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000183049 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 12307894 10 12265895 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 8.522878745280337 GCST002352 24509480 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000183049 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 12307894 10 12265895 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 28.522878745280337 GCST004894 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000183049 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 12307894 10 12265895 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 9.522878745280337 GCST004894_2 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000183049 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 12307894 10 12265895 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus East Asian=2729 GCST000796 8.0 GCST000796 20862305 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000183049 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 10 12314997 10 12272998 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=10128 GCST000167 10.0 GCST000167 18372903 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000183049 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000183049 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000183049 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 10 12328010 10 12286011 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 8.522878745280337 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000122859 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000122859 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000122859 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 10 71273357 10 69513601 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 8.522878745280337 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000122859 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000122859 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000122859 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 71332301 10 69572545 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=70127 GCST005413 8.073297505817354 GCST005413 29358691 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000122859 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000122859 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000122859 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 10 71465928 10 69706172 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 8.154901959985743 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000122859 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000122859 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000122859 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 10 71469514 10 69709758 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 10.522878745280337 GCST004894_2 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000108175 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 10 80942631 10 79182874 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 9.698970004336019 GCST002352 24509480 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000108175 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 10 80942631 10 79182874 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 19.69897000433602 GCST004894 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000108175 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 10 80942631 10 79182874 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033 GCST005047 9.619788758288394 GCST005047 22885922 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000108175 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 10 80942631 10 79182874 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=41646 GCST003400 7.522878745280337 GCST003400_2 26818947 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000108175 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 10 80943841 10 79184084 EFO_0001360 Type 2 diabetes [Japanese] type II diabetes mellitus European=459000 GCST007077 14.221848749616356 GCST007077 30595370 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000108175 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C G 10 80952826 10 79193069 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 15.025949097207123 SAIGE_250_2 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000108175 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 80954785 10 79195028 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 10.522878745280337 GCST006867 30054458 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000108175 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000108175 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000108175 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 10 80964975 10 79205218 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 10.698970004336019 GCST007077 30595370 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114737777 10 112978018 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=455607 GCST006868 10.397940008672037 GCST006868 30054458 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114737777 10 112978018 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=56799|African American or Afro-Caribbean=3571|East Asian=4735|Hispanic or Latin American=6499 GCST003619 52.221848749616356 GCST003619 27189021 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 10 114754071 10 112994312 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 135.64397414280688 SAIGE_250_2 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 10 114754071 10 112994312 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=41646 GCST003400 22.522878745280337 GCST003400_2 26818947 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 10 114754071 10 112994312 EFO_0001360 Type 2 diabetes [Japanese] type II diabetes mellitus European=4862 GCST000025 48.0 GCST000025_2 17463249 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 10 114754088 10 112994329 EFO_0001360 Type 2 diabetes [DGI+FUSION+WTCCC] type II diabetes mellitus East Asian=191764 GCST007847 48.52287874528034 GCST007847 30718926 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 10 114754088 10 112994329 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=361141 28.732802449449522 NEALE2_20002_1223 http://www.nealelab.is/uk-biobank functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 10 114754784 10 112995025 EFO_0001360 Type 2 diabetes | non-cancer illness code, self-reported type II diabetes mellitus European=4862 GCST000277 15.221848749616356 GCST000277_2 19056611 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [obese] type II diabetes mellitus NR=60647 GCST001550 39.69897000433602 GCST001550 22693455 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [Lean] type II diabetes mellitus European=459000 GCST007077 202.52287874528034 GCST007077 30595370 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033 GCST005047 74.10790539730952 GCST005047 22885922 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=1616 GCST001809 74.04575749056067 GCST001809_3 23300278 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [South Asian, East Asian, Europeans] type II diabetes mellitus European=997 GCST000049 7.301029995663981 GCST000049 17668382 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=1616 GCST001809 34.52287874528034 GCST001809_5 23300278 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [South Asians] type II diabetes mellitus East Asian=26805 GCST002128 14.698970004336019 GCST002128 23945395 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus Hispanic or Latin American=7746 GCST004758 11.0 GCST004758 28254843 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=2128 GCST001759 35.0 GCST001759_2 23209189 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [Indo-European South Asians] type II diabetes mellitus African American or Afro-Caribbean=23827 GCST002560 93.39794000867204 GCST002560 25102180 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=10128 GCST000167 22.522878745280337 GCST000167 18372903 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 347.0 GCST006867 30054458 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=1616 GCST001809 21.221848749616356 GCST001809 23300278 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [All Punjabi] type II diabetes mellitus European=4805|African American or Afro-Caribbean=1683 GCST001326 14.698970004336019 GCST001326 22101970 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=70127 GCST005413 93.92081875395237 GCST005413 29358691 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 183.69897000433602 GCST004894_2 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 74.09691001300806 GCST002352 24509480 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=1376 GCST000478 30.0 GCST000478 19734900 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus NR=60647 GCST001550 20.397940008672037 GCST001550_2 22693455 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [Obese] type II diabetes mellitus Hispanic or Latin American=8214 GCST002317 14.0 GCST002317 24390345 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus African American or Afro-Caribbean=23827 GCST002560 43.30102999566398 GCST002560_2 25102180 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [AA] type II diabetes mellitus European=2931 GCST000028 48.0 GCST000028 17463246 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=47117 GCST000712 50.69897000433602 GCST000712 20581827 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=1022 GCST000383 11.096910013008056 GCST000383 19401414 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=4862 GCST000277 29.045757490560675 GCST000277 19056611 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [non-obese] type II diabetes mellitus European=2335 GCST000024 8.0 GCST000024 17463248 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=1616 GCST001809 18.522878745280337 GCST001809_2 23300278 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [Punjabi Sikhs] type II diabetes mellitus European=1947 GCST007221 10.522878745280337 GCST007221 30470734 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=8686 GCST000027 9.698970004336019 GCST000027 17460697 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=1616 GCST001809 37.69897000433602 GCST001809_4 23300278 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [South Asians, East Asians] type II diabetes mellitus European=1275 GCST000012 33.69897000433602 GCST000012 17293876 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 22.522878745280337 GCST004894_3 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [South Asian] type II diabetes mellitus European=117775 GCST006801 44.15490195998574 GCST006801 26961502 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes [additive model] type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 219.0 GCST004894 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 10 114758349 10 112998590 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=390054 10.1038/s41588-018-0184-y 11.145693958198919 SAIGE_250_23 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A T 10 114798893 10 113039134 EFO_0001360 Type 2 diabetes with ophthalmic manifestations type II diabetes mellitus European=655666|South Asian=3650 GCST006867 12.397940008672037 GCST006867 30054458 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 10 114880342 10 113120583 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 8.397940008672037 GCST007077 30595370 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000148737 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000148737 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000148737 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 10 114880342 10 113120583 EFO_0001360 Type 2 diabetes type II diabetes mellitus Hispanic or Latin American=8658 GCST006145 13.221848749616356 GCST006145 28838971 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000167244 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 11 2161530 11 2140300 EFO_0001360 Type 2 diabetes type II diabetes mellitus African American or Afro-Caribbean=23827 GCST002560 7.522878745280337 GCST002560_2 25102180 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000167244 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 11 2178670 11 2157440 EFO_0001360 Type 2 diabetes [AA] type II diabetes mellitus European=459000 GCST007077 10.154901959985743 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000167244 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 11 2197112 11 2175882 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 12.522878745280337 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000167244 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 11 2197286 11 2176056 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 10.522878745280337 GCST004894 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000167244 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 11 2213166 11 2191936 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=41646 GCST003400 11.0 GCST003400 26818947 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000167244 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 11 2215089 11 2193859 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=41646 GCST003400 7.698970004336019 GCST003400_2 26818947 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000167244 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 11 2215089 11 2193859 EFO_0001360 Type 2 diabetes [Japanese] type II diabetes mellitus East Asian=191764 GCST007847 9.0 GCST007847_2 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000167244 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000167244 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000167244 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 11 2291050 11 2269820 EFO_0001360 Type 2 diabetes [Conditioned] type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 9.896196279044043 SAIGE_250_2 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 11 17408404 11 17386857 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 20.0 GCST004894 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 10.522878745280337 GCST002352 24509480 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007517 16.397940008672037 GCST007517 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 13.096910013008056 GCST004894_2 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus European=298957 GCST007518 21.30102999566398 GCST007518 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=69033 GCST005047 10.494850021680094 GCST005047 22885922 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 19.69897000433602 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=4862 GCST000025 10.301029995663981 GCST000025_2 17463249 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 11 17408630 11 17387083 EFO_0001360 Type 2 diabetes [DGI+FUSION+WTCCC] type II diabetes mellitus European=2335 GCST000024 10.154901959985743 GCST000024_2 17463248 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 11 17409572 11 17388025 EFO_0001360 Type 2 diabetes [DGI+FUSION+WTCCC] type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 21.221848749616356 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 11 17409572 11 17388025 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=2931 GCST000028 10.154901959985743 GCST000028 17463246 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 11 17409572 11 17388025 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 21.69897000433602 GCST007516 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 11 17409572 11 17388025 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=4862 GCST000277 9.0 GCST000277 19056611 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 11 17409572 11 17388025 EFO_0001360 Type 2 diabetes [non-obese] type II diabetes mellitus European=459000 GCST007077 11.698970004336019 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000187486 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000187486 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000187486 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000187486 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 11 17411821 11 17390274 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 9.301029995663981 GCST007516 29632382 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000214530 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C G 11 72408055 11 72697010 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 7.301029995663981 GCST007515 29632382 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000214530 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C G 11 72408055 11 72697010 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007518 8.698970004336019 GCST007518 29632382 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000214530 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C G 11 72408055 11 72697010 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus East Asian=191764 GCST007847 11.0 GCST007847 30718926 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000214530 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 11 72428172 11 72717127 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 16.522878745280337 GCST004894 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000214530 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C A 11 72433098 11 72722053 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 24.045757490560675 GCST006867 30054458 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000214530 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C A 11 72433098 11 72722053 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=47117 GCST000712 22.0 GCST000712 20581827 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000214530 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C A 11 72433098 11 72722053 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 13.0 GCST004894_2 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000214530 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C A 11 72433098 11 72722053 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus European=459000 GCST007077 16.522878745280337 GCST007077 30595370 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000214530 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T A 11 72460762 11 72749717 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 8.269217724333611 SAIGE_250_2 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000214530 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000214530 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000214530 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T A 11 72460762 11 72749717 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033 GCST005047 8.193820026016112 GCST005047 22885922 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000134640 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 11 92668975 11 92935809 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=47117 GCST000712 14.096910013008056 GCST000712 20581827 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000134640 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 11 92673828 11 92940662 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 17.397940008672037 GCST004894 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000134640 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 11 92708710 11 92975544 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 9.154901959985743 SAIGE_250_2 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000134640 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 11 92708710 11 92975544 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 29.221848749616356 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000134640 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 11 92708710 11 92975544 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 15.698970004336019 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000134640 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 11 92708710 11 92975544 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 15.522878745280337 GCST004894_2 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000134640 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000134640 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000134640 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000134640 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 11 92708710 11 92975544 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus European=70127 GCST005413 8.870954940112043 GCST005413 29358691 functional observational Medium Ed Mountjoy The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000118971 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 12 4328521 12 4219355 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 7.522878745280337 GCST004894 28869590 functional observational Medium Ed Mountjoy The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000118971 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 12 4374373 12 4265207 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 7.698970004336019 GCST004894_2 28869590 functional observational Medium Ed Mountjoy The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000118971 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 12 4374373 12 4265207 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 9.65169513695184 SAIGE_250_2 functional observational Medium Ed Mountjoy The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000118971 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 12 4384696 12 4275530 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 30.69897000433602 GCST007077 30595370 functional observational Medium Ed Mountjoy The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000118971 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G T 12 4384844 12 4275678 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 24.4145392704915 SAIGE_250_2 functional observational Medium Ed Mountjoy The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000118971 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G T 12 4384844 12 4275678 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=361141 8.217634170939927 NEALE2_20002_1223 http://www.nealelab.is/uk-biobank functional observational Medium Ed Mountjoy The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000118971 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G T 12 4384844 12 4275678 EFO_0001360 Type 2 diabetes | non-cancer illness code, self-reported type II diabetes mellitus European=655666|South Asian=3650 GCST006867 9.698970004336019 GCST006867 30054458 functional observational Medium Ed Mountjoy The is a likely causal T2D variant (2C) for ENSG00000118971 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000118971 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000118971 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000118971 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 12 4406281 12 4297115 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 7.698970004336019 GCST007516 29632382 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000087448 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 12 27867727 12 27714794 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957 GCST007517 8.698970004336019 GCST007517 29632382 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000087448 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 12 27867727 12 27714794 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007518 7.522878745280337 GCST007518 29632382 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000087448 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 12 27867727 12 27714794 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 11.0 GCST007515 29632382 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000087448 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 12 27867727 12 27714794 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 13.154901959985743 GCST007847 30718926 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000087448 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G T 12 27963507 12 27810574 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 11.045757490560675 GCST004894 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000087448 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 12 27965150 12 27812217 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 16.0 GCST006867 30054458 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000087448 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 12 27965150 12 27812217 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 9.698970004336019 GCST004894_2 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000087448 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000087448 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000087448 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 12 27965150 12 27812217 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus East Asian=191764 GCST007847 8.0 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000075035 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000075035 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 12 108613151 12 108219374 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 7.522878745280337 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000075035 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000075035 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 12 108618630 12 108224853 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 11.221848749616356 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000135100 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 12 121327809 12 120890006 EFO_0001360 Type 2 diabetes type II diabetes mellitus Hispanic or Latin American=2584 GCST001070 7.698970004336019 GCST001070 21573907 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000135100 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 12 121402932 12 120965129 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 11.0 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000135100 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C A 12 121416650 12 120978847 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 9.698970004336019 GCST007516 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000135100 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C A 12 121416650 12 120978847 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=459000 GCST007077 7.698970004336019 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000135100 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 12 121429194 12 120991391 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 13.698970004336019 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000135100 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T G 12 121456616 12 121018813 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 8.522878745280337 GCST004894_2 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000135100 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A T 12 121460686 12 121022883 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus European=47117 GCST000712 7.698970004336019 GCST000712 20581827 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000135100 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A T 12 121460686 12 121022883 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 9.0 GCST004894 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000135100 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000135100 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000135100 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A T 12 121460686 12 121022883 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 8.698970004336019 GCST006867 30054458 functional observational Medium Ed Mountjoy The is a likely causal T2D variant (2C) for ENSG00000150967 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000150967 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000150967 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000150967 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 12 123491572 12 123007025 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 8.0 GCST002352 24509480 functional observational Medium Ed Mountjoy The is a likely causal T2D variant (2C) for ENSG00000150967 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000150967 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000150967 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000150967 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 12 123640853 12 123156306 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 7.698970004336019 GCST006867 30054458 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000205502 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 15 62383155 15 62090956 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 16.69897000433602 GCST007847 30718926 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000205502 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C G 15 62394264 15 62102065 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 8.301029995663981 GCST004894 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000205502 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 15 62396389 15 62104190 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=7541 GCST000787 13.045757490560675 GCST000787 20818381 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000205502 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 15 62396389 15 62104190 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=41646 GCST003400 8.301029995663981 GCST003400_2 26818947 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000205502 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000205502 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000205502 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C G 15 62409070 15 62116871 EFO_0001360 Type 2 diabetes [Japanese] type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 7.627087997029894 SAIGE_250_2 functional observational Medium Ed Mountjoy The is a likely causal T2D variant (2C) for ENSG00000177508 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000177508 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000177508 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000177508 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 16 54490811 16 54456899 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 17.69897000433602 GCST006867 30054458 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000050820 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000050820 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000050820 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A C 16 75243772 16 75209874 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 8.449771646944907 SAIGE_250_2 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000050820 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000050820 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000050820 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 16 75245937 16 75212039 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 13.397940008672037 GCST007077 30595370 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000050820 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000050820 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000050820 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C G 16 75246035 16 75212137 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 9.301029995663981 GCST004894_2 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000050820 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000050820 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000050820 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G T 16 75247245 16 75213347 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus East Asian=26805 GCST002128 12.096910013008056 GCST002128 23945395 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000174326 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000174326 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000174326 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 17 6940393 17 7037074 EFO_0001360 Type 2 diabetes type II diabetes mellitus Hispanic or Latin American=8214 GCST002317 14.301029995663981 GCST002317 24390345 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000174326 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000174326 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000174326 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T G 17 6945087 17 7041768 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=41646 GCST003400 10.096910013008056 GCST003400_2 26818947 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000174326 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000174326 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000174326 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 17 6945483 17 7042164 EFO_0001360 Type 2 diabetes [Japanese] type II diabetes mellitus East Asian=191764 GCST007847 15.221848749616356 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000174326 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000174326 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000174326 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 17 6947453 17 7044134 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 13.301029995663981 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000166603 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 18 57838401 18 60171168 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 9.301029995663981 GCST004894_2 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000166603 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 18 57884750 18 60217517 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 11.522878745280337 GCST004894 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000166603 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 18 57884750 18 60217517 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 11.301029995663981 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000166603 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 18 57884750 18 60217517 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 7.522878745280337 GCST002352 24509480 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000166603 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000166603 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000166603 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000166603 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 18 57884750 18 60217517 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007517 9.698970004336019 GCST007517 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000213996 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 19 19379549 19 19268740 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 14.522878745280337 GCST007516 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000213996 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 19 19379549 19 19268740 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 11.301029995663981 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000213996 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 19 19379549 19 19268740 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007518 12.0 GCST007518 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000213996 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 19 19379549 19 19268740 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=655666|South Asian=3650 GCST006867 11.397940008672037 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000213996 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000213996 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000213996 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 19 19407718 19 19296909 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=56799|African American or Afro-Caribbean=3571|East Asian=4735|Hispanic or Latin American=6499 GCST003619 8.154901959985743 GCST003619 27189021 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000130203 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000130203 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000130203 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 19 45392254 19 44888997 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 7.72584215073632 SAIGE_250_2 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000010310 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 19 46147527 19 45644269 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 12.698970004336019 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000010310 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 19 46150182 19 45646924 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 15.522878745280337 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000010310 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G T 19 46158513 19 45655255 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 18.522878745280337 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000010310 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 19 46166604 19 45663346 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 11.522878745280337 GCST004894 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000010310 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 19 46172278 19 45669020 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 11.154901959985743 GCST007516 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000010310 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C G 19 46181392 19 45678134 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957 GCST007518 11.522878745280337 GCST007518 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000010310 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000010310 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000010310 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000010310 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C G 19 46181392 19 45678134 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957 GCST007518 14.0 GCST007518 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000084734 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 2 27730940 2 27508073 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 24.30102999566398 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000084734 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 2 27730940 2 27508073 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007517 15.0 GCST007517 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000084734 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 2 27730940 2 27508073 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 15.0 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000084734 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 2 27730940 2 27508073 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 17.522878745280337 GCST007516 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000084734 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 2 27730940 2 27508073 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus East Asian=191764 GCST007847 14.397940008672037 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000084734 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 2 27734972 2 27512105 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 16.69897000433602 GCST004894 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000084734 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 2 27741237 2 27518370 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 20.30102999566398 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000084734 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 2 27741237 2 27518370 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 11.072116589669292 SAIGE_250_2 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000084734 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000084734 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000084734 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 2 27742603 2 27519736 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=15000|South East Asian=2034|Asian unspecified=1783 GCST001351 11.0 GCST001351 22158537 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000101076 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G T 20 42946966 20 44318326 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033 GCST005047 7.698970004336019 GCST005047 22885922 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000101076 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 20 42964514 20 44335874 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 9.397940008672037 GCST004894 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000101076 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 20 42989267 20 44360627 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=20019 GCST001213 9.522878745280337 GCST001213 21874001 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000101076 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 20 42989267 20 44360627 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 7.301029995663981 GCST002352 24509480 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000101076 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 20 42989267 20 44360627 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 8.397940008672037 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000101076 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 20 42989777 20 44361137 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 7.698970004336019 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000101076 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 20 43001721 20 44373081 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 7.522878745280337 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000101076 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 20 43042364 20 44413724 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 10.698970004336019 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000101076 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 20 43042364 20 44413724 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 7.301029995663981 GCST007516 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000101076 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000101076 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000101076 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 20 43042364 20 44413724 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 10.522878745280337 GCST007516 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000100344 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000100344 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000100344 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 22 44324727 22 43928847 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957 GCST007518 7.522878745280337 GCST007518 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000100344 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000100344 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000100344 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 22 44324727 22 43928847 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 9.698970004336019 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000100344 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000100344 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000100344 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 22 44324727 22 43928847 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 9.522878745280337 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000100344 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000100344 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000100344 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 22 44377442 22 43981562 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 11.0 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000132170 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 3 12329783 3 12288284 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033 GCST005047 8.795880017344075 GCST005047 22885922 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000132170 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 3 12392272 3 12350773 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007518 16.0 GCST007518 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000132170 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 17.0 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000132170 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 13.698970004336019 GCST004894_2 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000132170 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus European=298957 GCST007517 11.301029995663981 GCST007517 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000132170 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 18.522878745280337 GCST007516 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000132170 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 9.221848749616356 GCST002352 24509480 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000132170 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 18.69897000433602 GCST004894 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000132170 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 3 12393125 3 12351626 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 23.69897000433602 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000132170 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 3 12394840 3 12353341 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=70127 GCST005413 15.357832365595055 GCST005413 29358691 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000132170 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000132170 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000132170 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 3 12396913 3 12355414 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 7.698970004336019 GCST006867 30054458 functional observational Medium Ed Mountjoy The is a likely causal T2D variant (2C) for ENSG00000163581 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000163581 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000163581 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000163581 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 3 170766618 3 171048829 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 14.096910013008056 GCST004894_2 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 4 6270056 4 6268329 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus European=1376 GCST000478 8.0 GCST000478 19734900 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 4 6270056 4 6268329 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 15.0 GCST004894 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 4 6270056 4 6268329 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 8.698970004336019 GCST002352 24509480 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G T 4 6289986 4 6288259 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 18.367542707815275 SAIGE_250_2 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 4 6299914 4 6298187 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007518 16.69897000433602 GCST007518 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 4 6302519 4 6300792 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 20.154901959985743 GCST007516 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 4 6302519 4 6300792 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=459000 GCST007077 17.522878745280337 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 4 6302519 4 6300792 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 24.0 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 4 6302519 4 6300792 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007517 19.154901959985743 GCST007517 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 4 6302519 4 6300792 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 33.221848749616356 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 4 6303022 4 6301295 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=47117 GCST000712 7.522878745280337 GCST000712 20581827 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 4 6303022 4 6301295 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033 GCST005047 8.366531544420413 GCST005047 22885922 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 4 6303955 4 6302228 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 7.698970004336019 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000109501 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000109501 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000109501 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000109501 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T G 4 6333669 4 6331942 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=455607 GCST006868 8.397940008672037 GCST006868 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000154122 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000154122 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000154122 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 5 14751305 5 14751196 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 7.723538195826756 SAIGE_250_2 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000154122 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000154122 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000154122 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 5 14751305 5 14751196 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 12.522878745280337 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000154122 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000154122 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000154122 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 5 14768092 5 14767983 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 8.522878745280337 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000154122 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000154122 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000154122 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 5 14847331 5 14847222 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 14.698970004336019 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000152359 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000152359 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000152359 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 5 75003678 5 75707853 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 7.522878745280337 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000152359 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000152359 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000152359 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 5 75003678 5 75707853 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007517 11.301029995663981 GCST007517 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000152359 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000152359 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000152359 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 5 75003678 5 75707853 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 17.0 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000145730 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 5 102100576 5 102764872 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 8.397940008672037 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000145730 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T A 5 102247916 5 102912212 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 11.85078088734462 SAIGE_250_2 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000145730 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T A 5 102331465 5 102995761 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=455607 GCST006868 13.397940008672037 GCST006868 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000145730 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 5 102338739 5 103003035 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 11.021363051615525 SAIGE_250_2 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000145730 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 5 102338739 5 103003035 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007518 12.397940008672037 GCST007518 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000145730 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 5 102338811 5 103003107 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 14.154901959985743 GCST007516 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000145730 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 5 102338811 5 103003107 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957 GCST007517 11.221848749616356 GCST007517 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000145730 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 5 102338811 5 103003107 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 16.0 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000145730 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 5 102338811 5 103003107 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 15.397940008672037 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000145730 at this locus. There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000145730 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000145730 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000145730 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 5 102422968 5 103087264 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 7.522878745280337 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000124782 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 6 7226959 6 7226726 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 13.0 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000124782 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 6 7231843 6 7231610 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007518 12.698970004336019 GCST007518 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000124782 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 6 7231843 6 7231610 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 16.69897000433602 GCST007516 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000124782 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 6 7231843 6 7231610 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957 GCST007517 11.698970004336019 GCST007517 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000124782 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 6 7231843 6 7231610 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 14.698970004336019 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000124782 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 6 7231843 6 7231610 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 8.844663962534938 SAIGE_250_2 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000124782 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 6 7231843 6 7231610 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 9.0 GCST002352 24509480 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000124782 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 6 7258617 6 7258384 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 10.522878745280337 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000124782 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 6 7281654 6 7281421 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 7.698970004336019 GCST004894 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000124782 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 6 7290437 6 7290204 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 9.0 GCST004894_2 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000124782 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000124782 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000124782 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 6 7290437 6 7290204 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 11.698970004336019 GCST004894_2 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000136267 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 7 14898282 7 14858657 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 12.0 GCST004894 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000136267 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 7 14898282 7 14858657 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 11.698970004336019 GCST007847 30718926 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000136267 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 7 14898282 7 14858657 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 14.698970004336019 GCST006867 30054458 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000136267 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 7 14898282 7 14858657 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033 GCST005047 8.221848749616356 GCST005047 22885922 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000136267 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 7 15053589 7 15013964 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 14.0 GCST007077 30595370 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000136267 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 7 15063926 7 15024301 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 12.492144128304169 SAIGE_250_2 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000136267 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 7 15063926 7 15024301 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 18.522878745280337 GCST006867 30054458 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000136267 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T G 7 15064255 7 15024630 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 9.0 GCST004894 28869590 functional observational Medium Ed Mountjoy There are multiple lines of regulatory evidence (2R) linking T2D to ENSG00000136267 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000136267 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000136267 Medium Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T G 7 15064309 7 15024684 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 11.301029995663981 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000106633 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000106633 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106633 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000106633 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G T 7 44174857 7 44135258 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 8.397940008672037 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000106633 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000106633 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106633 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000106633 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 7 44248828 7 44209229 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=15000|South East Asian=2034|Asian unspecified=1783 GCST001351 10.301029995663981 GCST001351 22158537 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000106331 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 7 127164958 7 127524904 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=41646 GCST003400 9.096910013008056 GCST003400_2 26818947 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000106331 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 7 127237312 7 127597258 EFO_0001360 Type 2 diabetes [Japanese] type II diabetes mellitus East Asian=1639 GCST001919 9.698970004336019 GCST001919 23532257 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000106331 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 7 127246903 7 127606849 EFO_0001360 Type 2 diabetes [East Asian] type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 12.397940008672037 GCST007516 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000106331 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 7 127253550 7 127613496 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 11.698970004336019 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000106331 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 7 127253550 7 127613496 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 73.39794000867204 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000106331 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000106331 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000106331 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 7 127253550 7 127613496 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 8.0 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000130675 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000130675 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000130675 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 7 156983847 7 157191153 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 8.154901959985743 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000175445 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000175445 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000175445 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000175445 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 8 19819724 8 19962213 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 7.522878745280337 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000175445 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000175445 at this locus. There is a single line of pertubation evidence (3P) linking T2D to ENSG00000175445 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000175445 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G C 8 19852310 8 19994799 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 7.522878745280337 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118024315 8 117012076 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=56799|African American or Afro-Caribbean=3571|East Asian=4735|Hispanic or Latin American=6499 GCST003619 11.0 GCST003619 27189021 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007517 29.221848749616356 GCST007517 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=1022 GCST000383 13.698970004336019 GCST000383 19401414 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007515 46.69897000433602 GCST007515 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=70127 GCST005413 14.522878745280337 GCST005413 29358691 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=298957 GCST007518 35.096910013008056 GCST007518 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 41.39794000867204 GCST004894 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 21.69897000433602 GCST004894_2 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes [EA] type II diabetes mellitus European=298957|South Asian, East Asian, African American or Afro-Caribbean, Hispanic or Latin American=153287 GCST007516 47.0 GCST007516 29632382 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes (adjusted for BMI) type II diabetes mellitus European=407701 10.1038/s41588-018-0184-y 19.041914151478913 SAIGE_250_2 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=2335 GCST000024 7.301029995663981 GCST000024_2 17463248 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes [DGI+FUSION+WTCCC] type II diabetes mellitus East Asian=191764 GCST007847 29.522878745280337 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=4862 GCST000025 7.301029995663981 GCST000025_2 17463249 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes [DGI+FUSION+WTCCC] type II diabetes mellitus European=2931 GCST000028 7.301029995663981 GCST000028 17463246 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=41646 GCST003400 12.045757490560675 GCST003400_2 26818947 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D T C 8 118184783 8 117172544 EFO_0001360 Type 2 diabetes [Japanese] type II diabetes mellitus European=459000 GCST007077 23.69897000433602 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 8 118185025 8 117172786 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=47117 GCST000712 8.0 GCST000712 20581827 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 8 118185025 8 117172786 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 51.69897000433602 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 8 118185025 8 117172786 EFO_0001360 Type 2 diabetes type II diabetes mellitus NR=60647 GCST001550 7.3979400086720375 GCST001550 22693455 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 8 118185025 8 117172786 EFO_0001360 Type 2 diabetes [Lean] type II diabetes mellitus European=69033|East Asian=18817|South Asian=20019|Hispanic or Latin American=2583 GCST002352 17.69897000433602 GCST002352 24509480 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A G 8 118185025 8 117172786 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033 GCST005047 15.2518119729938 GCST005047 22885922 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000164756 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000164756 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000164756 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C T 8 118220270 8 117208031 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=15000|South East Asian=2034|Asian unspecified=1783 GCST001351 13.698970004336019 GCST001351 22158537 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000107249 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 9 4287466 9 4287466 EFO_0001360 Type 2 diabetes type II diabetes mellitus South Asian=13532|European=20298|NR=149821 GCST004894 7.522878745280337 GCST004894 28869590 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000107249 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D G A 9 4287466 9 4287466 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=191764 GCST007847 11.096910013008056 GCST007847 30718926 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000107249 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D A C 9 4289050 9 4289050 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=69033 GCST005047 7.468521082957745 GCST005047 22885922 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000107249 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C G 9 4290085 9 4290085 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=459000 GCST007077 8.301029995663981 GCST007077 30595370 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000107249 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C A 9 4291928 9 4291928 EFO_0001360 Type 2 diabetes type II diabetes mellitus European=655666|South Asian=3650 GCST006867 14.522878745280337 GCST006867 30054458 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000107249 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C A 9 4291928 9 4291928 EFO_0001360 Type 2 diabetes type II diabetes mellitus East Asian=3712 GCST001666 11.221848749616356 GCST001666 22961080 functional observational High Ed Mountjoy The is a confirmed causal T2D variant (1C) for ENSG00000107249 at this locus. There is a single line of regulatory evidence (3R) linking T2D to ENSG00000107249 at this locus. There are multiple lines of pertubation evidence (2P) linking T2D to ENSG00000107249 at this locus. Type 2 Diabetes Knowledge Portal Effector Genes ENSG00000107249 High Gold-standard derived from the list of effector genes at the T2D Knowledge Portal 2019-07-17 Ed Mountjoy T2D Knowledge Portal Ed Mountjoy T2D C A 9 4293150 9 4293150 EFO_0001360 Type 2 diabetes type II diabetes mellitus GCST000760 GCST000760 20686565 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTLs in human liver, subcutaneous adipocytes, SORT1 expression arrays, EMSA|Original publication looked at variant rs12740374 using the following methods: Luciferase, siRNA, gene knockdown and overexpression, measuring lipids and lipoproteins 20686566|20686566 ENSG00000134243 High Cohort: MDC-CC & PARC 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini T G 1 109818306 1 109275684 EFO_0000612 Myocardial infarction myocardial infarction GCST000489 GCST000489 19767754 functional observational Medium Maya Ghoussaini 3C prostate cancer 21814516 ENSG00000136997 Medium Cohort: PRACTICAL 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini C T 8 128323181 8 127310936 EFO_0001663 Prostate carcinoma prostate carcinoma GCST000489 GCST000489 19767754 functional observational High Maya Ghoussaini ChIP-seq, 3C prostate cancer, expression 21814516 ENSG00000249859 High Cohort: PRACTICAL 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini C T 8 128323181 8 127310936 EFO_0001663 Prostate carcinoma prostate carcinoma GCST004950 GCST004950 25751625 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL, 3C in breast cancer|Original publication looked at variant rs554219 using the following methods: Luciferase 23540573|23540573 ENSG00000110092 High Cohort: BCAC 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini G C 11 69331642 11 69516874 EFO_0000305 Breast carcinoma breast carcinoma GCST004950 GCST004950 25751625 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL, 3C in breast cancer|Original publication looked at variant rs78540526 using the following methods: Luciferase 23540573|23540573 ENSG00000110092 High Cohort: BCAC 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini T C 11 69331418 11 69516650 EFO_0000305 Breast carcinoma breast carcinoma GCST004950 GCST004950 25751625 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL, 3C in breast cancer|Original publication looked at variant rs75915166 using the following methods: Luciferase 23540573|23540573 ENSG00000110092 High Cohort: BCAC 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini A C 11 69379161 11 69564393 EFO_0000305 Breast carcinoma breast carcinoma GCST000150 GCST000150 18245381 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini 3C, ChIP-seq, allele-specific expression, TALENs|Original publication looked at variant rs1427407, rs7606173 using the following methods: reporter assays, transgenic mouse models 24115442|24115442 ENSG00000119866 High Cohort: SCD 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini T C 2 60720246 2 60493111 EFO_0004576 Fetal hemoglobin levels fetal hemoglobin measurement GCST007039 GCST007039 30595370 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini 4C-seq in mouse and zebrafish embryoe, 3C adult mouse brain, CHIA-PET ENCODE, human fibroblasts and MCF7, eQTL in brains, KO IRX3|Original publication looked at variant Not specified: they refer to region of association using the following methods: reporter assays of fragments to assess enhancer activity 24646999|24646999 ENSG00000177508 High Cohort: GIANT 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini C T 16 53800954 16 53767042 EFO_0001073 Obesity/T2D obesity GCST004988 GCST004988 29059683 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL, 3C in breast cancer|Original publication looked at variant rs4442975 using the following methods: Luciferase 25248036|25248036 ENSG00000115461 High Cohort: BCAC 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini T G 2 217920769 2 217056046 EFO_0000305 Breast carcinoma breast carcinoma GCST007039 GCST007039 30595370 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL, 3C, 4C, mouse work, epigenomic data in 127 cells, eQTLs|Original publication looked at variant rs1421085 using the following methods: CRISPR in patients samples and mice followed by cellular phenotyping, knockdown and overexpression 26287746|26287746 ENSG00000176842 High Cohort: Obesity 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini C T 16 53800954 16 53767042 EFO_0001073 Obesity obesity GCST007039 GCST007039 30595370 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL, 3C, 4C, mouse work, epigenomic data in 127 cells, eQTLs|Original publication looked at variant rs1421085 using the following methods: CRISPR in patients samples and mice followed by cellular phenotyping, knockdown and overexpression 26287746|26287746 ENSG00000177508 High Cohort: Obesity 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini C T 16 53800954 16 53767042 EFO_0001073 Obesity obesity GCST001445 GCST001445_2 22438815 functional observational High Maya Ghoussaini Allele-specific qRT-PCR, Overlap with epigenetic marks, EMSA, SB, eQTL, Chip-qRT-PCR 27096366 ENSG00000145335 High Cohort: PD 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini A G 4 90637601 4 89716450 EFO_0002508 Parkinson's disease Parkinson's disease GCST000750 GCST000750 20676098 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini allele-specific Chip-qPCR, RNA immunoprecip, Chromatin conformation capture, eQTL|Original publication looked at variant rs7463708 using the following methods: SiRNA, site-directed mutgenesis + reporter assays, mouse xenograft 27526323|27526323 ENSG00000253438 High Cohort: PC 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini C T 8 128103937 8 127091692 EFO_0001663 Prostate carcinoma prostate carcinoma GCST003845 GCST003845 27117709 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL, 3C , overlap with reg elements|Original publication looked at variant rs56069439 using the following methods: Luciferase 27601076|27601076 ENSG00000127220 High Cohort: BCAC & OCAC 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini A C 19 17393925 19 17283116 EFO_0000305 Breast Cancer breast carcinoma GCST003845 GCST003845 27117709 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL, 3C , overlap with reg elements|Original publication looked at variant rs56069439 using the following methods: Luciferase 27601076|27601076 ENSG00000160117 High Cohort: BCAC & OCAC 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini A C 19 17393925 19 17283116 EFO_0000305 Breast Cancer breast carcinoma GCST004462 GCST004462 28346442 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL, 3C , overlap with reg elements|Original publication looked at variant rs56069439 using the following methods: Luciferase 27601076|27601076 ENSG00000127220 High Cohort: BCAC & OCAC 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini C T 19 17390291 19 17279482 EFO_0000305 Ovarian cancer breast carcinoma GCST004462 GCST004462 28346442 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL, 3C , overlap with reg elements|Original publication looked at variant rs56069439 using the following methods: Luciferase 27601076|27601076 ENSG00000160117 High Cohort: BCAC & OCAC 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini C T 19 17390291 19 17279482 EFO_0000305 Ovarian cancer breast carcinoma GCST004988 GCST004988 29059683 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL, allele-specific qPCR, chromatin conformation caprure (3C), allele-specific 3C, overlap with epigenetics marks|Original publication looked at variant rs10941679 using the following methods: luciferase (no allele-specific effect), EMSA and supershift (allele-specific effect) 27640304|27640304 ENSG00000070193 High Cohort: BCAC 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini G A 5 44706498 5 44706396 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL, allele-specific qPCR, chromatin conformation caprure (3C), allele-specific 3C, overlap with epigenetics marks|Original publication looked at variant rs10941679 using the following methods: luciferase (no allele-specific effect), EMSA and supershift (allele-specific effect) 27640304|27640304 ENSG00000112996 High Cohort: BCAC 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini G A 5 44706498 5 44706396 EFO_0000305 Breast carcinoma breast carcinoma GCST000760 GCST000760 20686565 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL|Original publication looked at variant rs2277862 using the following methods: CRISPR 28388432|28388432 ENSG00000214078 High Cohort: PhLiPS Study 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini T C 20 34152782 20 35564866 EFO_0004529 Blood lipid (HDL, LDL, TG, PP, …) lipid measurement GCST002221 GCST002221 24097068 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL|Original publication looked at variant rs10889356 using the following methods: CRISPR 28388432|28388432 ENSG00000116641 High Cohort: PhLiPS Study 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini A G 1 63145439 1 62679768 EFO_0004529 Blood lipid (HDL, LDL, TG, PP, …) lipid measurement GCST002221 GCST002221 24097068 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL|Original publication looked at variant rs10889356 using the following methods: CRISPR 28388432|28388432 ENSG00000132855 High Cohort: PhLiPS Study 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini A G 1 63145439 1 62679768 EFO_0004529 Blood lipid (HDL, LDL, TG, PP, …) lipid measurement GCST002221 GCST002221 24097068 functional observational|functional experimental High|High Maya Ghoussaini|Maya Ghoussaini eQTL|Original publication looked at variant rs10872142 using the following methods: CRISPR 28388432|28388432 ENSG00000111816 High Cohort: PhLiPS Study 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini A G 6 116337503 6 116016340 EFO_0004529 Blood lipid (HDL, LDL, TG, PP, …) lipid measurement GCST004441 GCST004441 27989323 functional observational High Maya Ghoussaini NLRC4-inflammasome hyperactivity causes infantile-onset Macrophage Activation Syndrome and enterocolitis with extraordinary serum IL-18 elevation (NLRC4-MAS). Herein, we report a critically ill infant with severe, refractory NLRC4-MAS who showed sustained response to treatment with experimental IL-18 inhibition. 27876626 ENSG00000091106 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini C T 2 32489851 2 32264782 EFO_0004581 Interleukin-18 levels interleukin 18 measurement GCST003845 GCST003845 27117709 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000171094 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini T A 2 29119585 2 28896719 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000171681 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini C G 12 14413931 12 14260997 EFO_0000305 Breast carcinoma breast carcinoma GCST005077 GCST005077 29058716 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000149311 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini GA G 11 108345515 11 108474788 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000139618 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini T A 13 32972626 13 32398489 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000064012 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini T C 2 202123430 2 201258707 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000110092 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini T C 11 69331418 11 69516650 EFO_0000305 Breast carcinoma breast carcinoma GCST005077 GCST005077 29058716 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000105173 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini T C 19 30277729 19 29786822 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000183765 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini T C 22 29272637 22 28876649 EFO_0000305 Breast carcinoma breast carcinoma GCST005077 GCST005077 29058716 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000005339 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini A C 16 4106788 16 4056787 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000257923 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini A G 7 101552440 7 101909160 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000119772 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini G A 2 25129473 2 24906604 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000091831 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini G A 6 151955914 6 151634779 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000066468 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini G GC 10 123340431 10 121580917 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000107485 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini T TG 10 9088113 10 9046150 EFO_0000305 Breast carcinoma breast carcinoma GCST003845 GCST003845 27117709 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000102554 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini G A 13 73957681 13 73383544 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000095015 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini G A 5 56027240 5 56731413 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000136997 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini G A 8 128372172 8 127359926 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000196712 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini A C 17 29180996 17 30853978 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000152217 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini C G 18 42411803 18 44831838 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000135111 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini A C 12 115106688 12 114668883 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000168769 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini G A 4 106073509 4 105152352 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000163513 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini T C 3 30684907 3 30643415 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000185650 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini C T 14 68979835 14 68513118 EFO_0000305 Breast carcinoma breast carcinoma GCST004988 GCST004988 29059683 functional observational High Maya Ghoussaini Breast cancer driver genes 00000000 ENSG00000183779 High Cohort: Breast cancer driver genes 2019-11-08 Maya Ghoussaini otg_curated_191108 Maya Ghoussaini G C 8 36849946 8 36992428 EFO_0000305 Breast carcinoma breast carcinoma East Asian=1999 GCST006137 18.397940008672037 GCST006137 29953918 expert curated High Eric Fauman enzyme involved in folate metabolism Eric Fauman's Twitter list based on biological plausability ENSG00000177000 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 1 11856378 1 11796321 EFO_0005111 metabolite: folate folic acid measurement European=404196 10.1038/s41588-018-0184-y 10.97061622231479 SAIGE_594_1 expert curated High Eric Fauman phosphatase Eric Fauman's Twitter list based on biological plausability ENSG00000162551 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C A 1 21904374 1 21577881 EFO_0004253 calculus of kidney and ureter nephrolithiasis European=215551|African American or Afro-Caribbean=57332|Hispanic or Latin American=24743 GCST006612 256.52287874528037 GCST006612 30275531 expert curated High Eric Fauman PCSK9 regulates LDL via LDLR Eric Fauman's Twitter list based on biological plausability ENSG00000169174 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T G 1 55505647 1 55039974 EFO_0004611 treatment: statin use low density lipoprotein cholesterol measurement European=359241 7.33164017904141 NEALE2_6151_5 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman important function in bone marrow cells in the regenerative response of bone and cartilage after injulry Eric Fauman's Twitter list based on biological plausability ENSG00000116678 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 1 66110284 1 65644601 EFO_0009515 wrist fracture wrist fracture European=393873 GCST007091 14.397940008672037 GCST007091 30664745 expert curated High Eric Fauman collagen gene, involved in ossification Eric Fauman's Twitter list based on biological plausability ENSG00000060718 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 1 103572927 1 103107371 EFO_1000786 arthrosis of hip osteoarthritis, hip European=25708 GCST000679 70.20616772397125 GCST000679 20453842 expert curated High Eric Fauman PTPN22 encodes a protein tyrosine phosphatase involved in immune response Eric Fauman's Twitter list based on biological plausability ENSG00000134242 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 1 114377568 1 113834946 EFO_0000685 rheumatoid arthritis rheumatoid arthritis European=80003 GCST007638 13.096910013008056 GCST007638 30837465 expert curated High Eric Fauman PHDGH encodes an enzyme involved in de novo serine biosynthesis Eric Fauman's Twitter list based on biological plausability ENSG00000092621 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 1 120254506 1 119711883 EFO_0009767 metabolite: glycine glycine measurement European=344728 307.6526555685888 NEALE2_30260_raw http://www.nealelab.is/uk-biobank expert curated High Eric Fauman SPTA1 encodes spectrin, a cytoskeleton protein that helps define the cell shape Eric Fauman's Twitter list based on biological plausability ENSG00000163554 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T G 1 158596438 1 158626648 reticulocyte volume European=204402 GCST007614 522.3979400086721 GCST007614 30388399 expert curated High Eric Fauman gene for the measured protein Eric Fauman's Twitter list based on biological plausability ENSG00000132693 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 1 159678816 1 159709026 EFO_0004458 CRP levels C-reactive protein measurement European=360527 182.1308557348547 NEALE2_6152_5 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman Factor V Leiden mutation Eric Fauman's Twitter list based on biological plausability ENSG00000198734 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 1 169519049 1 169549811 EFO_0003907 Blood clot in the leg, DVT deep vein thrombosis European=393873 GCST007091 9.221848749616356 GCST007091 30664745 expert curated High Eric Fauman collagen galactosyltransferase Eric Fauman's Twitter list based on biological plausability ENSG00000198756 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 1 183906245 1 183937111 EFO_1000786 arthrosis of hip osteoarthritis, hip European=91787 8.362829604311715 NEALE2_22504 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman MUC5AC encodes one of the principal mucins in lung. This is the protein portion of mucus. Eric Fauman's Twitter list based on biological plausability ENSG00000215182 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 11 1113133 11 1119225 EFO_0009824 bring up phlegm/sputum/mucus on most days bringing up phlegm, sputum or mucus on most days, self-reported European=360527 19.56919957537582 NEALE2_6152_5 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman encodes thrombin, the final step in the clotting cascade, converting fibrinogen to fibrin Eric Fauman's Twitter list based on biological plausability ENSG00000180210 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 11 46761055 11 46739505 EFO_0003907 Blood clot in the leg, DVT deep vein thrombosis European=361141 7.81005233185522 NEALE2_20002_1331 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman TCN1 encodes an intrinsic factor which transports vitamin B12 Eric Fauman's Twitter list based on biological plausability ENSG00000134827 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A C 11 59623378 11 59855905 EFO_0005576 pernicious anemia pernicious anemia European=346527 7.720768937672716 NEALE2_2000 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman GRM5 encodes a glutamate metabotropic receptor Eric Fauman's Twitter list based on biological plausability ENSG00000168959 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 11 88732956 11 88999788 EFO_0009589 worry too long worry measurement European=356530 307.6526555685888 NEALE2_1717 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman pigmentation gene Eric Fauman's Twitter list based on biological plausability ENSG00000077498 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 11 89017961 11 89284793 EFO_0003784 malignant neoplasms of skin skin pigmentation European=356530 307.6526555685888 NEALE2_1717 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman enzyme in melanin synthesis pathway Eric Fauman's Twitter list based on biological plausability ENSG00000077498 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 11 89017961 11 89284793 EFO_0003784 skin color skin pigmentation European=401024 10.1038/s41588-018-0184-y 15.23807216157947 SAIGE_361 expert curated High Eric Fauman AT3 is an atypical cadherin in brain, important for neurite outgrowth and establishment of polarity in the retina. Eric Fauman's Twitter list based on biological plausability ENSG00000165323 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 11 92607866 11 92874700 EFO_0005773 retinal detachment retinal detachment European=105318 GCST006803 11.698970004336019 GCST006803 29483656 expert curated High Eric Fauman DRD2 encodes a dopamine receptor which is the site of action for many antipsychotics Eric Fauman's Twitter list based on biological plausability ENSG00000149295 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 11 113392994 11 113522272 EFO_0000692 schizophrenia schizophrenia European=393873 GCST007091 24.0 GCST007091 30664745 expert curated High Eric Fauman hormone regulating bone development Eric Fauman's Twitter list based on biological plausability ENSG00000087494 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T G 12 28014970 12 27862037 EFO_1000786 arthrosis of hip osteoarthritis, hip European=407648 10.1038/s41588-018-0184-y 7.954677021213342 SAIGE_594 expert curated High Eric Fauman TNFS11 may influence circulating calcium levels via bone resorption Eric Fauman's Twitter list based on biological plausability ENSG00000120659 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T A 13 42701739 13 42127603 EFO_1000839 urolithiasis bladder calculus European=329134 12.835647144215564 NEALE2_1319 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman OR10G3 probably encodes an olfactory receptor. Could it relate to enjoyment from smelling and eating fruit? Eric Fauman's Twitter list based on biological plausability ENSG00000169208 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 14 22038125 14 21569994 EFO_0008111 dried fruit intake diet measurement European=205327 GCST007020 13.397940008672037 GCST007020 30573740 expert curated High Eric Fauman GSC, Goosecoid Homeobox, an important regulator of pattern formation and Wnt signaling Eric Fauman's Twitter list based on biological plausability ENSG00000133937 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 14 95237215 14 94770878 EFO_0007825 male balding pattern balding measurement European=408823 10.1038/s41588-018-0184-y 9.1331221856625 SAIGE_172 expert curated High Eric Fauman pigmentation gene Eric Fauman's Twitter list based on biological plausability ENSG00000104044 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 15 28230247 15 27985101 EFO_0009259 malignant neoplasms of skin skin carcinoma European=356530 314.5809997598978 NEALE2_1717 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman tyrosine transporter Eric Fauman's Twitter list based on biological plausability ENSG00000104044 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 15 28534777 15 28289631 EFO_0003784 skin color skin pigmentation European=392109 10.1038/s41588-018-0184-y 16.609064892896622 SAIGE_241_2 expert curated High Eric Fauman growth factor involved in thyroid gland development and thyroid hormone production Eric Fauman's Twitter list based on biological plausability ENSG00000140285 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 15 49706417 15 49414220 MONDO_0000334 non-toxic goitre multinodular goiter European=406659 10.1038/s41588-018-0184-y 9.385102783966865 SAIGE_351 expert curated High Eric Fauman SMAD6 encodes a transcription factor important for cartilage and bone development Eric Fauman's Twitter list based on biological plausability ENSG00000137834 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 15 67034812 15 66742474 EFO_0009387 nerve, nerve root and plexus disorders peripheral nervous system disease European=334659 115.46487811249987 NEALE2_1498 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman caffeine metabolism Eric Fauman's Twitter list based on biological plausability ENSG00000140465 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 15 75027880 15 74735539 EFO_0004330 coffee intake coffee consumption European=334659 115.46487811249987 NEALE2_1498 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman caffeine metabolism Eric Fauman's Twitter list based on biological plausability ENSG00000140465 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 15 75027880 15 74735539 EFO_0004330 coffee intake coffee consumption European=334659 115.46487811249987 NEALE2_1498 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman caffeine metabolism Eric Fauman's Twitter list based on biological plausability ENSG00000140505 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 15 75027880 15 74735539 EFO_0004330 coffee intake coffee consumption European=406659 10.1038/s41588-018-0184-y 7.510041520575165 SAIGE_351 expert curated High Eric Fauman ADAMTS17 encodes a extracellular matrix metaloprotease. By analogy with ADAMTS10, ADAMTS17 may also play a role in the maturation of microfibril arrays which may contribute to structures in the carpal tunnel of the wrist driving risk of carpal tunnel syndrome, the most common plexus disorder Eric Fauman's Twitter list based on biological plausability ENSG00000140470 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 15 100692953 15 100152748 EFO_0009387 Nerve, nerve root and plexus disorders peripheral nervous system disease European=191843 GCST003997 62.69897000433602 GCST003997 27182965 expert curated High Eric Fauman RBFOX1 encodes a transcription factor involved in eye development Eric Fauman's Twitter list based on biological plausability ENSG00000078328 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A T 16 7459347 16 7409346 HP_0000545 6 mm strong meridian angle Myopia European=404196 10.1038/s41588-018-0184-y 18.7594507517174 SAIGE_594_1 expert curated High Eric Fauman uromodulin is a highly expressed kidney specific protein. Eric Fauman's Twitter list based on biological plausability ENSG00000169344 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 16 20366507 16 20355185 EFO_0004253 calculus of kidney and ureter nephrolithiasis European=80003 GCST007638 41.0 GCST007638 30837465 expert curated High Eric Fauman GCSH encodes a component of the glycine cleavage system Eric Fauman's Twitter list based on biological plausability ENSG00000140905 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 16 81110903 16 81077298 EFO_0009767 metabolite: glycine glycine measurement European=350471 36.053639123304855 NEALE2_30090_raw http://www.nealelab.is/uk-biobank expert curated High Eric Fauman "In addition to GATA1 and GATA2, there are hits for the so-called ""Friends of GATA"" or FOG. These are additional TFs that heterodimerize with GATA1 and GATA2 encoded by ZFPM2 and ZFPM1" Eric Fauman's Twitter list based on biological plausability ENSG00000179588 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 16 88559699 16 88493291 EFO_0007985 platelet crit plateletcrit European=299651 GCST006986 307.69897000433605 GCST006986 30531825 expert curated High Eric Fauman melanin production switch Eric Fauman's Twitter list based on biological plausability ENSG00000258839 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A C 16 89985918 16 89919510 EFO_0003924 red hair hair color European=353697 307.6526555685888 NEALE2_1727 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman melanin production switch Eric Fauman's Twitter list based on biological plausability ENSG00000258839 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C G 16 89986546 16 89920138 Skin changes due to chronic exposure to nonionizing radiation European=353697 307.6526555685888 NEALE2_1727 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman melanin production switch Eric Fauman's Twitter list based on biological plausability ENSG00000258839 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C G 16 89986546 16 89920138 skin color European=350471 52.04034387198277 NEALE2_30090_raw http://www.nealelab.is/uk-biobank expert curated High Eric Fauman PAF is a lipid signaling molecule mediating platelet aggregation. PAF-AH deactivates PAF. PAFAH1B1 encodes the regulatory subunit of PAF-AH Eric Fauman's Twitter list based on biological plausability ENSG00000007168 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 17 1958536 17 2055242 EFO_0007985 platelet crit plateletcrit European=408823 10.1038/s41588-018-0184-y 21.008330992620053 SAIGE_172 expert curated High Eric Fauman tumor suppressor Eric Fauman's Twitter list based on biological plausability ENSG00000141510 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G T 17 7571752 17 7668434 EFO_0009259 malignant neoplasms of skin skin carcinoma European=426795 GCST006980 40.30102999566398 GCST006980 30598549 expert curated High Eric Fauman negative regulator of bone growth via wnt signaling pathway Eric Fauman's Twitter list based on biological plausability ENSG00000167941 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C G 17 41798855 17 43721487 EFO_0003931 wrist fracture bone fracture European=446000 GCST007066 94.0 GCST007066 30595370 expert curated High Eric Fauman transcription factor involved in limb development Eric Fauman's Twitter list based on biological plausability ENSG00000121075 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 17 59023998 17 60946637 EFO_0009270 arthrosis of hip heel bone mineral density European=446000 GCST007066 150.0 GCST007066 30595370 expert curated High Eric Fauman regulator of bone structure and function Eric Fauman's Twitter list based on biological plausability ENSG00000177150 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 18 13719510 18 13719511 EFO_0009270 wrist fracture heel bone mineral density European=354736 81.07626495694595 NEALE2_23120_raw http://www.nealelab.is/uk-biobank expert curated High Eric Fauman MC4R is a well-known BMI gene. It influences feeding behavior. Eric Fauman's Twitter list based on biological plausability ENSG00000166603 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G GTCT 18 57850927 18 60183694 EFO_0004995 arm fat mass (right) lean body mass European=394929 GCST006433 29.096910013008056 GCST006433 30048462 expert curated High Eric Fauman TNFRSF11A encodes RANK, a key receptor regulating bone growth Eric Fauman's Twitter list based on biological plausability ENSG00000141655 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C A 18 60054857 18 62387624 EFO_0009270 treatment with alendronate heel bone mineral density European=406659 10.1038/s41588-018-0184-y 10.721246399047171 SAIGE_351 expert curated High Eric Fauman ADAMTS10 encodes a extracellular matrix metaloprotease which plays a role in the maturation of microfibril arrays which may contribute to structures in the carpal tunnel of the wrist driving risk of carpal tunnel syndrome, the most common plexus disorder Eric Fauman's Twitter list based on biological plausability ENSG00000142303 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 19 8670147 19 8605262 EFO_0009387 Nerve, nerve root and plexus disorders peripheral nervous system disease European=215551|African American or Afro-Caribbean=57332|Hispanic or Latin American=24743 GCST006612 300.0 GCST006612 30275531 expert curated High Eric Fauman LDLR is involved in lipoprotein regulation Eric Fauman's Twitter list based on biological plausability ENSG00000130164 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G C 19 11187324 19 11076648 EFO_0004611 treatment: statin use low density lipoprotein cholesterol measurement European=360291 11.684659523372712 NEALE2_1428_3 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman APOE drives LDL-cholesterol levels, perhaps leading to a dietary choice to switch from butter to margarine Eric Fauman's Twitter list based on biological plausability ENSG00000130203 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 19 45411941 19 44908684 EFO_0008111 margarine intake diet measurement European=361141 78.44592291862462 NEALE2_20003_1140861958 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman APOE involved in lipoprotein regulation Eric Fauman's Twitter list based on biological plausability ENSG00000130203 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T G 19 45413233 19 44909976 CHEBI_9150 treatment: statin use simvastatin European=91787 9.45496765241607 NEALE2_22504 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman FUT2 encodes a fucosyltransferase, responsible for the glycosylation portion of mucus Eric Fauman's Twitter list based on biological plausability ENSG00000176920 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 19 49206417 19 48703160 EFO_0009824 bring up phlegm/sputum/mucus on most days bringing up phlegm, sputum or mucus on most days, self-reported European=350061 20.08594099932527 NEALE2_30530_raw http://www.nealelab.is/uk-biobank expert curated High Eric Fauman FGF21 encodes a growth factor that acts on the brain to increase reward associated with eating sugar Eric Fauman's Twitter list based on biological plausability ENSG00000105550 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 19 49259529 19 48756272 HP_0012603 sodium in urine Abnormal urine sodium concentration European=360468 14.522878745280337 NEALE2_1349 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman FGF21 encodes a growth factor that acts on the brain to increase reward associated with eating sugar Eric Fauman's Twitter list based on biological plausability ENSG00000105550 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 19 49259529 19 48756272 EFO_0008111 processed meat intake diet measurement European=406659 10.1038/s41588-018-0184-y 7.886056647693163 SAIGE_351 expert curated High Eric Fauman EFEMP1 encodes fibulin-3, an extracellular matrix protein with a role in elastic fiber production which could directly contribute to the properties of the carpal ligament or other structures in the carpal tunnel Eric Fauman's Twitter list based on biological plausability ENSG00000115380 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A C 2 56009382 2 55782247 EFO_0009387 Nerve, nerve root and plexus disorders peripheral nervous system disease European=360806 9.227682694932648 NEALE2_1418_6 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman LCT encodes lactase, necessary for break down of lactose Eric Fauman's Twitter list based on biological plausability ENSG00000115850 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 2 136707982 2 135950412 EFO_0008111 milk intake diet measurement European=80003 GCST007638 1631.5228787452804 GCST007638 30837465 expert curated High Eric Fauman CPS1 encodes an enzyme acting on the breakdown products of glycine catabolism Eric Fauman's Twitter list based on biological plausability ENSG00000021826 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 2 211543055 2 210678331 EFO_0009767 metabolite: glycine glycine measurement East Asian=110207 GCST005980 1254.5228787452804 GCST005980 29403010 expert curated High Eric Fauman the UGT1A1 encodes an enzyme which has UDP-glucuronosyltransferase activity against bilirubin Eric Fauman's Twitter list based on biological plausability ENSG00000241635 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T G 2 234671462 2 233762816 EFO_0004570 total bilirubin bilirubin measurement European=354798 10.226191621507935 NEALE2_23114_raw http://www.nealelab.is/uk-biobank expert curated High Eric Fauman bone morphogenic protein, growth factor influencing bone growth Eric Fauman's Twitter list based on biological plausability ENSG00000125845 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 20 6709838 20 6729191 EFO_0004995 leg predicted mass (right) lean body mass European=392109 10.1038/s41588-018-0184-y 10.661543506395395 SAIGE_241_2 expert curated High Eric Fauman transcription factor important for thyroid endoderm development Eric Fauman's Twitter list based on biological plausability ENSG00000125798 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 20 22625447 20 22644809 MONDO_0000334 non-toxic goitre multinodular goiter European=121296 GCST005897 315.0 GCST005897 29739929 expert curated High Eric Fauman MC1R antagonist Eric Fauman's Twitter list based on biological plausability ENSG00000101440 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 20 32665748 20 34077942 EFO_0004279 Skin changes due to chronic exposure to nonionizing radiation suntan European=121296 GCST005897 315.0 GCST005897 29739929 expert curated High Eric Fauman MC1R antagonist Eric Fauman's Twitter list based on biological plausability ENSG00000101440 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 20 32665748 20 34077942 EFO_0004279 skin color suntan European=360527 9.184008739942152 NEALE2_6152_5 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman protein C receptor, involved in clotting response Eric Fauman's Twitter list based on biological plausability ENSG00000101000 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G GAA 20 33724557 20 35136754 EFO_0003907 Blood clot in the leg, DVT deep vein thrombosis European=354798 111.76709786992673 NEALE2_23114_raw http://www.nealelab.is/uk-biobank expert curated High Eric Fauman GDF5 encodes a growth factor involved in limb and joint development Eric Fauman's Twitter list based on biological plausability ENSG00000125965 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 20 34025756 20 35437976 EFO_0004995 leg predicted mass (right) lean body mass European=350471 153.24222071603972 NEALE2_30090_raw http://www.nealelab.is/uk-biobank expert curated High Eric Fauman TUBB1 which contributes to the structure of the microtubules which are important for forming platelets from the megakaryocytes. Rare TUBB1 mutations cause congenital macrothrombocytopenia Eric Fauman's Twitter list based on biological plausability ENSG00000101162 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C G 20 57597971 20 59022916 EFO_0007985 platelet crit plateletcrit European=350471 22.632124355053705 NEALE2_30090_raw http://www.nealelab.is/uk-biobank expert curated High Eric Fauman One nifty analysis in Enrichr is finding upstream transcription factors that are enriched for the implicated genes. The top 3 TFs are GATA1 (upstream of 75 GWAS genes), GATA2 (67 genes) and RUNX1 (91 genes). *All 3 of these TFs are themselves GWAS hits!*https:// Eric Fauman's Twitter list based on biological plausability ENSG00000159216 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C G 21 36393747 21 35021450 EFO_0007985 platelet crit plateletcrit European=404196 10.1038/s41588-018-0184-y 12.095825631715837 SAIGE_594_1 expert curated High Eric Fauman a kidney-specific protein inivolved in calcium reabsorption Eric Fauman's Twitter list based on biological plausability ENSG00000159261 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 21 37818871 21 36446573 EFO_0004253 calculus of kidney and ureter nephrolithiasis European=7824 GCST002443 177.30102999566398 GCST002443_58 24816252 expert curated High Eric Fauman metabolite is a product of the encoded enzyme Eric Fauman's Twitter list based on biological plausability ENSG00000093010 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 22 19951271 22 19963748 EFO_0005664 metabolite: methylascorbic acid blood metabolite measurement European=334659 10.55425572432335 NEALE2_1498 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman response to caffeine Eric Fauman's Twitter list based on biological plausability ENSG00000128271 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C A 22 24771955 22 24375987 EFO_0004330 coffee intake coffee consumption European=402950 10.1038/s41588-018-0184-y 23.554395796726403 SAIGE_571 expert curated High Eric Fauman PNPLA3 encodes a triacylglycerol lipase with high expression in the liver Eric Fauman's Twitter list based on biological plausability ENSG00000100344 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 22 44324730 22 43928850 EFO_0001421|EFO_0001422 disease of liver liver disease European=7824 GCST002443 17.154901959985743 GCST002443_44 24816252 expert curated High Eric Fauman ARSA encodes the enzyme arylsulfatase A Eric Fauman's Twitter list based on biological plausability ENSG00000100299 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 22 51063477 22 50625049 EFO_0005664 metabolite: O-sulfo-tyrosine blood metabolite measurement European=80003 GCST007638 30.0 GCST007638 30837465 expert curated High Eric Fauman ALDH1L1 encodes an enzyme involved in the folate cycle Eric Fauman's Twitter list based on biological plausability ENSG00000144908 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 3 125910381 3 126191538 EFO_0009767 metabolite: glycine glycine measurement European=350471 10.522430206021097 NEALE2_30090_raw http://www.nealelab.is/uk-biobank expert curated High Eric Fauman One nifty analysis in Enrichr is finding upstream transcription factors that are enriched for the implicated genes. The top 3 TFs are GATA1 (upstream of 75 GWAS genes), GATA2 (67 genes) and RUNX1 (91 genes). *All 3 of these TFs are themselves GWAS hits!*https:// Eric Fauman's Twitter list based on biological plausability ENSG00000179348 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 3 128201889 3 128483046 EFO_0007985 platelet crit plateletcrit European=350471 139.91119437332395 NEALE2_30090_raw http://www.nealelab.is/uk-biobank expert curated High Eric Fauman THPO encodes thrombopoietin, a growth factor driving platelet production Eric Fauman's Twitter list based on biological plausability ENSG00000090534 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 3 184090242 3 184372454 EFO_0007985 platelet crit plateletcrit European=79366 GCST005367 307.6526555685888 GCST005367 29343764 expert curated High Eric Fauman GC encodes the vitamin D binding protein Eric Fauman's Twitter list based on biological plausability ENSG00000145321 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C G 4 72614267 4 71748550 EFO_0004631 metabolite: vitamin D vitamin D measurement European=941280 GCST007461 307.69897000433605 GCST007461 30643251 expert curated High Eric Fauman alcohol metabolism Eric Fauman's Twitter list based on biological plausability ENSG00000196616 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 4 100239319 4 99318162 EFO_0007878 average weekly red wine intake alcohol consumption measurement European=941280 GCST007461 307.69897000433605 GCST007461 30643251 expert curated High Eric Fauman encodes alcohol dehydrogenase, regulating clearance rate for alcohol Eric Fauman's Twitter list based on biological plausability ENSG00000196616 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 4 100239319 4 99318162 EFO_0007878 alcohol consumption alcohol consumption measurement European=360527 23.63941415920316 NEALE2_6152_5 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman Factor XI, a protease in the clotting cascade Eric Fauman's Twitter list based on biological plausability ENSG00000088926 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G T 4 187188094 4 186266940 EFO_0003907 Blood clot in the leg, DVT deep vein thrombosis European=356530 307.6526555685888 NEALE2_1717 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman melanocyte-specific transporter Eric Fauman's Twitter list based on biological plausability ENSG00000164175 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G C 5 33951693 5 33951588 EFO_0003784 skin color skin pigmentation European=215551|African American or Afro-Caribbean=57332|Hispanic or Latin American=24743 GCST006614 93.15490195998575 GCST006614 30275531 expert curated High Eric Fauman HMGCR encodes an enzyme in the cholesterol biosynthetic pathway Eric Fauman's Twitter list based on biological plausability ENSG00000113161 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 5 74656539 5 75360714 EFO_0004574 treatment: statin use total cholesterol measurement Other=1097|NR=150064 GCST003048 9.0 GCST003048 26198764 expert curated High Eric Fauman Glutamate receptor involved in synaptic transmissions Eric Fauman's Twitter list based on biological plausability ENSG00000155511 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 5 152608619 5 153229059 EFO_0000692 schizophrenia schizophrenia European=205327 GCST007020 266.39794000867204 GCST007020 30573740 expert curated High Eric Fauman EBF1 contributes to hair growth through regulation of adipocyte maturation in the skin Eric Fauman's Twitter list based on biological plausability ENSG00000164330 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 5 158343969 5 158916961 EFO_0007825 hair.balding pattern 4 balding measurement European=6880 GCST003270 24.0 GCST003270 26626624 expert curated High Eric Fauman cytokine involved in immune response Eric Fauman's Twitter list based on biological plausability ENSG00000113302 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 5 158764478 5 159337470 EFO_0003778 psoriatic arthropathy psoriatic arthritis European=404196 10.1038/s41588-018-0184-y 12.014124642691606 SAIGE_594_1 expert curated High Eric Fauman a kidney specific sodium/phosphate transporter Eric Fauman's Twitter list based on biological plausability ENSG00000131183 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 5 176799992 5 177372991 EFO_0004253 calculus of kidney and ureter nephrolithiasis European=121296 GCST005897 581.0 GCST005897 29739929 expert curated High Eric Fauman IRF4 encodes a transcription factor involved in skin pigmentation Eric Fauman's Twitter list based on biological plausability ENSG00000137265 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 6 396321 6 396321 EFO_0004279 melanocytic naevi suntan European=354798 24.351119148082883 NEALE2_23114_raw http://www.nealelab.is/uk-biobank expert curated High Eric Fauman bone morphogenic protein, growth factor influencing bone growth Eric Fauman's Twitter list based on biological plausability ENSG00000153162 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 6 7706004 6 7705771 EFO_0004995 leg predicted mass (right) lean body mass European=23986 GCST002679 96.52287874528034 GCST002679 25352340 expert curated High Eric Fauman HFE encodes the hemochromatosis Eric Fauman's Twitter list based on biological plausability ENSG00000010704 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 6 26093141 6 26092913 EFO_0004461|EFO_0006332 hemochromatosis iron biomarker measurement European=393873 GCST007091 8.522878745280337 GCST007091 30664745 expert curated High Eric Fauman bone morphogenic protein, involved in ossification Eric Fauman's Twitter list based on biological plausability ENSG00000112175 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 6 55636940 6 55772142 EFO_1000786 arthrosis of hip osteoarthritis, hip European=287323 GCST004346 41.69897000433602 GCST004346 28537254 expert curated High Eric Fauman receptor involved in immune response Eric Fauman's Twitter list based on biological plausability ENSG00000056972 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T G 6 111929862 6 111608659 EFO_0000676 psoriatic arthropathy psoriasis European=426795 GCST006980 64.04575749056067 GCST006980 30598549 expert curated High Eric Fauman activator of wnt signaling pathway, regulator of angiogenesis Eric Fauman's Twitter list based on biological plausability ENSG00000146374 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C A 6 127468274 6 127147129 EFO_0003931 wrist fracture bone fracture European=334659 94.49028415733696 NEALE2_1498 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman regulation of caffeine metabolism Eric Fauman's Twitter list based on biological plausability ENSG00000106546 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 7 17284577 7 17244953 EFO_0004330 coffee intake coffee consumption European=334659 94.49028415733696 NEALE2_1498 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman regulation of caffeine metabolism Eric Fauman's Twitter list based on biological plausability ENSG00000106546 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 7 17284577 7 17244953 EFO_0004330 coffee intake coffee consumption European=440328|East Asian=45564|South Asian=9144|African American or Afro-Caribbean=20687|Asian unspecified=555|Hispanic or Latin American=1247 GCST005843 13.045757490560675 GCST005843 29531354 expert curated High Eric Fauman TWIST1 is a transcription factor involved in cranial development and cerebral vein formation Eric Fauman's Twitter list based on biological plausability ENSG00000122691 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 7 19049388 7 19009765 HP_0002140 stroke Ischemic stroke European=80003 GCST007638 33.15490195998574 GCST007638 30837465 expert curated High Eric Fauman PSPH encodes an enzyme involved in de novo serine biosynthesis Eric Fauman's Twitter list based on biological plausability ENSG00000146733 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability C T 7 56079094 7 56011401 EFO_0009767 metabolite: glycine glycine measurement European=346635 9.289347081400459 NEALE2_2247_1 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman SLC26A5 encodes prestin, a critical outer hair cell membrane protein essential for mechanical signal transduction Eric Fauman's Twitter list based on biological plausability ENSG00000170615 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 7 103061825 7 103421378 EFO_0004238 hearing loss hearing loss European=394929 GCST006433 1699.1549019599856 GCST006433 30048462 expert curated High Eric Fauman WNT16 encodes a signaling protein involved in regulation of bone growth Eric Fauman's Twitter list based on biological plausability ENSG00000002745 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 7 120962164 7 121322110 EFO_0009270 wrist fracture heel bone mineral density European=394929 GCST006433 1699.1549019599856 GCST006433 30048462 expert curated High Eric Fauman WNT16 encodes a signaling protein involved in regulation of bone growth Eric Fauman's Twitter list based on biological plausability ENSG00000002745 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 7 120962164 7 121322110 EFO_0009270 heel bone mineral density heel bone mineral density European=394929 GCST006433 1699.1549019599856 GCST006433 30048462 expert curated High Eric Fauman WNT16 encodes a signaling protein involved in regulation of bone growth Eric Fauman's Twitter list based on biological plausability ENSG00000002745 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 7 120962164 7 121322110 EFO_0009270 Fracture of ankle heel bone mineral density European=367725 GCST006946 9.698970004336019 GCST006946 29500382 expert curated High Eric Fauman GRM8 encodes a glutamate metabotropic receptor Eric Fauman's Twitter list based on biological plausability ENSG00000179603 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T A 7 126378842 7 126738788 EFO_0009589 worry too long worry measurement European=257773 15.933081750658816 NEALE2_1568 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman receptor for bitter taste Eric Fauman's Twitter list based on biological plausability ENSG00000257138 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G C 7 141673345 7 141973545 EFO_0007878 average weekly red wine intake alcohol consumption measurement European=348284 43.29265980539296 NEALE2_1309 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman OR2A7 encodes an olfactory receptor that may respond to sweet smells Eric Fauman's Twitter list based on biological plausability ENSG00000243896 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 7 143723137 7 144026044 EFO_0008111 fresh fruit intake diet measurement European=350471 80.9294929792367 NEALE2_30090_raw http://www.nealelab.is/uk-biobank expert curated High Eric Fauman "In addition to GATA1 and GATA2, there are hits for the so-called ""Friends of GATA"" or FOG. These are additional TFs that heterodimerize with GATA1 and GATA2 encoded by ZFPM2 and ZFPM1" Eric Fauman's Twitter list based on biological plausability ENSG00000169946 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T A 8 106581528 8 105569300 EFO_0007985 platelet crit plateletcrit European=80003 GCST007638 39.69897000433602 GCST007638 30837465 expert curated High Eric Fauman GLDC encodes an enzyme involved glycine catabolism Eric Fauman's Twitter list based on biological plausability ENSG00000178445 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 9 6550024 9 6550024 EFO_0009767 metabolite: glycine glycine measurement European=356530 218.9201208247617 NEALE2_1717 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman BNC2 encodes a transcription factor involved in skin pigmentation Eric Fauman's Twitter list based on biological plausability ENSG00000173068 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A G 9 16885017 9 16885019 EFO_0003784 melanocytic naevi skin pigmentation NR=296525 GCST005194 222.0545314148682 GCST005194 29212778 expert curated High Eric Fauman locus associated with increased risk of heart disease Eric Fauman's Twitter list based on biological plausability ENSG00000147889 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 9 22098574 9 22098575 EFO_0000378 treatment with nicorandil coronary artery disease NR=296525 GCST005194 222.0545314148682 GCST005194 29212778 expert curated High Eric Fauman locus associated with increased risk of heart disease Eric Fauman's Twitter list based on biological plausability ENSG00000147883 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 9 22098574 9 22098575 EFO_0000378 treatment with nicorandil coronary artery disease European=392109 10.1038/s41588-018-0184-y 22.543633966870956 SAIGE_241_2 expert curated High Eric Fauman transcription factor exclusively expressed in thyroid, involved in thyroid development Eric Fauman's Twitter list based on biological plausability ENSG00000178919 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability G A 9 100538470 9 97776188 MONDO_0000334 non-toxic goitre multinodular goiter European=393873 GCST007091 11.522878745280337 GCST007091 30664745 expert curated High Eric Fauman transcription factor involved in limb development Eric Fauman's Twitter list based on biological plausability ENSG00000136944 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 9 129386860 9 126624581 EFO_1000786 arthrosis of hip osteoarthritis, hip European=360527 68.43321497559869 NEALE2_6152_5 http://www.nealelab.is/uk-biobank expert curated High Eric Fauman blood type is a risk factor for blood clots Eric Fauman's Twitter list based on biological plausability ENSG00000175164 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability T C 9 136143372 9 133267960 EFO_0003907 Blood clot in the leg, DVT deep vein thrombosis European=205327 GCST007020 282.52287874528037 GCST007020 30573740 expert curated High Eric Fauman AR encodes the androgen receptor, important for regulation of hair follicles Eric Fauman's Twitter list based on biological plausability ENSG00000169083 High 2019-07-30 Ed Mountjoy Eric Fauman Twitter Eric Fauman Fauman|Biological plausability A C X 66670566 X 67450724 EFO_0007825 hair.balding pattern 4 balding measurement